
<html lang="en"     class="pb-page"  data-request-id="652533fc-be6e-4c59-a1f0-d328a466bffc"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;article:article:10.1021/acs.jmedchem.9b00175;website:website:acspubs;issue:issue:10.1021/jmcmar.2019.62.issue-16;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Fifty Years in Search of Selective Antiviral Drugs" /></meta><meta name="dc.Creator" content="Erik  De Clercq" /></meta><meta name="dc.Description" content="Fifty years of research (1968–2018) toward the identification of selective antiviral drugs have been primarily focused on antiviral compounds active against DNA viruses (HSV, VZV, CMV, HBV) and ret..." /></meta><meta name="Description" content="Fifty years of research (1968–2018) toward the identification of selective antiviral drugs have been primarily focused on antiviral compounds active against DNA viruses (HSV, VZV, CMV, HBV) and ret..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="April 2, 2019" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.9b00175" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2019 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b00175" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.9b00175" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b00175" /></link>
        
    
    

<title>Fifty Years in Search of Selective Antiviral Drugs | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.9b00175" /></meta><meta property="og:title" content="Fifty Years in Search of Selective Antiviral Drugs" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/large/jm-2019-00175p_0026.jpeg" /></meta><meta property="og:description" content="Fifty years of research (1968–2018) toward the identification of selective antiviral drugs have been primarily focused on antiviral compounds active against DNA viruses (HSV, VZV, CMV, HBV) and retroviruses (HIV). For the treatment of HSV infections the aminoacyl esters of acyclovir were designed, and valacyclovir became the successor of acyclovir in the treatment of HSV and VZV infections. BVDU (brivudin) still stands out as the most potent among the marketed compounds for the treatment of VZV infections (i.e., herpes zoster). In the treatment of HIV infections 10 tenofovir-based drug combinations have been marketed, and tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF) have also proved effective in the treatment of HBV infections. As a spin-off of our anti-HIV research, a CXCR4 antagonist AMD-3100 was found to be therapeutically useful as a stem cell mobilizer, and has since 10 years been approved for the treatment of some hematological malignancies." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.9b00175"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b00175">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.9b00175&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.9b00175&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.9b00175&amp;href=/doi/10.1021/acs.jmedchem.9b00175" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2019</span><span class="cit-fg-volume">, 62</span><span class="cit-fg-issue">, 16</span><span class="cit-fg-pageRange">, 7322-7339</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/62/16" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.8b01595" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/acs.jmedchem.9b00196" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Fifty Years in Search of Selective Antiviral Drugs</span></h1><h2 class="article_header-subtitle"><span class="hlFld-SubTitle">Miniperspective</span></h2><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Erik De Clercq</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Erik De Clercq</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Microbiology and Immunology, Rega Institute for Medical Research, KU Leuven, Herestraat 49, 3000 Leuven, Belgium</div></div><span class="conrtib-corresp"><strong>*</strong>Phone: + 32 16 37 90 20. E-mail: <a href="/cdn-cgi/l/email-protection#8beef9e2e0a5efeee8e7eef9e8facbe0fee7eefefdeee5a5e9ee"><span class="__cf_email__" data-cfemail="7217001b195c1617111e170011033219071e170704171c5c1017">[email protected]</span></a></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Erik++De+Clercq">Erik De Clercq</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath1">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-2985-8890" title="Orcid link">http://orcid.org/0000-0002-2985-8890</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b00175&amp;href=/doi/10.1021%2Facs.jmedchem.9b00175" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2019</span></span><span class="cit-volume">, 62</span><span class="cit-issue">, 16</span><span class="cit-pageRange">, 7322–7339</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">April 2, 2019</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>28 January 2019</li><li><span class="item_label"><b>Published</b> online</span>2 April 2019</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 22 August 2019</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.9b00175" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00175</a></div><div class="article_header-article-copyright"><strong>Copyright © 2019 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D7322%26pageCount%3D18%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DErik%2BDe%2BClercq%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D62%26issueNum%3D16%26contentID%3Dacs.jmedchem.9b00175%26title%3DFifty%2BYears%2Bin%2BSearch%2Bof%2BSelective%2BAntiviral%2BDrugs%26numPages%3D18%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D7339%26publicationDate%3DAugust%2B2019">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.9b00175"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">3159</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">19</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.9b00175" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Fifty Years in Search of Selective Antiviral Drugs&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Erik&quot;,&quot;last_name&quot;:&quot;De Clercq&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2019&quot;,&quot;month&quot;:&quot;04&quot;,&quot;day&quot;:&quot;02&quot;,&quot;issue&quot;:&quot;16&quot;,&quot;volume&quot;:&quot;62&quot;,&quot;pages&quot;:&quot;7322-7339&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.9b00175&quot;},&quot;abstract&quot;:&quot;Fifty years of research (1968–2018) toward the identification of selective antiviral drugs have been primarily focused on antiviral compounds active against DNA viruses (HSV, VZV, CMV, HBV) and retroviruses (HIV). For the treatment of HSV infections the aminoacyl esters of acyclovir were designed, and valacyclovir became the successor of acyclovir in the treatment of HSV and VZV infections. BVDU (brivudin) still stands out as the most potent among the marketed compounds for the treatment of VZV infections (i.e., herpes zoster). In the treatment of HIV infections 10 tenofovir-based drug combinations have been marketed, and tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF) have also proved effective in the treatment of HBV infections. As a spin-off of our anti-HIV research, a CXCR4 antagonist AMD-3100 was found to be therapeutically useful as a stem cell mobilizer, and has since 10 years been approved for the treatment of some hematological malignancies.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b00175&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00175" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b00175&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00175" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b00175&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00175" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b00175&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00175&amp;href=/doi/10.1021/acs.jmedchem.9b00175" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.9b00175" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.9b00175" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (9 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00175&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.9b00175%26sid%3Dliteratum%253Aachs%26pmid%3D30939009%26genre%3Darticle%26aulast%3DDe%2BClercq%26date%3D2019%26atitle%3DFifty%2BYears%2Bin%2BSearch%2Bof%2BSelective%2BAntiviral%2BDrugs%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D62%26issue%3D16%26spage%3D7322%26epage%3D7339%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291430" title="Infectious diseases">Infectious diseases</a>,</li><li><a href="/action/doSearch?ConceptID=291362" title="Antimicrobial agents">Antimicrobial agents</a>,</li><li><a href="/action/doSearch?ConceptID=292035" title="Viruses">Viruses</a>,</li><li><a href="/action/doSearch?ConceptID=291788" title="Reaction products">Reaction products</a>,</li><li><a href="/action/doSearch?ConceptID=291070" title="Pharmaceuticals">Pharmaceuticals</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/62/16" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/jmcmar.2019.62.issue-16/20190822/jmcmar.2019.62.issue-16.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/medium/jm-2019-00175p_0026.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/large/jm-2019-00175p_0026.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00175&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Fifty years of research (1968–2018) toward the identification of selective antiviral drugs have been primarily focused on antiviral compounds active against DNA viruses (HSV, VZV, CMV, HBV) and retroviruses (HIV). For the treatment of HSV infections the aminoacyl esters of acyclovir were designed, and valacyclovir became the successor of acyclovir in the treatment of HSV and VZV infections. BVDU (brivudin) still stands out as the most potent among the marketed compounds for the treatment of VZV infections (i.e., herpes zoster). In the treatment of HIV infections 10 tenofovir-based drug combinations have been marketed, and tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF) have also proved effective in the treatment of HBV infections. As a spin-off of our anti-HIV research, a CXCR4 antagonist AMD-3100 was found to be therapeutically useful as a stem cell mobilizer, and has since 10 years been approved for the treatment of some hematological malignancies.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_32762" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_32762" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">In looking back at my scientific career now spanning 50 years in search of selective antiviral agents, I want to recount where my scientific research has, in some instances, yielded a successful outcome and in other cases, it did not, thereby illustrating that my scientific career, as life in general, was a mix of successes alternating with failures. In the framework of a “Miniperspective” article, I have not merely recounted the crucial events but also provided critical reflections, thus providing guidance for future developments.</div><div class="NLM_p last">After I had started to work in the laboratory (Rega Institute for Medical Research) of Prof. Piet De Somer in 1964, the real start of my scientific career could be situated in 1968, when on September 4, I flew together with my wife Lili, whom I had just married on August 31, to Palo Alto via London, Los Angeles, and San Francisco, the last segment by helicopter. I had obtained an Eli Lilly fellowship that would allow me to stay at Stanford University for 1 year in the laboratory of Thomas C. Merigan. After a few months, both Lili and I were so much enchanted by our life in the Bay Area that I continued to stay for another year, this time with the aid of a Damon Runyon fellowship. In November 1970 we returned home with mixed feelings, partly depressed for having to leave Stanford behind but partly looking forward to resuming the work with my boss, Prof. De Somer. He had, in the meantime, broken his ties with the company RIT in Genval, which he had founded, and instead had embarked on a new career as the first president (Rector) of the new autonomous Flemish University of Leuven while retaining his position as Director of the Rega Institute. Little did I know at the end of the 1970s that I would stay there for my whole life.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Interferon Inducers</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_23503" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_23503" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The discovery of interferon in 1957 by Isaacs and Lindenmann<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> as an antiviral substance stimulated worldwide efforts on (i) how to actively (i.e., endogenously) induce this substance and (ii) how to produce it (exogenously). When starting to work, as a young MD, in the Laboratory of Prof. Piet De Somer, I followed the first approach, and this swiftly led to the identification of some synthetic polyanions, i.e., polyacrylic acid, as inducers of interferon.<a onclick="showRef(event, 'ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref2 ref3">(2,3)</a> That synthetic polyanions such as pyran copolymer were able to induce interferon had already been shown by Tom Merigan,<a onclick="showRef(event, 'ref4 ref5'); return false;" href="javascript:void(0);" class="ref ref4 ref5">(4,5)</a> but what had really galvanized the field of interferon induction was the observation of Maurice Hilleman and his team at Merck that interferon could be induced by double-stranded (ds)RNAs, including poly(I)·poly(C), four articles being published in <i>Proc. Natl. Acad. Sci. U. S. A.</i> in 1967<a onclick="showRef(event, 'ref6 ref7 ref8 ref9'); return false;" href="javascript:void(0);" class="ref ref6 ref7 ref8 ref9">(6−9)</a> and one in 1968.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a></div><div class="NLM_p">When I left Leuven for Stanford in September 1968, high expectations were vested on interferon inducers, especially dsRNAs such as poly(I)·poly(C), and thus my research at Stanford was primarily focused on the mechanism and structured requirements of induction of interferon by dsRNAs. This led, within a few months, to two papers in <i>Nature</i>,<a onclick="showRef(event, 'ref11 ref12'); return false;" href="javascript:void(0);" class="ref ref11 ref12">(11,12)</a> and one in <i>Science</i>.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> The latter paper, coauthored by my first foreign collaborator, Fritz Eckstein, reported the thiophosphate-substituted polyribonucleotides, i.e., poly(As-Us), as inducers of interferon. This finding was patented and licensed by Stanford University to the company Wyeth, who abandoned the further pursuit of poly(As-Us) a few years later. Back in Leuven, I continued the study of the mechanism of interferon induction by poly(I)·poly(C),<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> and the structural requirements of dsRNAs to induce interferon,<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> and with Bill Carter, I reviewed the role of dsRNA during the virus infection process.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a></div><div class="NLM_p last">While arduous attempts to increase the interferon inducing potency and/or safety of poly(I)·poly(C) by a variety of chemical modifications did not yield the expected results, the compound proved to be of paramount importance in the cloning and expression of human β-interferon.<a onclick="showRef(event, 'ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref17 ref18">(17,18)</a> This work was based on a close collaboration between three laboratories, that of Walter Fiers (University of Ghent), that of Jean Content (Pasteur Institute in Brussels), and mine in Leuven. The human β-interferon, thus produced exogenously, found its primary application beyond the antiviral area that is in the treatment of multiple sclerosis (MS).</div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">Suramin</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_80386" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_80386" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Just before my return from Stanford to Leuven, I was fascinated by two consecutive papers in <i>Nature</i> reporting the discovery of the reverse transcriptase (RT).<a onclick="showRef(event, 'ref19 ref20'); return false;" href="javascript:void(0);" class="ref ref19 ref20">(19,20)</a> Upon my return in Leuven, I verified on my own whether murine (Moloney) leukemia virus really harbored such enzyme, and so it did, and the existence of the RT was confirmed in several other laboratories, including that of Robert C. (“Bob”) Gallo. With the RT assay system at hand, I evaluated a series of compounds as potential RT inhibitors. Sol Spiegelman had published in PNAS on the purported role of the RT in all sorts of cancers, and when in 1975 I found the polysulfonate suramin (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>) to be exquisitely inhibitory to the (murine) RT, I instantly was determined to measure its propensity to block leukemia in mice.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/medium/jm-2019-00175p_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/large/jm-2019-00175p_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Suramin.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/large/jm-2019-00175p_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00175&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To my great disillusion, it did not. This made me disbelieve in the role of RT in cancer. When several years later (1978), Bob Gallo visited us at the Rega Institute and I informed him about my observations with suramin, he told me I should publish these findings in his journal <i>Cancer Letters</i>, and so I finally did.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> This was 2 years before AIDS (acquired immune deficiency syndrome) was identified and 4 years before HIV, then called HTLV-III (human T-cell lymphotropic virus type 3) or LAV (lymphadenopathy-associated virus), was suggested to be the possible cause of the disease.</div><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5"> Comment</h3><div class="NLM_p">When suramin was first evaluated for its activity against HTLV-III, it was assumed to act as an RT inhibitor. It was later ascertained that this was only part of its mode of action. Being a polyanionic substance, it also proved inhibitory to the virus adsorption to the cells.</div><div class="NLM_p last">I was pleasantly surprised that in 1984, based on my original paper in <i>Cancer Letters</i>, Gallo and his colleagues at the NCI (National Cancer Institute) had found suramin to be active against the replication of HTLV-III in vitro<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> and in vivo in AIDS patients.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> However, suramin, which had been marketed for the treatment of African trypanosomiasis (“sleeping sickness”) since 1920, was considered to be too toxic for therapeutic use in the treatment of AIDS, especially because at the NCI they had in the meantime come across a compound, azidothymidine (AZT),<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> that was more active against HTLV-III and apparently less toxic than suramin. Ironically, I had already evaluated AZT for its antiviral activity at the end of the 1970s,<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> but retroviruses at that time had not been included in our assay systems. Furman would then further ascertain that RT was the final target for the mode of action of AZT,<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> and in 1987, AZT (Retrovir) would become the first anti-HIV drug formally approved by the U.S. Food and Drug Administration (FDA).</div></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i6">DHPA</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_76235" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_76235" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">In 1976, a few months after we had met for the first time at the Max Planck Institut für Biophysikalische Chemie in Göttingen, Antonı́n Holý sent me three compounds for antiviral evaluation. One of the three compounds, <i>S</i>-9-(2,3-dihydroxypropyl)adenine (DHPA) (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>), turned out to be antivirally active. We published this finding in <i>Science</i>.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> We thought DHPA was the first acyclic nucleoside analogue ever shown to be antivirally active until we learned that just a few months earlier that year Schaeffer et al.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> had published on the activity of acyclovir (9-(2-hydroxyethoxymethyl)guanine) “against viruses of the herpes group”. In fact, the selective anti-herpes activity of acydovir, due to a specific recognition by the viral thymidine kinase, had already been introduced by Gertrude (“Trudy”) Elion in the December 1977 issue of <i>Proc. Natl. Acad. Sci. U. S. A</i>.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a></div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/medium/jm-2019-00175p_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/large/jm-2019-00175p_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. DHPA.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/large/jm-2019-00175p_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00175&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In contrast with acyclovir, DHPA exhibited broad-spectrum antiviral activity against both DNA and RNA viruses, which, as we later demonstrated, was due to a specific interaction with the <i>S</i>-adenosylhomocysteine (SAH) hydrolase.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> Various adenosine analogues, whether acyclic or cabocyclic, were found to display broad-spectrum antiviral activity,<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> due to a specific interaction with the SAH hydrolase, which was first recognized by John Montgomery et al. as a pharmacological target in 1982.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a></div><div class="NLM_p">DHPA was marketed in the former Czechoslovakia by Lachema Company as Duviragel for the topical treatment of herpes labialis (“cold sores”) due to herpes simplex virus (HSV) infection; it was later abandoned.</div><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> Comment</h3><div class="NLM_p last">DHPA was brought onto the market despite the paucity of clinical data in this regard. More convincing data were generated for the potential of BVDU in the topical treatment of herpes labialis, but ultimately, the only compound licensed for clinical use in the topical treatment of HSV infections was acyclovir (Zovirax).</div></div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i8">BVDU</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_01340" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_01340" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Within a year following acyclovir, BVDU [(<i>E</i>)-5-(2-bromovinyl)-2′-deoxyuridine] was described as a specific anti-herpesvirus agent.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> Among the herpesviruses, particularly HSV-1 (herpes simplex virus type I) and VZV (varicella-zoster virus) proved highly sensitive to BVDU, as the thymidine kinase encoded by these viruses efficiently phosphorylated BVDU in the virus-infected cells, the ultimate target for the antiviral action being the viral DNA polymerase.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> BVDU entered the clinic on a compassionate basis in 1980 for the treatment of VZV infections (i.e., herpes zoster).<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> In cell culture, it proved about 1000-fold more potent an inhibitor of VZV replication than acyclovir, and anecdotal evidence also indicated that BVDU was more effective than acyclovir in the topical treatment of HSV-1 infections (i.e., herpes labialis and herpetic keratitis). Yet, unlike acyclovir, BVDU was never commercialized for these indications. Instead, it was widely marketed, first in East Germany (as Helpin) and later in the whole of Germany (as Zostex) and other countries [as Brivirac (Italy), Zerpex (Belgium), etc.] (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>), for the treatment of VZV infections (i.e., herpes zoster).</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/medium/jm-2019-00175p_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/large/jm-2019-00175p_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. BVDU and BVDU 5′-triphosphate.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/large/jm-2019-00175p_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00175&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The commercial package mentions that BVDU (also known as brivudin) should not be given concomitantly with anticancer agents: this restriction only concerns 5-fluorouracil (derivatives), since in Japan the concomitant use of fluorouracil (derivatives) and sorivudine (BV-araU, which is not identical but structurally related to BVDU) was found to lead to some casualties, due to an increased toxicity of 5-fluorouracil. However, for BVDU no such casualties have ever been noted or reported.</div><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> Comment</h3><div class="NLM_p last">Why was BVDU not marketed for herpes zoster in the U.S. and not marketed for the treatment of HSV-1 infections worldwide? The main reason is that acyclovir (and valcyclovir) had monopolized the market for this indication, which added up to the paucity of comparative clinical data for HSV infections and the inactivity of BVDU against HSV-2.</div></div></div><div id="sec6" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i10">Aminoacyl Esters of Acyclovir</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_85281" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_85281" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Acyclovir was the first specific antiviral compound ever introduced in the medical practice for the systemic treatment of (herpes) viral infections [actually, vidarabine (ara-A) was the first to be introduced in the systemic treatment of VZV infections,<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> but this compound was not considered as “specifically” antiviral]. The problem with acyclovir, however, was that, first, it was not sufficiently bioavailable by the oral route and, second, not highly soluble in aqueous medium (although more so than vidarabine). In attempts to overcome the second problem, aminoacyl (i.e., glycyl and alanyl) esters of acyclovir were developed.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> Glycyl acyclovir proved applicable as eye drops in the treatment of herpetic eye infections (i.e., keratitis),<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> an advantage over acyclovir that had to be administered as an eye ointment. The most important advantage, however, was that one of the aminoacyl esters, particularly the valine ester valacyclovir, showed a much better oral bioavailability than the parent compound.<a onclick="showRef(event, 'ref39 ref40'); return false;" href="javascript:void(0);" class="ref ref39 ref40">(39,40)</a> Valacyclovir would finally replace acyclovir, when the latter turned out to be generic (in 1995), and be marketed as Valtrex (U.S.) or Zelitrex (EU) (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>) for the oral treatment of both HSV and VZV infections.</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/medium/jm-2019-00175p_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/large/jm-2019-00175p_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Valacyclovir (VACV) and ACV triphosphate.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/large/jm-2019-00175p_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00175&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div id="sec6_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> Comment</h3><div class="NLM_p last">When acyclovir was launched, its main benefit in comparison with the then known antivirals was that it was considered to be the first selective antiviral agent active against HSV infection,<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> based on its specific recognition (and phosphorylation) by the HSV-encoded thymidine kinase.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a></div></div></div><div id="sec7" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i12">Acyclic Nucleoside Phosphonates (ANPs): (<i>S</i>)-HPMPA, PMEA (Adefovir), (<i>S</i>)-HPMPC (Cidofovir)</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_62361" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_62361" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The prototype of the acyclic nucleoside phosphonates (ANPs) was [(<i>S</i>)-9-(3-hydroxy-2-phosphonomethoxypropyl)adenine] (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>). It was first described in 1986.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> It showed selective activity against a broad range of DNA viruses, including herpes-, papilloma-, polyoma-, adeno-, hepadna-, and poxviruses. Although (<i>S</i>)-HPMPA was not commercialized for clinical use in humans, it paved the way for the development of tenofovir [(<i>R</i>)-PMPA], which in its prodrug form, tenofovir disoproxil fumarate (TDF) and later on TAF (tenofovir alafenamide), would become the key compound for the treatment of human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infections.</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/medium/jm-2019-00175p_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/large/jm-2019-00175p_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (<i>S</i>)-HPMPA or (<i>S</i>)-9-(3-hydroxy-2-phosphonomethoxypropyl)adenine.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/large/jm-2019-00175p_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00175&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Concomitantly with (<i>S</i>)-HPMPA, PMEA [9-(2-phosphonomethoxyethyl)adenine] was described as an antiviral agent specifically active against retroviruses.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> PMEA (adefovir) in its prodrug form adefovir dipivoxil (Hepsera) (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>) would be approved in 2002 by the U.S. FDA and marketed worldwide by Gilead Sciences for the treatment of HBV infections. It was originally intended for clinical use in the treatment of HIV infections.</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/medium/jm-2019-00175p_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/large/jm-2019-00175p_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. PMEA, PMEA dipivoxil, and PMEA diphosphate.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/large/jm-2019-00175p_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00175&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In 1987, the pyrimidine counterpart of (<i>S</i>)-HPMPA, (<i>S</i>)-HPMPC [(<i>S</i>)-1-(3-hydroxy-2-phosphonomethoxypropyl)cytosine], was described as a broad-spectrum anti-DNA virus agent with an activity profile similar to that of (<i>S</i>)-HPMPA.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> After Gilead acquired the licensing rights on the whole family of the ANPs in 1991, it took them only 5 years to launch (<i>S</i>)-HPMPC (cidofovir, Vistide) (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>) in 1996 as the first ANP ever marketed by Gilead for the parenteral treatment of human cytomegalovirus (CMV) retinitis in AIDS patients. CMV retinitis was a severe infection of the eye (retina) leading to blindness that is no longer observed nowadays because of the efficient chemotherapy that in the meantime has been developed to treat HIV infection (AIDS). Cidofovir has been sublicensed by Gilead to Upjohn, then Pharmacia, and later to Pfizer. It has been used, off label, on a compassionate basis for the treatment of various DNA virus infections, including herpes-, adeno-, papilloma-, polyoma- and poxvirus infections [representative examples of the human papilloma virus (HPV) infections being laryngeal papillomatosis and genital warts and of the poxvirus infections being monkeypox and molluscum contagiosum].</div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/medium/jm-2019-00175p_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/large/jm-2019-00175p_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. (<i>S</i>)-HPMPC (cidofovir and (<i>S</i>)-HPMPC diphosphate.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/large/jm-2019-00175p_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00175&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div id="sec7_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> Comment</h3><div class="NLM_p last">When the choice had to be made for clinical development of (<i>S</i>)-HPMPA versus (<i>S</i>)-HPMPC, the latter was chosen because it had a more favorable safety profile in the initial toxicity studies. This, in turn, explains why (<i>S</i>)-HPMPC was later licensed for clinical use and why little or no attention was reserved for the possible clinical use of (<i>S</i>)-HPMPA in the treatment of DNA virus infections.</div></div></div><div id="sec8" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i14">Stavudine</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_07257" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_07257" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The first antiretroviral drug ever approved in the U.S. by the FDA was AZT (azidothymidine, zidovudine) in 1987. AZT is the prototype of the nucleoside reverse transcriptase (RT) inhibitors (NRTIs), which, following their intracellular phosphorylation to the triphosphorylated metabolite, act as chain terminators of their target enzyme RT. Following AZT, several other 2′,3′-dideoxynucleoside analogues were found at the NCI by Mitsuya and Broder<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> to inhibit the replication of HTLV-III. Two of these compounds, 2′,3′-dideoxyinosine (ddI, didanosine) and 2′,3′-dideoxycytidine (ddC, zalcitabine) would be commercialized by Bristol-Myers (now Bristol-Myers Squibb) for the treatment of HIV infections (zalcitabine is no longer used in medical practice). The fourth NRTI ever approved by the U.S. FDA as an anti-HIV drug, 2′,3′-dideoxy-2′,3′-didehydrothymidine (d4T), was first described in our laboratory at the Rega Institute in Leuven<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> and independently but several months later confirmed by Lin et al.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> at Yale University and Hamamoto et al.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> in Tokyo. The compound, meanwhile known as stavudine, was commercialized by Bristol-Myers Squibb under the trade name Zerit (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>). It would gain wide acceptance all over the world as an anti-HIV drug until it was superseded by the acyclic nucleoside phosphonate, tenofovir (vide infra).</div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/medium/jm-2019-00175p_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/large/jm-2019-00175p_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. d4T Stavudine and d4T 5′-triphosphate.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/large/jm-2019-00175p_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00175&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div id="sec8_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> Comment</h3><div class="NLM_p last">The discovery of AZT as inhibitor of HTLV-III/LAV replication<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> generated worldwide interest in many chemical laboratories, including our own, where it prompted Piet Herdewijn to synthesize several related thymidine analogues, including d4T. These compounds were sent for evaluation against HTLV-III/LAV to Sam Broder’s lab, which, using the ATH8 cell line, did not detect meaningful specificity in their activity against the virus (first few months of 1986). When Masanori Baba (in the second half of 1986) evaluated d4T for its activity against the AIDS virus (then called HIV), using the MT-4 cell line, he found remarkable activity.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a></div></div></div><div id="sec9" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i16">NNRTIs</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_18702" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_18702" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The original discovery of the non-nucleoside reverse transcriptase inhibitors (NNRTIs) dates from 1989 to 1990 when I described two seemingly unrelated classes of compounds, (i) the HEPT [1-[(2-hydroxyethoxy)methyl]-6-phenylthiothymine] derivatives<a onclick="showRef(event, 'ref47 ref48'); return false;" href="javascript:void(0);" class="ref ref47 ref48">(47,48)</a> and (ii) the TIBO [tetrahydroimidazo[4,5,1-<i>jk</i>][1,4]benzodiazepin-2(1<i>H</i>)-one] derivatives,<a onclick="showRef(event, 'ref49 ref50'); return false;" href="javascript:void(0);" class="ref ref49 ref50">(49,50)</a> which appeared to act as RT inhibitors by a mechanism (allosteric inhibition) that was totally different from that of the classical NRTIs.<a onclick="showRef(event, 'ref51 ref52'); return false;" href="javascript:void(0);" class="ref ref51 ref52">(51,52)</a></div><div class="NLM_p">The HEPT and TIBO derivatives could be regarded as the first NNRTIs, which, although they were themselves finally not marketed, gave rise to five compounds that were eventually commercialized for the treatment of HIV infections: nevirapine (Viramune), delavirdine (Rescriptor, later abandoned), efavirenz (Stocrin, Sustiva), etravirine (Intelence), and rilpivirine (Edurant). Of the HEPT derivatives, emivirine (Coactinon) (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>) proceeded to phase III clinical trials,<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> when its further development was halted mainly because of a too competitive market. The cumbersome chemical synthesis of the TIBO derivatives hampered their further clinical development but instead gave rise to the DAPYs that ultimately yielded etravirine, rilpivirine (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>) [which has become part of the cocktails with TDF and TAF (vide infra), and dapivirine, which has been pursued in a vaginal ring for HIV prevention in women.<a onclick="showRef(event, 'ref54 ref55'); return false;" href="javascript:void(0);" class="ref ref54 ref55">(54,55)</a></div><figure id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/medium/jm-2019-00175p_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/large/jm-2019-00175p_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. HEPT and emivirine.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/large/jm-2019-00175p_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00175&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/medium/jm-2019-00175p_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/large/jm-2019-00175p_0010.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. TIBO and rilpivirine.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/large/jm-2019-00175p_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00175&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">All NNRTIs, while structurally unrelated, behave conformationally as similar structures that could be described as a “butterfly” or “horseshoe”, and fit snugly within the non-nucleoside binding “pocket” site within the HIV-I reverse transcriptase located at some distance (10–15 Å) from the catalytic site.<a onclick="showRef(event, 'ref56 ref57 ref58'); return false;" href="javascript:void(0);" class="ref ref56 ref57 ref58">(56−58)</a> The conformational similarity between the HEPT derivatives (i.e., emivirine) and TIBO derivatives (i.e., tivirapine) had originally been suggested long before it was elaborated for all the other NNRTIs.<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a></div><div id="sec9_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> Comment</h3><div class="NLM_p last">The first NNRTIs ever discovered were the HEPT<a onclick="showRef(event, 'ref47 ref48'); return false;" href="javascript:void(0);" class="ref ref47 ref48">(47,48)</a> and TIBO<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> derivatives. From the HEPT analogues, emivirine was derived, which eventually was not marketed, and thus could be considered a failure in drug development. The TIBOs, however, through a process of judicious medicinal chemistry led by the late Dr. Paul Janssen, culminated in the identification of rilpivirine as an almost ideal anti-HIV drug.<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a> The compound was marketed as such and in combination with tenofovir disoproxil fumarate (TDF) and emtricitabine as Complera (U.S.)/Eviplera (EU) and in combination with tenofovir alafenamide (TAF) and emtricitabine as Odefsey for the treatment of HIV infections.</div></div></div><div id="sec10" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i18">Bicyclams, Plerixafor</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_07471" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_07471" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">In our search for new and more potent and selective anti-HIV agents, we discovered in 1992, totally unexpectedly, a totally new class of compounds, the bicyclams, as an impurity present in a commercial cyclam preparation obtained from the company Lancaster; the impurity itself could not be resynthesized, so at Johnson Matthey a program was started to synthesize bicyclams tethered by an aliphatic (propyl) linker. The compound thus obtained, JM2763, had reasonable anti-HIV activity, as published in a <i>Proc. Natl. Acad. Sci. U. S. A.</i> article sponsored by the Nobel laureate Max Perutz.<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a></div><div class="NLM_p">When, however, the aliphatic bridge between the two cyclam rings was replaced by a phenylbis(methylene) linker as in JM3100, the anti-HIV potency increased by 100-fold<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> [effective concentration being 1–10 nM; selectivity index of 100 000]. The target of action was initially thought to be the viral envelope glycoprotein gp120. It appeared only to be the indirect target. The direct target of action turned out to be the co-receptor CXCR4 used by T-lymphotropic HIV strains to enter the cells.<a onclick="showRef(event, 'ref63 ref64'); return false;" href="javascript:void(0);" class="ref ref63 ref64">(63,64)</a></div><div class="NLM_p">CXCR4 normally functions as the receptor for the chemokine SDF-1 (stromal derived factor -1) (now called CXCL12) and is involved in various physiopathological processes, one being the “homing” of hematopoietic stem cells (HSCs) to the bone marrow.</div><div class="NLM_p">When initial (phase I) clinical trials were undertaken with AMD3100 (new name for JM3100 after AnorMED had been founded) (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>) as a prelude to its development as a candidate anti-HIV drug, an unexpected side effect, an increase in the white blood cell (WBC) counts, was observed.<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a> On closer inspection, these WBCs appeared to be CD34<sup>+</sup> HSCs.<a onclick="showRef(event, 'ref66 ref67'); return false;" href="javascript:void(0);" class="ref ref66 ref67">(66,67)</a> And thus AMD3100 could be regarded as a stem cell mobilizer. The AMD3100 saga has been the subject of consecutive review articles.<a onclick="showRef(event, 'ref68 ref69 ref70 ref71 ref72'); return false;" href="javascript:void(0);" class="ref ref68 ref69 ref70 ref71 ref72">(68−72)</a></div><figure id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/medium/jm-2019-00175p_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/large/jm-2019-00175p_0011.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Bicyclam AMD3100, plerixafor.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/large/jm-2019-00175p_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00175&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">AMD3100 has, since December 2008, been formally approved by the U.S. FDA for autologous transplantation in patients with non-Hodgkin’s lymphoma (NHL) or multiple myeloma (MM). The compound is also known as plerixafor and marketed as Mozobil. AnorMED has in the meantime been taken over by Genzyme, which in turn has been incorporated into Sanofi. As a stem cell mobilizer, AMD3100 may be pursued for various other applications than it was originally intended for.<a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">(72)</a></div><div id="sec10_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> Comment</h3><div class="NLM_p last">The discovery of AMD3100 as a stem cell mobilizer should be viewed as the result of a few serendipitous events: it started with the identification of an impurity (“bicyclams”) in a monocyclam preparation, which appeared to be quite active against HIV, and upon further clinical studies, the compound appeared to cause an increase in the WBC counts, due to the mobilization of the hematopoietic stem cells from the bone marrow.</div></div></div><div id="sec11" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i20">(<i>R</i>)-PMPA (Tenofovir), Tenofovir Disoproxil Fumarate (TDF, Viread)</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_88776" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_88776" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">In 1993, we described two closely related derivatives of (<i>S</i>)-HPMPA called (<i>R</i>)-PMPA [(<i>R</i>)-9-(2-phosphonomethoxypropyl)adenine] and (<i>R</i>)-PMPDAP [(<i>R</i>)-9-(2-phosphonomethoxypropyl-2,6-diaminopurine].<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a> The DAP (2,6-diaminopurine) derivative was actually more potent than its adenine (6-aminopurine) counterpart, but the latter was chosen by Gilead Sciences for further clinical development. It was named tenofovir, and in its prodrug form, tenofovir disoproxil fumarate (TDF) (<a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>) became worldwide one of the best known antiretroviral drugs for the treatment of HIV infections. [Disoproxil stands for bis(isopropyloxycarbonyloxymethyl), the bis ester of (<i>R</i>)-PMPA that had been designed to ensure the oral bioavailability of (<i>R</i>)-PMPA<a onclick="showRef(event, 'ref74 ref75'); return false;" href="javascript:void(0);" class="ref ref74 ref75">(74,75)</a>].</div><figure id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/medium/jm-2019-00175p_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/large/jm-2019-00175p_0012.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. (<i>R</i>)-PMPA (tenofovir), tenofovir disoproxil fumarate (TDF), (<i>R</i>)-PMPA diphosphate.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/large/jm-2019-00175p_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00175&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div id="sec11_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> Comment</h3><div class="NLM_p">(<i>R</i>)-PMPA, rather than (<i>R</i>)-PMDAP, was chosen for clinical development for the simple reason that the adenine was a natural base, whereas the 2,6-diaminopurine (DAP) was not, and it was felt that if nature had selected adenine over DAP, there must have been a good reason for it (i.e., mutagenicity).</div><div class="NLM_p last">In retrospect, a decisive observation was made in 1995 by Tsai and his colleagues,<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a> who demonstrated that (<i>R</i>)-PMPA could completely prevent the infection of simian immunodeficiency virus (SIV) in monkeys, whereas AZT, tested in parallel, only slightly did so. At the time this paper was published in <i>Science</i> (November 17, 1995), it could hardly be foreseen that 17 years later, on July 16, 2012, exactly the same day that Antonı́n Holý died, the U.S. FDA would approve, as the first chemical ever, Truvada, or the combination of TDF with emtricitabine, for the prophylaxis of HIV infections.</div></div><div id="sec11_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> Comment</h3><div class="NLM_p">The observations of Tsai et al.<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a> laid the basis for the use of the combination of TDF and emtricitabine in the pre-exposure prophylaxis (PrEP) of HIV infections, as formally approved in 2012 in the U.S. and 4 years later in the EU.</div><div class="NLM_p">Tenofovir disoproxil fumarate (TDF) was approved by the U.S. FDA in 2001 for the treatment of HIV infections and in 2008 for the treatment of HBV infections. After it had been approved (<a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>) for the prevention of HIV infections in the U.S. in 2012, it was also approved on August 22, 2016, in the EU for what is now commonly referred to as PrEP (pre-exposure prophylaxis) of HIV infections. Among African women, tenofovir-based prophylaxis did not appear to significantly reduce the rate of HIV infections [FEM-PrEP study;<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a> VOICE study<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a>], but the negative outcome of these studies could be attributed to the low drug adherence.</div><figure id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/medium/jm-2019-00175p_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/large/jm-2019-00175p_0013.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Tenofovir disoproxil fumarate (TDF) (<a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>) and (−)FTC (emtricitabine).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/large/jm-2019-00175p_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00175&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec12" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i23">TDF as Cornerstone of Anti-HIV Drug Combinations</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_26328" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_26328" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">After the combination of TDF and emtricitabine had been approved by the U.S. FDA in 2004 for the treatment of HIV infections, there followed in 2006 Atripla (<a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>) (combination of TDF with emtricitabine and efavirenz), in 2011 Complera (U.S.) and Eviplera (EU) (combination of TDF with emtricitabine and rilpivirine) (<a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>), and in 2012 the quadruple drug combination of TDF, emtricitabine, elvitegravir, and cobicistat (Stribild) (<a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a></a>), all for the treatment of HIV infections.</div><figure id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/medium/jm-2019-00175p_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/large/jm-2019-00175p_0014.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. Tenofovir disoproxil fumarate (TDF) (<a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>), (−)FTC (emtricitabine) (<a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>), and efavirenz.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/large/jm-2019-00175p_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00175&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig15" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/medium/jm-2019-00175p_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/large/jm-2019-00175p_0015.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Tenofovir disoproxil fumarate (TDF) (<a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>), (−)FTC (emtricitabine) (<a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>), and rilpivirine.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/large/jm-2019-00175p_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00175&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig16" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/medium/jm-2019-00175p_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/large/jm-2019-00175p_0016.jpeg" id="gr16" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. Tenofovir disoproxil fumarate (TDF) (<a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>), (−)FTC (emtricitabine) (<a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>), elvitegravir, and cobicistat.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/large/jm-2019-00175p_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00175&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec13" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i24">Tenofovir Alafenamide (TAF): Successor of TDF in Anti-HIV Combinations</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_34208" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_34208" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Provisions were taken from 2015 to replace tenofovir disoproxil by another prodrug of tenofovir, tenofovir alafenamide (TAF), which by Gilead scientists (Lee et al.)<a onclick="showRef(event, 'ref79'); return false;" href="javascript:void(0);" class="ref ref79">(79)</a> had been shown to be preferentially taken up by the lymphatic tissue and, as shown by Birkus et al.,<a onclick="showRef(event, 'ref80'); return false;" href="javascript:void(0);" class="ref ref80">(80)</a> by liver cells as well. Thus, the marketed drug for TDF was replaced by Vemlidy (<a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">17</a></a>) in 2016 for the treatment of both HIV and HBV infections; it was approved in the U.S. on November 10, 2016, in Japan on December 19, 2016, and in the EU on January 11, 2017. The quad tablet that combined elvitegravir, cobicistat, emtricitabine, and TDF (<a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a></a>) was replaced by Genvoya (<a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">18</a></a>) (combination of TAF, emtricitabine, elvitegravir, and cobicistat) for the treatment of HIV infections; it was approved in the U.S. on November 5, 2015, and in the EU on November 23, 2015. Then followed approval of Descovy (combination of TAF with emtricitabine) (<a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">19</a></a>) on April 4, 2016 (U.S.) and April 25, 2016 (EU), Odefsey (combination of TAF, emtricitabine, and rilpivirine) (<a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">20</a></a>) on March 1, 2016 (U.S.) and April 29, 2016 (EU), Biktarvy (combination of TAF, emtricitabine and bictegravir) (<a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">21</a></a>) on February 7, 2018 (U.S.) and April 27, 2018 (EU), and Symtuza (combination of TAF, emtricitabine, darunavir, and cobicistat) (<a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">22</a></a>) on September 26, 2017 (EU) and July 17, 2018 (U.S.), all for the treatment of HIV infections. Whether the combination of TAF with emtricitabine (<a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">19</a></a>), akin to the combination of TDF with emtricitabine (<a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>), or any of the other TAF-based drug regimens might ever replace the drug based on the combination of TDF with emtricitabine (<a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>) in the prophylaxis (PrEP) of HIV infections needs to be further explored.</div><figure id="fig17" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/medium/jm-2019-00175p_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/large/jm-2019-00175p_0017.jpeg" id="gr17" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 17. Tenofovir alafenamide (TAF).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/large/jm-2019-00175p_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00175&amp;id=fig17"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig18" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 18</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/medium/jm-2019-00175p_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/large/jm-2019-00175p_0018.jpeg" id="gr18" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 18. Tenofovir alafenamide (TAF) (<a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">17</a></a>), (−)FTC (emtricitabine (<a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>), elvitegravir (<a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a></a>), and cobicistat (<a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a></a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/large/jm-2019-00175p_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00175&amp;id=fig18"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig19" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Figure 19</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/medium/jm-2019-00175p_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/large/jm-2019-00175p_0019.jpeg" id="gr19" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 19. Tenofovir alafenamide (TAF) (<a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">17</a></a>) and (−)FTC (emtricitabine) (<a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/large/jm-2019-00175p_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00175&amp;id=fig19"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig20" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Figure 20</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/medium/jm-2019-00175p_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/large/jm-2019-00175p_0020.jpeg" id="gr20" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 20. Tenofovir alafenamide (TAF) (<a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">17</a></a>), (−)FTC (emtricitabine) (<a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>), and rilpivirine (<a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/large/jm-2019-00175p_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00175&amp;id=fig20"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig21" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Figure 21</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/medium/jm-2019-00175p_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/large/jm-2019-00175p_0021.jpeg" id="gr21" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 21. Tenofovir alafenamide (TAF) (<a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">17</a></a>), (−)FTC (emtricitabine) (<a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>), and bictegravir (BIC).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/large/jm-2019-00175p_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00175&amp;id=fig21"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig22" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Figure 22</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/medium/jm-2019-00175p_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/large/jm-2019-00175p_0022.jpeg" id="gr22" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 22. Tenofovir alafenamide (TAF) (<a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">17</a></a>), (−)FTC (emtricitabine) (<a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>), darunavir, and cobicistat (<a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a></a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/large/jm-2019-00175p_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00175&amp;id=fig22"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">With the current TAF-based drug combinations, we now have at hand a series of anti-HIV therapeutics (i.e., see <a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">18</a></a>, <a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">20</a>, <a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">21</a>, and <a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">22</a>) that fulfill the requirements for the optimal treatment of HIV infections, a single oral pill per day, which combines efficiency with safety, tolerability, and the quasi lack of resistance development.</div><div id="sec13_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> Comment</h3><div class="NLM_p last">The use of drug combination therapy based on either TDF or TAF in the treatment of HIV infections is reminiscent of the strategy that has, since half a century, been followed for the treatment of tuberculosis (TB), that is, combination therapy of isoniazid, rifampicin, and pyrazinamide (with or without ethambutol). The goals are the same: (i) to reduce the individual dosages so as to maximize tolerability, (ii) to stimulate synergism between compounds interacting at different molecular targets, and (iii) to minimize the risk for resistance development.</div></div></div><div id="sec14" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i26">Rabacfosadine</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_77105" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_77105" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Among the first ANPs ever described for their antiviral properties was also featured PMEG [9-(2-phosphonomethoxyethylguanine].<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> However, the compound was considered to be too cytotoxic for further development as a potential antiviral drug. Instead, John C. Martin and his colleagues at Gilead Sciences found it more active than (<i>S</i>)-HPMPA and PMEA in inhibiting P388 leukemia in mice.<a onclick="showRef(event, 'ref81'); return false;" href="javascript:void(0);" class="ref ref81">(81)</a> We then found a prodrug of PMEG, cPr-PMEDAP [9-(2-phosphonomethoxyethyl)-<i>N</i><sup>6</sup>-cyclopropyl-2,6-diaminopurine], to block choriocarcinoma in rats.<a onclick="showRef(event, 'ref82'); return false;" href="javascript:void(0);" class="ref ref82">(82)</a> Apparently, cPr-PMEDAP would be converted to PMEG through the same enzyme converting abacavir 5′-monophosphate to carbovir 5′-monophosphate.<a onclick="showRef(event, 'ref83'); return false;" href="javascript:void(0);" class="ref ref83">(83)</a></div><div class="NLM_p">When further equipped with a phosphonoamidate moiety to increase the efficiency of lymphoid cell loading, a proprodrug of PMEG was obtained, namely, GS-9219 (diethyl <i>N</i>,<i>N</i>′-[({2-[2-amino-6-(cyclopropylamino)-9<i>H</i>-purin-9-yl]ethoxy}methyl)phosphonoyl]di-<span class="smallcaps smallerCapital">l</span>-alaninate).<a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(84)</a> This compound would later also be known as VDC-1101 and rabacfosadine. It was shown by Reiser et al.<a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(84)</a> to be exquisitely effective in the treatment of non-Hodgkin’s lymphoma (NHL) in dogs, and after being sublicensed by Gilead Sciences to VetDC, it was (conditionally) approved in 2017 by the U.S. FDA for the treatment of lymphoma in dogs. The compound is marketed as Tanovea (<a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">23</a></a>) by VetDC. It acts as a proprodrug of PMEG, and its eventual active metabolite is the diphosphate of PMEG (PMEGpp), which inhibits DNA synthesis in direct competition with the natural substrate dGTP.<a onclick="showRef(event, 'ref85'); return false;" href="javascript:void(0);" class="ref ref85">(85)</a></div><figure id="fig23" data-index="23" class="article__inlineFigure"><h2 class="fig-label">Figure 23</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/medium/jm-2019-00175p_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/large/jm-2019-00175p_0023.jpeg" id="gr23" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 23. GS-9219 (rabacfosadine), cPr-PMEDAP, PMEG, and PMEG diphosphate.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/large/jm-2019-00175p_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00175&amp;id=fig23"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div id="sec14_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> Comment</h3><div class="NLM_p last">GS-9219 was originally pursued for its potential in the treatment of NHL in humans. The rationale behind it was its preferential activity against tumors of the lymphoid system. Veterinary use (in the treatment of NHL in dogs) has been given higher priority than its potential medical use.</div></div></div><div id="sec15" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i28">Bicyclic Nucleoside Analogues (BCNAs): Cf1743, FV100</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_33724" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_33724" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The bicyclic nucleoside analogues [prototype Cf1743 (Cf standing for Cardiff)] were first described by McGuigan et al.<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a> They are called bicyclic because they contain a furan ring condensed with a pyrimidine ring mounted on a 2-deoxyribose. The unique feature of Cf1743 is that it is specifically active against VZV and not any other viruses, not even HSV-1 (unlike BVDU), but against VZV, and it is still the most potent inhibitor that has ever been discovered.<a onclick="showRef(event, 'ref87'); return false;" href="javascript:void(0);" class="ref ref87">(87)</a> Its mechanism of action has only partly been resolved. For its anti-VZV activity it strictly depends on the viral thymidine kinase (TK), as TK-negative mutants are not sensitive to the inhibitory activity of the compound.<a onclick="showRef(event, 'ref88'); return false;" href="javascript:void(0);" class="ref ref88">(88)</a> Unlike BVDU, it cannot be cleaved at its <i>N</i>-glycosidic linkage by (pyrimidine) phosphorylase(s) so that it would not interfere with the degradation of FU (5-fluorouracil), which (as has been shown for BVaraU) would otherwise increase the toxicity of FU (and its derivatives). FV-100 (FV standing for Fermavir), the 5′-valine ester of Cf1743 (<a data-tab="pane-pcw-Figures" href="#fig24" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig24" id="" class=" internalNav">24</a></a>), has been designed to increase the oral bioavailability of Cf1743<a onclick="showRef(event, 'ref89'); return false;" href="javascript:void(0);" class="ref ref89">(89)</a>). FV-100 has been the subject of a phase II clinical trial in patients with herpes zoster;<a onclick="showRef(event, 'ref90'); return false;" href="javascript:void(0);" class="ref ref90">(90)</a> the promising results obtained in this trial suggested that follow-up studies were warranted, but these have, to the best of my knowledge, not been divulged or published (so far).</div><figure id="fig24" data-index="24" class="article__inlineFigure"><h2 class="fig-label">Figure 24</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/medium/jm-2019-00175p_0024.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/large/jm-2019-00175p_0024.jpeg" id="gr24" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 24. Cf1743 and FV100 (5′-valine ester of Cf1743).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/large/jm-2019-00175p_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00175&amp;id=fig24"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div id="sec15_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> Comment</h3><div class="NLM_p last">FV100 suffers in its further development from the same problem that has also hampered the wide application of BVDU, that is, that its activity is restricted to VZV (while BVDU also covers HSV-1), and for big pharmaceutical internationals this is often regarded as too small a market, certainly when the compound has to be given for a short period of time (i.e., herpes zoster) and cannot be extended to a larger patient population (HSV-1 and HSV-2 infections).</div></div></div><div id="sec16" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i30">ANPs That Deserve Further Exploration</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_05002" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_05002" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">From the PMEG prodrug cPrPMEDAP, two prodrugs were developed, termed GS-9191 and GS-9219, respectively, which could thus be regarded as “proprodrugs” of PMEG. GS-9219 (<a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">23</a></a>) has in the meantime been marketed for the treatment of non-Hodgkin’s lymphoma in dogs, whereas GS-9191 (<a data-tab="pane-pcw-Figures" href="#fig25" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig25" id="" class=" internalNav">25</a></a>) was further pursued for its potential usefulness in the topical treatment of genital warts.<a onclick="showRef(event, 'ref91'); return false;" href="javascript:void(0);" class="ref ref91">(91)</a> How GS-9191 eventually fared is at present unclear.</div><figure id="fig25" data-index="25" class="article__inlineFigure"><h2 class="fig-label">Figure 25</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/medium/jm-2019-00175p_0025.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/large/jm-2019-00175p_0025.jpeg" id="gr25" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 25. Acyclic nucleoside phosphonates deserving further exploration.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/large/jm-2019-00175p_0025.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00175&amp;id=fig25"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">A new class of ANPs, that of the O-DAPys, {6-[2-(phosphonomethoxy)alkoxy]-2,4-diaminopyrimidines, with (<i>R</i>)-HPMPO-DAPy, PMEO-DAPy, and (<i>R</i>)-PMPO-DAPy (<a data-tab="pane-pcw-Figures" href="#fig25" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig25" id="" class=" internalNav">25</a></a>) as the prototypes, was introduced by Holý and his colleagues in 2002.<a onclick="showRef(event, 'ref92 ref93'); return false;" href="javascript:void(0);" class="ref ref92 ref93">(92,93)</a> (<i>R</i>)-HPMPO-DAPy showed a similar spectrum of activity as cidofovir (and should have been further explored for its potential in the treatment of herpes-, polyoma-, papilloma-, adeno-, and poxvirus infections), whereas PMEO-DAPy and (<i>R</i>)PMPO-DAPy deserved further attention for their potential in the treatment of HIV and HBV infections.<a onclick="showRef(event, 'ref94'); return false;" href="javascript:void(0);" class="ref ref94">(94)</a> What makes the O-DAPys so attractive from a mechanistic viewpoint is that, being pyrimidine derivatives, they behave as purine nucleotide mimetics in inhibiting the DNA polymerase (i.e., reverse transcriptase) reaction.</div><div class="NLM_p">Following an old tradition at the Institute of Organic Chemistry and Biochemistry (IOCB), Holý and his colleagues also synthesized the triazine counterpart of (<i>S</i>)-HPMPC, 5-aza-(<i>S</i>)-HPMPC.<a onclick="showRef(event, 'ref95 ref96'); return false;" href="javascript:void(0);" class="ref ref95 ref96">(95,96)</a> Although 5-aza-(<i>S</i>)-HPMPC (<a data-tab="pane-pcw-Figures" href="#fig25" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig25" id="" class=" internalNav">25</a></a>) had some favorable pharmacological advantages over (<i>S</i>)-HPMPC,<a onclick="showRef(event, 'ref97'); return false;" href="javascript:void(0);" class="ref ref97">(97)</a> neither 5-aza-(<i>S</i>)-HPMPC nor its alkoxyalkyl prodrugs have heretofore been further pursued for their therapeutic potential.</div><div id="sec16_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> Comment</h3><div class="NLM_p last">Whether any of the new ANPs originating from Dr. Holý’s legacy will ever be developed in human or veterinary medicine will depend on a number of factors, including the specific advantages over the established ANPs and/or the new needs that may eventually emerge in the future.</div></div></div><div id="sec17" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i32">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_51662" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_51662" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">The compounds reviewed here have been approved (and marketed) for the treatment of HSV infections (valacyclovir), VZV infections (BVDU), CMV infections (cidofovir), HBV infections (adefovir dipivoxil, TDF, TAF), and HIV infections (stavudine, TDF, TAF). For the treatment of HIV infections, TDF has also been launched in several drug combinations (<a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>–<a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a>) and so has been TAF (<a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">18</a></a>–<a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">22</a>). The combination of TDF and emtricitabine is the only “chemical” approved for the pre-exposure prophylaxis (PrEP) of HIV infections. In addition, plerixafor (AMD3100, <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>) has been approved as a stem cell mobilizer in the autologous transplantation of non-Hodgkin’s lymphoma (NHL) and multiple myeloma (MM), and rabacfosadine (<a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">23</a></a>) is marketed for the treatment of NHL in dogs.</div></div><div class="NLM_back"><div class="article_supporting-info" id=""></div><div class="testing" data-doi="10.1021/acs.jmedchem.9b00175" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_57334" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_57334" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Erik De Clercq</span> - <span class="hlFld-Affiliation affiliation">Department of Microbiology and Immunology,
Rega Institute for Medical Research, KU
Leuven, Herestraat 49, 3000 Leuven, Belgium</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-2985-8890" title="Orcid link">http://orcid.org/0000-0002-2985-8890</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#4b2e392220652f2e28272e39283a0b203e272e3e3d2e2565292e"><span class="__cf_email__" data-cfemail="95f0e7fcfebbf1f0f6f9f0e7f6e4d5fee0f9f0e0e3f0fbbbf7f0">[email protected]</span></a></span></div></li></ul></li><li><ul></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The author declares no competing financial interest.<br /></br></div></li></ul></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i33">Biography</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_81713" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_81713" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="26" class="article__inlineFigure"><h2 class="fig-label">Erik De Clercq</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00175&amp;id=BIO-d7e1406-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Erik De Clercq</b>, since 2007 (until present), has been teaching the course “Chemistry at the Service of Medicine” at the Faculty of Sciences at the University of South Bohemia (České Budějovice, Czech Republic) in a joint program with Keppler University (Linz, Austria). He received in 2010 jointly with Dr. Anthony S. Fauci the Dr. Paul Janssen Award for Biomedical Research. He has (co)discovered a number of antiviral drugs currently used in the treatment of HSV (valaciclovir), VZV (brivudin), CMV (cidofovir), HBV [adefovir dipivoxil, tenofovir disoproxil fumarate (TDF), and tenofovir alafenamide (TAF)], and HIV infections (TDF, TAF). The combination of TDF with emtricitabine (Truvada) has been approved worldwide for the prophylaxis of HIV infections (PrEP).</p></figure></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i34">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_33880" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_33880" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">I thank Myriam Cornelis for her proficient editorial assistance.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">ACV</td><td class="NLM_def"><p class="first last">acyclovir</p></td></tr><tr><td class="NLM_term">AMD</td><td class="NLM_def"><p class="first last">AnorMeD</p></td></tr><tr><td class="NLM_term">AZT</td><td class="NLM_def"><p class="first last">azidothymidine</p></td></tr><tr><td class="NLM_term">BVDU</td><td class="NLM_def"><p class="first last">(<i>E</i>)-5-(2-bromovinyl)-2′-deoxyuridine</p></td></tr><tr><td class="NLM_term">CMV</td><td class="NLM_def"><p class="first last">cytomegalovirus</p></td></tr><tr><td class="NLM_term">cPrPMEDAP</td><td class="NLM_def"><p class="first last">9-(2-phosphonylmethoxyethyl)-<i>N</i>(6)-cyclopropyl-2,6,diaminopurine</p></td></tr><tr><td class="NLM_term">d4T</td><td class="NLM_def"><p class="first last">2′,3′-dideoxy-2′,3′-didehydrothymidine</p></td></tr><tr><td class="NLM_term">DAP</td><td class="NLM_def"><p class="first last">2,6-diaminopurine</p></td></tr><tr><td class="NLM_term">ddC</td><td class="NLM_def"><p class="first last">zalcitabine</p></td></tr><tr><td class="NLM_term">ddI</td><td class="NLM_def"><p class="first last">didanosine</p></td></tr><tr><td class="NLM_term">DHPA</td><td class="NLM_def"><p class="first last"><i>S</i>-9-(2,3-dihydroxypropyl)adenine</p></td></tr><tr><td class="NLM_term">(−)FTC</td><td class="NLM_def"><p class="first last">(−)5-fluoro-3′-thiacytidine</p></td></tr><tr><td class="NLM_term">HBV</td><td class="NLM_def"><p class="first last">hepatitis B virus</p></td></tr><tr><td class="NLM_term">HEPT</td><td class="NLM_def"><p class="first last">1-[(2-hydroxyethoxy)methyl]-6-phenylthiothymine</p></td></tr><tr><td class="NLM_term">HIV</td><td class="NLM_def"><p class="first last">human immunodeficiency virus</p></td></tr><tr><td class="NLM_term">HSV</td><td class="NLM_def"><p class="first last">herpes simplex virus</p></td></tr><tr><td class="NLM_term">MM</td><td class="NLM_def"><p class="first last">multiple myeloma</p></td></tr><tr><td class="NLM_term">NHL</td><td class="NLM_def"><p class="first last">non-Hodgkin’s lymphoma</p></td></tr><tr><td class="NLM_term">NNRTI</td><td class="NLM_def"><p class="first last">non-nucleoside reverse transcriptase inhibitors</p></td></tr><tr><td class="NLM_term">NRTI</td><td class="NLM_def"><p class="first last">nucleoside reverse transcriptase inhibitor</p></td></tr><tr><td class="NLM_term">PMEA</td><td class="NLM_def"><p class="first last">9-(2-phosphonomethoxyethyl)adenine</p></td></tr><tr><td class="NLM_term">PMEG</td><td class="NLM_def"><p class="first last">9-(2-phosphonomethoxyethylguanine</p></td></tr><tr><td class="NLM_term">(<i>R</i>)-PMPA</td><td class="NLM_def"><p class="first last">(<i>R</i>)-9-(2-phosphonomethoxypropyl)adenine</p></td></tr><tr><td class="NLM_term">(<i>R</i>)-PMPDAP</td><td class="NLM_def"><p class="first last">(<i>R</i>)-9-(2-phosphonomethoxypropyl-2,6-diaminopurine</p></td></tr><tr><td class="NLM_term">(<i>S</i>)-HPMPA</td><td class="NLM_def"><p class="first last">(<i>S</i>)-9-(3-hydroxy-2-phosphonomethoxypropyl)adenine</p></td></tr><tr><td class="NLM_term">(<i>S</i>)-HPMPC</td><td class="NLM_def"><p class="first last">(<i>S</i>)-1-(3-hydroxy-2-phosphonomethoxypropyl)cytosine</p></td></tr><tr><td class="NLM_term">TAF</td><td class="NLM_def"><p class="first last">tenofovir alafenamide</p></td></tr><tr><td class="NLM_term">TDF</td><td class="NLM_def"><p class="first last">tenofovir disoproxil fumarate</p></td></tr><tr><td class="NLM_term">TIBO</td><td class="NLM_def"><p class="first last">tetrahydroimidazo[4,5,1-<i>jk</i>][1,4]benzodiazepin-2(1<i>H</i>)-one</p></td></tr><tr><td class="NLM_term">VACV</td><td class="NLM_def"><p class="first last">valacyclovir</p></td></tr><tr><td class="NLM_term">VZV</td><td class="NLM_def"><p class="first last">varicella-zoster virus</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i36">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_81151" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_81151" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 97 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Isaacs, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindenmann, J.</span></span> <span> </span><span class="NLM_article-title">Virus interference. I. The interferon</span>. <i>Proc. R. Soc. London, Ser. B</i> <span class="NLM_year" style="font-weight: bold;">1957</span>,  <span class="NLM_volume"><i>147</i></span>,  <span class="NLM_fpage">258</span>– <span class="NLM_lpage">267</span>, <span class="refDoi"> DOI: 10.1098/rspb.1957.0048</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1098%2Frspb.1957.0048" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=13465720" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A280%3ADyaG1c%252FgvVekuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=147&publication_year=1957&pages=258-267&author=A.+Isaacsauthor=J.+Lindenmann&title=Virus+interference.+I.+The+interferon&doi=10.1098%2Frspb.1957.0048"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Virus interference. I. The interferon</span></div><div class="casAuthors">ISAACS A; LINDENMANN J</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the Royal Society of London. Series B, Biological sciences</span>
        (<span class="NLM_cas:date">1957</span>),
    <span class="NLM_cas:volume">147</span>
        (<span class="NLM_cas:issue">927</span>),
    <span class="NLM_cas:pages">258-67</span>
        ISSN:<span class="NLM_cas:issn">0950-1193</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSHJGGj_jKWF5otVjB3IRIyfW6udTcc2eYyj93CkgST_rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaG1c%252FgvVekuw%253D%253D&md5=c8c357491601f40e87ee3d2bc5ed49c0</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1098%2Frspb.1957.0048&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1098%252Frspb.1957.0048%26sid%3Dliteratum%253Aachs%26aulast%3DIsaacs%26aufirst%3DA.%26aulast%3DLindenmann%26aufirst%3DJ.%26atitle%3DVirus%2520interference.%2520I.%2520The%2520interferon%26jtitle%3DProc.%2520R.%2520Soc.%2520London%252C%2520Ser.%2520B%26date%3D1957%26volume%3D147%26spage%3D258%26epage%3D267%26doi%3D10.1098%2Frspb.1957.0048" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De Somer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Billiau, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schonne, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Claesen, M.</span></span> <span> </span><span class="NLM_article-title">Antiviral activity of polyacrylic and polymethacrylic acids: I. Mode of action in vitro</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">1968</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">878</span>– <span class="NLM_lpage">885</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=4302187" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADyaF1cXkslCksL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=1968&pages=878-885&author=P.+De+Somerauthor=E.+De+Clercqauthor=A.+Billiauauthor=E.+Schonneauthor=M.+Claesen&title=Antiviral+activity+of+polyacrylic+and+polymethacrylic+acids%3A+I.+Mode+of+action+in+vitro"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Antiviral activity of polyacrylic and polymethacrylic acids.  I.  Mode of action in vitro</span></div><div class="casAuthors">De Somer, P.; De Clercq, E.; Billiau, A.; Schonne, E.; Claesen, M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">1968</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">878-85</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    </div><div class="casAbstract">Polyacrylic acid (PAA) and polymethacrylic acid (PMAA) were investigated for their antiviral properties in tissue culture.  Compared to other related polyanions, as dextran sulfate, polystyrene sulfonate, polyvinyl sulfate, and polyphloroglucinol phosphate, PAA and PMAA were more antivirally active and less cytotoxic.  PMAA added 24 hrs. prior to virus inoculation inhibited viral growth most efficiently, but it was also effective when added 3 hrs. after infection.  Neither a direct irreversible action on the virus nor inhibition of virus penetration into the cell could explain the antiviral activity of PMAA.  PMAA inhibited the adsorption of the virus to the host cell and suppressed the one-cycle viral synthesis in tissue cultures inoculated with infectious RNA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJi6VIR5HcoLVg90H21EOLACvtfcHk0ljIwHJnIg49vw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF1cXkslCksL4%253D&md5=88a60981c861fc88ca6113b8751b7a8f</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BSomer%26aufirst%3DP.%26aulast%3DDe%2BClercq%26aufirst%3DE.%26aulast%3DBilliau%26aufirst%3DA.%26aulast%3DSchonne%26aufirst%3DE.%26aulast%3DClaesen%26aufirst%3DM.%26atitle%3DAntiviral%2520activity%2520of%2520polyacrylic%2520and%2520polymethacrylic%2520acids%253A%2520I.%2520Mode%2520of%2520action%2520in%2520vitro%26jtitle%3DJ.%2520Virol.%26date%3D1968%26volume%3D2%26spage%3D878%26epage%3D885" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De Somer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Billiau, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schonne, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Claesen, M.</span></span> <span> </span><span class="NLM_article-title">Antiviral activity of polyacrylic and polymethacrylic acids: II. Mode of action in vivo</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">1968</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">886</span>– <span class="NLM_lpage">893</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=5725320" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADyaF1cXkslGntbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=1968&pages=886-893&author=P.+De+Somerauthor=E.+De+Clercqauthor=A.+Billiauauthor=E.+Schonneauthor=M.+Claesen&title=Antiviral+activity+of+polyacrylic+and+polymethacrylic+acids%3A+II.+Mode+of+action+in+vivo"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Antiviral activity of polyacrylic and polymethacrylic acids.  II.  Mode of action in vivo</span></div><div class="casAuthors">De Somer, P.; De Clercq, E.; Billiau, A.; Schonne, E.; Claesen, M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">1968</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">886-93</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    </div><div class="casAbstract">A marked virus-inhibiting potency is obtained in the serum after i.p. injection of poly(acrylic acid) (PAA) and poly(methacrylic acid) (PMAA) in mice.  Much higher antiviral levels were reached than for other related polymers including dextran sulfate, heparin, poly(vinyl sulfate), pyran copolymer, poly(styrenesulfonate), and macrodex.  The broad antiviral action of PAA and PMAA was attributed both to a direct interference with the virus-cell interaction and the viral RNA metabolism and to the formation of an interferon-like factor.  Both polyanions differed in interferon-inducing ability: highest serum interferon titer was obtained 18 hrs. after the i.p. injection of PAA.  The mechanism of interferon production by PAA and PMAA is discussed.  As described previously for Sindbis virus and endotoxin, the animals also became hyporeactive after injection of PAA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXYc-KBQopz7Vg90H21EOLACvtfcHk0ljIwHJnIg49vw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF1cXkslGntbg%253D&md5=d3ab37fb7cc556ea3931f81ddbb40aff</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BSomer%26aufirst%3DP.%26aulast%3DDe%2BClercq%26aufirst%3DE.%26aulast%3DBilliau%26aufirst%3DA.%26aulast%3DSchonne%26aufirst%3DE.%26aulast%3DClaesen%26aufirst%3DM.%26atitle%3DAntiviral%2520activity%2520of%2520polyacrylic%2520and%2520polymethacrylic%2520acids%253A%2520II.%2520Mode%2520of%2520action%2520in%2520vivo%26jtitle%3DJ.%2520Virol.%26date%3D1968%26volume%3D2%26spage%3D886%26epage%3D893" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Merigan, T.</span></span> <span> </span><span class="NLM_article-title">Induction of circulating interferon by synthetic anionic polymers of known composition</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1967</span>,  <span class="NLM_volume"><i>214</i></span>,  <span class="NLM_fpage">416</span>– <span class="NLM_lpage">417</span>, <span class="refDoi"> DOI: 10.1038/214416a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1038%2F214416a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=6032855" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADyaF2sXktV2rsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=214&publication_year=1967&pages=416-417&author=T.+Merigan&title=Induction+of+circulating+interferon+by+synthetic+anionic+polymers+of+known+composition&doi=10.1038%2F214416a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Induction of circulating interferon by synthetic anionic polymers of known composition</span></div><div class="casAuthors">Merigan, Thomas C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">1967</span>),
    <span class="NLM_cas:volume">214</span>
        (<span class="NLM_cas:issue">5086</span>),
    <span class="NLM_cas:pages">416-17</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    </div><div class="casAbstract">Maleic anhydride-divinyl ether copolymer (I) injected into mice at 75-500 mg./kg. (i.v. or i.p.) induced the formation of interferon (II) (mol. wt. 70,000; 100-257 units/4 ml.) at peak levels 18 hrs. after injection.  Other structural variations (14) of the maleic acid copolymer were also tested, and those of 40-1250 × 106 mol. wt. were less active and required higher doses to achieve full responses.  Maleic anhydridevinyl Me ether and maleic anhydride-vinyl acetate copolymers could not be distinguished from I in their activities, but the introduction of styrene side chains practically abolished II-inducing ability and increased the toxicity of the copolymer.  Up to 50% Me esterification of the carboxyl group did not block II-inducing capacity, but amidation to the same extent somewhat decreased it.  The most inactive of the polymers, maleic anhydride-vinyl Me ether (50% amidated), was a thick gel and probably did not reach the receptor site.  The serum II produced by these anionic copolymers resembled that produced by statolon in mol. wt. and pattern of production, although the levels produced by the latter were 3-8-fold greater.  The failure of these compds. to be metabolized by the animal, which could lead to their deposition in the reticuloendothelial system, is the major drawback against the therapeutic use of such compds.  19 references.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0pF6GWWCvbLVg90H21EOLACvtfcHk0ljIwHJnIg49vw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF2sXktV2rsb8%253D&md5=3de06a4b45c1bb421df859edb0a7bbbb</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2F214416a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F214416a0%26sid%3Dliteratum%253Aachs%26aulast%3DMerigan%26aufirst%3DT.%26atitle%3DInduction%2520of%2520circulating%2520interferon%2520by%2520synthetic%2520anionic%2520polymers%2520of%2520known%2520composition%26jtitle%3DNature%26date%3D1967%26volume%3D214%26spage%3D416%26epage%3D417%26doi%3D10.1038%2F214416a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Merigan, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Regelson, W.</span></span> <span> </span><span class="NLM_article-title">Interferon induction in man by a synthetic polyanion of defined composition</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">1967</span>,  <span class="NLM_volume"><i>277</i></span>,  <span class="NLM_fpage">1283</span>– <span class="NLM_lpage">1287</span>, <span class="refDoi"> DOI: 10.1056/NEJM196712142772403</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1056%2FNEJM196712142772403" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=6073272" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADyaF1cXivVChsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=277&publication_year=1967&pages=1283-1287&author=T.+C.+Meriganauthor=W.+Regelson&title=Interferon+induction+in+man+by+a+synthetic+polyanion+of+defined+composition&doi=10.1056%2FNEJM196712142772403"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Interferon induction in man by a synthetic polyanion of defined composition</span></div><div class="casAuthors">Merigan, Thomas C.; Regelson, William</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">1967</span>),
    <span class="NLM_cas:volume">277</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">1283-7</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    </div><div class="casAbstract">Ten patients with advanced cancer not amenable to other forms of therapy received pyran copolymer.  A single i.v. injection of pyran at a dose level of 12 mg./kg. produced antiviral activity in the serum of only 1 of 4 patients, but higher doses (15-16 mg./kg.) were consistently effective in 3 patients.  Antiviral responses were regularly observed when a dose of 12 mg./kg. was given on 2 successive days.  This antiviral activity was similar to that of human interferon found in the serum after vaccination with primary live virus or with naturally occurring virus infection.  Thrombocytopenia and fever (>101°F) were the major side effects, the former appeared in all patients at the dose of 8 mg./kg. or higher and the latter was seen in 10 of 13 patients at doses >8 mg./kg.  Autopsies revealed reticuloendothelial stimulation as demonstrated by splenic and hepatic phagocytic activity.  32 references.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKwD8Ot84BPbVg90H21EOLACvtfcHk0ljy6a2bHZNIqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF1cXivVChsQ%253D%253D&md5=e80705e09258761ab78b00108aad9217</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1056%2FNEJM196712142772403&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM196712142772403%26sid%3Dliteratum%253Aachs%26aulast%3DMerigan%26aufirst%3DT.%2BC.%26aulast%3DRegelson%26aufirst%3DW.%26atitle%3DInterferon%2520induction%2520in%2520man%2520by%2520a%2520synthetic%2520polyanion%2520of%2520defined%2520composition%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D1967%26volume%3D277%26spage%3D1283%26epage%3D1287%26doi%3D10.1056%2FNEJM196712142772403" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lampson, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tytell, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Field, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nemes, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hilleman, M. R.</span></span> <span> </span><span class="NLM_article-title">Inducers of interferon and host resistance. I. Double-stranded RNA from extracts of Penicillium funiculosum</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1967</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">782</span>– <span class="NLM_lpage">789</span>, <span class="refDoi"> DOI: 10.1073/pnas.58.2.782</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1073%2Fpnas.58.2.782" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=5233474" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADyaF2sXkvVSktL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=1967&pages=782-789&author=G.+P.+Lampsonauthor=A.+A.+Tytellauthor=A.+K.+Fieldauthor=M.+M.+Nemesauthor=M.+R.+Hilleman&title=Inducers+of+interferon+and+host+resistance.+I.+Double-stranded+RNA+from+extracts+of+Penicillium+funiculosum&doi=10.1073%2Fpnas.58.2.782"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Inducers of interferon and host resisance. I.  Double-stranded RNA from extracts of Penicillium funiculosum</span></div><div class="casAuthors">Lampson, George P.; Tytell, Alfred A.; Field, A. K.; Nemes, Marjorie M.; Hilleman, Maurice R.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1967</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">782-9</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    </div><div class="casAbstract">A highly purified double-stranded RNA termed HeI-RNA (I) which was active in μg. amts. in inducing interferon in rabbits and resistance to virus infection in vivo in mice and in vitro was recovered from P. funiculosum mycelial exts.  The biol., chem., and phys. properties of the RNA and the interferon induced by it were given.  I induced resistance to both PVM (pneumonia virus of mice) and to Columbia SK viruses in mice.  The uv absorption spectrum of the purified I was typical for nucleic acid.  The I contained 38% ribose, 8.4% P, plus purine and pyrimidine bases.  Protein, polysaccharide, and deoxyribose were absent.  The interferon-inducing activity was resistant to DNase, HIO4, and HCHO, but was destroyed by RNase at 56°.  I had a high level of thermal stability.  The sedimentation coeff. was 12.1 s.  The finding of the requirement of double-strandedness for activity is new and adds to the understanding of some of the requirements for induction of interferon and host resistance by RNA.  30 references.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5QuyjUD-r7bVg90H21EOLACvtfcHk0ljy6a2bHZNIqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF2sXkvVSktL4%253D&md5=82fecd273fc849b62e42287220695a13</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1073%2Fpnas.58.2.782&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.58.2.782%26sid%3Dliteratum%253Aachs%26aulast%3DLampson%26aufirst%3DG.%2BP.%26aulast%3DTytell%26aufirst%3DA.%2BA.%26aulast%3DField%26aufirst%3DA.%2BK.%26aulast%3DNemes%26aufirst%3DM.%2BM.%26aulast%3DHilleman%26aufirst%3DM.%2BR.%26atitle%3DInducers%2520of%2520interferon%2520and%2520host%2520resistance.%2520I.%2520Double-stranded%2520RNA%2520from%2520extracts%2520of%2520Penicillium%2520funiculosum%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1967%26volume%3D58%26spage%3D782%26epage%3D789%26doi%3D10.1073%2Fpnas.58.2.782" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Field, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tytell, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lampson, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hilleman, M. R.</span></span> <span> </span><span class="NLM_article-title">Inducers of interferon and host resistance. II. Multistranded synthetic polynucleotide complexes</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1967</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">1004</span>– <span class="NLM_lpage">1010</span>, <span class="refDoi"> DOI: 10.1073/pnas.58.3.1004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1073%2Fpnas.58.3.1004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=5233831" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADyaF2sXltFGltLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=1967&pages=1004-1010&author=A.+K.+Fieldauthor=A.+A.+Tytellauthor=G.+P.+Lampsonauthor=M.+R.+Hilleman&title=Inducers+of+interferon+and+host+resistance.+II.+Multistranded+synthetic+polynucleotide+complexes&doi=10.1073%2Fpnas.58.3.1004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Inducers of interferon and host resistance.  II.  Multistranded synthetic polynucleotide complexes</span></div><div class="casAuthors">Field, A. K.; Tytell, Alfred A.; Lampson, George P.; Hilleman, Maurice R.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1967</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1004-10</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    </div><div class="casAbstract">cf. CA 67: 80760u.  A complex of polyinosinic acid and polycytidylic acid, a complex of polyadenylic acid and polyuridylic acid, and a mixt. of polyinosinic acid and cytidylyl-cytidine were active in microgram amts. in inducing interferon in rabbits.  A variety of homopolymers and copolymers tested singly and in combination were inactive, as were a large no. of oligonucleotides, dinucleotides, nucleotides, nucleosides, and free bases.  A complex of polyinosinic acid and polycytidylic acid also induced resistance to viral infection in mice and induced interferon and evoked resistance to viruses in cell culture.  This was the first reported demonstration of the biol. activity of complexed homopolynucleotides.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkyEErWzAE-LVg90H21EOLACvtfcHk0ljy6a2bHZNIqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF2sXltFGltLs%253D&md5=e3ad73f4fadf5f8e0062e5630b64d63f</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1073%2Fpnas.58.3.1004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.58.3.1004%26sid%3Dliteratum%253Aachs%26aulast%3DField%26aufirst%3DA.%2BK.%26aulast%3DTytell%26aufirst%3DA.%2BA.%26aulast%3DLampson%26aufirst%3DG.%2BP.%26aulast%3DHilleman%26aufirst%3DM.%2BR.%26atitle%3DInducers%2520of%2520interferon%2520and%2520host%2520resistance.%2520II.%2520Multistranded%2520synthetic%2520polynucleotide%2520complexes%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1967%26volume%3D58%26spage%3D1004%26epage%3D1010%26doi%3D10.1073%2Fpnas.58.3.1004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tytell, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lampson, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Field, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hilleman, M. R.</span></span> <span> </span><span class="NLM_article-title">Inducers of interferon and host resistance. 3. Double-stranded RNA from reovirus type 3 virions (reo 3-RNA)</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1967</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">1719</span>– <span class="NLM_lpage">1722</span>, <span class="refDoi"> DOI: 10.1073/pnas.58.4.1719</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1073%2Fpnas.58.4.1719" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=4295834" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADyaF1cXitVGguw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=1967&pages=1719-1722&author=A.+A.+Tytellauthor=G.+P.+Lampsonauthor=A.+K.+Fieldauthor=M.+R.+Hilleman&title=Inducers+of+interferon+and+host+resistance.+3.+Double-stranded+RNA+from+reovirus+type+3+virions+%28reo+3-RNA%29&doi=10.1073%2Fpnas.58.4.1719"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Inducers of interferon and host resistance.  III.  Double-stranded RNA from reovirus type 3 virions (Reo 3-RNA)</span></div><div class="casAuthors">Tytell, Alfred A.; Lampson, George P.; Field, A. K.; Hilleman, Maurice R.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1967</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1719-22</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    </div><div class="casAbstract">A purified double-stranded RNA obtained from reovirus 3 virions and designated Reo 3-RNA was active in μg. amts. in inducing interferon in vivo and resistance to viral infection in vitro.  The induction period of Reo 3-RNA was 1 hr. or less in contrast to 5-6 hrs. for the whole infectious virus; this may be related to the time requirement for removal of the capsid from the RNA before induction can occur.  The induced interferon exhibited a host species-specificity of inhibitory titers of 128-256 in homologous rabbit kidney cells and <32 in heterologous mouse and chick embryo cells in culture, a redn. in titer from 32 to <5 by treatment for 4 hrs. at 35° with 50 μg. trypsin/ml., a mol. wt. of 40,000 based on Sephadex G-200 gel filtration, and an isoelec. point of 7.0 measured by chromatog. on CM-Sephadex.  The Reo 3-RNA exhibited uv absorption spectrum max. and min. of 260 and 232 mμ., resp., a thermal transition midpoint of 110°, and a significantly lower sensitivity to RNase than was observed with single-stranded yeast RNA.  The requirement for double stranding of viral RNA in order to induce interferon and host resistance to viral infection is consistent with the previously observed necessity of double-stranding for similar activities of the RNA from Penicillium funiculosum (HeI-RNA) and for active complexes of polynucleotides.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJusmiznSvuLVg90H21EOLACvtfcHk0ljy6a2bHZNIqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF1cXitVGguw%253D%253D&md5=a2f9181daccec07c154d534fcbcc62c2</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1073%2Fpnas.58.4.1719&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.58.4.1719%26sid%3Dliteratum%253Aachs%26aulast%3DTytell%26aufirst%3DA.%2BA.%26aulast%3DLampson%26aufirst%3DG.%2BP.%26aulast%3DField%26aufirst%3DA.%2BK.%26aulast%3DHilleman%26aufirst%3DM.%2BR.%26atitle%3DInducers%2520of%2520interferon%2520and%2520host%2520resistance.%25203.%2520Double-stranded%2520RNA%2520from%2520reovirus%2520type%25203%2520virions%2520%2528reo%25203-RNA%2529%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1967%26volume%3D58%26spage%3D1719%26epage%3D1722%26doi%3D10.1073%2Fpnas.58.4.1719" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Field, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lampson, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tytell, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nemes, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hilleman, M. R.</span></span> <span> </span><span class="NLM_article-title">Inducers of interferon and host resistance, IV. Double-stranded replicative form RNA (MS2-Ff-RNA) from E. coli infected with MS2 coliphage</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1967</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">2102</span>– <span class="NLM_lpage">2108</span>, <span class="refDoi"> DOI: 10.1073/pnas.58.5.2102</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1073%2Fpnas.58.5.2102" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=4295588" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADyaF1cXitVGnsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=1967&pages=2102-2108&author=A.+K.+Fieldauthor=G.+P.+Lampsonauthor=A.+A.+Tytellauthor=M.+M.+Nemesauthor=M.+R.+Hilleman&title=Inducers+of+interferon+and+host+resistance%2C+IV.+Double-stranded+replicative+form+RNA+%28MS2-Ff-RNA%29+from+E.+coli+infected+with+MS2+coliphage&doi=10.1073%2Fpnas.58.5.2102"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Inducers of interferon and host resistance.  IV.  Double-stranded replicative form RNA (MS2-RF-RNA) from Escherichia coli infected with MS2 coliphage</span></div><div class="casAuthors">Field, A. K.; Lampson, George P.; Tytell, Alfred A.; Nemes, Marjorie M.; Hilleman, Maurice R.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1967</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2102-8</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    </div><div class="casAbstract">A purified double-stranded replicative form of RNA (I) obtained from Escherichia coli infected with MS2 coliphage was active in inducing interferon in rabbits, with as little as 0.5 mg. of I inducing resistance to viral infection in vivo and in vitro.  Single-stranded RNA derived from the MS2 virion was inactive.  Data relating to the biol., chem., and phys. properties of I and the interferon induced by it was presented.  The finding of the requirements of double-stranding of viral RNA for induction of interferon and host resistance to viral infection is consistent with previous findings.  16 references.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZAeKrTXiCyLVg90H21EOLACvtfcHk0lg_5oiIJSwqdQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF1cXitVGnsg%253D%253D&md5=e89f37be863e724ea0865cde51abdd3e</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1073%2Fpnas.58.5.2102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.58.5.2102%26sid%3Dliteratum%253Aachs%26aulast%3DField%26aufirst%3DA.%2BK.%26aulast%3DLampson%26aufirst%3DG.%2BP.%26aulast%3DTytell%26aufirst%3DA.%2BA.%26aulast%3DNemes%26aufirst%3DM.%2BM.%26aulast%3DHilleman%26aufirst%3DM.%2BR.%26atitle%3DInducers%2520of%2520interferon%2520and%2520host%2520resistance%252C%2520IV.%2520Double-stranded%2520replicative%2520form%2520RNA%2520%2528MS2-Ff-RNA%2529%2520from%2520E.%2520coli%2520infected%2520with%2520MS2%2520coliphage%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1967%26volume%3D58%26spage%3D2102%26epage%3D2108%26doi%3D10.1073%2Fpnas.58.5.2102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Field, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tytell, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lampson, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hilleman, M. R.</span></span> <span> </span><span class="NLM_article-title">Inducers of interferon and host resistance, V. In vitro studies</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1968</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">340</span>– <span class="NLM_lpage">346</span>, <span class="refDoi"> DOI: 10.1073/pnas.61.1.340</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1073%2Fpnas.61.1.340" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=4301592" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADyaF1cXltVCksLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=1968&pages=340-346&author=A.+K.+Fieldauthor=A.+A.+Tytellauthor=G.+P.+Lampsonauthor=M.+R.+Hilleman&title=Inducers+of+interferon+and+host+resistance%2C+V.+In+vitro+studies&doi=10.1073%2Fpnas.61.1.340"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Inducers of interferon and host resistance.  V.  In vitro studies</span></div><div class="casAuthors">Field, A. K.; Tytell, A. A.; Lampson, G. P.; Hilleman, M. R.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1968</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">340-6</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    </div><div class="casAbstract">The induction of resistance against several viruses (vesicular stomatitis, vaccinia, herpes simplex, and rhinovirus) in a variety of cell cultures (including rabbit, dog, and calf kidney and mouse embryo) by the poly(riboinosinic acid)-poly(ribocytidylic acid) complex was studied.  The complex was highly active in inducing the resistance to viral infection in cell culture.  Such resistance was broad-spectrum with respect to kinds of viruses, but the amt. of the complex required for induction varied considerably for different cells and was not always consistent for a particular kind of cell.  Single-stranded poly(riboinosinic acid) and poly(ribocytidylic acid) were inactive in vitro, and the purported activity of such materials was due to the presence of a contaminant that was double-stranded.  The development of resistance to viral infection following treatment with the complex was accompanied by production of interferon.  The induction of interferon by the poly(riboinosinic acid)-poly(ribocytidylic acid) complex in vitro was prevented by prior treatment of cells with actinomycin D (0.5 μg./ml.), indicating an apparent requirement for DNA-dependent RNA synthesis.  16 references.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzp4zYnlnQwLVg90H21EOLACvtfcHk0lg_5oiIJSwqdQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF1cXltVCksLg%253D&md5=118d17852907d9bc15aaad0073eba4aa</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1073%2Fpnas.61.1.340&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.61.1.340%26sid%3Dliteratum%253Aachs%26aulast%3DField%26aufirst%3DA.%2BK.%26aulast%3DTytell%26aufirst%3DA.%2BA.%26aulast%3DLampson%26aufirst%3DG.%2BP.%26aulast%3DHilleman%26aufirst%3DM.%2BR.%26atitle%3DInducers%2520of%2520interferon%2520and%2520host%2520resistance%252C%2520V.%2520In%2520vitro%2520studies%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1968%26volume%3D61%26spage%3D340%26epage%3D346%26doi%3D10.1073%2Fpnas.61.1.340" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De
Clercq, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merigan, T.</span></span> <span> </span><span class="NLM_article-title">Requirement of a stable secondary structure for the antiviral activity of polynucleotides</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1969</span>,  <span class="NLM_volume"><i>222</i></span>,  <span class="NLM_fpage">1148</span>– <span class="NLM_lpage">1152</span>, <span class="refDoi"> DOI: 10.1038/2221148a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1038%2F2221148a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=4307027" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADyaF1MXkvVyru74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=222&publication_year=1969&pages=1148-1152&author=E.+De%0AClercqauthor=T.+Merigan&title=Requirement+of+a+stable+secondary+structure+for+the+antiviral+activity+of+polynucleotides&doi=10.1038%2F2221148a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Requirement of a stable secondary structure for the antiviral activity of polynucleotides</span></div><div class="casAuthors">De Clercq, E.; Merigan, T. C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">1969</span>),
    <span class="NLM_cas:volume">222</span>
        (<span class="NLM_cas:issue">5199</span>),
    <span class="NLM_cas:pages">1148-52</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    </div><div class="casAbstract">Homopolymer pairs with higher melting temp. (Tm) values were more active against bovine vesicular stomatitis virus (BVSV) in tissue culture.  Both Tm and antiviral activity increased in the order A/I, U/X, A/U, and I/C.  I/X induced a higher resistance against BVSV than U/X and A/I.  The activity of I/X was a summation of the antiviral effects of the individual homopolymers sep.  Differences in antiviral activity between homopolynucleotide complexes were accounted for by the differences in melting behavior and helical stability of the complex.  The 3-stranded complex A/2X gave min. antiviral activity.  With the homopolymer pairs U/X and A/I, the addn. of Mg2+ and decrease in pH increased thermal stability and antiviral activity of A/I.  The addn. of Mg2+ at pH 7 or 7.5 caused a minor shift in both Tm and viral inhibition of U/X; at pH 6 Mg2+ caused a redn. of both Tm and antiviral affect.  A decrease in pH and addn. of Mg2+ did not enhance interferon induction by I/C and A/U.  At 40 γ/ml., G, I, and X induced significant cellular resistance to BVSV; U, C, and A did not induce any activity but slightly stimulated virus plaque formation.  Hypochromicity was greatest for G, I, and X.  Mg2+ had little effect on antiviral activity of U, G, I, or X; C and A became more active in the presence of mg2+.  Both C and A became active at pH <7.5, and antiviral activity increased with decreasing pH.  The antiviral capacity or U, C, and A at pH 6 increased in the same order as their degree of hypochromicity.  The antiviral activity of single homopolymers was due to the homopolynucleotide itself and not to foreign double-stranded contaminants.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFW9g91t5VxLVg90H21EOLACvtfcHk0lg_5oiIJSwqdQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF1MXkvVyru74%253D&md5=bd38006fb6d491f923053e3cc3a41c5d</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2F2221148a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F2221148a0%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BClercq%26aufirst%3DE.%26aulast%3DMerigan%26aufirst%3DT.%26atitle%3DRequirement%2520of%2520a%2520stable%2520secondary%2520structure%2520for%2520the%2520antiviral%2520activity%2520of%2520polynucleotides%26jtitle%3DNature%26date%3D1969%26volume%3D222%26spage%3D1148%26epage%3D1152%26doi%3D10.1038%2F2221148a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merigan, T.</span></span> <span> </span><span class="NLM_article-title">Increase in antiviral activity of polynucleotides by thermal activation</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1970</span>,  <span class="NLM_volume"><i>226</i></span>,  <span class="NLM_fpage">364</span>– <span class="NLM_lpage">366</span>, <span class="refDoi"> DOI: 10.1038/226364a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1038%2F226364a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=4314782" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADyaE3cXktFWltLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=226&publication_year=1970&pages=364-366&author=E.+De+Clercqauthor=R.+Wellsauthor=T.+Merigan&title=Increase+in+antiviral+activity+of+polynucleotides+by+thermal+activation&doi=10.1038%2F226364a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Increase in antiviral activity of polynucleotides by thermal activation</span></div><div class="casAuthors">De Clercq, Erik; Wells, Robert D.; Merigan, Thomas C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">1970</span>),
    <span class="NLM_cas:volume">226</span>
        (<span class="NLM_cas:issue">5243</span>),
    <span class="NLM_cas:pages">364-6</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    </div><div class="casAbstract">Incubation of several synthetic polynucleotides at 37° for 5 min-2 hr increased their antiviral activity in subsequent in vitro and in vivo tests.  Thermal activation occurred with both alternating copolymer and homopolymer pairs of either the RNA or DNA types, but this effect was greatest for poly(A-U).  Thus, 5-min incubation at 37° increased the antiviral activity of poly(A-U) by >106-fold, as judged by the concn. required to decrease viral plaque formation 50% in cultures of human skin fibroblasts inoculated with bovine vesicular stomatitis virus.  Heat treatment of poly(A-U) also increased its ability to induce interferon formation in fibroblasts cultures and in mice after i.v. injection.  Incubation at 32 or 56° increased the antiviral activity of poly(A-U) as efficiently as at 37°, but there was no activation at 25°, and 90° destroyed activity.  The random copolymer poly(A,U) was devoid of antiviral activity at the highest concn. tested (10 μg/ml), and incubation at 37° did not activate it.  Moderate heating apparently increases the antiviral activity of some polynucleotides by stabilizing their double-stranded structure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprWvaSx4Lm8LVg90H21EOLACvtfcHk0ligb7QgmvEM3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE3cXktFWltLg%253D&md5=d76282f00bfc77be3db88f9e5ec15f79</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1038%2F226364a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F226364a0%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BClercq%26aufirst%3DE.%26aulast%3DWells%26aufirst%3DR.%26aulast%3DMerigan%26aufirst%3DT.%26atitle%3DIncrease%2520in%2520antiviral%2520activity%2520of%2520polynucleotides%2520by%2520thermal%2520activation%26jtitle%3DNature%26date%3D1970%26volume%3D226%26spage%3D364%26epage%3D366%26doi%3D10.1038%2F226364a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eckstein, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merigan, T. C.</span></span> <span> </span><span class="NLM_article-title">Interferon induction increased through chemical modification of a synthetic polyribonucleotide</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1969</span>,  <span class="NLM_volume"><i>165</i></span>,  <span class="NLM_fpage">1137</span>– <span class="NLM_lpage">1139</span>, <span class="refDoi"> DOI: 10.1126/science.165.3898.1137</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1126%2Fscience.165.3898.1137" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=5801596" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADyaF1MXkvFyhtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=165&publication_year=1969&pages=1137-1139&author=E.+De+Clercqauthor=F.+Ecksteinauthor=T.+C.+Merigan&title=Interferon+induction+increased+through+chemical+modification+of+a+synthetic+polyribonucleotide&doi=10.1126%2Fscience.165.3898.1137"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Interferon induction increased through chemical modification of a synthetic polyribonucleotide</span></div><div class="casAuthors">De Clercq, Erik; Eckstein, F.; Merigan, T. C.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">1969</span>),
    <span class="NLM_cas:volume">165</span>
        (<span class="NLM_cas:issue">3898</span>),
    <span class="NLM_cas:pages">1137-9</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    </div><div class="casAbstract">The alternating copolymer riboadenylic-ribouridylic acid gained a significant increase in ability to stimulate interferon production (2-20-fold) and cellular resistance (100-10,000-fold) both in vitro and in vivo upon substitution of phosphate by thiophosphate groups.  The resulting nucleotide analog was also 10-100 times less sensitive to degradation by pancreatic RNase, as detd. by residual antiviral activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRvxIdM6f5abVg90H21EOLACvtfcHk0ligb7QgmvEM3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF1MXkvFyhtLc%253D&md5=0fd2a4047a3edf7602e14884af43f58a</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1126%2Fscience.165.3898.1137&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.165.3898.1137%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BClercq%26aufirst%3DE.%26aulast%3DEckstein%26aufirst%3DF.%26aulast%3DMerigan%26aufirst%3DT.%2BC.%26atitle%3DInterferon%2520induction%2520increased%2520through%2520chemical%2520modification%2520of%2520a%2520synthetic%2520polyribonucleotide%26jtitle%3DScience%26date%3D1969%26volume%3D165%26spage%3D1137%26epage%3D1139%26doi%3D10.1126%2Fscience.165.3898.1137" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Somer, P.</span></span> <span> </span><span class="NLM_article-title">Antiviral activity of polyribocytidylic acid in cells primed with polyriboinosinic acid</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1971</span>,  <span class="NLM_volume"><i>173</i></span>,  <span class="NLM_fpage">260</span>– <span class="NLM_lpage">262</span>, <span class="refDoi"> DOI: 10.1126/science.173.3993.260</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1126%2Fscience.173.3993.260" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=4325867" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADyaE3MXkvFOjsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=173&publication_year=1971&pages=260-262&author=E.+De+Clercqauthor=P.+De+Somer&title=Antiviral+activity+of+polyribocytidylic+acid+in+cells+primed+with+polyriboinosinic+acid&doi=10.1126%2Fscience.173.3993.260"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Antiviral activity of polyribocytidylic acid in cells primed with polyriboinosinic acid</span></div><div class="casAuthors">De Clercq, E.; De Somer, P.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">1971</span>),
    <span class="NLM_cas:volume">173</span>
        (<span class="NLM_cas:issue">3993</span>),
    <span class="NLM_cas:pages">260-2</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    </div><div class="casAbstract">Polyribocytylic acid [poly(rC)] or polyriboinosinic acid [poly(rI)] added separately to 7 different cell cultures challenged with different viruses induced antiviral activity which was identical to or greater than that resulting from addn. of the poly(rI).poly(rC) complex.  Poly(rI) priming of cells, followed by treatment with poly(rC), gave consistently greater antiviral activity than poly(rI).poly(rC) itself.  When poly(rI) and poly(rC) were injected (i.v. and i.p.) successively into mice, lower interferon levels resulted than with injection of the poly(rI).poly(rC) complex.  Prior injection of poly(rI) proved superior in restoring the interferon inducing capacity of poly(rI).poly(rC) in vivo, as compared to prior injection of poly(rC).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjofojGG9IsLVg90H21EOLACvtfcHk0ligb7QgmvEM3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE3MXkvFOjsbc%253D&md5=151c0998e043025a77a8c95da8fb1e48</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1126%2Fscience.173.3993.260&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.173.3993.260%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BClercq%26aufirst%3DE.%26aulast%3DDe%2BSomer%26aufirst%3DP.%26atitle%3DAntiviral%2520activity%2520of%2520polyribocytidylic%2520acid%2520in%2520cells%2520primed%2520with%2520polyriboinosinic%2520acid%26jtitle%3DScience%26date%3D1971%26volume%3D173%26spage%3D260%26epage%3D262%26doi%3D10.1126%2Fscience.173.3993.260" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span> <span> </span><span class="NLM_article-title">Synthetic interferon inducers</span>. <i>Top. Curr. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1974</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">173</span>– <span class="NLM_lpage">208</span>, <span class="refDoi"> DOI: 10.1007/3-540-06873-2_17</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1007%2F3-540-06873-2_17" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=4617338" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADyaE2MXltFagsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=1974&pages=173-208&author=E.+De+Clercq&title=Synthetic+interferon+inducers&doi=10.1007%2F3-540-06873-2_17"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic interferon inducers</span></div><div class="casAuthors">De Clercq, Erik</div><div class="citationInfo"><span class="NLM_cas:title">Topics in Current Chemistry</span>
        (<span class="NLM_cas:date">1974</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">173-208</span>CODEN:
                <span class="NLM_cas:coden">TPCCAQ</span>;
        ISSN:<span class="NLM_cas:issn">0340-1022</span>.
    </div><div class="casAbstract">A review emphasizing the structure-activity relationships of synthetic interferon inducers; 202 refs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBiLSHqFUQibVg90H21EOLACvtfcHk0ligb7QgmvEM3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE2MXltFagsg%253D%253D&md5=e25e1bfbb5d65053912290a638eb32ed</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1007%2F3-540-06873-2_17&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F3-540-06873-2_17%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BClercq%26aufirst%3DE.%26atitle%3DSynthetic%2520interferon%2520inducers%26jtitle%3DTop.%2520Curr.%2520Chem.%26date%3D1974%26volume%3D52%26spage%3D173%26epage%3D208%26doi%3D10.1007%2F3-540-06873-2_17" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Carter, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span> <span> </span><span class="NLM_article-title">Viral infection and host defense</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1974</span>,  <span class="NLM_volume"><i>186</i></span>,  <span class="NLM_fpage">1172</span>– <span class="NLM_lpage">1178</span>, <span class="refDoi"> DOI: 10.1126/science.186.4170.1172</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1126%2Fscience.186.4170.1172" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=4610750" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADyaE2MXotl2ntQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=186&publication_year=1974&pages=1172-1178&author=W.+A.+Carterauthor=E.+De+Clercq&title=Viral+infection+and+host+defense&doi=10.1126%2Fscience.186.4170.1172"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Viral infection and host defense</span></div><div class="casAuthors">Carter, William A.; De Clercq, Erik</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">1974</span>),
    <span class="NLM_cas:volume">186</span>
        (<span class="NLM_cas:issue">4170</span>),
    <span class="NLM_cas:pages">1172-8</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    </div><div class="casAbstract">A review with 61 refs. of interferon induction by double-stranded RNA (dsRNA), intrinsic toxicity of dsRNA, dsRNA in acute infections, host defense mechanism and recovery from acute virus infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmJsNvFei7oLVg90H21EOLACvtfcHk0lgx1CnBD3oh9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE2MXotl2ntQ%253D%253D&md5=83c9d2eaf12de0f3c9689e811491f36b</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1126%2Fscience.186.4170.1172&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.186.4170.1172%26sid%3Dliteratum%253Aachs%26aulast%3DCarter%26aufirst%3DW.%2BA.%26aulast%3DDe%2BClercq%26aufirst%3DE.%26atitle%3DViral%2520infection%2520and%2520host%2520defense%26jtitle%3DScience%26date%3D1974%26volume%3D186%26spage%3D1172%26epage%3D1178%26doi%3D10.1126%2Fscience.186.4170.1172" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Derynck, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Content, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volckaert, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tavernier, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devos, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiers, W.</span></span> <span> </span><span class="NLM_article-title">Isolation and structure of a human fibroblast interferon gene</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1980</span>,  <span class="NLM_volume"><i>285</i></span>,  <span class="NLM_fpage">542</span>– <span class="NLM_lpage">547</span>, <span class="refDoi"> DOI: 10.1038/285542a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1038%2F285542a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=6157094" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADyaL3cXls1GrsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=285&publication_year=1980&pages=542-547&author=R.+Derynckauthor=J.+Contentauthor=E.+De+Clercqauthor=G.+Volckaertauthor=J.+Tavernierauthor=R.+Devosauthor=W.+Fiers&title=Isolation+and+structure+of+a+human+fibroblast+interferon+gene&doi=10.1038%2F285542a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Isolation and structure of a human fibroblast interferon gene</span></div><div class="casAuthors">Derynck, Rik; Content, Jean; De Clercq, Erik; Volckaert, Guido; Tavernier, Jan; Devos, Rene; Fiers, Walter</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">1980</span>),
    <span class="NLM_cas:volume">285</span>
        (<span class="NLM_cas:issue">5766</span>),
    <span class="NLM_cas:pages">542-7</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    </div><div class="casAbstract">An RNA selection method was used to screen chimeric plasmids contg. double-stranded complementary DNA copies of mRNA induced in human fibroblasts by poly I·C.  A series of clones to which human fibroblast interferon mRNA selectively hybridized was identified.  From the nucleotide sequence of the gene, the complete amino acid sequence was deduced.  The protein was 166 amino acids long and was preceded by a 21-amino acid signal sequence.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbKnjBREPEWLVg90H21EOLACvtfcHk0lgx1CnBD3oh9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3cXls1GrsLg%253D&md5=49da061868df75ab6153c8ac67a4c353</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1038%2F285542a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F285542a0%26sid%3Dliteratum%253Aachs%26aulast%3DDerynck%26aufirst%3DR.%26aulast%3DContent%26aufirst%3DJ.%26aulast%3DDe%2BClercq%26aufirst%3DE.%26aulast%3DVolckaert%26aufirst%3DG.%26aulast%3DTavernier%26aufirst%3DJ.%26aulast%3DDevos%26aufirst%3DR.%26aulast%3DFiers%26aufirst%3DW.%26atitle%3DIsolation%2520and%2520structure%2520of%2520a%2520human%2520fibroblast%2520interferon%2520gene%26jtitle%3DNature%26date%3D1980%26volume%3D285%26spage%3D542%26epage%3D547%26doi%3D10.1038%2F285542a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Derynck, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Remaut, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saman, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stanssens, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Content, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiers, W.</span></span> <span> </span><span class="NLM_article-title">Expression of human fibroblast interferon gene in <i>Escherichia coli</i></span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1980</span>,  <span class="NLM_volume"><i>287</i></span>,  <span class="NLM_fpage">193</span>– <span class="NLM_lpage">197</span>, <span class="refDoi"> DOI: 10.1038/287193a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1038%2F287193a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=6159534" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADyaL3MXht1Khtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=287&publication_year=1980&pages=193-197&author=R.+Derynckauthor=E.+Remautauthor=E.+Samanauthor=P.+Stanssensauthor=E.+De+Clercqauthor=J.+Contentauthor=W.+Fiers&title=Expression+of+human+fibroblast+interferon+gene+in+Escherichia+coli&doi=10.1038%2F287193a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Expression of human fibroblast interferon gene in Escherichia coli</span></div><div class="casAuthors">Derynck, Rik; Remaut, Erik; Saman, Erik; Stanssens, Patrick; De Clercq, Erik; Content, Jean; Fiers, Walter</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">1980</span>),
    <span class="NLM_cas:volume">287</span>
        (<span class="NLM_cas:issue">5779</span>),
    <span class="NLM_cas:pages">193-7</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    </div><div class="casAbstract">The human fibroblast interferon gene was inserted in a thermoinducible expression plasmid under control of the strong leftward promoter (PL) of bacteriophage λ.  The functioning of the promoter could be controlled by using host strains which formed a temp.-sensitive repressor.  The primary translation products predicted on the basis of the plasmid constructions were hybrid proteins starting with β-lactamase or phage MS2 polymerase information followed by the total preinterferon.  On induction, antiviral activity, whose physico-chem., immunol., and biol. characteristics closely corresponded to those of authentic human fibroblast interferon, was formed (titer of ∼100 units/5 × 108 cells/mL).  Processing to a size compatible with mature but unglycosylated authentic product was obsd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfJrm5cXhc_rVg90H21EOLACvtfcHk0lgx1CnBD3oh9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3MXht1Khtw%253D%253D&md5=fed9c6436634d0530a97944a5027d036</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1038%2F287193a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F287193a0%26sid%3Dliteratum%253Aachs%26aulast%3DDerynck%26aufirst%3DR.%26aulast%3DRemaut%26aufirst%3DE.%26aulast%3DSaman%26aufirst%3DE.%26aulast%3DStanssens%26aufirst%3DP.%26aulast%3DDe%2BClercq%26aufirst%3DE.%26aulast%3DContent%26aufirst%3DJ.%26aulast%3DFiers%26aufirst%3DW.%26atitle%3DExpression%2520of%2520human%2520fibroblast%2520interferon%2520gene%2520in%2520Escherichia%2520coli%26jtitle%3DNature%26date%3D1980%26volume%3D287%26spage%3D193%26epage%3D197%26doi%3D10.1038%2F287193a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Temin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizutani, S.</span></span> <span> </span><span class="NLM_article-title">RNA-dependent DNA polymerase in virions of Rous sarcoma virus</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1970</span>,  <span class="NLM_volume"><i>226</i></span>,  <span class="NLM_fpage">1211</span>– <span class="NLM_lpage">1213</span>, <span class="refDoi"> DOI: 10.1038/2261211a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1038%2F2261211a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=4316301" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADyaE3cXkvVCru70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=226&publication_year=1970&pages=1211-1213&author=H.+Teminauthor=S.+Mizutani&title=RNA-dependent+DNA+polymerase+in+virions+of+Rous+sarcoma+virus&doi=10.1038%2F2261211a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">RNA-dependent DNA polymerase in virions of Rous sarcoma virus</span></div><div class="casAuthors">Temin, Howard M.; Mizutani, Satoshi</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">1970</span>),
    <span class="NLM_cas:volume">226</span>
        (<span class="NLM_cas:issue">5252</span>),
    <span class="NLM_cas:pages">1211-13</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    </div><div class="casAbstract">A new polymerase was demonstrated inside the virions of Rous sarcoma virus but was not present in supernatants from normal host cells.  The polymerase seems to catalyze the incorporation of deoxyribonucleotide triphosphates into DNA from a RNA template.  If the present results and those of Baltimore (1970) are upheld they will constitute strong evidence that the DNA provirus hypothesis is correct and that RNA tumor viruses have a DNA genome when they are in cells and a RNA genome when they are virions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpinyJgw88blbVg90H21EOLACvtfcHk0ljyLPjI2Hngcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE3cXkvVCru70%253D&md5=cb9fb0bce2dfea6e8f060d953c2a1493</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1038%2F2261211a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F2261211a0%26sid%3Dliteratum%253Aachs%26aulast%3DTemin%26aufirst%3DH.%26aulast%3DMizutani%26aufirst%3DS.%26atitle%3DRNA-dependent%2520DNA%2520polymerase%2520in%2520virions%2520of%2520Rous%2520sarcoma%2520virus%26jtitle%3DNature%26date%3D1970%26volume%3D226%26spage%3D1211%26epage%3D1213%26doi%3D10.1038%2F2261211a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baltimore, D.</span></span> <span> </span><span class="NLM_article-title">RNA-dependent DNA polymerase in virions of RNA tumour viruses</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1970</span>,  <span class="NLM_volume"><i>226</i></span>,  <span class="NLM_fpage">1209</span>– <span class="NLM_lpage">1211</span>, <span class="refDoi"> DOI: 10.1038/2261209a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1038%2F2261209a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=4316300" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADyaE3cXkvVCru7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=226&publication_year=1970&pages=1209-1211&author=D.+Baltimore&title=RNA-dependent+DNA+polymerase+in+virions+of+RNA+tumour+viruses&doi=10.1038%2F2261209a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Viral RNA-dependent DNA polymerase</span></div><div class="casAuthors">Baltimore, David</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">1970</span>),
    <span class="NLM_cas:volume">226</span>
        (<span class="NLM_cas:issue">5252</span>),
    <span class="NLM_cas:pages">1209-11</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    </div><div class="casAbstract">A RNA-dependent DNA polymerase was present in the virions of 2 RNA tumor viruses, Rauscher mouse leukemia virus and Rous sarcoma virus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyV2nIllstQbVg90H21EOLACvtfcHk0ljyLPjI2Hngcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE3cXkvVCru7o%253D&md5=043600fe8afa5bf080e8528d595e3874</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1038%2F2261209a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F2261209a0%26sid%3Dliteratum%253Aachs%26aulast%3DBaltimore%26aufirst%3DD.%26atitle%3DRNA-dependent%2520DNA%2520polymerase%2520in%2520virions%2520of%2520RNA%2520tumour%2520viruses%26jtitle%3DNature%26date%3D1970%26volume%3D226%26spage%3D1209%26epage%3D1211%26doi%3D10.1038%2F2261209a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span> <span> </span><span class="NLM_article-title">Suramin: a potent inhibitor of the reverse transcriptase of RNA tumor viruses</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">1979</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">9</span>– <span class="NLM_lpage">22</span>, <span class="refDoi"> DOI: 10.1016/0304-3835(79)90017-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1016%2F0304-3835%2879%2990017-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=92362" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADyaL3cXjtl2gsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=1979&pages=9-22&author=E.+De+Clercq&title=Suramin%3A+a+potent+inhibitor+of+the+reverse+transcriptase+of+RNA+tumor+viruses&doi=10.1016%2F0304-3835%2879%2990017-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Suramin:  a potent inhibitor of the reverse transcriptase of RNA tumor viruses</span></div><div class="casAuthors">De Clercq, Erik</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (Shannon, Ireland)</span>
        (<span class="NLM_cas:date">1979</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">9-22</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    </div><div class="casAbstract">Moranyl (suramin hexasodium)(I)  [129-46-4] exerted a strong inhibitory effect on the RNA-directed DNA polymerase (reverse transcriptase)  [9012-90-2] activity of several oncornaviruses such as Moloney murine leukemia virus, murine Rauscher leukemia viruses, Moloney murine sarcoma virus and avian myeloblastosis virus.  Inhibition of enzyme activity was obtained with both endogenous viral RNA and (A)n · oligo(dT) as the template primer.  I effected a 50% inhibition of the reverse transcriptase activity of oncornaviruses at a concn. range of 0.1-1 μg/mL.  In this aspect I compared favorably to ethidium bromide, another trypanocide drug which is considered as one of the most powerful inhibitors of oncornavirus DNA polymerases.  The inhibition of reverse transcriptase activity by I was competitive with the template-primer, (A)n · oligo(dT), suggesting that the drug may interact with the template-primer binding site of the enzyme.  The possibility of I being an antitumor agent is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofyfy4FtJC6rVg90H21EOLACvtfcHk0ljyLPjI2Hngcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3cXjtl2gsg%253D%253D&md5=3d0cf6a877be7a2a910081415791f0c7</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2F0304-3835%2879%2990017-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0304-3835%252879%252990017-X%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BClercq%26aufirst%3DE.%26atitle%3DSuramin%253A%2520a%2520potent%2520inhibitor%2520of%2520the%2520reverse%2520transcriptase%2520of%2520RNA%2520tumor%2520viruses%26jtitle%3DCancer%2520Lett.%26date%3D1979%26volume%3D8%26spage%3D9%26epage%3D22%26doi%3D10.1016%2F0304-3835%2879%2990017-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mitsuya, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Popovic, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yarchoan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsushita, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broder, S.</span></span> <span> </span><span class="NLM_article-title">Suramin protection of T cells in vitro against infectivity and cytopathic effect of HTLV-III</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1984</span>,  <span class="NLM_volume"><i>226</i></span>,  <span class="NLM_fpage">172</span>– <span class="NLM_lpage">174</span>, <span class="refDoi"> DOI: 10.1126/science.6091268</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1126%2Fscience.6091268" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=6091268" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADyaL2cXmtVeqtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=226&publication_year=1984&pages=172-174&author=H.+Mitsuyaauthor=M.+Popovicauthor=R.+Yarchoanauthor=S.+Matsushitaauthor=R.+Galloauthor=S.+Broder&title=Suramin+protection+of+T+cells+in+vitro+against+infectivity+and+cytopathic+effect+of+HTLV-III&doi=10.1126%2Fscience.6091268"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Suramin protection of T cells in vitro against infectivity and cytopathic effect of HTLV-III</span></div><div class="casAuthors">Mitsuya, Hiroaki; Popovic, Mikulas; Yarchoan, Robert; Matsushita, Shuzo; Gallo, Robert C.; Broder, Samuel</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">1984</span>),
    <span class="NLM_cas:volume">226</span>
        (<span class="NLM_cas:issue">4671</span>),
    <span class="NLM_cas:pages">172-4</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    </div><div class="casAbstract">A recently discovered member of the human T-cell leukemia virus (HTLV) family of retroviruses has been etiol. linked to the acquired immune deficiency syndrome (AIDS).  This virus, which has been designated HTLV-III, is tropic for OKT4-bearing (helper-inducer) T cells.  Moreover, the virus is cytopathic for these cells.  Suramin  [145-63-1] is a drug used in the therapy of Rhodesian trypanosomiasis and onchocerciasis, and it is known to inhibit the reverse transcriptase of a no. of retroviruses.  Suramin has now been found to block in vitro the infectivity and cytopathic effect of HTLV-III at concns. that are clin. attainable in human beings.  The possible use of suramin in the treatment of AIDS is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWci4wMb_TXrVg90H21EOLACvtfcHk0ljyLPjI2Hngcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2cXmtVeqtrs%253D&md5=e6ac09c4226b01f517940421695584de</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1126%2Fscience.6091268&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.6091268%26sid%3Dliteratum%253Aachs%26aulast%3DMitsuya%26aufirst%3DH.%26aulast%3DPopovic%26aufirst%3DM.%26aulast%3DYarchoan%26aufirst%3DR.%26aulast%3DMatsushita%26aufirst%3DS.%26aulast%3DGallo%26aufirst%3DR.%26aulast%3DBroder%26aufirst%3DS.%26atitle%3DSuramin%2520protection%2520of%2520T%2520cells%2520in%2520vitro%2520against%2520infectivity%2520and%2520cytopathic%2520effect%2520of%2520HTLV-III%26jtitle%3DScience%26date%3D1984%26volume%3D226%26spage%3D172%26epage%3D174%26doi%3D10.1126%2Fscience.6091268" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Broder, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Markham, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Redfield, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoth, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groopman, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallo, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yarchoan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clifford
Lane, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klecker, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitsuya, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelmann, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Resnick, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myers, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fauci, A. S.</span></span> <span> </span><span class="NLM_article-title">Effects of suramin on HTLV-III/LAV infection presenting as Kaposi’s sarcoma or AIDS-related complex: clinical pharmacology and suppression of virus replication <i>in vivo</i></span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">1985</span>,  <span class="NLM_volume"><i>326</i></span>,  <span class="NLM_fpage">627</span>– <span class="NLM_lpage">630</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(85)90002-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1016%2FS0140-6736%2885%2990002-9" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=326&publication_year=1985&pages=627-630&author=S.+Broderauthor=J.+M.+Collinsauthor=P.+D.+Markhamauthor=R.+R.+Redfieldauthor=D.+F.+Hothauthor=J.+E.+Groopmanauthor=R.+C.+Galloauthor=R.+Yarchoanauthor=H.+Clifford%0ALaneauthor=R.+W.+Kleckerauthor=H.+Mitsuyaauthor=E.+Gelmannauthor=L.+Resnickauthor=C.+E.+Myersauthor=A.+S.+Fauci&title=Effects+of+suramin+on+HTLV-III%2FLAV+infection+presenting+as+Kaposi%E2%80%99s+sarcoma+or+AIDS-related+complex%3A+clinical+pharmacology+and+suppression+of+virus+replication+in+vivo&doi=10.1016%2FS0140-6736%2885%2990002-9"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2885%2990002-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252885%252990002-9%26sid%3Dliteratum%253Aachs%26aulast%3DBroder%26aufirst%3DS.%26aulast%3DCollins%26aufirst%3DJ.%2BM.%26aulast%3DMarkham%26aufirst%3DP.%2BD.%26aulast%3DRedfield%26aufirst%3DR.%2BR.%26aulast%3DHoth%26aufirst%3DD.%2BF.%26aulast%3DGroopman%26aufirst%3DJ.%2BE.%26aulast%3DGallo%26aufirst%3DR.%2BC.%26aulast%3DYarchoan%26aufirst%3DR.%26aulast%3DClifford%2BLane%26aufirst%3DH.%26aulast%3DKlecker%26aufirst%3DR.%2BW.%26aulast%3DMitsuya%26aufirst%3DH.%26aulast%3DGelmann%26aufirst%3DE.%26aulast%3DResnick%26aufirst%3DL.%26aulast%3DMyers%26aufirst%3DC.%2BE.%26aulast%3DFauci%26aufirst%3DA.%2BS.%26atitle%3DEffects%2520of%2520suramin%2520on%2520HTLV-III%252FLAV%2520infection%2520presenting%2520as%2520Kaposi%25E2%2580%2599s%2520sarcoma%2520or%2520AIDS-related%2520complex%253A%2520clinical%2520pharmacology%2520and%2520suppression%2520of%2520virus%2520replication%2520in%2520vivo%26jtitle%3DLancet%26date%3D1985%26volume%3D326%26spage%3D627%26epage%3D630%26doi%3D10.1016%2FS0140-6736%2885%2990002-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mitsuya, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinhold, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furman, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">St Clair, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehrman, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallo, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolognesi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barry, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broder, S.</span></span> <span> </span><span class="NLM_article-title">3′-Azido-3′-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1985</span>,  <span class="NLM_volume"><i>82</i></span>,  <span class="NLM_fpage">7096</span>– <span class="NLM_lpage">7100</span>, <span class="refDoi"> DOI: 10.1073/pnas.82.20.7096</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1073%2Fpnas.82.20.7096" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=2413459" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADyaL2MXlvV2htbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=1985&pages=7096-7100&author=H.+Mitsuyaauthor=K.+J.+Weinholdauthor=P.+A.+Furmanauthor=M.+H.+St+Clairauthor=S.+N.+Lehrmanauthor=R.+C.+Galloauthor=D.+Bolognesiauthor=D.+W.+Barryauthor=S.+Broder&title=3%E2%80%B2-Azido-3%E2%80%B2-deoxythymidine+%28BW+A509U%29%3A+an+antiviral+agent+that+inhibits+the+infectivity+and+cytopathic+effect+of+human+T-lymphotropic+virus+type+III%2Flymphadenopathy-associated+virus+in+vitro&doi=10.1073%2Fpnas.82.20.7096"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">3'-Azido-3'-deoxythymidine (BW A509U):  an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro</span></div><div class="casAuthors">Mitsuya, Hiroaki; Weinhold, Kent J.; Furman, Phillip A.; St. Clair, Marty H.; Lehrman, Sandra Nusinoff; Gallo, Robert C.; Bolognesi, Dani; Barry, David W.; Broder, Samuel</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1985</span>),
    <span class="NLM_cas:volume">82</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">7096-100</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    </div><div class="casAbstract">The antiviral effects of a thymidine analog, 3'-azido-3'-deoxythymidine (BW A509U)(I)  [30516-87-1], which, as a triphosphate, inhibits the reverse transcriptase of human T-lymphotropic virus type III (HTLV-III)/lymphadenopathy-assocd. virus (LAV) was detd.  This agent blocked the expression of the p24 gag protein of HTLV-III/LAV in H9 cells following exposure to virus.  The drug also inhibited the cytopathic effect of HTLV-IIIB (a virus derived from a pool of American patients) and HTLV-III/RF-II (an isolate obtained from a Haitian patient that differs by about 20% in the amino acid sequence of the envelope gene from several isolates of HTLV-III/LAV, including HTLV-IIIB, analyzed so far).  3'-Azido-3'-deoxythymidine also completely blocked viral replication as assessed by reverse transcriptase prodn. in normal human peripheral blood mononuclear cells exposed to HTLV-III.  Finally, at concns. of 3'-azido-3'-deoxythymidine that block the in vitro infectively and cytopathic effect of HTLV-IIIB, the in vitro immune functions of normal T cells remain basically intact.  These results are relevant to the treatment of AIDS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6ef2jfFgGQbVg90H21EOLACvtfcHk0lj7BvhqCiy2ew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2MXlvV2htbk%253D&md5=f56aaaed3c081c9a393e5fa8893f769c</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1073%2Fpnas.82.20.7096&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.82.20.7096%26sid%3Dliteratum%253Aachs%26aulast%3DMitsuya%26aufirst%3DH.%26aulast%3DWeinhold%26aufirst%3DK.%2BJ.%26aulast%3DFurman%26aufirst%3DP.%2BA.%26aulast%3DSt%2BClair%26aufirst%3DM.%2BH.%26aulast%3DLehrman%26aufirst%3DS.%2BN.%26aulast%3DGallo%26aufirst%3DR.%2BC.%26aulast%3DBolognesi%26aufirst%3DD.%26aulast%3DBarry%26aufirst%3DD.%2BW.%26aulast%3DBroder%26aufirst%3DS.%26atitle%3D3%25E2%2580%25B2-Azido-3%25E2%2580%25B2-deoxythymidine%2520%2528BW%2520A509U%2529%253A%2520an%2520antiviral%2520agent%2520that%2520inhibits%2520the%2520infectivity%2520and%2520cytopathic%2520effect%2520of%2520human%2520T-lymphotropic%2520virus%2520type%2520III%252Flymphadenopathy-associated%2520virus%2520in%2520vitro%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1985%26volume%3D82%26spage%3D7096%26epage%3D7100%26doi%3D10.1073%2Fpnas.82.20.7096" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balzarini, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Descamps, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eckstein, F.</span></span> <span> </span><span class="NLM_article-title">Antiviral, antimetabolic and antineoplastic activities of 2′- or 3′-amino or -azido-substituted deoxyribonucleosides</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1980</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">1849</span>– <span class="NLM_lpage">1851</span>, <span class="refDoi"> DOI: 10.1016/0006-2952(80)90149-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1016%2F0006-2952%2880%2990149-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=7406907" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADyaL3cXmtFGhtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=1980&pages=1849-1851&author=E.+De+Clercqauthor=J.+Balzariniauthor=J.+Descampsauthor=F.+Eckstein&title=Antiviral%2C+antimetabolic+and+antineoplastic+activities+of+2%E2%80%B2-+or+3%E2%80%B2-amino+or+-azido-substituted+deoxyribonucleosides&doi=10.1016%2F0006-2952%2880%2990149-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Antiviral, antimetabolic, antineoplastic activities of 2'- or 3'-amino or -azido-substituted deoxyribonucleosides</span></div><div class="casAuthors">De Clercq, Erik; Balzarini, Jan; Descamps, Johan; Eckstein, Fritz</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology</span>
        (<span class="NLM_cas:date">1980</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1849-51</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    </div><div class="casAbstract">None of the nucleoside analogs tested inhibited herpes simplex virus or vesicular stomatitis virus replication in primary rabbit kidney cell culture, but vaccinia virus replication was inhibited by several compds. at 4 μg/mL; cytotoxicity was obsd. at 40 μg/mL.  3'-Azido-3'-deoxyaraadenosine  [29411-70-9] was effective at 20 μg/mL and not cytotoxic at 200 μg/mL, but generally antiviral activity correlated with cytotoxicity.  Thus, antiviral activity was probably mediated via host cell DNA formation inhibition.  L1210 cell growth was inhibited specifically by 3'-amino-2',3'-dideoxyadenosine  [7403-25-0], 3'-azido-2',3'-dideoxyguanosine  [66323-46-4], and 2'-amino-2'-deoxyguanosine  [60966-26-9].</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoetUIei8s0o7Vg90H21EOLACvtfcHk0lj7BvhqCiy2ew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3cXmtFGhtLg%253D&md5=c6ba754f83e2476edd2d2b7beaba93ab</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2F0006-2952%2880%2990149-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0006-2952%252880%252990149-5%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BClercq%26aufirst%3DE.%26aulast%3DBalzarini%26aufirst%3DJ.%26aulast%3DDescamps%26aufirst%3DJ.%26aulast%3DEckstein%26aufirst%3DF.%26atitle%3DAntiviral%252C%2520antimetabolic%2520and%2520antineoplastic%2520activities%2520of%25202%25E2%2580%25B2-%2520or%25203%25E2%2580%25B2-amino%2520or%2520-azido-substituted%2520deoxyribonucleosides%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D1980%26volume%3D29%26spage%3D1849%26epage%3D1851%26doi%3D10.1016%2F0006-2952%2880%2990149-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Furman, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fyfe, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">St Clair, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinhold, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rideout, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freeman, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehrman, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolognesi, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broder, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitsuya, H.</span></span> <span> </span><span class="NLM_article-title">Phosphorylation of 3′-azido-3′-deoxythymidine and selective interaction of the 5′-triphosphate with human immunodeficiency virus reverse transcriptase</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1986</span>,  <span class="NLM_volume"><i>83</i></span>,  <span class="NLM_fpage">8333</span>– <span class="NLM_lpage">8337</span>, <span class="refDoi"> DOI: 10.1073/pnas.83.21.8333</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1073%2Fpnas.83.21.8333" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=2430286" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADyaL2sXktlCqug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=1986&pages=8333-8337&author=P.+A.+Furmanauthor=J.+A.+Fyfeauthor=M.+H.+St+Clairauthor=K.+Weinholdauthor=J.+L.+Rideoutauthor=G.+A.+Freemanauthor=S.+N.+Lehrmanauthor=D.+P.+Bolognesiauthor=S.+Broderauthor=H.+Mitsuya&title=Phosphorylation+of+3%E2%80%B2-azido-3%E2%80%B2-deoxythymidine+and+selective+interaction+of+the+5%E2%80%B2-triphosphate+with+human+immunodeficiency+virus+reverse+transcriptase&doi=10.1073%2Fpnas.83.21.8333"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase</span></div><div class="casAuthors">Furman, Phillip A.; Fyfe, James A.; St. Clair, Marty H.; Weinhold, Kent; Rideout, Janet L.; Freeman, George A.; Lehrman, Sandra Nusinoff; Bolognesi, Dani P.; Broder, Samuel; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1986</span>),
    <span class="NLM_cas:volume">83</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">8333-7</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    </div><div class="casAbstract">The thymidine analog 3'-azido-3'-deoxythymidine (azidothymidine)  [30516-87-1] was previously shown to inhibit human immunodeficiency virus (HIV) replication effectively in the 50-500 nM range.  In contrast, inhibition of the growth of uninfected human fibroblasts and lymphocytes was obsd. only at concns. above 1 mM.  The nature of this selectivity was investigated.  Azidothymidine anabolism to the 5'-mono-  [29706-85-2], -di-  [106060-89-3], and -triphosphate  [92586-35-1] derivs. was similar in uninfected and HIV-infected cells.  The level of azidothymidine monophosphate was high, whereas the levels of the di- and triphosphate were low (≤5 μM and ≤2 μM, resp.).  Cytosolic thymidine kinase (EC 2.7.1.21)  [9002-06-6] was responsible for phosphorylation of azidothymidine to its monophosphate.  Purified thymidine kinase catalyzed the phosphorylations of thymidine  [50-89-5] and azidothymidine with apparent Km values of 2.9 μM and 3.0 μM.  The maximal rate of phosphorylation with azidothymidine was equal to 60% of the rate with thymidine.  Phosphorylation of azidothymidine monophosphate to the diphosphate also appeared to be catalyzed by a host-cell enzyme, thymidylate kinase (EC 2.7.4.9)  [9014-43-1].  The apparent Km value for azidothymidine monophosphate was 2-fold greater than the value for dTMP  [365-07-1] (8.6 μM vs. 4.1 μM), but the maximal phosphorylation rate was only 0.3% of the dTMP rate.  These kinetic consts. were consistent with the anabolism results and indicated that azidothymidine monophosphate is an alternative-substrate inhibitor of thymidylate kinase.  This conclusion was reflected in the observation that cell incubated with azidothymidine had reduced intracellular levels of dTTP  [365-08-2].  IC50 (concn. of inhibitor that inhibits enzyme activity 50%) values were detd. for azidothymidine triphosphate with reverse transcriptase  [9068-38-6] and with immortalized human lymphocyte (H9 cell) DNA polymerase  [9012-90-2] α .  Azidothymidine triphosphate competed about 100-fold better for the HIV reverse transcriptase than for the cellular DNA polymerase α.  These results suggest that azidothymidine is nonselectively phosphorylated but that the triphosphate deriv. efficiently and selectively binds to the HIV reverse transcriptase.  Incorporation of azidothymidylate into a growing DNA strand should terminate DNA elongation and thus inhibit DNA synthesis.  These results may have relevance to the antiviral action mechanism for azidothymidine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1_5UurNpyQrVg90H21EOLACvtfcHk0lj0CfzS-2c3sg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2sXktlCqug%253D%253D&md5=2dcdd98db3c5708b2c31058cc47eeb41</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1073%2Fpnas.83.21.8333&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.83.21.8333%26sid%3Dliteratum%253Aachs%26aulast%3DFurman%26aufirst%3DP.%2BA.%26aulast%3DFyfe%26aufirst%3DJ.%2BA.%26aulast%3DSt%2BClair%26aufirst%3DM.%2BH.%26aulast%3DWeinhold%26aufirst%3DK.%26aulast%3DRideout%26aufirst%3DJ.%2BL.%26aulast%3DFreeman%26aufirst%3DG.%2BA.%26aulast%3DLehrman%26aufirst%3DS.%2BN.%26aulast%3DBolognesi%26aufirst%3DD.%2BP.%26aulast%3DBroder%26aufirst%3DS.%26aulast%3DMitsuya%26aufirst%3DH.%26atitle%3DPhosphorylation%2520of%25203%25E2%2580%25B2-azido-3%25E2%2580%25B2-deoxythymidine%2520and%2520selective%2520interaction%2520of%2520the%25205%25E2%2580%25B2-triphosphate%2520with%2520human%2520immunodeficiency%2520virus%2520reverse%2520transcriptase%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1986%26volume%3D83%26spage%3D8333%26epage%3D8337%26doi%3D10.1073%2Fpnas.83.21.8333" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Descamps, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Somer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holý, A.</span></span> <span> </span><span class="NLM_article-title">(S)-9-(2,3-dihydroxypropyl)adenine: an aliphatic nucleoside analog with broad-spectrum antiviral activity</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1978</span>,  <span class="NLM_volume"><i>200</i></span>,  <span class="NLM_fpage">563</span>– <span class="NLM_lpage">565</span>, <span class="refDoi"> DOI: 10.1126/science.200.4341.563</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1126%2Fscience.200.4341.563" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=17839440" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADyaE1cXkvF2qtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=200&publication_year=1978&pages=563-565&author=E.+De+Clercqauthor=J.+Descampsauthor=P.+De+Somerauthor=A.+Hol%C3%BD&title=%28S%29-9-%282%2C3-dihydroxypropyl%29adenine%3A+an+aliphatic+nucleoside+analog+with+broad-spectrum+antiviral+activity&doi=10.1126%2Fscience.200.4341.563"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">(S)-9-(2,3-Dihydroxypropyl)adenine:  an aliphatic nucleoside analog with broad-spectrum antiviral activity</span></div><div class="casAuthors">De Clercq, Erik; Descamps, Johan; De Somer, Pierre; Holy, Antonin</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">1978</span>),
    <span class="NLM_cas:volume">200</span>
        (<span class="NLM_cas:issue">4341</span>),
    <span class="NLM_cas:pages">563-5</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    </div><div class="casAbstract">(S)-9-(2,3-Dihydroxypropyl)adenine (I)  [54262-83-8], a novel nucleoside analog, the sugar moiety of which is replaced by an aliph. chain, inhibited the replication in vitro of several DNA and RNA viruses, including vaccinia, herpes simplex (types 1 and 2), measles, and vesicular stomatitis.  It was also effective in vivo in reducing the mortality rate of mice inoculated intranasally with vesicular stomatitis virus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkW_-BORiddbVg90H21EOLACvtfcHk0lj0CfzS-2c3sg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE1cXkvF2qtbk%253D&md5=fdeb3a0d1bf06684d4fd995f6879fae2</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1126%2Fscience.200.4341.563&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.200.4341.563%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BClercq%26aufirst%3DE.%26aulast%3DDescamps%26aufirst%3DJ.%26aulast%3DDe%2BSomer%26aufirst%3DP.%26aulast%3DHol%25C3%25BD%26aufirst%3DA.%26atitle%3D%2528S%2529-9-%25282%252C3-dihydroxypropyl%2529adenine%253A%2520an%2520aliphatic%2520nucleoside%2520analog%2520with%2520broad-spectrum%2520antiviral%2520activity%26jtitle%3DScience%26date%3D1978%26volume%3D200%26spage%3D563%26epage%3D565%26doi%3D10.1126%2Fscience.200.4341.563" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schaeffer, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beauchamp, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Miranda, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elion, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, P.</span></span> <span> </span><span class="NLM_article-title">9-(2-Hydroxyethoxymethyl)guanine activity against viruses of the herpes group</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1978</span>,  <span class="NLM_volume"><i>272</i></span>,  <span class="NLM_fpage">583</span>– <span class="NLM_lpage">585</span>, <span class="refDoi"> DOI: 10.1038/272583a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1038%2F272583a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=205792" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADyaE1cXltVSjsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=272&publication_year=1978&pages=583-585&author=H.+Schaefferauthor=L.+Beauchampauthor=P.+De+Mirandaauthor=G.+Elionauthor=D.+Bauerauthor=P.+Collins&title=9-%282-Hydroxyethoxymethyl%29guanine+activity+against+viruses+of+the+herpes+group&doi=10.1038%2F272583a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">9-(2-Hydroxyethoxymethyl)guanine activity against viruses of the herpes group</span></div><div class="casAuthors">Schaeffer, H. J.; Beauchamp, Lilia; De Miranda, P.; Elion, Gertrude B.; Bauer, D. J.; Collins, P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">1978</span>),
    <span class="NLM_cas:volume">272</span>
        (<span class="NLM_cas:issue">5654</span>),
    <span class="NLM_cas:pages">583-5</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    </div><div class="casAbstract">Of a series of nucleoside analogs synthesized, 9-(2-hydroxyethoxymethyl)guanine (I)  [59277-89-3] had marked antiviral activity with low toxicity in animal models of herpes virus infections.  In mice the oral and i.p. LD50 values for I were >10,000 and 1000 mg/kg, resp.; no toxicity was obsd. in mice given oral I (450 mg/kg) daily for 30 days.  In mice given I, 14C-labeled at the 8-position of the guanine nucleus, 82 and 94% of label was excreted in urine by 4 and 24 h, resp., essentially as unmetabolized I.  No appreciable I binding to plasma or tissues was obsd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3OmyVfempg7Vg90H21EOLACvtfcHk0lj0CfzS-2c3sg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE1cXltVSjsr0%253D&md5=383b527f72528e860c4b21f2fdb7fccd</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1038%2F272583a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F272583a0%26sid%3Dliteratum%253Aachs%26aulast%3DSchaeffer%26aufirst%3DH.%26aulast%3DBeauchamp%26aufirst%3DL.%26aulast%3DDe%2BMiranda%26aufirst%3DP.%26aulast%3DElion%26aufirst%3DG.%26aulast%3DBauer%26aufirst%3DD.%26aulast%3DCollins%26aufirst%3DP.%26atitle%3D9-%25282-Hydroxyethoxymethyl%2529guanine%2520activity%2520against%2520viruses%2520of%2520the%2520herpes%2520group%26jtitle%3DNature%26date%3D1978%26volume%3D272%26spage%3D583%26epage%3D585%26doi%3D10.1038%2F272583a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Elion, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furman, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fyfe, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Miranda, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beauchamp, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaeffer, H. J.</span></span> <span> </span><span class="NLM_article-title">Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl)guanine</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1977</span>,  <span class="NLM_volume"><i>74</i></span>,  <span class="NLM_fpage">5716</span>– <span class="NLM_lpage">5720</span>, <span class="refDoi"> DOI: 10.1073/pnas.74.12.5716</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1073%2Fpnas.74.12.5716" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=202961" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADyaE1cXhvVanurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=1977&pages=5716-5720&author=G.+B.+Elionauthor=P.+A.+Furmanauthor=J.+A.+Fyfeauthor=P.+de+Mirandaauthor=L.+Beauchampauthor=H.+J.+Schaeffer&title=Selectivity+of+action+of+an+antiherpetic+agent%2C+9-%282-hydroxyethoxymethyl%29guanine&doi=10.1073%2Fpnas.74.12.5716"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl)guanine</span></div><div class="casAuthors">Elion, Gertrude B.; Furman, Phillip A.; Fyfe, James A.; De Miranda, Paulo; Beauchamp, Lilia; Schaeffer, Howard J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1977</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5716-20</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    </div><div class="casAbstract">Acycloguanosine (I)  [59277-89-3] had potent antiviral activity (ED50 = 0.1 μM) against herpes simplex virus type I.  I was converted to a monophosphate  [66341-16-0] by a virus-specified thymidine kinase  [9002-06-6] and was subsequently converted to I di-  [66341-17-1] and I triphosphates  [66341-18-2].  In the uninfected host cell (Vero), these phosphorylations of I occurred at only a very limited extent.  I triphosphate inhibited herpes simplex virus DNA nucleotidyltransferase  [9012-90-2] 10-30 times more effectively than cellular (HeLa S3) DNA nucleotidyltransferase.  These factors contribute to I selectivity; inhibition of growth of the host cell requires a 3000-fold greater concn. of drug than does the inhibition of viral multiplication.  The identify of the kinase that phosphorylates I was detd. after sepn. of the cellular and virus-specified thymidine kinase activities by affinity chromatog., by reversal studies with thymidine, and by the lack of monophosphate formation in a temp.-sensitive, thymidine kinase-deficient mutant of the KOS strain of herpes simplex virus type 1 (tsA1).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4WWPCnssW2bVg90H21EOLACvtfcHk0lju6gpdQKhm7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE1cXhvVanurw%253D&md5=ed4071cc91116c4f97715e203614b005</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1073%2Fpnas.74.12.5716&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.74.12.5716%26sid%3Dliteratum%253Aachs%26aulast%3DElion%26aufirst%3DG.%2BB.%26aulast%3DFurman%26aufirst%3DP.%2BA.%26aulast%3DFyfe%26aufirst%3DJ.%2BA.%26aulast%3Dde%2BMiranda%26aufirst%3DP.%26aulast%3DBeauchamp%26aufirst%3DL.%26aulast%3DSchaeffer%26aufirst%3DH.%2BJ.%26atitle%3DSelectivity%2520of%2520action%2520of%2520an%2520antiherpetic%2520agent%252C%25209-%25282-hydroxyethoxymethyl%2529guanine%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1977%26volume%3D74%26spage%3D5716%26epage%3D5720%26doi%3D10.1073%2Fpnas.74.12.5716" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span> <span> </span><span class="NLM_article-title"><i>S</i>-Adenosylhomocysteine hydrolase inhibitors as broad-spectrum antiviral agents</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1987</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">2567</span>– <span class="NLM_lpage">2575</span>, <span class="refDoi"> DOI: 10.1016/0006-2952(87)90533-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1016%2F0006-2952%2887%2990533-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=3300656" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADyaL2sXltVylurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=1987&pages=2567-2575&author=E.+De+Clercq&title=S-Adenosylhomocysteine+hydrolase+inhibitors+as+broad-spectrum+antiviral+agents&doi=10.1016%2F0006-2952%2887%2990533-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">S-Adenosylhomocysteine hydrolase inhibitors as broad-spectrum antiviral agents</span></div><div class="casAuthors">De Clercq, Erik</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology</span>
        (<span class="NLM_cas:date">1987</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">2567-75</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    </div><div class="casAbstract">A review with 99 refs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9PnsyZJUH4bVg90H21EOLACvtfcHk0lju6gpdQKhm7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2sXltVylurs%253D&md5=52d6b2b153b1757d03d6ea98836fccb5</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2F0006-2952%2887%2990533-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0006-2952%252887%252990533-8%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BClercq%26aufirst%3DE.%26atitle%3DS-Adenosylhomocysteine%2520hydrolase%2520inhibitors%2520as%2520broad-spectrum%2520antiviral%2520agents%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D1987%26volume%3D36%26spage%3D2567%26epage%3D2575%26doi%3D10.1016%2F0006-2952%2887%2990533-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span> <span> </span><span class="NLM_article-title">John Montgomery’s Legacy: Carbocyclic adenosine analogues as SAH hydrolase inhibitors with broad-spectrum antiviral activity</span>. <i>Nucleosides, Nucleotides Nucleic Acids</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">1395</span>– <span class="NLM_lpage">1415</span>, <span class="refDoi"> DOI: 10.1080/15257770500265638</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1080%2F15257770500265638" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=16438025" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlakt7jL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2005&pages=1395-1415&author=E.+De+Clercq&title=John+Montgomery%E2%80%99s+Legacy%3A+Carbocyclic+adenosine+analogues+as+SAH+hydrolase+inhibitors+with+broad-spectrum+antiviral+activity&doi=10.1080%2F15257770500265638"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">John Montgomery's Legacy: Carbocyclic Adenosine Analogues as Sah Hydrolase Inhibitors with Broad-Spectrum Antiviral Activity</span></div><div class="casAuthors">De Clercq, E.</div><div class="citationInfo"><span class="NLM_cas:title">Nucleosides, Nucleotides & Nucleic Acids</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">10-12</span>),
    <span class="NLM_cas:pages">1395-1415</span>CODEN:
                <span class="NLM_cas:coden">NNNAFY</span>;
        ISSN:<span class="NLM_cas:issn">1525-7770</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis, Inc.</span>)
        </div><div class="casAbstract">A review.  Ever since the S-adenosylhomocysteine (AdoHcy, SAH) hydrolase was recognized as a pharmacol. target for antiviral agents (J. A. Montgomery et al., J. Med. Chem. 25:626-629, 1982), an increasing no. of adenosine, acyclic adenosine, and carbocyclic adenosine analogs have been described as potent SAH hydrolase inhibitors endowed with broad-spectrum antiviral activity.  The antiviral activity spectrum of the SAH hydrolase inhibitors include pox-, rhabdo-, filo-, arena-, paramyxo-, reo-, and retroviruses.  Among the most potent SAH hydrolase inhibitors and antiviral agents rank carbocyclic 3-deazaadenosine (C-c3 Ado), neplanocin A, 3-deazaneplanocin A, the 5'-nor derivs. of carbocyclic adenosine (C-Ado, aristeromycin), and the 2-halo (i.e., 2-fluoro) and 6'-R-alkyl (i.e., 6'-R-methyl) derivs. of neplanocin A.  These compds. are particularly active against poxviruses (i.e., vaccinia virus), and rhabdoviruses (i.e., vesicular stomatitis virus).  The in vivo efficacy of C-c3 Ado and 3-deazaneplanocin A has been established in mouse models for vaccinia virus, vesicular stomatitis virus, and Ebola virus.  SAH hydrolase inhibitors such as C-c3 Ado and 3-deazaneplanocin A should in the first place be considered for therapeutic (or prophylactic) use against poxvirus infections, including smallpox, and hemorrhagic fever virus infections such as Ebola.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmm33arKaCVLVg90H21EOLACvtfcHk0lju6gpdQKhm7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlakt7jL&md5=342541d1bd112f9ee6f1b04faddd2958</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1080%2F15257770500265638&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F15257770500265638%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BClercq%26aufirst%3DE.%26atitle%3DJohn%2520Montgomery%25E2%2580%2599s%2520Legacy%253A%2520Carbocyclic%2520adenosine%2520analogues%2520as%2520SAH%2520hydrolase%2520inhibitors%2520with%2520broad-spectrum%2520antiviral%2520activity%26jtitle%3DNucleosides%252C%2520Nucleotides%2520Nucleic%2520Acids%26date%3D2005%26volume%3D24%26spage%3D1395%26epage%3D1415%26doi%3D10.1080%2F15257770500265638" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Montgomery, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clayton, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shannon, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnett, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bodner, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kion, I. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantoni, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiang, P.</span></span> <span> </span><span class="NLM_article-title">Carbocyclic analogue of 3-deazaadenosine: A novel antiviral agent using S-adenosylhomocysteine hydrolase as a pharmacological target</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1982</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">626</span>– <span class="NLM_lpage">629</span>, <span class="refDoi"> DOI: 10.1021/jm00348a004</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00348a004" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADyaL38XhvFaqtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=1982&pages=626-629&author=J.+Montgomeryauthor=S.+Claytonauthor=H.+Thomasauthor=W.+Shannonauthor=G.+Arnettauthor=A.+Bodnerauthor=I.+K.+Kionauthor=G.+L.+Cantoniauthor=P.+Chiang&title=Carbocyclic+analogue+of+3-deazaadenosine%3A+A+novel+antiviral+agent+using+S-adenosylhomocysteine+hydrolase+as+a+pharmacological+target&doi=10.1021%2Fjm00348a004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Carbocyclic analog of 3-deazaadenosine:  a novel antiviral agent using S-adenosylhomocysteine hydrolase as a pharmacological target</span></div><div class="casAuthors">Montgomery, John A.; Clayton, Sarah J.; Thomas, H. Jeanette; Shannon, William M.; Arnett, Gussie; Bodner, Anne J.; Kion, In Kyung; Cantoni, Giulio L.; Chiang, Peter K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1982</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">626-9</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    </div><div class="casAbstract">The carbocyclic analog of 3-deazaadenosine (3-deaza-C-Ado)(I)  [81601-33-4] has been synthesized and found to have antiviral activity in cell culture against herpes simplex virus type 1, vaccinia virus, and HL-23 C-type virus.  It is relatively noncytotoxic at effective antiviral concns. and is not subject to deamination or phosphorylation.  It acts as a competitive inhibitor of S-adenosyl-L-homocysteine hydrolase  [9025-54-1], is at best a poor substrate, and does not inactivate the enzyme significantly.  3-Deaza-C-Ado may cause a selective inhibition of the methylation of the polynucleotide 5' cap of viral mRNA via the higher cellular concns. of S-adenosyl-L-homocysteine resulting from the inhibition of S-adenosylhomocysteine hydrolase in infected cells, since increases in the intracellular level of S-adenosylhomocysteine, but no effects on DNA or RNA synthesis, were obsd. after incubation of these cells with it.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpA2CkZFy7L3bVg90H21EOLACvtfcHk0lgfhG4DXw_lvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL38XhvFaqtbw%253D&md5=f27c8e7dc8c7dfd829bd75085bbbd007</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Fjm00348a004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00348a004%26sid%3Dliteratum%253Aachs%26aulast%3DMontgomery%26aufirst%3DJ.%26aulast%3DClayton%26aufirst%3DS.%26aulast%3DThomas%26aufirst%3DH.%26aulast%3DShannon%26aufirst%3DW.%26aulast%3DArnett%26aufirst%3DG.%26aulast%3DBodner%26aufirst%3DA.%26aulast%3DKion%26aufirst%3DI.%2BK.%26aulast%3DCantoni%26aufirst%3DG.%2BL.%26aulast%3DChiang%26aufirst%3DP.%26atitle%3DCarbocyclic%2520analogue%2520of%25203-deazaadenosine%253A%2520A%2520novel%2520antiviral%2520agent%2520using%2520S-adenosylhomocysteine%2520hydrolase%2520as%2520a%2520pharmacological%2520target%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1982%26volume%3D25%26spage%3D626%26epage%3D629%26doi%3D10.1021%2Fjm00348a004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Descamps, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Somer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barr, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, R. T.</span></span> <span> </span><span class="NLM_article-title">(<i>E</i>)-5-(2-Bromovinyl)-2′-deoxyuridine: a potent and selective anti-herpes agent</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1979</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">2947</span>– <span class="NLM_lpage">2951</span>, <span class="refDoi"> DOI: 10.1073/pnas.76.6.2947</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1073%2Fpnas.76.6.2947" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=223163" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADyaE1MXltlersbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=1979&pages=2947-2951&author=E.+De+Clercqauthor=J.+Descampsauthor=P.+De+Somerauthor=P.+J.+Barrauthor=A.+S.+Jonesauthor=R.+T.+Walker&title=%28E%29-5-%282-Bromovinyl%29-2%E2%80%B2-deoxyuridine%3A+a+potent+and+selective+anti-herpes+agent&doi=10.1073%2Fpnas.76.6.2947"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">(E)-5-(2-bromovinyl)-2'-deoxyuridine:  A potent and selective anti-herpes agent</span></div><div class="casAuthors">De Clercq, E.; Descamps, J.; De Somer, P.; Barr, P. J.; Jones, A. S.; Walker, R. T.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1979</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2947-51</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    </div><div class="casAbstract">Of a series of 5 newly synthesized 2'-deoxyuridine derivs., including 5-vinyl-dUrd  [55520-67-7], 5-ethynyl-dUrd  [61135-33-9], 5-(1-chlorovinyl)-dUrd  [69304-46-7], (E)-5-(2-bromovinyl)-dUrd (I)  [69304-47-8], and (E)-5-(2-iodovinyl)-dUrd (II)  [69304-48-9], the last 2 compds. exerted a marked inhibitory effect on the replication of herpes simplex virus type 1 [ID50 (mean inhibitory dose), 0.004-0.02 μg/mL].  Both I and II were highly selective in their antiherpes activity in that they did not affect the growth or metab. of the host (primary rabbit kidney) cells unless drug concns. were used that were 5,000- to 10,000-fold greater than those required to inhibit virus multiplication.  In this sense I and II proved more selective in their activity against herpes simplex virus type 1 than all other antiherpes compds. that have been described so far.  In animal model systems (namely, cutaneous herpes infections of athymic nude mice), I suppressed the development of herpetic skin lesions and mortality therewith assocd., whether the compd. was administered topically or systemically.  Under the same conditions, the std. antiherpes drug 5-iodo-dUrd (Idoxuridine) offered little, if any, protection.  Although the precise mechanism of action of I and II remains to be established, preliminary findings indicate that they do not specifically act at the thymidylate synthetase step.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdVSomZVeCh7Vg90H21EOLACvtfcHk0liGVi9E9IFyWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE1MXltlersbg%253D&md5=5e18394296c56142473f8d539855deb8</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1073%2Fpnas.76.6.2947&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.76.6.2947%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BClercq%26aufirst%3DE.%26aulast%3DDescamps%26aufirst%3DJ.%26aulast%3DDe%2BSomer%26aufirst%3DP.%26aulast%3DBarr%26aufirst%3DP.%2BJ.%26aulast%3DJones%26aufirst%3DA.%2BS.%26aulast%3DWalker%26aufirst%3DR.%2BT.%26atitle%3D%2528E%2529-5-%25282-Bromovinyl%2529-2%25E2%2580%25B2-deoxyuridine%253A%2520a%2520potent%2520and%2520selective%2520anti-herpes%2520agent%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1979%26volume%3D76%26spage%3D2947%26epage%3D2951%26doi%3D10.1073%2Fpnas.76.6.2947" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span> <span> </span><span class="NLM_article-title">Discovery and development of BVDU (brivudin) as a therapeutic for the treatment of herpes zoster</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">2301</span>– <span class="NLM_lpage">2315</span>, <span class="refDoi"> DOI: 10.1016/j.bcp.2004.07.039</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1016%2Fj.bcp.2004.07.039" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=15548377" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVWjsLzN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2004&pages=2301-2315&author=E.+De+Clercq&title=Discovery+and+development+of+BVDU+%28brivudin%29+as+a+therapeutic+for+the+treatment+of+herpes+zoster&doi=10.1016%2Fj.bcp.2004.07.039"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and development of BVDU (brivudine) as a therapeutic for the treatment of herpes zoster</span></div><div class="casAuthors">De Clercq, E.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2301-2315</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  This commentary is dedicated to the memory of Dr. Jacques Gielen, the late Editor of Biochem. Pharmacol., whom I have known as both an author and reviewer for the Journal for about 25 years.  This is, quite incidentally, about the time it took for bringing brivudine (BVDU) [(E)-5-(2-bromovinyl)-2'-deoxyuridine] from its original description as an antiviral agent to the market place (in a no. of European countries, including Germany and Italy) for the treatment of herpes zoster in immunocompetent persons.  BVDU is exquisitely active and selective against varicella-zoster virus (VZV) and herpes simplex virus type 1 (HSV-1).  BVDU owes this high selectivity and activity profile to a specific phosphorylation by the virus-encoded thymidine kinase, followed by a potent interaction with the viral DNA polymerase.  The (E)-5-(2-bromovinyl)-substituent can be considered as the hallmark for the activity of BVDU against VZV and HSV-1.  Extensive clin. studies have indicated that BVDU as a single (oral) daily dose of 125 mg (for no more than 7 days) is effective in the treatment of herpes zoster, as regards both short-term (suppression of new lesion formation) and long-term effects (prevention of post-herpetic neuralgia).  In this sense, BVDU is as efficient and/or convenient, if not more so, than the other drugs (acyclovir, valaciclovir, famciclovir) that have been licensed for the treatment of herpes zoster.  There is one caveat; however, BVDU should not be given to patients under 5-fluorouracil therapy, as the degrdn. product of BVDU, namely (E)-5-(2-bromovinyl)uracil (BVU), may potentiate the toxicity of 5-fluorouracil, due to inhibition of dihydropyrimidine dehydrogenase, the enzyme involved in the catabolism of 5-fluorouracil.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqklZzJgQDBq7Vg90H21EOLACvtfcHk0liGVi9E9IFyWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVWjsLzN&md5=c43449f70ae0d4d31a17f4c34bf4db06</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2004.07.039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2004.07.039%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BClercq%26aufirst%3DE.%26atitle%3DDiscovery%2520and%2520development%2520of%2520BVDU%2520%2528brivudin%2529%2520as%2520a%2520therapeutic%2520for%2520the%2520treatment%2520of%2520herpes%2520zoster%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2004%26volume%3D68%26spage%3D2301%26epage%3D2315%26doi%3D10.1016%2Fj.bcp.2004.07.039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Degreef, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wildiers, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Jonge, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drochmans, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Descamps, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Somer, P.</span></span> <span> </span><span class="NLM_article-title">Oral (E)-5-(2-bromovinyl)-2′-deoxyuridine in severe herpes zoster</span>. <i>Br. Med. J.</i> <span class="NLM_year" style="font-weight: bold;">1980</span>,  <span class="NLM_volume"><i>281</i></span>,  <span class="NLM_fpage">1178</span>– <span class="NLM_lpage">1178</span>, <span class="refDoi"> DOI: 10.1136/bmj.281.6249.1178</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1136%2Fbmj.281.6249.1178" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=7427624" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A280%3ADyaL3M%252FktFCksw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=281&publication_year=1980&pages=1178-1178&author=E.+De+Clercqauthor=H.+Degreefauthor=J.+Wildiersauthor=G.+De+Jongeauthor=A.+Drochmansauthor=J.+Descampsauthor=P.+De+Somer&title=Oral+%28E%29-5-%282-bromovinyl%29-2%E2%80%B2-deoxyuridine+in+severe+herpes+zoster&doi=10.1136%2Fbmj.281.6249.1178"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Oral (E)-5-(2-bromovinyl)-2'-deoxyuridine in severe herpes zoster</span></div><div class="casAuthors">de Clercq E; Degreef H; Wildiers J; de Jonge G; Drochmans A; Descamps J; de Somer P</div><div class="citationInfo"><span class="NLM_cas:title">British medical journal</span>
        (<span class="NLM_cas:date">1980</span>),
    <span class="NLM_cas:volume">281</span>
        (<span class="NLM_cas:issue">6249</span>),
    <span class="NLM_cas:pages">1178</span>
        ISSN:<span class="NLM_cas:issn">0007-1447</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSk7obhVLONGnT4ugvCDgnZfW6udTcc2eYciqSk8wMCKLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL3M%252FktFCksw%253D%253D&md5=1009f624f16c0a5a759041c639820103</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1136%2Fbmj.281.6249.1178&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fbmj.281.6249.1178%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BClercq%26aufirst%3DE.%26aulast%3DDegreef%26aufirst%3DH.%26aulast%3DWildiers%26aufirst%3DJ.%26aulast%3DDe%2BJonge%26aufirst%3DG.%26aulast%3DDrochmans%26aufirst%3DA.%26aulast%3DDescamps%26aufirst%3DJ.%26aulast%3DDe%2BSomer%26aufirst%3DP.%26atitle%3DOral%2520%2528E%2529-5-%25282-bromovinyl%2529-2%25E2%2580%25B2-deoxyuridine%2520in%2520severe%2520herpes%2520zoster%26jtitle%3DBr.%2520Med.%2520J.%26date%3D1980%26volume%3D281%26spage%3D1178%26epage%3D1178%26doi%3D10.1136%2Fbmj.281.6249.1178" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Whitley, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ch’ien, L. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dolin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galasso, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alford, C. A.</span></span> <span> </span><span class="NLM_article-title">Adenine arabinoside therapy of herpes zoster in the immunosuppressed</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">1976</span>,  <span class="NLM_volume"><i>294</i></span>,  <span class="NLM_fpage">1193</span>– <span class="NLM_lpage">1199</span>, <span class="refDoi"> DOI: 10.1056/NEJM197605272942201</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1056%2FNEJM197605272942201" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=177866" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A280%3ADyaE287nsVeitw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=294&publication_year=1976&pages=1193-1199&author=R.+J.+Whitleyauthor=L.+T.+Ch%E2%80%99ienauthor=R.+Dolinauthor=G.+J.+Galassoauthor=C.+A.+Alford&title=Adenine+arabinoside+therapy+of+herpes+zoster+in+the+immunosuppressed&doi=10.1056%2FNEJM197605272942201"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Adenine arabinoside therapy of herpes zoster in the immunosuppressed. NIAID collaborative antiviral study</span></div><div class="casAuthors">Whitley R J; Ch'ien L T; Dolin R; Galasso G J; Alford C A Jr</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">1976</span>),
    <span class="NLM_cas:volume">294</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">1193-9</span>
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    </div><div class="casAbstract">We evaluated adenine arabinoside treatment of herpes zoster in immunodeficient patients in a randomized, controlled crossover study.  The two study groups had similar characteristics.  In spite of rapid natural healing, those receiving adenine arabinoside over the first five days had accelerated clearance of virus from vesicles (P = 0.01), and cessation of new vesicle formation (P = 0.004), and a shorter time to total pustulation (P = 0.001).  Factors modifying the response to therapy included age, underlying disease, and the duration of zoster prior to therapy.  Clinical toxicity was minimal.  Laboratory assessment of bone-marrow, liver and renal function showed insignificant alterations as a result of therapy.  These studies show that adenine arabinoside is a drug with promise for therapy of systemic herpes zoster in immunocompromised patients.  It is most efficacious when administered during the first six days of disease (P = 0.001) to those who have reticuloendothelial neoplasia (P = 0.001) and are less than 38 years of age (P = 0.001).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ7E33NyFJ7Xf6BottYdIAWfW6udTcc2ebOli3g7oemtrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaE287nsVeitw%253D%253D&md5=c3d727ec1f540969574e7e42ac55e0ac</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1056%2FNEJM197605272942201&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM197605272942201%26sid%3Dliteratum%253Aachs%26aulast%3DWhitley%26aufirst%3DR.%2BJ.%26aulast%3DCh%25E2%2580%2599ien%26aufirst%3DL.%2BT.%26aulast%3DDolin%26aufirst%3DR.%26aulast%3DGalasso%26aufirst%3DG.%2BJ.%26aulast%3DAlford%26aufirst%3DC.%2BA.%26atitle%3DAdenine%2520arabinoside%2520therapy%2520of%2520herpes%2520zoster%2520in%2520the%2520immunosuppressed%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D1976%26volume%3D294%26spage%3D1193%26epage%3D1199%26doi%3D10.1056%2FNEJM197605272942201" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Colla, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Busson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanderhaeghe, H.</span></span> <span> </span><span class="NLM_article-title">Synthesis and antiviral activity of water-soluble esters of acyclovir [9-[(2-hydroxyethoxy)methyl]guanine]</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1983</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">602</span>– <span class="NLM_lpage">604</span>, <span class="refDoi"> DOI: 10.1021/jm00358a029</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00358a029" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADyaL3sXhtF2hs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=1983&pages=602-604&author=L.+Collaauthor=E.+De+Clercqauthor=R.+Bussonauthor=H.+Vanderhaeghe&title=Synthesis+and+antiviral+activity+of+water-soluble+esters+of+acyclovir+%5B9-%5B%282-hydroxyethoxy%29methyl%5Dguanine%5D&doi=10.1021%2Fjm00358a029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and antiviral activity of water-soluble esters of acyclovir [9-[(2-hydroxyethoxy)methyl]guanine)</span></div><div class="casAuthors">Colla, Leon; De Clercq, Erik; Busson, Roger; Vanderhaeghe, Hubert</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1983</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">602-4</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    </div><div class="casAbstract">The title compds. I (R = COCH2NH2, COCHMeNH2, COCH2CH2NH2, COCH2CH2CO2H, and COCH2N3) as the HCl and Na salts were prepd. by direct esterification of acyclovir  [59277-89-3] and evaluated for virucidal activity in vitro.  The compds. were as active or slightly less active than acyclovir itself against herpes simplex virus type 1 and type 2 in primary rabbit kidney cells, showed little activity against vaccinia virus and no activity against stomatitits virus, and no cytotoxicity.  9-[2-(glycyloxy)ethoxymethyl]guanine-HCl  [84499-61-6] Effectively suppressed the development of both epithelial and stromal keratitis and iritis.  I was stable at room temp. for 6 days in isotonic borate buffer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvzWgI3CTaYLVg90H21EOLACvtfcHk0lgewlDJ0u8mOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3sXhtF2hs78%253D&md5=e3b4f5cf614b82a1befcff949a246e30</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Fjm00358a029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00358a029%26sid%3Dliteratum%253Aachs%26aulast%3DColla%26aufirst%3DL.%26aulast%3DDe%2BClercq%26aufirst%3DE.%26aulast%3DBusson%26aufirst%3DR.%26aulast%3DVanderhaeghe%26aufirst%3DH.%26atitle%3DSynthesis%2520and%2520antiviral%2520activity%2520of%2520water-soluble%2520esters%2520of%2520acyclovir%2520%255B9-%255B%25282-hydroxyethoxy%2529methyl%255Dguanine%255D%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1983%26volume%3D26%26spage%3D602%26epage%3D604%26doi%3D10.1021%2Fjm00358a029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maudgal, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Descamps, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Missotten, L.</span></span> <span> </span><span class="NLM_article-title">Topical treatment of experimental herpes simplex keratouveitis with 2′-O-glycylacyclovir</span>. <i>Arch. Ophthalmol.</i> <span class="NLM_year" style="font-weight: bold;">1984</span>,  <span class="NLM_volume"><i>102</i></span>,  <span class="NLM_fpage">140</span>– <span class="NLM_lpage">142</span>, <span class="refDoi"> DOI: 10.1001/archopht.1984.01040030118049</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1001%2Farchopht.1984.01040030118049" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=6703958" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A280%3ADyaL2c7ltlCisA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=1984&pages=140-142&author=P.+C.+Maudgalauthor=E.+De+Clercqauthor=J.+Descampsauthor=L.+Missotten&title=Topical+treatment+of+experimental+herpes+simplex+keratouveitis+with+2%E2%80%B2-O-glycylacyclovir&doi=10.1001%2Farchopht.1984.01040030118049"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Topical treatment of experimental herpes simplex keratouveitis with 2'-O-glycylacyclovir. A water-soluble ester of acyclovir</span></div><div class="casAuthors">Maudgal P C; De Clercq K; Descamps J; Missotten L</div><div class="citationInfo"><span class="NLM_cas:title">Archives of ophthalmology (Chicago, Ill. : 1960)</span>
        (<span class="NLM_cas:date">1984</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">140-2</span>
        ISSN:<span class="NLM_cas:issn">0003-9950</span>.
    </div><div class="casAbstract">2'-O-glycylacyclovir, a water-soluble ester derivative of acyclovir, has proved efficacious in the topical treatment of epithelial and stromal herpes simplex keratitis, and iritis therewith associated, when administered as a 1% eyedrop formulation to rabbits.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRSmFpK9ihjY-b6AVA-44PTfW6udTcc2ebOli3g7oemtrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL2c7ltlCisA%253D%253D&md5=7882ab70d2f929d8cdb4b4268d30cc4d</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1001%2Farchopht.1984.01040030118049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Farchopht.1984.01040030118049%26sid%3Dliteratum%253Aachs%26aulast%3DMaudgal%26aufirst%3DP.%2BC.%26aulast%3DDe%2BClercq%26aufirst%3DE.%26aulast%3DDescamps%26aufirst%3DJ.%26aulast%3DMissotten%26aufirst%3DL.%26atitle%3DTopical%2520treatment%2520of%2520experimental%2520herpes%2520simplex%2520keratouveitis%2520with%25202%25E2%2580%25B2-O-glycylacyclovir%26jtitle%3DArch.%2520Ophthalmol.%26date%3D1984%26volume%3D102%26spage%3D140%26epage%3D142%26doi%3D10.1001%2Farchopht.1984.01040030118049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beauchamp, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orr, G. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Miranda, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bumette, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krenitsky, T. A.</span></span> <span> </span><span class="NLM_article-title">Amino acid ester prodrugs of acyclovir</span>. <i>Antiviral Chem. Chemother.</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">157</span>– <span class="NLM_lpage">164</span>, <span class="refDoi"> DOI: 10.1177/095632029200300305</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1177%2F095632029200300305" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADyaK38XltVelsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=1992&pages=157-164&author=L.+M.+Beauchampauthor=G.+F.+Orrauthor=P.+de+Mirandaauthor=T.+Bumetteauthor=T.+A.+Krenitsky&title=Amino+acid+ester+prodrugs+of+acyclovir&doi=10.1177%2F095632029200300305"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Amino acid ester prodrugs of acyclovir</span></div><div class="casAuthors">Beauchamp, L. M.; Orr, G. F.; De Miranda, P.; Burnette, T.; Krenitsky, T. A.</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Chemistry & Chemotherapy</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">157-64</span>CODEN:
                <span class="NLM_cas:coden">ACCHEH</span>;
        ISSN:<span class="NLM_cas:issn">0956-3202</span>.
    </div><div class="casAbstract">Eighteen amino acid esters of the antiherpetic drug, acyclovir, were synthesized as potential prodrugs for oral administration.  The esters were examd. for in vitro antiviral activity against herpes simplex virus Type 1 (HSV-1).  They had less potency than the parent compd.  Their efficiencies as prodrugs were evaluated in rats by measuring the urinary recovery of acyclovir.  Ten prodrugs produced greater amts. of the parent drug in the urine.  The L-amino acid esters were better prodrugs than the corresponding D- or D,L-isomers, suggesting the involvement of a stereoselective transporter.  The L-valyl ester, 256U87, was the best prodrug.  Sixty-three percent of its administered dose was excreted as acyclovir in the urine, a considerable improvement over acyclovir itself, for which this value was 19%.  Since 256U87 was stable in aq. solns., its conversion to acyclovir in vivo was probably enzyme catalyzed.  This L-valyl ester prodrug of acyclovir is now undergoing clin. evaluation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriTQ5TOWVr3LVg90H21EOLACvtfcHk0lgewlDJ0u8mOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38XltVelsbw%253D&md5=a1befed5efcf119abf7ce4660a133fc8</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1177%2F095632029200300305&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F095632029200300305%26sid%3Dliteratum%253Aachs%26aulast%3DBeauchamp%26aufirst%3DL.%2BM.%26aulast%3DOrr%26aufirst%3DG.%2BF.%26aulast%3Dde%2BMiranda%26aufirst%3DP.%26aulast%3DBumette%26aufirst%3DT.%26aulast%3DKrenitsky%26aufirst%3DT.%2BA.%26atitle%3DAmino%2520acid%2520ester%2520prodrugs%2520of%2520acyclovir%26jtitle%3DAntiviral%2520Chem.%2520Chemother.%26date%3D1992%26volume%3D3%26spage%3D157%26epage%3D164%26doi%3D10.1177%2F095632029200300305" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Purifoy, D. J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beauchamp, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Miranda, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ertl, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lacey, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahim, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darby, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krenitsky, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, K. L.</span></span> <span> </span><span class="NLM_article-title">Review of research leading to new anti-herpesvirus agents in clinical development: valaciclovir hydrochloride (256U, the L-valyl ester of acyclovir) and 882C, a specific agent for varicella zoster virus</span>. <i>J. Med. Virol.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">139</span>– <span class="NLM_lpage">145</span>, <span class="refDoi"> DOI: 10.1002/jmv.1890410527</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1002%2Fjmv.1890410527" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=1993&pages=139-145&author=D.+J.+M.+Purifoyauthor=L.+M.+Beauchampauthor=P.+de+Mirandaauthor=P.+Ertlauthor=S.+Laceyauthor=G.+Robertsauthor=S.+G.+Rahimauthor=G.+Darbyauthor=T.+A.+Krenitskyauthor=K.+L.+Powell&title=Review+of+research+leading+to+new+anti-herpesvirus+agents+in+clinical+development%3A+valaciclovir+hydrochloride+%28256U%2C+the+L-valyl+ester+of+acyclovir%29+and+882C%2C+a+specific+agent+for+varicella+zoster+virus&doi=10.1002%2Fjmv.1890410527"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1002%2Fjmv.1890410527&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjmv.1890410527%26sid%3Dliteratum%253Aachs%26aulast%3DPurifoy%26aufirst%3DD.%2BJ.%2BM.%26aulast%3DBeauchamp%26aufirst%3DL.%2BM.%26aulast%3Dde%2BMiranda%26aufirst%3DP.%26aulast%3DErtl%26aufirst%3DP.%26aulast%3DLacey%26aufirst%3DS.%26aulast%3DRoberts%26aufirst%3DG.%26aulast%3DRahim%26aufirst%3DS.%2BG.%26aulast%3DDarby%26aufirst%3DG.%26aulast%3DKrenitsky%26aufirst%3DT.%2BA.%26aulast%3DPowell%26aufirst%3DK.%2BL.%26atitle%3DReview%2520of%2520research%2520leading%2520to%2520new%2520anti-herpesvirus%2520agents%2520in%2520clinical%2520development%253A%2520valaciclovir%2520hydrochloride%2520%2528256U%252C%2520the%2520L-valyl%2520ester%2520of%2520acyclovir%2529%2520and%2520882C%252C%2520a%2520specific%2520agent%2520for%2520varicella%2520zoster%2520virus%26jtitle%3DJ.%2520Med.%2520Virol.%26date%3D1993%26volume%3D41%26spage%3D139%26epage%3D145%26doi%3D10.1002%2Fjmv.1890410527" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holý, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenberg, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakuma, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balzarini, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maudgal, P. C.</span></span> <span> </span><span class="NLM_article-title">A novel selective broad-spectrum anti-DNA virus agent</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1986</span>,  <span class="NLM_volume"><i>323</i></span>,  <span class="NLM_fpage">464</span>– <span class="NLM_lpage">467</span>, <span class="refDoi"> DOI: 10.1038/323464a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1038%2F323464a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=3762696" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADyaL28XmtFygtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=323&publication_year=1986&pages=464-467&author=E.+De+Clercqauthor=A.+Hol%C3%BDauthor=I.+Rosenbergauthor=T.+Sakumaauthor=J.+Balzariniauthor=P.+C.+Maudgal&title=A+novel+selective+broad-spectrum+anti-DNA+virus+agent&doi=10.1038%2F323464a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">A novel selective broad-spectrum anti-DNA virus agent</span></div><div class="casAuthors">De Clercq, Erik; Holy, Antonin; Rosenberg, Ivan; Sakuma, Takashi; Balzarini, Jan; Maudgal, Prabhat C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">1986</span>),
    <span class="NLM_cas:volume">323</span>
        (<span class="NLM_cas:issue">6087</span>),
    <span class="NLM_cas:pages">464-7</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    </div><div class="casAbstract">A new compd. was found, (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine (I)  [92999-29-6], that has potent and selective activity against a broad spectrum of DNA viruses, including herpes simplex virus (types 1 and 2), varicella zoster virus, thymidine kinase-deficient (TK-) mutants of herpes simplex and varicella zoster virus, human cytomegalovirus, phocid, simian, suid, bovid, and equid herpes viruses, African swine fever virus, vaccinia virus, and human adenoviruses.  It is also active against retroviruses.  In mice and rabbits in vivo, the compd. is effective against both local and systemic infections with herpes simplex virus type 1, including herpetic keratitis caused by a TK- mutant which is resistant to the classical anti-herpes drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHvD011SupIbVg90H21EOLACvtfcHk0lgtccPXxw-ghQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL28XmtFygtrY%253D&md5=774d0545b43b01b98d46406674e16f0d</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1038%2F323464a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F323464a0%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BClercq%26aufirst%3DE.%26aulast%3DHol%25C3%25BD%26aufirst%3DA.%26aulast%3DRosenberg%26aufirst%3DI.%26aulast%3DSakuma%26aufirst%3DT.%26aulast%3DBalzarini%26aufirst%3DJ.%26aulast%3DMaudgal%26aufirst%3DP.%2BC.%26atitle%3DA%2520novel%2520selective%2520broad-spectrum%2520anti-DNA%2520virus%2520agent%26jtitle%3DNature%26date%3D1986%26volume%3D323%26spage%3D464%26epage%3D467%26doi%3D10.1038%2F323464a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakuma, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baba, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pauwels, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balzarini, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenberg, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holý, A.</span></span> <span> </span><span class="NLM_article-title">Antiviral activity of phosphonylmethoxyalkyl derivatives of purine and pyrimidines</span>. <i>Antiviral Res.</i> <span class="NLM_year" style="font-weight: bold;">1987</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">261</span>– <span class="NLM_lpage">272</span>, <span class="refDoi"> DOI: 10.1016/S0166-3542(87)80004-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1016%2FS0166-3542%2887%2980004-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=3451698" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADyaL1cXhsl2lsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=1987&pages=261-272&author=E.+De+Clercqauthor=T.+Sakumaauthor=M.+Babaauthor=R.+Pauwelsauthor=J.+Balzariniauthor=I.+Rosenbergauthor=A.+Hol%C3%BD&title=Antiviral+activity+of+phosphonylmethoxyalkyl+derivatives+of+purine+and+pyrimidines&doi=10.1016%2FS0166-3542%2887%2980004-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Antiviral activity of phosphonylmethoxyalkyl derivatives of purines and pyrimidines</span></div><div class="casAuthors">De Clercq, Erik; Sakuma, Takashi; Baba, Masanori; Pauwels, Rudi; Balzarini, Jan; Rosenberg, Ivan; Holy, Antonin</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">1987</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5-6</span>),
    <span class="NLM_cas:pages">261-72</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    </div><div class="casAbstract">Various 3-hydroxy-2-phosphonylmethoxypropyl (HPMP) and 2-phosphonylmethoxyethyl (PME) derivs. of purines [adenine (A), guanine (G), 2,6-diaminopurine (DAP), 2-monoaminopurine (MAP), hypoxanthine (HX)] and pyrimidines [cytosine (C), uracil (U), thymine (T)] were evaluated for their antiviral properties.  PMEDAP, (S)-HPMPA [and the cyclic phosphonate thereof, (S)-cHPMPA)], (S)-HPMPC, PMEG, PMEA, HPMPG, and HPMPDAP were effective inhibitors of herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2).  (S)-HPMPA and (S)-cHPMPA were the most effective inhibitors of varicella-zoster virus (VZV), and (s)-HPMPC was the most effective inhibitor of cytomegalovirus (CMV).  (S)-HPMPA and (S)-cHPMPA showed the greatest inhibitory activity against adenovirus (types 2, 3, and 4) and vaccinia virus.  The PME derivs. were much less inhibitory to VZV, CMV, vaccinia and adenovirus than the HPMP derivs.  However, PMEA, PMEDAP, and PMEMAP showed marked and selective activity against the human immunodeficiency virus.  (S)-HPMPA proved efficacious in the topical treatment of HSV-1 keratitis in rabbits and cutaneous HSV-1 infection in hairless mice, and in the systemic treatment of both HSV-1 and vaccinia virus infections in mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzijl5gXLtPbVg90H21EOLACvtfcHk0lgtccPXxw-ghQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1cXhsl2lsbg%253D&md5=aaf3aa204ab0a5fc34e6557c6158313b</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2FS0166-3542%2887%2980004-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0166-3542%252887%252980004-9%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BClercq%26aufirst%3DE.%26aulast%3DSakuma%26aufirst%3DT.%26aulast%3DBaba%26aufirst%3DM.%26aulast%3DPauwels%26aufirst%3DR.%26aulast%3DBalzarini%26aufirst%3DJ.%26aulast%3DRosenberg%26aufirst%3DI.%26aulast%3DHol%25C3%25BD%26aufirst%3DA.%26atitle%3DAntiviral%2520activity%2520of%2520phosphonylmethoxyalkyl%2520derivatives%2520of%2520purine%2520and%2520pyrimidines%26jtitle%3DAntiviral%2520Res.%26date%3D1987%26volume%3D8%26spage%3D261%26epage%3D272%26doi%3D10.1016%2FS0166-3542%2887%2980004-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mitsuya, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broder, S.</span></span> <span> </span><span class="NLM_article-title">Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2′,3′-dideoxynucleosides</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1986</span>,  <span class="NLM_volume"><i>83</i></span>,  <span class="NLM_fpage">1911</span>– <span class="NLM_lpage">1915</span>, <span class="refDoi"> DOI: 10.1073/pnas.83.6.1911</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1073%2Fpnas.83.6.1911" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=3006077" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADyaL28XhvVehs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=1986&pages=1911-1915&author=H.+Mitsuyaauthor=S.+Broder&title=Inhibition+of+the+in+vitro+infectivity+and+cytopathic+effect+of+human+T-lymphotrophic+virus+type+III%2Flymphadenopathy-associated+virus+%28HTLV-III%2FLAV%29+by+2%E2%80%B2%2C3%E2%80%B2-dideoxynucleosides&doi=10.1073%2Fpnas.83.6.1911"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2',3'-dideoxynucleosides</span></div><div class="casAuthors">Mitsuya, Hiroaki; Broder, Samuel</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1986</span>),
    <span class="NLM_cas:volume">83</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1911-15</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    </div><div class="casAbstract">Human T-lymphotropic virus type III (HTLV-III)/lymphadenopathy-assocd. virus (LAV) is a newly discovered lymphotropic retrovirus that is cytopathic for helper/inducer T cells in vitro.  This virus is the etiol. agent of the acquired immunodeficiency syndrome and related diseases.  In the current study, the capacity of purine and pyrimidine nucleoside derivs. to inhibit the infectivity and cytopathic effect of human T-lymphotropic virus type III in vitro was detd.  With the ribose moiety of the mol. in a 2',3'-dideoxy configuration, every purine (adenosine, guanosine, and inosine) and pyrimidine (cytidine and thymidine) nucleoside tested suppressed the virus, although the thymidine deriv. seemed to have substantially less activity in our system than the others.  In general, essentially complete suppression of the virus were obsd. at doses that were lower by a factor of 10 to 20 than those needed to inhibit the proliferation of the target T cells and the immune reactivity of normal T cells in vitro.  An anal. of 5 adenosine congeners, which differed only in the sugar moiety, revealed that redn. (an absence of hydroxyl determinants) at both the 2' and 3' carbons of the ribose was necessary for an anti-viral effect, and an addnl. redn. at the 5' carbon nullified the anti-viral activity.  These observations may be of value in developing a new class of exptl. drugs for the therapy of human T-lymphotropic virus type III infections.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqd8dTpxg1q8LVg90H21EOLACvtfcHk0ljoazgaMwKQEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL28XhvVehs7g%253D&md5=d2541c7e2684dfa6563c44db18186755</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1073%2Fpnas.83.6.1911&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.83.6.1911%26sid%3Dliteratum%253Aachs%26aulast%3DMitsuya%26aufirst%3DH.%26aulast%3DBroder%26aufirst%3DS.%26atitle%3DInhibition%2520of%2520the%2520in%2520vitro%2520infectivity%2520and%2520cytopathic%2520effect%2520of%2520human%2520T-lymphotrophic%2520virus%2520type%2520III%252Flymphadenopathy-associated%2520virus%2520%2528HTLV-III%252FLAV%2529%2520by%25202%25E2%2580%25B2%252C3%25E2%2580%25B2-dideoxynucleosides%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1986%26volume%3D83%26spage%3D1911%26epage%3D1915%26doi%3D10.1073%2Fpnas.83.6.1911" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baba, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pauwels, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herdewijn, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desmyter, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vandeputte, M.</span></span> <span> </span><span class="NLM_article-title">Both 2′,3′-dideoxythymidine and its 2′,3′-unsaturated derivative (2′,3′-dideoxythymidinene) are potent and selective inhibitors of human immunodeficiency virus replication in vitro</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">1987</span>,  <span class="NLM_volume"><i>142</i></span>,  <span class="NLM_fpage">128</span>– <span class="NLM_lpage">134</span>, <span class="refDoi"> DOI: 10.1016/0006-291X(87)90460-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1016%2F0006-291X%2887%2990460-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=3028398" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADyaL2sXhs1yms7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=142&publication_year=1987&pages=128-134&author=M.+Babaauthor=R.+Pauwelsauthor=P.+Herdewijnauthor=E.+De+Clercqauthor=J.+Desmyterauthor=M.+Vandeputte&title=Both+2%E2%80%B2%2C3%E2%80%B2-dideoxythymidine+and+its+2%E2%80%B2%2C3%E2%80%B2-unsaturated+derivative+%282%E2%80%B2%2C3%E2%80%B2-dideoxythymidinene%29+are+potent+and+selective+inhibitors+of+human+immunodeficiency+virus+replication+in+vitro&doi=10.1016%2F0006-291X%2887%2990460-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Both 2',3'-dideoxythymidine and its 2',3'-unsaturated derivative (2',3'-dideoxythymidinene) are potent and selective inhibitors of human immunodeficiency virus replication in vitro</span></div><div class="casAuthors">Baba, Masanori; Pauwels, Rudi; Herdewijn, Piet; De Clercq, Erik; Desmyter, Jan; Vandeputte, Michel</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical and Biophysical Research Communications</span>
        (<span class="NLM_cas:date">1987</span>),
    <span class="NLM_cas:volume">142</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">128-34</span>CODEN:
                <span class="NLM_cas:coden">BBRCA9</span>;
        ISSN:<span class="NLM_cas:issn">0006-291X</span>.
    </div><div class="casAbstract">2',3'-Dideoxythymidine (ddThd)  [3416-05-5] and its 2',3'-unsatd. deriv., 2',3'-dideoxythymidinene (ddeThd)  [3056-17-5], are potent and selective inhibitors of human immunodeficiency virus (HIV) in vitro.  When evaluated for their inhibitory effects on the cytopathogenicity of HIV in MT-4 cells, ddThd and ddeThd completely protected the cells against destruction by the virus at a concn. of 1 and 0.04 μM, resp.  In this aspect, ddeThd was ∼5-fold more potent than 2',3'-dideoxycytidine (ddCyd)  [7481-89-2], one of the most potent and selective anti-HIV compds. now pursued for its therapeutic potential in the treatment of AIDS.  Both ddThd and ddeThd also suppressed HIV antigen expression at 1 and 0.04 μM, resp.  Their selectivity indexes, as based on the ratio of the 50% cytotoxic dose to the 50% antiviral ED, were 120 (ddeThd) and >625 (ddThd).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDUfA6sIjZ_rVg90H21EOLACvtfcHk0ljoazgaMwKQEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2sXhs1yms7c%253D&md5=8859861892f9d739d191e1934a34c27f</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2F0006-291X%2887%2990460-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0006-291X%252887%252990460-8%26sid%3Dliteratum%253Aachs%26aulast%3DBaba%26aufirst%3DM.%26aulast%3DPauwels%26aufirst%3DR.%26aulast%3DHerdewijn%26aufirst%3DP.%26aulast%3DDe%2BClercq%26aufirst%3DE.%26aulast%3DDesmyter%26aufirst%3DJ.%26aulast%3DVandeputte%26aufirst%3DM.%26atitle%3DBoth%25202%25E2%2580%25B2%252C3%25E2%2580%25B2-dideoxythymidine%2520and%2520its%25202%25E2%2580%25B2%252C3%25E2%2580%25B2-unsaturated%2520derivative%2520%25282%25E2%2580%25B2%252C3%25E2%2580%25B2-dideoxythymidinene%2529%2520are%2520potent%2520and%2520selective%2520inhibitors%2520of%2520human%2520immunodeficiency%2520virus%2520replication%2520in%2520vitro%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D1987%26volume%3D142%26spage%3D128%26epage%3D134%26doi%3D10.1016%2F0006-291X%2887%2990460-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, T.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schinazi, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prusoff, W. H.</span></span> <span> </span><span class="NLM_article-title">Potent and selective in vitro activity of 3′-deoxythymidin-2′-ene (3′-deoxy-2′,3′-didehydrothymidine) against human immunodeficiency virus</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1987</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">2713</span>– <span class="NLM_lpage">2718</span>, <span class="refDoi"> DOI: 10.1016/0006-2952(87)90253-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1016%2F0006-2952%2887%2990253-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=2443141" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADyaL2sXmtFWnurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=1987&pages=2713-2718&author=T.-S.+Linauthor=R.+F.+Schinaziauthor=W.+H.+Prusoff&title=Potent+and+selective+in+vitro+activity+of+3%E2%80%B2-deoxythymidin-2%E2%80%B2-ene+%283%E2%80%B2-deoxy-2%E2%80%B2%2C3%E2%80%B2-didehydrothymidine%29+against+human+immunodeficiency+virus&doi=10.1016%2F0006-2952%2887%2990253-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Potent and selective in vitro activity of 3'-deoxythymidin-2'-ene (3'-deoxy-2',3'-didehydrothymidine) against human immunodeficiency virus</span></div><div class="casAuthors">Lin, Tai Shun; Schinazi, Raymond F.; Prusoff, William H.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology</span>
        (<span class="NLM_cas:date">1987</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">2713-18</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    </div><div class="casAbstract">3'-Deoxy-2',3'-didehydrothymidine (d4T) is a more potent inhibitor of human immunodeficiency virus (HIV) than 3'-deoxythymidine (d2T) in human peripheral blood mononuclear cells in vitro.  Although d2T was at least 10-fold less toxic than d4T to uninfected cells, the unsatd. analog (d4T) was about 19 times more potent as an antiviral agent.  D4T (0.1 μM) was markedly more effective in inhibiting viral replication than d2T (1.0 μM) when treatment was delayed by 1 or 2 days after infection.  The therapeutic index of d4T appears to be close to 5000.  The potent activity of d4T against HIV-1 and its very high therapeutic index make it to be a potentially useful agent for control of AIDS and related disorders.  A review is also presented on the compds. which have shown activity against HIV.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrF9l_kho8bdrVg90H21EOLACvtfcHk0ljoazgaMwKQEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2sXmtFWnurg%253D&md5=7de431cda4747fb43a9e5840c75a9001</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1016%2F0006-2952%2887%2990253-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0006-2952%252887%252990253-X%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DT.-S.%26aulast%3DSchinazi%26aufirst%3DR.%2BF.%26aulast%3DPrusoff%26aufirst%3DW.%2BH.%26atitle%3DPotent%2520and%2520selective%2520in%2520vitro%2520activity%2520of%25203%25E2%2580%25B2-deoxythymidin-2%25E2%2580%25B2-ene%2520%25283%25E2%2580%25B2-deoxy-2%25E2%2580%25B2%252C3%25E2%2580%25B2-didehydrothymidine%2529%2520against%2520human%2520immunodeficiency%2520virus%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D1987%26volume%3D36%26spage%3D2713%26epage%3D2718%26doi%3D10.1016%2F0006-2952%2887%2990253-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hamamoto, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakashima, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsui, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsuda, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, N.</span></span> <span> </span><span class="NLM_article-title">Inhibitory effect of 2′,3′-didehydro-2′,3′-dideoxynucleosides on infectivity, cytopathic effects, and replication of human immunodeficiency virus</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">1987</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">907</span>– <span class="NLM_lpage">910</span>, <span class="refDoi"> DOI: 10.1128/AAC.31.6.907</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1128%2FAAC.31.6.907" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=3039911" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADyaL2sXkslSgs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=1987&pages=907-910&author=Y.+Hamamotoauthor=H.+Nakashimaauthor=T.+Matsuiauthor=A.+Matsudaauthor=T.+Uedaauthor=N.+Yamamoto&title=Inhibitory+effect+of+2%E2%80%B2%2C3%E2%80%B2-didehydro-2%E2%80%B2%2C3%E2%80%B2-dideoxynucleosides+on+infectivity%2C+cytopathic+effects%2C+and+replication+of+human+immunodeficiency+virus&doi=10.1128%2FAAC.31.6.907"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitory effect of 2',3'-didehydro-2',3'-dideoxynucleosides on infectivity, cytopathic effects, and replication of human immunodeficiency virus</span></div><div class="casAuthors">Hamamoto, Yoshiaki; Nakashima, Hideki; Matsui, Toshio; Matsuda, Akira; Ueda, Toru; Yamamoto, Naoki</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">1987</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">907-10</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    </div><div class="casAbstract">It is generally accepted that human immunodeficiency virus (HIV) is the etiol. agent of the acquired immunodeficiency syndrome and related diseases.  This report demonstrates the antiviral effect of the nucleoside analogs 2',3'-didehydro-2'-3'-dideoxythymidine (DHT) (I) and 2',3'-didehydro-2',3'-dideoxycytidine (DHC) (II) by using human T-cell lymphotropic virus type I-carrying MT-4 cells, which are extremely susceptible to HIV infection.  These agents efficiently inhibited the cytopathic effects and expression of HIV-specific antigens in MT-4 cells after infection of the virus.  Both DHT and DHC also strongly blocked viral replication as detd. by a quant. bioassay system using a plaque-forming assay.  These antiviral effects were obtained at concns. at which the drugs produced little or no toxicity and were comparable to those with 3'-azido-3'-deoxythymidine and 2',3'-dideoxynucleosides.  These findings warrant further investigation of the use of DHT and DHC for the treatment of the acquired immunodeficiency syndrome and related diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSgD_l_EHcSrVg90H21EOLACvtfcHk0lgG6FM7qDOOTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2sXkslSgs7c%253D&md5=cee133f0b41bc0ce51882949d808cee5</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1128%2FAAC.31.6.907&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.31.6.907%26sid%3Dliteratum%253Aachs%26aulast%3DHamamoto%26aufirst%3DY.%26aulast%3DNakashima%26aufirst%3DH.%26aulast%3DMatsui%26aufirst%3DT.%26aulast%3DMatsuda%26aufirst%3DA.%26aulast%3DUeda%26aufirst%3DT.%26aulast%3DYamamoto%26aufirst%3DN.%26atitle%3DInhibitory%2520effect%2520of%25202%25E2%2580%25B2%252C3%25E2%2580%25B2-didehydro-2%25E2%2580%25B2%252C3%25E2%2580%25B2-dideoxynucleosides%2520on%2520infectivity%252C%2520cytopathic%2520effects%252C%2520and%2520replication%2520of%2520human%2520immunodeficiency%2520virus%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D1987%26volume%3D31%26spage%3D907%26epage%3D910%26doi%3D10.1128%2FAAC.31.6.907" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baba, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pauwels, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balzarini, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schols, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakashima, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perno, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyasaka, T.</span></span> <span> </span><span class="NLM_article-title">Highly specific inhibition of human immunodeficiency virus type 1 by a novel 6-substituted acyclouridine derivative</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">1989</span>,  <span class="NLM_volume"><i>165</i></span>,  <span class="NLM_fpage">1375</span>– <span class="NLM_lpage">1381</span>, <span class="refDoi"> DOI: 10.1016/0006-291X(89)92756-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1016%2F0006-291X%2889%2992756-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=2575380" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADyaK3cXptFaktw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=165&publication_year=1989&pages=1375-1381&author=M.+Babaauthor=H.+Tanakaauthor=E.+De+Clercqauthor=R.+Pauwelsauthor=J.+Balzariniauthor=D.+Scholsauthor=H.+Nakashimaauthor=C.+F.+Pernoauthor=R.+T.+Walkerauthor=T.+Miyasaka&title=Highly+specific+inhibition+of+human+immunodeficiency+virus+type+1+by+a+novel+6-substituted+acyclouridine+derivative&doi=10.1016%2F0006-291X%2889%2992756-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Highly specific inhibition of human immunodeficiency virus type 1 by a novel 6-substituted acyclouridine derivative</span></div><div class="casAuthors">Baba, M.; Tanaka, H.; De Clercq, E.; Pauwels, R.; Balzarini, J.; Schols, D.; Nakashima, H.; Perno, C. F.; Walker, R. T.; Miyasaka, T.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical and Biophysical Research Communications</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">165</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1375-81</span>CODEN:
                <span class="NLM_cas:coden">BBRCA9</span>;
        ISSN:<span class="NLM_cas:issn">0006-291X</span>.
    </div><div class="casAbstract">A 6-substituted acyclouridine deriv., 1-[(2-hydroxyethoxy)methyl]-6-phenylthiothymine (HEPT) (I), was a potent and selective inhibitor of human immunodeficiency virus type 1 (HIV-1) in vitro.  HEPT inhibited HIV-1 replication in various T4 cell cultures as well as peripheral blood lymphocytes and macrophages.  The 50% antiviral concn. for HIV-1 in MT-4 cells was 7.0 μM, while the 0% cytotoxic concn. for mock-infected MT-4 cells was 740 μM.  Although HEPT was inhibitory to various strains of HIV-1, it had no effect on the replication of other retroviruses, including HIV type 2.  In contrast with the dideoxynucleoside (i.e., azidothymidine) 5'-triphosphates, the triphosphate of HEPT did not interact with HIV-1 reverse transcriptase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqoXXr46wZ9Z7Vg90H21EOLACvtfcHk0lgG6FM7qDOOTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXptFaktw%253D%253D&md5=f4d0802cedbe7e906378fb1ece9da4bb</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1016%2F0006-291X%2889%2992756-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0006-291X%252889%252992756-3%26sid%3Dliteratum%253Aachs%26aulast%3DBaba%26aufirst%3DM.%26aulast%3DTanaka%26aufirst%3DH.%26aulast%3DDe%2BClercq%26aufirst%3DE.%26aulast%3DPauwels%26aufirst%3DR.%26aulast%3DBalzarini%26aufirst%3DJ.%26aulast%3DSchols%26aufirst%3DD.%26aulast%3DNakashima%26aufirst%3DH.%26aulast%3DPerno%26aufirst%3DC.%2BF.%26aulast%3DWalker%26aufirst%3DR.%2BT.%26aulast%3DMiyasaka%26aufirst%3DT.%26atitle%3DHighly%2520specific%2520inhibition%2520of%2520human%2520immunodeficiency%2520virus%2520type%25201%2520by%2520a%2520novel%25206-substituted%2520acyclouridine%2520derivative%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D1989%26volume%3D165%26spage%3D1375%26epage%3D1381%26doi%3D10.1016%2F0006-291X%2889%2992756-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miyasaka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baba, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayakawa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balzarini, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span> <span> </span><span class="NLM_article-title">A novel lead for specific anti-HIV-1 agents: 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1989</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">2507</span>– <span class="NLM_lpage">2509</span>, <span class="refDoi"> DOI: 10.1021/jm00132a002</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00132a002" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADyaL1MXlvFGgs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=1989&pages=2507-2509&author=T.+Miyasakaauthor=H.+Tanakaauthor=M.+Babaauthor=H.+Hayakawaauthor=R.+T.+Walkerauthor=J.+Balzariniauthor=E.+De+Clercq&title=A+novel+lead+for+specific+anti-HIV-1+agents%3A+1-%5B%282-hydroxyethoxy%29methyl%5D-6-%28phenylthio%29thymine&doi=10.1021%2Fjm00132a002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">A novel lead for specific anti-HIV-1 agents:  1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine</span></div><div class="casAuthors">Miyasaka, Tadashi; Tanaka, Hiromichi; Baba, Masanori; Hayakawa, Hiroyuki; Walker, Richard T.; Balzarini, Jan; De Clercq, Erik</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2507-9</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    </div><div class="casAbstract">Uracil acyclonucleosides I (R = H; R1 = H, F, Cl, Br, Me; R2 = SPh, iodo) were synthesized via lithiation of I (R = SiMe2CMe3; R1 = H, F, Cl; R2 = H) and reaction of the C-6 lithiated species with I2 or PhSSPh.  Among the compds. synthesized, I (R = H, R1 = Me, R2 = SPh) was a highly specific anti-HIV-1 agent with a selectivity index comparable to that of 2',3'-dideoxyadenosine.  The compd. showed no activity against HIV-2 and its triphosphate did not inhibit HIV-1 reverse transcriptase.  This suggests that this compd. manifests its activity through a mechanism different from that so far known for other nucleoside analogs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGos-Y3AIQxUPbVg90H21EOLACvtfcHk0lgG6FM7qDOOTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXlvFGgs70%253D&md5=fb74b02b0fdd8de1c5cc0486d550b4c6</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1021%2Fjm00132a002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00132a002%26sid%3Dliteratum%253Aachs%26aulast%3DMiyasaka%26aufirst%3DT.%26aulast%3DTanaka%26aufirst%3DH.%26aulast%3DBaba%26aufirst%3DM.%26aulast%3DHayakawa%26aufirst%3DH.%26aulast%3DWalker%26aufirst%3DR.%2BT.%26aulast%3DBalzarini%26aufirst%3DJ.%26aulast%3DDe%2BClercq%26aufirst%3DE.%26atitle%3DA%2520novel%2520lead%2520for%2520specific%2520anti-HIV-1%2520agents%253A%25201-%255B%25282-hydroxyethoxy%2529methyl%255D-6-%2528phenylthio%2529thymine%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1989%26volume%3D32%26spage%3D2507%26epage%3D2509%26doi%3D10.1021%2Fjm00132a002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pauwels, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andries, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desmyter, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schols, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kukla, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breslin, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raeymaeckers, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Gelder, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woestenborghs, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heykants, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schellekens, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janssen, M. A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janssen, P. A. J.</span></span> <span> </span><span class="NLM_article-title">Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>343</i></span>,  <span class="NLM_fpage">470</span>– <span class="NLM_lpage">474</span>, <span class="refDoi"> DOI: 10.1038/343470a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1038%2F343470a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1689015" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADyaK3cXhslGntL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=343&publication_year=1990&pages=470-474&author=R.+Pauwelsauthor=K.+Andriesauthor=J.+Desmyterauthor=D.+Scholsauthor=M.+J.+Kuklaauthor=H.+J.+Breslinauthor=A.+Raeymaeckersauthor=J.+Van+Gelderauthor=R.+Woestenborghsauthor=J.+Heykantsauthor=K.+Schellekensauthor=M.+A.+C.+Janssenauthor=E.+De+Clercqauthor=P.+A.+J.+Janssen&title=Potent+and+selective+inhibition+of+HIV-1+replication+in+vitro+by+a+novel+series+of+TIBO+derivatives&doi=10.1038%2F343470a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives</span></div><div class="casAuthors">Pauwels, Rudi; Andries, Koen; Desmyter, Jan; Schols, Dominique; Kukla, Michael J.; Breslin, Henry J.; Raeymaeckers, Alfons; Van Gelder, Jozef; Woestenborghs, Robert; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">343</span>
        (<span class="NLM_cas:issue">6257</span>),
    <span class="NLM_cas:pages">470-4</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    </div><div class="casAbstract">In the search for compds. active against human immunodeficiency virus (HIV), it was found that members of a novel series of tetrahydro-imidazol[4,5,1-jk][1,4]-benzodiazepin-2(1H)-one and -thione (TIBO) derivs. inhibit the replication of HIV-1, the main etiol. agent of AIDS, but not of HIV-2 or of any other DNA or RNA viruses.  In five cell systems, HIV-1 is inhibited by TIBO derivs. in nanomolar amts., which are 104-105 times lower that the cytotoxic concn.  The unprecedented specificity of these compds. may be due to an interaction with a reverse transcriptase-assocd. process.  By contrast, AZT (3'-azido-2',3'-dideoxythymidine), which is used for the treatment of AIDS, and DDC (2',3'-dideoxycytidine) and DDI (2',3'-dideoxyinosine), whose clin. application is being assessed, inhibit both HIV-1 and HIV-2 at concns. that, depending on the cell systems, are 2 to 4 orders of magnitude below their cytotoxic concn.  TIBO-derivs. are new chems. unrelated to any other antiviral agents.  They may be the most specific and potent inhibitors of HIV-1 replication studied so far.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodXWsMmazOdrVg90H21EOLACvtfcHk0ljwk4y69Fyb_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXhslGntL0%253D&md5=c303b47ff312a49dded6132ebbaa4ca1</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1038%2F343470a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F343470a0%26sid%3Dliteratum%253Aachs%26aulast%3DPauwels%26aufirst%3DR.%26aulast%3DAndries%26aufirst%3DK.%26aulast%3DDesmyter%26aufirst%3DJ.%26aulast%3DSchols%26aufirst%3DD.%26aulast%3DKukla%26aufirst%3DM.%2BJ.%26aulast%3DBreslin%26aufirst%3DH.%2BJ.%26aulast%3DRaeymaeckers%26aufirst%3DA.%26aulast%3DVan%2BGelder%26aufirst%3DJ.%26aulast%3DWoestenborghs%26aufirst%3DR.%26aulast%3DHeykants%26aufirst%3DJ.%26aulast%3DSchellekens%26aufirst%3DK.%26aulast%3DJanssen%26aufirst%3DM.%2BA.%2BC.%26aulast%3DDe%2BClercq%26aufirst%3DE.%26aulast%3DJanssen%26aufirst%3DP.%2BA.%2BJ.%26atitle%3DPotent%2520and%2520selective%2520inhibition%2520of%2520HIV-1%2520replication%2520in%2520vitro%2520by%2520a%2520novel%2520series%2520of%2520TIBO%2520derivatives%26jtitle%3DNature%26date%3D1990%26volume%3D343%26spage%3D470%26epage%3D474%26doi%3D10.1038%2F343470a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Debyser, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pauwels, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andries, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desmyter, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kukla, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janssen, P. A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De
Clercq, E.</span></span> <span> </span><span class="NLM_article-title">An antiviral target on reverse transcriptase of human immunodeficiency virus type 1 revealed by tetrahydroimidazo-[4,5,1-jk][1,4-benzodiazepin-2(1H)-one and -thione derivatives</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>88</i></span>,  <span class="NLM_fpage">1451</span>– <span class="NLM_lpage">1455</span>, <span class="refDoi"> DOI: 10.1073/pnas.88.4.1451</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1073%2Fpnas.88.4.1451" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1705038" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADyaK3MXhvF2isLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=88&publication_year=1991&pages=1451-1455&author=Z.+Debyserauthor=R.+Pauwelsauthor=K.+Andriesauthor=J.+Desmyterauthor=M.+J.+Kuklaauthor=P.+A.+J.+Janssenauthor=E.+De%0AClercq&title=An+antiviral+target+on+reverse+transcriptase+of+human+immunodeficiency+virus+type+1+revealed+by+tetrahydroimidazo-%5B4%2C5%2C1-jk%5D%5B1%2C4-benzodiazepin-2%281H%29-one+and+-thione+derivatives&doi=10.1073%2Fpnas.88.4.1451"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">An antiviral target on reverse transcriptase of human immunodeficiency virus type 1 revealed by tetrahydroimidazo[4,5,1-jk][1,4]benzodiazepin-2(1H)-one and -thione derivatives</span></div><div class="casAuthors">Debyser, Z.; Pauwels, R.; Andries, K.; Desmyter, J.; Kukla, M.; Janssen, P. A. J.; De Clercq, E.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">88</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1451-5</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    </div><div class="casAbstract">Screening of pharmacol. acceptable prototype compds. has recently led to the discovery of a series of ultraselective inhibitors of human immunodeficiency virus (HIV)-1 replication, the tetrahydroimidazo[4,5,1-jk][1,4]benzodiazepin-2(1H)-one and -thione (TIBO) derivs.  The TIBO compds. completely suppress the formation of proviral DNA in acutely infected cells, as revealed by polymerase chain reaction (PCR) anal.  TIBO derivs. are inhibitory to the reverse transcriptase (RT) of HIV-1 but not that of HIV-2 or other retroviruses.  The inhibition is most effective with poly(C)·oligo(dG) as the template/primer, and it is selectively directed against the RNA-dependent DNA polymerase activity and not the accompanying DNA-dependent DNA polymerase and RNase H activity of HIV-1 RT.  Kinetic studies point to an uncompetitive inhibition with regard to the template/primer.  TIBO compds. are active against HIV-1 replication through a unique interaction with HIV-1 RT.  The exptl. data indicate the existence of a target on HIV-1 RT that is responsible for the inhibition of replication and a mode of action unrelated to that of previously studied RT inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpN8No7nB72TrVg90H21EOLACvtfcHk0ljwk4y69Fyb_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXhvF2isLc%253D&md5=5bea83a78e98a232c6a5669bcc54e73a</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1073%2Fpnas.88.4.1451&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.88.4.1451%26sid%3Dliteratum%253Aachs%26aulast%3DDebyser%26aufirst%3DZ.%26aulast%3DPauwels%26aufirst%3DR.%26aulast%3DAndries%26aufirst%3DK.%26aulast%3DDesmyter%26aufirst%3DJ.%26aulast%3DKukla%26aufirst%3DM.%2BJ.%26aulast%3DJanssen%26aufirst%3DP.%2BA.%2BJ.%26aulast%3DDe%2BClercq%26aufirst%3DE.%26atitle%3DAn%2520antiviral%2520target%2520on%2520reverse%2520transcriptase%2520of%2520human%2520immunodeficiency%2520virus%2520type%25201%2520revealed%2520by%2520tetrahydroimidazo-%255B4%252C5%252C1-jk%255D%255B1%252C4-benzodiazepin-2%25281H%2529-one%2520and%2520-thione%2520derivatives%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1991%26volume%3D88%26spage%3D1451%26epage%3D1455%26doi%3D10.1073%2Fpnas.88.4.1451" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baba, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ubasawa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takashima, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sekiya, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nitta, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Umezu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakashima, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mori, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shigeta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyasaka, T.</span></span> <span> </span><span class="NLM_article-title">Potent and selective inhibition of human immunodeficiency virus type 1 (HIV-1) by 5-ethyl-6-phenylthiouracil derivatives through their interaction with the HIV-1 reverse transcriptase</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>88</i></span>,  <span class="NLM_fpage">2356</span>– <span class="NLM_lpage">2360</span>, <span class="refDoi"> DOI: 10.1073/pnas.88.6.2356</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1073%2Fpnas.88.6.2356" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1706522" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADyaK3MXhvF2itr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=88&publication_year=1991&pages=2356-2360&author=M.+Babaauthor=E.+De+Clercqauthor=H.+Tanakaauthor=M.+Ubasawaauthor=H.+Takashimaauthor=K.+Sekiyaauthor=I.+Nittaauthor=K.+Umezuauthor=H.+Nakashimaauthor=S.+Moriauthor=S.+Shigetaauthor=R.+T.+Walkerauthor=T.+Miyasaka&title=Potent+and+selective+inhibition+of+human+immunodeficiency+virus+type+1+%28HIV-1%29+by+5-ethyl-6-phenylthiouracil+derivatives+through+their+interaction+with+the+HIV-1+reverse+transcriptase&doi=10.1073%2Fpnas.88.6.2356"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Potent and selective inhibition of human immunodeficiency virus type 1 (HIV-1) by 5-ethyl-6-phenylthiouracil derivatives through their interaction with the HIV-1 reverse transcriptase</span></div><div class="casAuthors">Baba, Masanori; De Clercq, Erik; Tanaka, Hiromichi; Ubasawa, Masaru; Takashima, Hideaki; Sekiya, Kouichi; Nitta, Issei; Umezu, Kohei; Nakashima, Hideki; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">88</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2356-60</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    </div><div class="casAbstract">Several 5-ethyl-6-(phenylthio)uracil analogs with potent and selective activity against human immunodeficiency virus (HIV) type 1 are described.  1-Benzyloxymethyl-5-ethyl-6-phenylthiouracil (I), the most potent congener of the series, inhibits HIV-1 replication in a variety of cell systems, including peripheral blood lymphocytes, at a concn. of 1.5-7.0 nM, which is lower by a factor of 103 than the 50% antivirally effective concn. of the parent compd. 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT).  The 5-ethyl-6-(phenylthio)uracil analogs, like HEPT itself, do not inhibit HIV-2 replication but do inhibit replication of 3'-azido-3'-deoxythymidine-resistant mutants of HIV-1.  1-Benzyloxymethyl-5-ethyl-6-phenylthiouracil and its congeners are targeted at the HIV-1 reverse transcriptase (RT).  They do not inhibit HIV-2 RT.  They do not need to be metabolized to exert their inhibitory effect on HIV-1 RT.  Yet this inhibitory effect is competitive with the natural substrate dTTP.  The HEPT derivs. represent a group of RT inhibitors with a unique mode of interaction with HIV-1 RT.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYnSYWYZLeGLVg90H21EOLACvtfcHk0ljwk4y69Fyb_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXhvF2itr4%253D&md5=4146b2f499ed22492194b3acbb378c2d</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1073%2Fpnas.88.6.2356&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.88.6.2356%26sid%3Dliteratum%253Aachs%26aulast%3DBaba%26aufirst%3DM.%26aulast%3DDe%2BClercq%26aufirst%3DE.%26aulast%3DTanaka%26aufirst%3DH.%26aulast%3DUbasawa%26aufirst%3DM.%26aulast%3DTakashima%26aufirst%3DH.%26aulast%3DSekiya%26aufirst%3DK.%26aulast%3DNitta%26aufirst%3DI.%26aulast%3DUmezu%26aufirst%3DK.%26aulast%3DNakashima%26aufirst%3DH.%26aulast%3DMori%26aufirst%3DS.%26aulast%3DShigeta%26aufirst%3DS.%26aulast%3DWalker%26aufirst%3DR.%2BT.%26aulast%3DMiyasaka%26aufirst%3DT.%26atitle%3DPotent%2520and%2520selective%2520inhibition%2520of%2520human%2520immunodeficiency%2520virus%2520type%25201%2520%2528HIV-1%2529%2520by%25205-ethyl-6-phenylthiouracil%2520derivatives%2520through%2520their%2520interaction%2520with%2520the%2520HIV-1%2520reverse%2520transcriptase%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1991%26volume%3D88%26spage%3D2356%26epage%3D2360%26doi%3D10.1073%2Fpnas.88.6.2356" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baba, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ubasawa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takashima, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sekiya, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nitta, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Umezu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mori, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shigeta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyasaka, T.</span></span> <span> </span><span class="NLM_article-title">Highly potent and selective inhibition of human immunodeficiency virus type 1 by a novel series of 6-substituted acyclouridine derivatives</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">805</span>– <span class="NLM_lpage">810</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1711148" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADyaK3MXmslSjsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=1991&pages=805-810&author=M.+Babaauthor=E.+De+Clercqauthor=H.+Tanakaauthor=M.+Ubasawaauthor=H.+Takashimaauthor=K.+Sekiyaauthor=I.+Nittaauthor=K.+Umezuauthor=R.+T.+Walkerauthor=S.+Moriauthor=M.+Itoauthor=S.+Shigetaauthor=T.+Miyasaka&title=Highly+potent+and+selective+inhibition+of+human+immunodeficiency+virus+type+1+by+a+novel+series+of+6-substituted+acyclouridine+derivatives"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Highly potent and selective inhibition of human immunodeficiency virus type 1 by a novel series of 6-substituted acyclouridine derivatives</span></div><div class="casAuthors">Baba, Masanori; De Clercq, Erik; Tanaka, Hiromichi; Ubasawa, Masaru; Takashima, Hideaki; Sekiya, Kouichi; Nitta, Issei; Umezu, Kohei; Walker, Richard T.; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">805-10</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    </div><div class="casAbstract">In the search for novel derivs. of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT), the authors have found that several 5-ethyl-6-(3,5-dimethylphenylthio)uracil and 5-ethyl-6-(3,5-dimethylbenzyl)uracil analogs are potent and selective inhibitors of human immunodeficiency virus type 1 (HIV-1) replication in a variety of cell culture systems.  Of this series, 5-ethyl-1-ethoxymethyl-6-(3,5-dimethylbenzyl)uracil (E-EBU-dM) emerged as the most active congener.  Its 50% inhibitory concn. for HIV-1 (HTLV-IIIB) in MT-4 cells and peripheral blood lymphocytes is 2.2 and 0.45 nM, resp.  These concns. are more than 105-fold lower than the 50% cytotoxic concns. of E-EBU-dM for the host cells.  All compds. proved equally inhibitory to a no. of clin. HIV-1 isolates, including a 3'-azido-2',3'-dideoxythymidine-resistant variant.  However, as previously noted for HEPT, they do not inhibit human immunodeficiency virus type 2 replication.  Reverse transcriptase assays have revealed that these HEPT derivs. act specifically on HIV-1 reverse transcriptase, according to a mechanism that is different from that of the dideoxynucleosides.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdV0375oS1SbVg90H21EOLACvtfcHk0lirLGXTqEd39Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXmslSjsb0%253D&md5=4fb2a59c01b75b9cb24298bc5ec75ec7</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBaba%26aufirst%3DM.%26aulast%3DDe%2BClercq%26aufirst%3DE.%26aulast%3DTanaka%26aufirst%3DH.%26aulast%3DUbasawa%26aufirst%3DM.%26aulast%3DTakashima%26aufirst%3DH.%26aulast%3DSekiya%26aufirst%3DK.%26aulast%3DNitta%26aufirst%3DI.%26aulast%3DUmezu%26aufirst%3DK.%26aulast%3DWalker%26aufirst%3DR.%2BT.%26aulast%3DMori%26aufirst%3DS.%26aulast%3DIto%26aufirst%3DM.%26aulast%3DShigeta%26aufirst%3DS.%26aulast%3DMiyasaka%26aufirst%3DT.%26atitle%3DHighly%2520potent%2520and%2520selective%2520inhibition%2520of%2520human%2520immunodeficiency%2520virus%2520type%25201%2520by%2520a%2520novel%2520series%2520of%25206-substituted%2520acyclouridine%2520derivatives%26jtitle%3DMol.%2520Pharmacol.%26date%3D1991%26volume%3D39%26spage%3D805%26epage%3D810" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baba, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shigeta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuasa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takashima, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sekiya, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ubasawa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyasaka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span> <span> </span><span class="NLM_article-title">Preclinical evaluation of MKC-442, a highly potent and specific inhibitor of human immunodeficiency virus type 1 <i>in vitro</i></span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">688</span>– <span class="NLM_lpage">692</span>, <span class="refDoi"> DOI: 10.1128/AAC.38.4.688</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1128%2FAAC.38.4.688" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=7518216" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADyaK2cXis1SltLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=1994&pages=688-692&author=M.+Babaauthor=S.+Shigetaauthor=S.+Yuasaauthor=H.+Takashimaauthor=K.+Sekiyaauthor=M.+Ubasawaauthor=H.+Tanakaauthor=T.+Miyasakaauthor=R.+T.+Walkerauthor=E.+De+Clercq&title=Preclinical+evaluation+of+MKC-442%2C+a+highly+potent+and+specific+inhibitor+of+human+immunodeficiency+virus+type+1+in+vitro&doi=10.1128%2FAAC.38.4.688"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical evaluation of MKC-442, a highly potent and specific inhibitor of human immunodeficiency virus type 1 in vitro</span></div><div class="casAuthors">Baba, Masanori; Shigeta, Shiro; Yuasa, Satoshi; Takashima, Hideaki; Sekiya, Kouichi; Ubasawa, Masaru; Tanaka, Hiromichi; Miyasaka, Tadashi; Walker, Richard T.; De Clercq, Erik</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">688-92</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    </div><div class="casAbstract">MKC-442 (6-benzyl-1-ethoxymethyl-5-isopropyluracil or I-EBU) has recently been identified as a highly potent and specific inhibitor of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase.  Since the compd. has favorable pharmacokinetic and toxicity profiles in vivo, the authors have evaluated MKC-442 for its inhibitory effect on the replication of HIV-1 in various cell cultures, including human peripheral blood lymphocytes and monocyte-macrophages.  The 50 and 90% effective concns. for HIV-1 (HTLV-IIIB strain) replication in MT-4 cells were 15 and 98 nM, resp.  MKC-442 was also inhibitory to HIV-1 replication in peripheral blood lymphocytes and monocyte-macrophages as detd. by the prodn. of p24 antigens in the culture supernatant.  Fluorescence-activated cell sorter anal. revealed that MKC-442 was equally active against zidovudine-resistant mutants and zidovudine-susceptible strains.  Furthermore, combinations of MKC-442 with either 3'-azido-3'-deoxythymidine, 2',3'-dideoxycytidine, or 2',3'-dideoxyinosine synergistically inhibited the replication of HIV-1.  Thus, MKC-442 has been considered as a candidate for clin. efficacy studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoU-uQYSEovsbVg90H21EOLACvtfcHk0lirLGXTqEd39Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXis1SltLo%253D&md5=9afb2a93369d5bdf1d734c4148902677</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1128%2FAAC.38.4.688&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.38.4.688%26sid%3Dliteratum%253Aachs%26aulast%3DBaba%26aufirst%3DM.%26aulast%3DShigeta%26aufirst%3DS.%26aulast%3DYuasa%26aufirst%3DS.%26aulast%3DTakashima%26aufirst%3DH.%26aulast%3DSekiya%26aufirst%3DK.%26aulast%3DUbasawa%26aufirst%3DM.%26aulast%3DTanaka%26aufirst%3DH.%26aulast%3DMiyasaka%26aufirst%3DT.%26aulast%3DWalker%26aufirst%3DR.%2BT.%26aulast%3DDe%2BClercq%26aufirst%3DE.%26atitle%3DPreclinical%2520evaluation%2520of%2520MKC-442%252C%2520a%2520highly%2520potent%2520and%2520specific%2520inhibitor%2520of%2520human%2520immunodeficiency%2520virus%2520type%25201%2520in%2520vitro%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D1994%26volume%3D38%26spage%3D688%26epage%3D692%26doi%3D10.1128%2FAAC.38.4.688" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baeten, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palanee-Phillips, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soto-Torres, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Govender, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mgodi, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matovu Kiweewa, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nair, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mhlanga, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siva, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bekker, L.-G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeenarain, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaffoor, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinson, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makanani, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pather, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naidoo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Husnik, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parikh, U. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mellors, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marzinke, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendrix, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Straten, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramjee, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chirenje, Z. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakabiito, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taha, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheckter, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berthiaume, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Livant, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ndase, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patterson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Germuga, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galaska, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bunge, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szydlo, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montgomery, E. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mensch, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torjesen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grossman, C. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chakhtoura, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenberg, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGowan, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hillier, S.</span></span> <span> </span><span class="NLM_article-title">Use of a vaginal ring containing dapivirine for HIV-1 prevention in women</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>375</i></span>,  <span class="NLM_fpage">2121</span>– <span class="NLM_lpage">2132</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1506110</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1056%2FNEJMoa1506110" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=26900902" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADC%252BC28XitFaqt7%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=375&publication_year=2016&pages=2121-2132&author=J.+M.+Baetenauthor=T.+Palanee-Phillipsauthor=E.+R.+Brownauthor=K.+Schwartzauthor=L.+E.+Soto-Torresauthor=V.+Govenderauthor=N.+M.+Mgodiauthor=F.+Matovu+Kiweewaauthor=G.+Nairauthor=F.+Mhlangaauthor=S.+Sivaauthor=L.-G.+Bekkerauthor=N.+Jeenarainauthor=Z.+Gaffoorauthor=F.+Martinsonauthor=B.+Makananiauthor=A.+Patherauthor=L.+Naidooauthor=M.+Husnikauthor=B.+A.+Richardsonauthor=U.+M.+Parikhauthor=J.+W.+Mellorsauthor=M.+A.+Marzinkeauthor=C.+W.+Hendrixauthor=A.+van+der+Stratenauthor=G.+Ramjeeauthor=Z.+M.+Chirenjeauthor=C.+Nakabiitoauthor=T.+E.+Tahaauthor=J.+Jonesauthor=A.+Mayoauthor=R.+Scheckterauthor=J.+Berthiaumeauthor=E.+Livantauthor=C.+Jacobsonauthor=P.+Ndaseauthor=R.+Whiteauthor=K.+Pattersonauthor=D.+Germugaauthor=B.+Galaskaauthor=K.+Bungeauthor=D.+Singhauthor=D.+W.+Szydloauthor=E.+T.+Montgomeryauthor=B.+S.+Menschauthor=K.+Torjesenauthor=C.+I.+Grossmanauthor=N.+Chakhtouraauthor=A.+Nelauthor=Z.+Rosenbergauthor=I.+McGowanauthor=S.+Hillier&title=Use+of+a+vaginal+ring+containing+dapivirine+for+HIV-1+prevention+in+women&doi=10.1056%2FNEJMoa1506110"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Use of a vaginal ring containing dapivirine for HIV-1 prevention in women</span></div><div class="casAuthors">Baeten, J. M.; Palanee-Phillips, T.; Brown, E. R.; Schwartz, K.; Soto-Torres, L. E.; Govender, V.; Mgodi, N. M.; Kiweewa, F. Matovu; Nair, G.; Mhlanga, F.; Siva, S.; Bekker, L.-G.; Jeenarain, N.; Gaffoor, Z.; Martinson, F.; Makanani, B.; Pather, A.; Naidoo, L.; Husnik, M.; Richardson, B. A.; Parikh, U. M.; Mellors, J. W.; Marzinke, M. A.; Hendrix, C. W.; van der Straten, A.; Ramjee, G.; Chirenje, Z. M.; Nakabiito, C.; Taha, T. E.; Jones, J.; Mayo, A.; Scheckter, R.; Berthiaume, J.; Livant, E.; Jacobson, C.; Ndase, P.; White, R.; Patterson, K.; Germuga, D.; Galaska, B.; Bunge, K.; Singh, D.; Szydlo, D. W.; Montgomery, E. T.; Mensch, B. S.; Torjesen, K.; Grossman, C. I.; Chakhtoura, N.; Nel, A.; Rosenberg, Z.; McGowan, I.; Hillier, S.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">375</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">2121-2132</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND Antiretroviral medications that are used as prophylaxis can prevent acquisition of human immunodeficiency virus type 1 (HIV-1) infection.  However, in clin. trials among African women, the incidence of HIV-1 infection was not reduced, probably because of low adherence.  Longer-acting methods of drug delivery, such as vaginal rings, may simplify use of antiretroviral medications and provide HIV-1 protection.  METHODS We conducted a phase 3, randomized, double-blind, placebo-controlled trial of a monthly vaginal ring contg. dapivirine, a non-nucleoside HIV-1 reverse-transcriptase inhibitor, involving women between the ages of 18 and 45 years in Malawi, South Africa, Uganda, and Zimbabwe.  RESULTS Among the 2629 women who were enrolled, 168 HIV-1 infections occurred: 71 in the dapivirine group and 97 in the placebo group (incidence, 3.3 and 4.5 per 100 personyears, resp.).  The incidence of HIV-1 infection in the dapivirine group was lower by 27% (95% confidence interval [CI], 1 to 46; P = 0.046) than that in the placebo group.  In an anal. that excluded data from two sites that had reduced rates of retention and adherence, the incidence of HIV-1 infection in the dapivirine group was lower by 37% (95% CI, 12 to 56; P = 0.007) than that in the placebo group.  In a post hoc anal., higher rates of HIV-1 protection were obsd. among women over the age of 21 years (56%; 95% CI, 31 to 71; P<0.001) but not among those 21 years of age or younger (-27%; 95% CI, -133 to 31; P = 0.45), a difference that was correlated with reduced adherence.  The rates of adverse medical events and antiretroviral resistance among women who acquired HIV-1 infection were similar in the two groups.  CONCLUSIONS A monthly vaginal ring contg. dapivirine reduced the risk of HIV-1 infection among African women, with increased efficacy in subgroups with evidence of increased adherence.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohJjDza7DrCrVg90H21EOLACvtfcHk0lgUZ8s2y64XPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitFaqt7%252FN&md5=be3a0c5c5d1a57d7b3343d84b9a28e9c</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1506110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1506110%26sid%3Dliteratum%253Aachs%26aulast%3DBaeten%26aufirst%3DJ.%2BM.%26aulast%3DPalanee-Phillips%26aufirst%3DT.%26aulast%3DBrown%26aufirst%3DE.%2BR.%26aulast%3DSchwartz%26aufirst%3DK.%26aulast%3DSoto-Torres%26aufirst%3DL.%2BE.%26aulast%3DGovender%26aufirst%3DV.%26aulast%3DMgodi%26aufirst%3DN.%2BM.%26aulast%3DMatovu%2BKiweewa%26aufirst%3DF.%26aulast%3DNair%26aufirst%3DG.%26aulast%3DMhlanga%26aufirst%3DF.%26aulast%3DSiva%26aufirst%3DS.%26aulast%3DBekker%26aufirst%3DL.-G.%26aulast%3DJeenarain%26aufirst%3DN.%26aulast%3DGaffoor%26aufirst%3DZ.%26aulast%3DMartinson%26aufirst%3DF.%26aulast%3DMakanani%26aufirst%3DB.%26aulast%3DPather%26aufirst%3DA.%26aulast%3DNaidoo%26aufirst%3DL.%26aulast%3DHusnik%26aufirst%3DM.%26aulast%3DRichardson%26aufirst%3DB.%2BA.%26aulast%3DParikh%26aufirst%3DU.%2BM.%26aulast%3DMellors%26aufirst%3DJ.%2BW.%26aulast%3DMarzinke%26aufirst%3DM.%2BA.%26aulast%3DHendrix%26aufirst%3DC.%2BW.%26aulast%3Dvan%2Bder%2BStraten%26aufirst%3DA.%26aulast%3DRamjee%26aufirst%3DG.%26aulast%3DChirenje%26aufirst%3DZ.%2BM.%26aulast%3DNakabiito%26aufirst%3DC.%26aulast%3DTaha%26aufirst%3DT.%2BE.%26aulast%3DJones%26aufirst%3DJ.%26aulast%3DMayo%26aufirst%3DA.%26aulast%3DScheckter%26aufirst%3DR.%26aulast%3DBerthiaume%26aufirst%3DJ.%26aulast%3DLivant%26aufirst%3DE.%26aulast%3DJacobson%26aufirst%3DC.%26aulast%3DNdase%26aufirst%3DP.%26aulast%3DWhite%26aufirst%3DR.%26aulast%3DPatterson%26aufirst%3DK.%26aulast%3DGermuga%26aufirst%3DD.%26aulast%3DGalaska%26aufirst%3DB.%26aulast%3DBunge%26aufirst%3DK.%26aulast%3DSingh%26aufirst%3DD.%26aulast%3DSzydlo%26aufirst%3DD.%2BW.%26aulast%3DMontgomery%26aufirst%3DE.%2BT.%26aulast%3DMensch%26aufirst%3DB.%2BS.%26aulast%3DTorjesen%26aufirst%3DK.%26aulast%3DGrossman%26aufirst%3DC.%2BI.%26aulast%3DChakhtoura%26aufirst%3DN.%26aulast%3DNel%26aufirst%3DA.%26aulast%3DRosenberg%26aufirst%3DZ.%26aulast%3DMcGowan%26aufirst%3DI.%26aulast%3DHillier%26aufirst%3DS.%26atitle%3DUse%2520of%2520a%2520vaginal%2520ring%2520containing%2520dapivirine%2520for%2520HIV-1%2520prevention%2520in%2520women%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2016%26volume%3D375%26spage%3D2121%26epage%3D2132%26doi%3D10.1056%2FNEJMoa1506110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Niekerk, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kapiga, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bekker, L.-G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gama, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gill, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamali, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kotze, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Louw, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mabude, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miti, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kusemererwa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tempelman, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carstens, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devlin, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isaacs, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malherbe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mans, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nuttall, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russell, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ntshele, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smit, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solai, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spence, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steytler, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Windle, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borremans, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Resseler, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Roey, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parys, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vangeneugden, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Baelen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenberg, Z.</span></span> <span> </span><span class="NLM_article-title">Safety and efficacy of a dapivirine vaginal ring for HIV prevention in women</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>375</i></span>,  <span class="NLM_fpage">2133</span>– <span class="NLM_lpage">2143</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1602046</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1056%2FNEJMoa1602046" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=27959766" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADC%252BC28XitFaqt7%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=375&publication_year=2016&pages=2133-2143&author=A.+Nelauthor=N.+van+Niekerkauthor=S.+Kapigaauthor=L.-G.+Bekkerauthor=C.+Gamaauthor=K.+Gillauthor=A.+Kamaliauthor=P.+Kotzeauthor=C.+Louwauthor=Z.+Mabudeauthor=N.+Mitiauthor=S.+Kusemererwaauthor=H.+Tempelmanauthor=H.+Carstensauthor=B.+Devlinauthor=M.+Isaacsauthor=M.+Malherbeauthor=W.+Mansauthor=J.+Nuttallauthor=M.+Russellauthor=S.+Ntsheleauthor=M.+Smitauthor=L.+Solaiauthor=P.+Spenceauthor=J.+Steytlerauthor=K.+Windleauthor=M.+Borremansauthor=S.+Resselerauthor=J.+Van+Roeyauthor=W.+Parysauthor=T.+Vangeneugdenauthor=B.+Van+Baelenauthor=Z.+Rosenberg&title=Safety+and+efficacy+of+a+dapivirine+vaginal+ring+for+HIV+prevention+in+women&doi=10.1056%2FNEJMoa1602046"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Safety and efficacy of a dapivirine vaginal ring for HIV prevention in women</span></div><div class="casAuthors">Nel, A.; van Niekerk, N.; Kapiga, S.; Bekker, L.-G.; Gama, C.; Gill, K.; Kamali, A.; Kotze, P.; Louw, C.; Mabude, Z.; Miti, N.; Kusemererwa, S.; Tempelman, H.; Carstens, H.; Devlin, B.; Isaacs, M.; Malherbe, M.; Mans, W.; Nuttall, J.; Russell, M.; Ntshele, S.; Smit, M.; Solai, L.; Spence, P.; Steytler, J.; Windle, K.; Borremans, M.; Resseler, S.; Van Roey, J.; Parys, W.; Vangeneugden, T.; Van Baelen, B.; Rosenberg, Z.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">375</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">2133-2143</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: The incidence of human immunodeficiency virus (HIV) infection remains high among women in sub-Saharan Africa.  We evaluated the safety and efficacy of extended use of a vaginal ring contg. dapivirine for the prevention of HIV infection in 1959 healthy, sexually active women, 18 to 45 years of age, from seven communities in South Africa and Uganda.  METHODS: In this randomized, double-blind, placebo-controlled, phase 3 trial, we randomly assigned participants in a 2:1 ratio to receive vaginal rings contg. either 25 mg of dapivirine or placebo.  Participants inserted the rings themselves every 4 wk for up to 24 mo.  The primary efficacy end point was the rate of HIV type 1 (HIV-1) seroconversion.  RESULTS: A total of 77 participants in the dapivirine group underwent HIV-1 seroconversion during 1888 person-years of follow-up (4.1 seroconversions per 100 person-years), as compared with 56 in the placebo group who underwent HIV-1 seroconversion during 917 person-years of follow-up (6.1 seroconversions per 100 person-years).  The incidence of HIV-1 infection was 31% lower in the dapivirine group than in the placebo group (hazard ratio, 0.69; 95% confidence interval [CI], 0.49 to 0.99; P = 0.04).  There was no significant difference in efficacy of the dapivirine ring among women older than 21 years of age (hazard ratio for infection, 0.63; 95% CI, 0.41 to 0.97) and those 21 years of age or younger (hazard ratio, 0.85; 95% CI, 0.45 to 1.60; P = 0.43 for treatment-by-age interaction).  Among participants with HIV-1 infection, nonnucleoside reverse-transcriptase inhibitor resistance mutations were detected in 14 of 77 participants in the dapivirine group (18.2%) and in 9 of 56 (16.1%) in the placebo group.  Serious adverse events occurred more often in the dapivirine group (in 38 participants [2.9%]) than in the placebo group (in 6 [0.9%]).  However, no clear pattern was identified.  CONCLUSIONS: Among women in sub-Saharan Africa, the dapivirine ring was not assocd. with any safety concerns and was assocd. with a rate of acquisition of HIV-1 infection that was lower than the rate with placebo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_wx1pEUBBCrVg90H21EOLACvtfcHk0lgUZ8s2y64XPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitFaqt7%252FM&md5=970e69fc1a0fc725671e9e372fba6737</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1602046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1602046%26sid%3Dliteratum%253Aachs%26aulast%3DNel%26aufirst%3DA.%26aulast%3Dvan%2BNiekerk%26aufirst%3DN.%26aulast%3DKapiga%26aufirst%3DS.%26aulast%3DBekker%26aufirst%3DL.-G.%26aulast%3DGama%26aufirst%3DC.%26aulast%3DGill%26aufirst%3DK.%26aulast%3DKamali%26aufirst%3DA.%26aulast%3DKotze%26aufirst%3DP.%26aulast%3DLouw%26aufirst%3DC.%26aulast%3DMabude%26aufirst%3DZ.%26aulast%3DMiti%26aufirst%3DN.%26aulast%3DKusemererwa%26aufirst%3DS.%26aulast%3DTempelman%26aufirst%3DH.%26aulast%3DCarstens%26aufirst%3DH.%26aulast%3DDevlin%26aufirst%3DB.%26aulast%3DIsaacs%26aufirst%3DM.%26aulast%3DMalherbe%26aufirst%3DM.%26aulast%3DMans%26aufirst%3DW.%26aulast%3DNuttall%26aufirst%3DJ.%26aulast%3DRussell%26aufirst%3DM.%26aulast%3DNtshele%26aufirst%3DS.%26aulast%3DSmit%26aufirst%3DM.%26aulast%3DSolai%26aufirst%3DL.%26aulast%3DSpence%26aufirst%3DP.%26aulast%3DSteytler%26aufirst%3DJ.%26aulast%3DWindle%26aufirst%3DK.%26aulast%3DBorremans%26aufirst%3DM.%26aulast%3DResseler%26aufirst%3DS.%26aulast%3DVan%2BRoey%26aufirst%3DJ.%26aulast%3DParys%26aufirst%3DW.%26aulast%3DVangeneugden%26aufirst%3DT.%26aulast%3DVan%2BBaelen%26aufirst%3DB.%26aulast%3DRosenberg%26aufirst%3DZ.%26atitle%3DSafety%2520and%2520efficacy%2520of%2520a%2520dapivirine%2520vaginal%2520ring%2520for%2520HIV%2520prevention%2520in%2520women%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2016%26volume%3D375%26spage%3D2133%26epage%3D2143%26doi%3D10.1056%2FNEJMoa1602046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tantillo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobo-Molina, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nanni, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyer, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pauwels, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andries, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janssen, P. A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnold, E.</span></span> <span> </span><span class="NLM_article-title">Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse tTranscriptase: implications for mechanisms of drug inhibition and resistance</span>. <i>J. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>243</i></span>,  <span class="NLM_fpage">369</span>– <span class="NLM_lpage">387</span>, <span class="refDoi"> DOI: 10.1006/jmbi.1994.1665</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1006%2Fjmbi.1994.1665" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=7525966" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADyaK2cXmvFWrt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=243&publication_year=1994&pages=369-387&author=C.+Tantilloauthor=J.+Dingauthor=A.+Jacobo-Molinaauthor=R.+G.+Nanniauthor=P.+L.+Boyerauthor=S.+H.+Hughesauthor=R.+Pauwelsauthor=K.+Andriesauthor=P.+A.+J.+Janssenauthor=E.+Arnold&title=Locations+of+anti-AIDS+drug+binding+sites+and+resistance+mutations+in+the+three-dimensional+structure+of+HIV-1+reverse+tTranscriptase%3A+implications+for+mechanisms+of+drug+inhibition+and+resistance&doi=10.1006%2Fjmbi.1994.1665"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase: implications for mechanisms of drug inhibition and resistance</span></div><div class="casAuthors">Tantillo, Chris; Ding, Jianping; Jacobo-Molina, Alfredo; Nanni, Raymond G.; Boyer, Paul L.; Hughes, Stephen H.; Pauwels, Rudi; Andries, Koen; Janssen, Paul A. J.; Arnold, Edward</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">243</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">369-87</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Academic</span>)
        </div><div class="casAbstract">A review with many refs.  The locations HIV-1 reverse transcriptase (RT) nucleoside and non-nucleoside inhibitor-binding sites and inhibitor-resistance mutations are analyzed in the context of the three-dimensional structure of the enzyme and implications for mechanisms of drug inhibition and resistance are discussed.  In order to help identify residues that may play a role in inhibitor binding, solvent accessibilities of amino acids that comprise the inhibitor-binding sites in the structure of HIV-1 RT complexed with a dsDNA template-primer are anal.  While some mutations that cause resistance to nucleoside analogs, such as AZT, ddI, and ddC, are located near enough to the dNTP-binding site to directly interfere with binding of nucleoside analogs, many are located away from the dNTP-binding site and more likely confer resistance by other mechanisms.  Many of the latter mutations are located on the surface of the DNA-binding cleft and may lead to altered template-primer positioning or conformation, causing a distortion of the geometry of the polymerase active site and consequent discrimination between normal and altered dNTP substrates.  Other nucleoside analog-resistance mutations located on the periphery of the dNTP-binding site may exert their effects via altered interactions with dNTP-binding site residues.  The structure of the hydrophobic region in HIV-I RT that binds non-nucleoside inhibitors, for example, nevirapine and TIBO, has been analyzed in the absence of bound ligand.  The pocket that is present when non-nucleoside inhibitors are bound is not obsd. in the inhibitor-free structure of HIV-1 RT with dsDNA.  In particular, it is filled by Tyr181 and Tyr188, suggesting that the pocket is formed primarily by rotation of these large arom. side chains.  Existing biochem. data, taken together with the three-dimensional structure of HIV-I RT, makes it possible to propose potential mechanisms of inhibition by non-nucleoside inhibitors.  One such mechanism is local distortion of HIV-1 RT structural elements thought to participate in catalysis: the β9-β10 hairpin (which contains polymerase active site residues) and the β12-β13 hairpin ("primer grip").  An alternative possibility is restricted mobility of the p66 thumb subdomain, which is supported by the observation that structural elements of the non-nucleoside inhibitor-binding pocket may act as a "hinge" for the thumb.  Mutations that have been shown to confer resistance to non-nucleoside inhibitors are obsd. to cluster around the pocket, suggest that most of these resistance mutations lead to direct alteration of inhibitor binding.  A comparison of residues in the non-nucleoside inhibitor-binding pocket of HIV-1 RT and the corresponding residues in HIV-2 RT can explain the low activity of non-nucleoside compds. against HIV-2 RT.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRLzLpBoN22LVg90H21EOLACvtfcHk0lgG8VkGGkqVhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXmvFWrt7k%253D&md5=212f30b81658c8549abdacf4af19f1c6</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1006%2Fjmbi.1994.1665&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fjmbi.1994.1665%26sid%3Dliteratum%253Aachs%26aulast%3DTantillo%26aufirst%3DC.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DJacobo-Molina%26aufirst%3DA.%26aulast%3DNanni%26aufirst%3DR.%2BG.%26aulast%3DBoyer%26aufirst%3DP.%2BL.%26aulast%3DHughes%26aufirst%3DS.%2BH.%26aulast%3DPauwels%26aufirst%3DR.%26aulast%3DAndries%26aufirst%3DK.%26aulast%3DJanssen%26aufirst%3DP.%2BA.%2BJ.%26aulast%3DArnold%26aufirst%3DE.%26atitle%3DLocations%2520of%2520anti-AIDS%2520drug%2520binding%2520sites%2520and%2520resistance%2520mutations%2520in%2520the%2520three-dimensional%2520structure%2520of%2520HIV-1%2520reverse%2520tTranscriptase%253A%2520implications%2520for%2520mechanisms%2520of%2520drug%2520inhibition%2520and%2520resistance%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D1994%26volume%3D243%26spage%3D369%26epage%3D387%26doi%3D10.1006%2Fjmbi.1994.1665" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ding, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moereels, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koymans, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andries, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janssen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnold, E.</span></span> <span> </span><span class="NLM_article-title">Structure of HIV-1 RT/TIBO R 86183 complex reveals similarity in the binding of diverse nonnucleoside inhibitors</span>. <i>Nat. Struct. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">407</span>– <span class="NLM_lpage">415</span>, <span class="refDoi"> DOI: 10.1038/nsb0595-407</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1038%2Fnsb0595-407" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=1995&pages=407-415&author=J.+Dingauthor=K.+Dasauthor=H.+Moereelsauthor=L.+Koymansauthor=P.+Andriesauthor=S.+Janssenauthor=E.+Hughesauthor=E.+Arnold&title=Structure+of+HIV-1+RT%2FTIBO+R+86183+complex+reveals+similarity+in+the+binding+of+diverse+nonnucleoside+inhibitors&doi=10.1038%2Fnsb0595-407"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1038%2Fnsb0595-407&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsb0595-407%26sid%3Dliteratum%253Aachs%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DDas%26aufirst%3DK.%26aulast%3DMoereels%26aufirst%3DH.%26aulast%3DKoymans%26aufirst%3DL.%26aulast%3DAndries%26aufirst%3DP.%26aulast%3DJanssen%26aufirst%3DS.%26aulast%3DHughes%26aufirst%3DE.%26aulast%3DArnold%26aufirst%3DE.%26atitle%3DStructure%2520of%2520HIV-1%2520RT%252FTIBO%2520R%252086183%2520complex%2520reveals%2520similarity%2520in%2520the%2520binding%2520of%2520diverse%2520nonnucleoside%2520inhibitors%26jtitle%3DNat.%2520Struct.%2520Mol.%2520Biol.%26date%3D1995%26volume%3D2%26spage%3D407%26epage%3D415%26doi%3D10.1038%2Fnsb0595-407" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chimirri, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grasso, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monforte, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monforte, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zappalà, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruno, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicolò, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pannecouque, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witvrouw, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span> <span> </span><span class="NLM_article-title">Synthesis, structure and in vitro anti-human immunodeficiency virus activity of novel 3-Methyl-1H,3H-Thiazolo[3,4-a]Benzimidazoles</span>. <i>Antiviral Chem. Chemother.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">431</span>– <span class="NLM_lpage">438</span>, <span class="refDoi"> DOI: 10.1177/095632029800900507</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1177%2F095632029800900507" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=9875396" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADyaK1cXmsFCmsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=1998&pages=431-438&author=A.+Chimirriauthor=S.+Grassoauthor=A.+Monforteauthor=P.+Monforteauthor=A.+Raoauthor=M.+Zappal%C3%A0author=G.+Brunoauthor=F.+Nicol%C3%B2author=C.+Pannecouqueauthor=M.+Witvrouwauthor=E.+De+Clercq&title=Synthesis%2C+structure+and+in+vitro+anti-human+immunodeficiency+virus+activity+of+novel+3-Methyl-1H%2C3H-Thiazolo%5B3%2C4-a%5DBenzimidazoles&doi=10.1177%2F095632029800900507"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, structure and in vitro anti-human immunodeficiency virus activity of novel 3-methyl-1H,3H-thiazolo[3,4-a]benzimidazoles</span></div><div class="casAuthors">Chimirri, A.; Monforte, A. M.; Monforte, P.; Rao, A.; Zappala, M.; Bruno, G.; Nicolo, F.; Pannecouque, C.; Witvrouw, M.; De Clercq, E.</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Chemistry & Chemotherapy</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">431-438</span>CODEN:
                <span class="NLM_cas:coden">ACCHEH</span>;
        ISSN:<span class="NLM_cas:issn">0956-3202</span>.
    
            (<span class="NLM_cas:orgname">International Medical Press</span>)
        </div><div class="casAbstract">A series of novel 1-aryl-3-methyl-1H,3H-thiazolo[3,4-a]benzimidazoles (TBZ analogs) were synthesized and investigated as anti-human immunodeficiency virus (HIV) agents to study the effects of structural modifications on antiviral activity and cytotoxicity.  They were proved to inhibit significantly HIV-1 replication in vitro without showing inhibitory activity on HIV-2 or simian immunodeficiency virus.  Their potency was influenced by the presence of suitable substituents in the Ph ring at C-1 as well as by their stereochem. characteristics.  In fact, the most active compd. of the series was the trans-1-(2,6-difluorophenyl)-3-methyl-1H,3H-thiazolo[3,4-a]benzimidazole, in which the butterfly-like conformation is stabilized by two intramol. hydrogen bonds between the fluorine atoms and H-1 and H-3.  This was made possible by the trans arrangement of C-1 and C-3 substituents, as shown by x-ray and NMR anal.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVKhkh2GecubVg90H21EOLACvtfcHk0lgG8VkGGkqVhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXmsFCmsrk%253D&md5=ebf72ed3bd2963fc2b3794c1a4071a05</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1177%2F095632029800900507&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F095632029800900507%26sid%3Dliteratum%253Aachs%26aulast%3DChimirri%26aufirst%3DA.%26aulast%3DGrasso%26aufirst%3DS.%26aulast%3DMonforte%26aufirst%3DA.%26aulast%3DMonforte%26aufirst%3DP.%26aulast%3DRao%26aufirst%3DA.%26aulast%3DZappal%25C3%25A0%26aufirst%3DM.%26aulast%3DBruno%26aufirst%3DG.%26aulast%3DNicol%25C3%25B2%26aufirst%3DF.%26aulast%3DPannecouque%26aufirst%3DC.%26aulast%3DWitvrouw%26aufirst%3DM.%26aulast%3DDe%2BClercq%26aufirst%3DE.%26atitle%3DSynthesis%252C%2520structure%2520and%2520in%2520vitro%2520anti-human%2520immunodeficiency%2520virus%2520activity%2520of%2520novel%25203-Methyl-1H%252C3H-Thiazolo%255B3%252C4-a%255DBenzimidazoles%26jtitle%3DAntiviral%2520Chem.%2520Chemother.%26date%3D1998%26volume%3D9%26spage%3D431%26epage%3D438%26doi%3D10.1177%2F095632029800900507" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span> <span> </span><span class="NLM_article-title">Non-nucleoside reverse transcriptase inhibitors (NNRTIs): past, present and future</span>. <i>Chem. Biodiversity</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">44</span>– <span class="NLM_lpage">64</span>, <span class="refDoi"> DOI: 10.1002/cbdv.200490012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1002%2Fcbdv.200490012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=17191775" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADC%252BD2cXitV2nsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2004&pages=44-64&author=E.+De+Clercq&title=Non-nucleoside+reverse+transcriptase+inhibitors+%28NNRTIs%29%3A+past%2C+present+and+future&doi=10.1002%2Fcbdv.200490012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Non-nucleoside reverse transcriptase inhibitors (NNRTIs): past, present, and future</span></div><div class="casAuthors">De Clercq, Erik</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biodiversity</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">44-64</span>CODEN:
                <span class="NLM_cas:coden">CBHIAM</span>;
        ISSN:<span class="NLM_cas:issn">1612-1872</span>.
    
            (<span class="NLM_cas:orgname">Verlag Helvetica Chimica Acta AG</span>)
        </div><div class="casAbstract">A review with refs.  Non-nucleoside reverse transcriptase (RT) inhibitors (NNRTIs) have become an inherent ingredient of the drug combination schemes that are currently used in the treatment of human immunodeficiency virus type 1 (HIV-1) infections.  Starting from the 1-[(2-hydroxyethoxy)methyl]-6-(phenylsulfanyl)thymine (HEPT) and 4,5,6,7-tetrahydroimidazo[4,5,1-jk][1,4]benzodiazepin-2(1H)-one and -thione (TIBO) derivs., numerous classes of compds. have been described as NNRTIs.  Only three compds. have so far been approved for clin. use: nevirapine, delavirdine, and efavirenz.  NNRTIs are notorious for rapidly leading to virus-drug resistance development, primarily based on the emergence of the K103N and Y181C mutations in the HIV-1 RT.  Newer NNRTIs, such as capravirine, dapivirine (TMC 125), and DPC 083, are resilient to these "NNRTI" mutations, and, therefore, offer considerable promise as future anti-HIV-1 drugs.  NNRTIs are targeted at a specific "pocket" binding site within the HIV-1 RT, that is distinct from, but both spatially and functionally related to, the catalytic site, where the nucleoside RT inhibitors (NRTIs) and nucleotide RT inhibitors (NtRTIs) interact.  NNRTIs have acquired a definitive position, as part of a combination regimen with NRTIs and NtRTIs, in the first-line treatment of HIV-1 infections.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjIKlSEqbUHLVg90H21EOLACvtfcHk0lhYjkG3GjFEwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXitV2nsrY%253D&md5=4e681cc76745c156d8494e57136fd777</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1002%2Fcbdv.200490012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcbdv.200490012%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BClercq%26aufirst%3DE.%26atitle%3DNon-nucleoside%2520reverse%2520transcriptase%2520inhibitors%2520%2528NNRTIs%2529%253A%2520past%252C%2520present%2520and%2520future%26jtitle%3DChem.%2520Biodiversity%26date%3D2004%26volume%3D1%26spage%3D44%26epage%3D64%26doi%3D10.1002%2Fcbdv.200490012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Janssen, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewi, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnold, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daeyaert, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Jonge, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heeres, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koymans, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vinkers, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guillemont, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasquier, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kukla, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ludovici, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andries, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Bethune, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pauwels, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, A. D.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frenkel, Y. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medaer, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Knaep, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohets, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Clerck, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lampo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoffels, P.</span></span> <span> </span><span class="NLM_article-title">In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2- pyrimidinyl]amino]benzonitrile (R278474, rilpivirine)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">1901</span>– <span class="NLM_lpage">1909</span>, <span class="refDoi"> DOI: 10.1021/jm040840e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm040840e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADC%252BD2cXptlOisb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=1901-1909&author=P.+A.+Janssenauthor=P.+J.+Lewiauthor=E.+Arnoldauthor=F.+Daeyaertauthor=M.+de+Jongeauthor=J.+Heeresauthor=L.+Koymansauthor=M.+Vinkersauthor=J.+Guillemontauthor=E.+Pasquierauthor=M.+Kuklaauthor=D.+Ludoviciauthor=K.+Andriesauthor=M.+P.+de+Bethuneauthor=R.+Pauwelsauthor=K.+Dasauthor=A.+D.+Clarkauthor=Y.+V.+Frenkelauthor=S.+H.+Hughesauthor=B.+Medaerauthor=F.+De+Knaepauthor=H.+Bohetsauthor=F.+De+Clerckauthor=A.+Lampoauthor=P.+Williamsauthor=P.+Stoffels&title=In+search+of+a+novel+anti-HIV+drug%3A+multidisciplinary+coordination+in+the+discovery+of+4-%5B%5B4-%5B%5B4-%5B%281E%29-2-cyanoethenyl%5D-2%2C6-dimethylphenyl%5Damino%5D-2-+pyrimidinyl%5Damino%5Dbenzonitrile+%28R278474%2C+rilpivirine%29&doi=10.1021%2Fjm040840e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">In Search of a Novel Anti-HIV Drug: Multidisciplinary Coordination in the Discovery of 4-[[4-[[4-[(1E)-2-Cyanoethenyl]-2,6-dimethylphenyl]amino]-2- pyrimidinyl]amino]benzonitrile (R278474, Rilpivirine)</span></div><div class="casAuthors">Janssen, Paul A. J.; Lewi, Paul J.; Arnold, Eddy; Daeyaert, Frits; de Jonge, Marc; Heeres, Jan; Koymans, Luc; Vinkers, Maarten; Guillemont, Jerome; Pasquier, Elisabeth; Kukla, Mike; Ludovici, Don; Andries, Koen; de Bethune, Marie-Pierre; Pauwels, Rudi; Das, Kalyan; Clark, Art D., Jr.; Frenkel, Yulia Volovik; Hughes, Stephen H.; Medaer, Bart; De Knaep, Fons; Bohets, Hilde; De Clerck, Fred; Lampo, Ann; Williams, Peter; Stoffels, Paul</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1901-1909</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Ideally, an anti-HIV drug should (1) be highly active against wild-type and mutant HIV without allowing breakthrough; (2) have high oral bioavailability and long elimination half-life, allowing once-daily oral treatment at low doses; (3) have minimal adverse effects; and (4) be easy to synthesize and formulate.  R278474, a new diarylpyrimidine (DAPY) non-nucleoside reverse transcriptase inhibitor (NNRTI), appears to meet these criteria and to be suitable for high compliance oral treatment of HIV-1 infection.  The discovery of R278474 was the result of a coordinated multidisciplinary effort involving medicinal chemists, virologists, crystallographers, mol. modelers, toxicologists, anal. chemists, pharmacists, and many others.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8upgC3x1GuLVg90H21EOLACvtfcHk0lhYjkG3GjFEwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXptlOisb8%253D&md5=d4b650dcaa248d5cdb1dd500135c8f7e</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1021%2Fjm040840e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm040840e%26sid%3Dliteratum%253Aachs%26aulast%3DJanssen%26aufirst%3DP.%2BA.%26aulast%3DLewi%26aufirst%3DP.%2BJ.%26aulast%3DArnold%26aufirst%3DE.%26aulast%3DDaeyaert%26aufirst%3DF.%26aulast%3Dde%2BJonge%26aufirst%3DM.%26aulast%3DHeeres%26aufirst%3DJ.%26aulast%3DKoymans%26aufirst%3DL.%26aulast%3DVinkers%26aufirst%3DM.%26aulast%3DGuillemont%26aufirst%3DJ.%26aulast%3DPasquier%26aufirst%3DE.%26aulast%3DKukla%26aufirst%3DM.%26aulast%3DLudovici%26aufirst%3DD.%26aulast%3DAndries%26aufirst%3DK.%26aulast%3Dde%2BBethune%26aufirst%3DM.%2BP.%26aulast%3DPauwels%26aufirst%3DR.%26aulast%3DDas%26aufirst%3DK.%26aulast%3DClark%26aufirst%3DA.%2BD.%26aulast%3DFrenkel%26aufirst%3DY.%2BV.%26aulast%3DHughes%26aufirst%3DS.%2BH.%26aulast%3DMedaer%26aufirst%3DB.%26aulast%3DDe%2BKnaep%26aufirst%3DF.%26aulast%3DBohets%26aufirst%3DH.%26aulast%3DDe%2BClerck%26aufirst%3DF.%26aulast%3DLampo%26aufirst%3DA.%26aulast%3DWilliams%26aufirst%3DP.%26aulast%3DStoffels%26aufirst%3DP.%26atitle%3DIn%2520search%2520of%2520a%2520novel%2520anti-HIV%2520drug%253A%2520multidisciplinary%2520coordination%2520in%2520the%2520discovery%2520of%25204-%255B%255B4-%255B%255B4-%255B%25281E%2529-2-cyanoethenyl%255D-2%252C6-dimethylphenyl%255Damino%255D-2-%2520pyrimidinyl%255Damino%255Dbenzonitrile%2520%2528R278474%252C%2520rilpivirine%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D1901%26epage%3D1909%26doi%3D10.1021%2Fjm040840e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pauwels, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baba, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schols, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakashima, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balzarini, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debyser, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murrer, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thornton, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bridger, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fricker, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henson, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abrams, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Picker, D.</span></span> <span> </span><span class="NLM_article-title">Potent and selective inhibition of human immunodeficiency virus (HIV)-1 and HIV-2 replication by a class of bicyclams interacting with a viral uncoating event</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>89</i></span>,  <span class="NLM_fpage">5286</span>– <span class="NLM_lpage">5290</span>, <span class="refDoi"> DOI: 10.1073/pnas.89.12.5286</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1073%2Fpnas.89.12.5286" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1608936" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADyaK38XkvVaqtro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=1992&pages=5286-5290&author=E.+De+Clercqauthor=N.+Yamamotoauthor=R.+Pauwelsauthor=M.+Babaauthor=D.+Scholsauthor=H.+Nakashimaauthor=J.+Balzariniauthor=Z.+Debyserauthor=B.+A.+Murrerauthor=D.+Schwartzauthor=D.+Thorntonauthor=G.+Bridgerauthor=S.+Frickerauthor=G.+Hensonauthor=M.+Abramsauthor=D.+Picker&title=Potent+and+selective+inhibition+of+human+immunodeficiency+virus+%28HIV%29-1+and+HIV-2+replication+by+a+class+of+bicyclams+interacting+with+a+viral+uncoating+event&doi=10.1073%2Fpnas.89.12.5286"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Potent and selective inhibition of human immunodeficiency virus (HIV)-1 and HIV-2 replication by a class of cicyclams interacting with a viral uncoating event</span></div><div class="casAuthors">De Clercq, Erik; Yamamoto, Naohiko; Pauwels, Rudi; Baba, Masanori; Schols, Dominique; Nakashima, Hideki; Balzarini, Jan; Debyser, Zeger; Murrer, Barry A.; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5286-90</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    </div><div class="casAbstract">A series of bicyclams have been shown to be potent and selective inhibitors of human immunodeficiency virus (HIV).  The compds. are inhibitory to the replication of various HIV-1 and HIV-2 strains in various human T-cell systems, including peripheral blood lymphocytes, at 0.14-1.4 μM, without being toxic to the host cells at 2.2 mM.  The bicyclam JM2763 (I) is active against 3'-azido-3'-deoxythymidine (zidovudine; AZT)-resistant HIV-1 strains and acts additively with AZT.  Mechanism of action studies revealed that the bicyclams (i.e., I) interact with an early event of the retrovirus replicative cycle, which could be tentatively identified as a viral uncoating event.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdkZ-WLPGwyLVg90H21EOLACvtfcHk0lipOz87QBmkOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38XkvVaqtro%253D&md5=67db6384097fedeb73572d8f7628be34</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1073%2Fpnas.89.12.5286&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.89.12.5286%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BClercq%26aufirst%3DE.%26aulast%3DYamamoto%26aufirst%3DN.%26aulast%3DPauwels%26aufirst%3DR.%26aulast%3DBaba%26aufirst%3DM.%26aulast%3DSchols%26aufirst%3DD.%26aulast%3DNakashima%26aufirst%3DH.%26aulast%3DBalzarini%26aufirst%3DJ.%26aulast%3DDebyser%26aufirst%3DZ.%26aulast%3DMurrer%26aufirst%3DB.%2BA.%26aulast%3DSchwartz%26aufirst%3DD.%26aulast%3DThornton%26aufirst%3DD.%26aulast%3DBridger%26aufirst%3DG.%26aulast%3DFricker%26aufirst%3DS.%26aulast%3DHenson%26aufirst%3DG.%26aulast%3DAbrams%26aufirst%3DM.%26aulast%3DPicker%26aufirst%3DD.%26atitle%3DPotent%2520and%2520selective%2520inhibition%2520of%2520human%2520immunodeficiency%2520virus%2520%2528HIV%2529-1%2520and%2520HIV-2%2520replication%2520by%2520a%2520class%2520of%2520bicyclams%2520interacting%2520with%2520a%2520viral%2520uncoating%2520event%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1992%26volume%3D89%26spage%3D5286%26epage%3D5290%26doi%3D10.1073%2Fpnas.89.12.5286" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pauwels, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balzarini, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witvrouw, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Vreese, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debyser, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenwirth, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peichl, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Datema, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thornton, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skerlj, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaul, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padmanabhan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bridger, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henson, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abrams, M.</span></span> <span> </span><span class="NLM_article-title">Highly potent and selective inhibition of human immunodeficiency virus by the bicyclam derivative JM3100</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">668</span>– <span class="NLM_lpage">674</span>, <span class="refDoi"> DOI: 10.1128/AAC.38.4.668</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1128%2FAAC.38.4.668" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=7913308" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A280%3ADyaK2czgsVWjtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=1994&pages=668-674&author=E.+De+Clercqauthor=N.+Yamamotoauthor=R.+Pauwelsauthor=J.+Balzariniauthor=M.+Witvrouwauthor=K.+De+Vreeseauthor=Z.+Debyserauthor=B.+Rosenwirthauthor=P.+Peichlauthor=R.+Datemaauthor=D.+Thorntonauthor=R.+Skerljauthor=F.+Gaulauthor=S.+Padmanabhanauthor=G.+Bridgerauthor=G.+Hensonauthor=M.+Abrams&title=Highly+potent+and+selective+inhibition+of+human+immunodeficiency+virus+by+the+bicyclam+derivative+JM3100&doi=10.1128%2FAAC.38.4.668"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Highly potent and selective inhibition of human immunodeficiency virus by the bicyclam derivative JM3100</span></div><div class="casAuthors">De Clercq E; Yamamoto N; Pauwels R; Balzarini J; Witvrouw M; De Vreese K; Debyser Z; Rosenwirth B; Peichl P; Datema R</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial agents and chemotherapy</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">668-74</span>
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    </div><div class="casAbstract">Bicyclams, in which the cyclam (1,4,8,11-tetraazacyclotetradecane) moieties are tethered via an aliphatic bridge (i.e., propylene, as in JM2763) are potent and selective inhibitors of human immunodeficiency virus type 1 (HIV-1) and type 2 (HIV-2) (E.  De Clercq, N.  Yamamoto, R.  Pauwels, M.  Baba, D.  Schols, H.  Nakashima, J.  Balzarini, Z.  Debyser, B.  A.  Murrer, D.  Schwartz, D.  Thornton, G.  Bridger, S.  Fricker, G.  Henson, M.  Abrams, and D.  Picker, Proc.  Natl.  Acad.  Sci.  USA 89:5286-5290, 1992).  We have now found that the bicyclam JM3100, in which the cyclam moieties are tethered by an aromatic bridge [i.e., phenylenebis(methylene)], inhibits the replication of various HIV-1 and HIV-2 strains in various cell lines at a 50% effective concentration (EC50) of 1 to 10 ng/ml, which is about 100-fold lower than the concentration required for JM2763 to inhibit HIV replication and at least 100,000-fold lower than the cytotoxic concentration (> 500 micrograms/ml).  In primary T4 lymphocytes or primary monocytes, JM3100 proved inhibitory to HIV-1(IIIB) and several clinical HIV-1 isolates at an EC50 of less than 1 ng/ml.  On the basis of time-of-addition experiments, JM3100 appeared to interact with a viral uncoating event, and this was further corroborated by an uncoating assay in which RNase sensitivity of [5-3H]uridine-labeled virions was monitored.  In addition, but possibly mechanistically related, JM3100 blocks formation of infectious particles.  JM3100 was also found to interfere directly with virus-induced syncytium formation, albeit at a higher concentration (1 to 2 microgram/ml) than that required for inhibition of viral replication.  Following subcutaneous injection of 10 mg of JM3100 per kg of body weight to rabbits, anti-HIV activity was detected in serum corresponding to serum drug levels exceeding for at least 6 h by >100-fold the EC(50) required to inhibit HIV replication in vitro.  When combined with either 3'-azido-2',3' -dideoxythymidine or 2',3' -dideoxyinosine, JM3100 achieved a additive inhibition of HIV replication, and when repeatedly subcultivated in the presence of JM3100, the virus remained sensitive to the compound for at least 30 passages (120 days) in cell culture.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTwBIyQ7x-DR8K3uFsUIZtkfW6udTcc2ebVXkB-kIvwXLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK2czgsVWjtQ%253D%253D&md5=8dc19841c28dcd2ce9277898f69addf1</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1128%2FAAC.38.4.668&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.38.4.668%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BClercq%26aufirst%3DE.%26aulast%3DYamamoto%26aufirst%3DN.%26aulast%3DPauwels%26aufirst%3DR.%26aulast%3DBalzarini%26aufirst%3DJ.%26aulast%3DWitvrouw%26aufirst%3DM.%26aulast%3DDe%2BVreese%26aufirst%3DK.%26aulast%3DDebyser%26aufirst%3DZ.%26aulast%3DRosenwirth%26aufirst%3DB.%26aulast%3DPeichl%26aufirst%3DP.%26aulast%3DDatema%26aufirst%3DR.%26aulast%3DThornton%26aufirst%3DD.%26aulast%3DSkerlj%26aufirst%3DR.%26aulast%3DGaul%26aufirst%3DF.%26aulast%3DPadmanabhan%26aufirst%3DS.%26aulast%3DBridger%26aufirst%3DG.%26aulast%3DHenson%26aufirst%3DG.%26aulast%3DAbrams%26aufirst%3DM.%26atitle%3DHighly%2520potent%2520and%2520selective%2520inhibition%2520of%2520human%2520immunodeficiency%2520virus%2520by%2520the%2520bicyclam%2520derivative%2520JM3100%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D1994%26volume%3D38%26spage%3D668%26epage%3D674%26doi%3D10.1128%2FAAC.38.4.668" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schols, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esté, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henson, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span> <span> </span><span class="NLM_article-title">Bicyclams, a class of potent anti-HIV agents, are targeted at the HIV coreceptor fusin/CXCR-4</span>. <i>Antiviral Res.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">147</span>– <span class="NLM_lpage">156</span>, <span class="refDoi"> DOI: 10.1016/S0166-3542(97)00025-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1016%2FS0166-3542%2897%2900025-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=9298754" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADyaK2sXltl2nt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=1997&pages=147-156&author=D.+Scholsauthor=J.+A.+Est%C3%A9author=G.+Hensonauthor=E.+De+Clercq&title=Bicyclams%2C+a+class+of+potent+anti-HIV+agents%2C+are+targeted+at+the+HIV+coreceptor+fusin%2FCXCR-4&doi=10.1016%2FS0166-3542%2897%2900025-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Bicyclams, a class of potent anti-HIV agents, are targeted at the HIV coreceptor Fusin/CXCR-4</span></div><div class="casAuthors">Schols, Dominique; Este, JoseA.; Henson, Geoffrey; De Clercq, Erik</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">147-156</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Bicyclams are a novel class of antiviral compds. which are highly potent and selective inhibitors of the replication of HIV-1 and HIV-2.  The prototype compd., AMD3100, has an IC50 of 1-10 ng/mL, which is a least 100000 fold lower than the cytotoxic concn.  AMD3100 does not inhibit virus binding to the CD4 receptor and based on time-of-addn. expts., has been assumed to interact with the HIV fusion-uncoating process.  Resistance of HIV-1 strains to AMD3100 is assocd. with the accumulation of several mutations in the viral envelope glycoprotein gp120.  Here, we demonstrate that AMD3100 interacts with fusin (CXCR-4), the coreceptor used by T-tropic viruses to infect the target cells.  The replication of NL4-3 wild type virus and NL4-3 dextran sulfate-resistant virus was inhibited by the CXC-chemokine, stromal cell-derived factor 1 (SDF-1), the natural ligand for CXCR-4.  In contrast, the replication of the HIV-1 NL4-3 AMD3100-resistant virus was no longer inhibited by SDF-1.  The bicyclams are the first low-mol.-wt. anti-HIV agents shown to interact with the coreceptor for T-tropic viruses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGNGBTNI6aUrVg90H21EOLACvtfcHk0lipOz87QBmkOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXltl2nt7w%253D&md5=f718cc6007c7874c015c9724903aa1e5</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1016%2FS0166-3542%2897%2900025-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0166-3542%252897%252900025-9%26sid%3Dliteratum%253Aachs%26aulast%3DSchols%26aufirst%3DD.%26aulast%3DEst%25C3%25A9%26aufirst%3DJ.%2BA.%26aulast%3DHenson%26aufirst%3DG.%26aulast%3DDe%2BClercq%26aufirst%3DE.%26atitle%3DBicyclams%252C%2520a%2520class%2520of%2520potent%2520anti-HIV%2520agents%252C%2520are%2520targeted%2520at%2520the%2520HIV%2520coreceptor%2520fusin%252FCXCR-4%26jtitle%3DAntiviral%2520Res.%26date%3D1997%26volume%3D35%26spage%3D147%26epage%3D156%26doi%3D10.1016%2FS0166-3542%2897%2900025-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schols, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Struyf, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Damme, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esté, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henson, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span> <span> </span><span class="NLM_article-title">Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor CXCR4</span>. <i>J. Exp. Med.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>186</i></span>,  <span class="NLM_fpage">1383</span>– <span class="NLM_lpage">1388</span>, <span class="refDoi"> DOI: 10.1084/jem.186.8.1383</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1084%2Fjem.186.8.1383" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=9334378" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADyaK2sXmvVelu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=186&publication_year=1997&pages=1383-1388&author=D.+Scholsauthor=S.+Struyfauthor=J.+Van+Dammeauthor=J.+Est%C3%A9author=G.+Hensonauthor=E.+De+Clercq&title=Inhibition+of+T-tropic+HIV+strains+by+selective+antagonization+of+the+chemokine+receptor+CXCR4&doi=10.1084%2Fjem.186.8.1383"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor CXCR4</span></div><div class="casAuthors">Schols, Dominique; Struyf, Sofie; Van Damme, Jo; Este, Jose A.; Henson, Geoffrey; De Clercq, Erik</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Experimental Medicine</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">186</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1383-1388</span>CODEN:
                <span class="NLM_cas:coden">JEMEAV</span>;
        ISSN:<span class="NLM_cas:issn">0022-1007</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">Bicyclams are a novel class of antiviral compds. that are highly potent and selective inhibitors of the replication of HIV-1 and HIV-2.  Surprisingly, however, when the prototype compd. AMD3100 was tested against M-tropic virus strains such as BaL, ADA, JR-CSF, and SF-162 in human peripheral blood mononuclear cells, the compd. was completely inactive.  Because of the specific and potent inhibitory effect of AMD3100 on T-tropic viruses, but not M-tropic viruses, it was verified that AMD3100 interacts with the CXC-chemokine receptor CXCR4, the main coreceptor used by T-tropic viruses.  AMD3100 dose dependently inhibited the binding of a specific CXCR4 monoclonal antibody to SUP-T1 cells as measured by flow cytometry.  It did not inhibit the binding of the biotinylated CC-chemokine macrophage inflammatory protein (MIP) α1 or MIP-1β, ligands for the chemokine receptor CCR5 (the main coreceptor for M-tropic viruses).  In addn., AMD3100 completely blocked (a) the Ca2+ flux at 100 ng/mL in lymphocytic SUP-T1 and monocytic THP-1 cells, and (b) the chemotactic responses of THP-1 cells induced by stromal cell-derived factor 1α, the natural ligand for CXCR4.  Finally, AMD3100 had no effect on the Ca2+ flux induced by the CC-chemokines MIP-1α, regulated on activation normal T cell expressed and secreted (RANTES; also a ligand for CCR5), or monocyte chemoattractant protein 3 (a ligand for CCR1 and CCR2b), nor was it able to induce Ca2+ fluxes by itself.  The bicyclams are, to our knowledge, the first low mol. wt. anti-HIV agents shown to act as potent and selective CXCR4 antagonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQ5dssLvsuLrVg90H21EOLACvtfcHk0lgWKkMMlQMUxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXmvVelu7s%253D&md5=1d0dce8df250d0723de73cf83c98d92a</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1084%2Fjem.186.8.1383&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1084%252Fjem.186.8.1383%26sid%3Dliteratum%253Aachs%26aulast%3DSchols%26aufirst%3DD.%26aulast%3DStruyf%26aufirst%3DS.%26aulast%3DVan%2BDamme%26aufirst%3DJ.%26aulast%3DEst%25C3%25A9%26aufirst%3DJ.%26aulast%3DHenson%26aufirst%3DG.%26aulast%3DDe%2BClercq%26aufirst%3DE.%26atitle%3DInhibition%2520of%2520T-tropic%2520HIV%2520strains%2520by%2520selective%2520antagonization%2520of%2520the%2520chemokine%2520receptor%2520CXCR4%26jtitle%3DJ.%2520Exp.%2520Med.%26date%3D1997%26volume%3D186%26spage%3D1383%26epage%3D1388%26doi%3D10.1084%2Fjem.186.8.1383" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hendrix, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flexner, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacFarland, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giandomenico, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuchs, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Redpath, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bridger, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henson, G. W.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">1667</span>– <span class="NLM_lpage">1673</span>, <span class="refDoi"> DOI: 10.1128/AAC.44.6.1667-1673.2000</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1128%2FAAC.44.6.1667-1673.2000" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10817726" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADC%252BD3cXjs1Ols70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2000&pages=1667-1673&author=C.+W.+Hendrixauthor=C.+Flexnerauthor=R.+T.+MacFarlandauthor=C.+Giandomenicoauthor=E.+J.+Fuchsauthor=E.+Redpathauthor=G.+Bridgerauthor=G.+W.+Henson&title=Pharmacokinetics+and+safety+of+AMD-3100%2C+a+novel+antagonist+of+the+CXCR-4+chemokine+receptor%2C+in+human+volunteers&doi=10.1128%2FAAC.44.6.1667-1673.2000"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers</span></div><div class="casAuthors">Hendrix, Craig W.; Flexner, Charles; MacFarland, Ronald T.; Giandomenico, Christen; Fuchs, Edward J.; Redpath, Ella; Bridger, Gary; Henson, Geoffrey W.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1667-1673</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">AMD-3100, a bicyclam, is a novel agent that uniquely inhibits the entry of human immunodeficiency virus type 1 (HIV-1) into CD4+ T cells via selective blockade of the chemokine CXCR-4 receptor.  Twelve healthy volunteers were given AMD-3100 as a single 15-min i.v. infusion at 10, 20, 40, or 80 μg/kg.  Five subjects also received a single s.c. injection of AMD-3100 (40 or 80 μg/kg).  Three subjects received two escalating oral doses each (80 and 160 μg/kg).  All subjects tolerated their dose(s) well without any grade 2 toxicity or dose adjustment.  Six subjects experienced mild, transient symptoms, primarily gastrointestinal in nature and not dose related.  All subjects experienced a dose-related elevation of the white blood cell count, from 1.5 to 3.1 times the baseline, which returned to the baseline 24 h after dosing.  AMD-3100 demonstrated dose proportionality for the max. drug concn. in serum (Cmax) and the area under the concn.-time curve from 0 h to ∞ (AUC0-∞) over the entire dose range.  At the highest i.v. dose (80 μg/kg), the median Cmax was 515 (range, 470 to 521) ng/mL and the AUC0-∞ was 1,044 (range, 980 to 1,403) ng-h/mL.  The median systemic absorption after s.c. dosing was 87% (range, 67 to 106%).  No drug was detectable in the blood following oral dosing.  Using a two-compartment model, the median pharmacokinetic parameter ests. (ranges) were as follows: vol. of distribution, 0.34 (0.27 to 0.36) liter/kg; clearance, 1.30 (0.97 to 1.34) liters/h; elimination half-life, 3.6 (3.5 to 4.9) h.  After a single, well-tolerated i.v. dose of AMD-3100, concns. were sustained for 12 h above the in vitro antiretroviral 90% inhibitory concns. and for 8 h above antiviral concns. identified in the SCID-hu Thy/Liv mouse model of HIV infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqE-1RkZBONd7Vg90H21EOLACvtfcHk0lgWKkMMlQMUxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXjs1Ols70%253D&md5=972608b60b1d2cb7a0150ebd0280b629</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1128%2FAAC.44.6.1667-1673.2000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.44.6.1667-1673.2000%26sid%3Dliteratum%253Aachs%26aulast%3DHendrix%26aufirst%3DC.%2BW.%26aulast%3DFlexner%26aufirst%3DC.%26aulast%3DMacFarland%26aufirst%3DR.%2BT.%26aulast%3DGiandomenico%26aufirst%3DC.%26aulast%3DFuchs%26aufirst%3DE.%2BJ.%26aulast%3DRedpath%26aufirst%3DE.%26aulast%3DBridger%26aufirst%3DG.%26aulast%3DHenson%26aufirst%3DG.%2BW.%26atitle%3DPharmacokinetics%2520and%2520safety%2520of%2520AMD-3100%252C%2520a%2520novel%2520antagonist%2520of%2520the%2520CXCR-4%2520chemokine%2520receptor%252C%2520in%2520human%2520volunteers%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2000%26volume%3D44%26spage%3D1667%26epage%3D1673%26doi%3D10.1128%2FAAC.44.6.1667-1673.2000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liles, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broxmeyer, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodger, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hübel, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hangoc, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bridger, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henson, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calandra, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dale, D. C.</span></span> <span> </span><span class="NLM_article-title">Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>102</i></span>,  <span class="NLM_fpage">2728</span>– <span class="NLM_lpage">2730</span>, <span class="refDoi"> DOI: 10.1182/blood-2003-02-0663</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1182%2Fblood-2003-02-0663" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=12855591" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADC%252BD3sXotF2ntb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2003&pages=2728-2730&author=W.+C.+Lilesauthor=H.+E.+Broxmeyerauthor=E.+Rodgerauthor=B.+Woodauthor=K.+H%C3%BCbelauthor=S.+Cooperauthor=G.+Hangocauthor=G.+J.+Bridgerauthor=G.+W.+Hensonauthor=G.+Calandraauthor=D.+C.+Dale&title=Mobilization+of+hematopoietic+progenitor+cells+in+healthy+volunteers+by+AMD3100%2C+a+CXCR4+antagonist&doi=10.1182%2Fblood-2003-02-0663"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist</span></div><div class="casAuthors">Liles, W. Conrad; Broxmeyer, Hal E.; Rodger, Elin; Wood, Brent; Huebel, Kai; Cooper, Scott; Hangoc, Giao; Bridger, Gary J.; Henson, Geoffrey W.; Calandra, Gary; Dale, David C.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2728-2730</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Stromal cell-derived factor 1 (SDF1/CXCL12) and its cognate receptor, CXCR4, play key regulatory roles in CD34+ cell trafficking.  We investigated whether AMD3100, a selective CXCR4 antagonist, could mobilize hematopoietic progenitor cells from marrow to peripheral blood in healthy human volunteers.  Initially, 10 persons each received a single dose of AMD3100 (80 μg/kg s.c.), which induced rapid, generalized leukocytosis assocd. with an increase in peripheral blood CD34+ cells, representing pluripotent hematopoietic progenitors by in vitro colony-forming unit assays, from 3.8 ± 0.5/μL to 20.7 ± 3.5/μL at 6 h.  Subsequent dose-response studies showed a max. increase in circulating CD34+ cells from 2.6 ± 0.3/μL to 40.4 ± 3.4/μL at 9 h after 240 μg/kg AMD3100.  Serial administration of AMD3100 (80 μg/kg/d for 3 days) resulted in consistent, reversible increases in peripheral blood CD34+ cells.  AMD3100 was well tolerated and caused only mild, transient toxicity.  These findings suggest potential clin. application of AMD3100 for CD34+ cell mobilization and collection for hematopoietic stem cell transplantation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTITlBQQs3EbVg90H21EOLACvtfcHk0lgWKkMMlQMUxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXotF2ntb8%253D&md5=c0a000f9ac7f12cf85f4bd086f205240</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1182%2Fblood-2003-02-0663&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2003-02-0663%26sid%3Dliteratum%253Aachs%26aulast%3DLiles%26aufirst%3DW.%2BC.%26aulast%3DBroxmeyer%26aufirst%3DH.%2BE.%26aulast%3DRodger%26aufirst%3DE.%26aulast%3DWood%26aufirst%3DB.%26aulast%3DH%25C3%25BCbel%26aufirst%3DK.%26aulast%3DCooper%26aufirst%3DS.%26aulast%3DHangoc%26aufirst%3DG.%26aulast%3DBridger%26aufirst%3DG.%2BJ.%26aulast%3DHenson%26aufirst%3DG.%2BW.%26aulast%3DCalandra%26aufirst%3DG.%26aulast%3DDale%26aufirst%3DD.%2BC.%26atitle%3DMobilization%2520of%2520hematopoietic%2520progenitor%2520cells%2520in%2520healthy%2520volunteers%2520by%2520AMD3100%252C%2520a%2520CXCR4%2520antagonist%26jtitle%3DBlood%26date%3D2003%26volume%3D102%26spage%3D2728%26epage%3D2730%26doi%3D10.1182%2Fblood-2003-02-0663" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Broxmeyer, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orschell, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clapp, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hangoc, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plett, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liles, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham-Evans, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calandra, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bridger, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dale, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srour, E. F.</span></span> <span> </span><span class="NLM_article-title">Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist</span>. <i>J. Exp. Med.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>201</i></span>,  <span class="NLM_fpage">1307</span>– <span class="NLM_lpage">1318</span>, <span class="refDoi"> DOI: 10.1084/jem.20041385</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1084%2Fjem.20041385" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=15837815" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjs1Citbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=201&publication_year=2005&pages=1307-1318&author=H.+E.+Broxmeyerauthor=C.+M.+Orschellauthor=D.+W.+Clappauthor=G.+Hangocauthor=S.+Cooperauthor=P.+A.+Plettauthor=W.+C.+Lilesauthor=X.+Liauthor=B.+Graham-Evansauthor=T.+B.+Campbellauthor=G.+Calandraauthor=G.+Bridgerauthor=D.+C.+Daleauthor=E.+F.+Srour&title=Rapid+mobilization+of+murine+and+human+hematopoietic+stem+and+progenitor+cells+with+AMD3100%2C+a+CXCR4+antagonist&doi=10.1084%2Fjem.20041385"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist</span></div><div class="casAuthors">Broxmeyer, Hal E.; Orschell, Christie M.; Clapp, D. Wade; Hangoc, Giao; Cooper, Scott; Plett, P. Artur; Liles, W. Conrad; Li, Xiaxin; Graham-Evans, Barbara; Campbell, Timothy B.; Calandra, Gary; Bridger, Gary; Dale, David C.; Srour, Edward F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Experimental Medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">201</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1307-1318</span>CODEN:
                <span class="NLM_cas:coden">JEMEAV</span>;
        ISSN:<span class="NLM_cas:issn">0022-1007</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">Improving approaches for hematopoietic stem cell (HSC) and hematopoietic progenitor cell (HPC) mobilization is clin. important because increased nos. of these cells are needed for enhanced transplantation.  Chemokine stromal cell derived factor-1 (also known as CXCL12) is believed to be involved in retention of HSCs and HPCs in bone marrow.  AMD3100, a selective antagonist of CXCL12 that binds to its receptor, CXCR4, was evaluated in murine and human systems for mobilizing capacity, alone and in combination with granulocyte colony-stimulating factor (G-CSF).  AMD3100 induced rapid mobilization of mouse and human HPCs and synergistically augmented G-CSF-induced mobilization of HPCs.  AMD3100 also mobilized murine long-term repopulating (LTR) cells that engrafted primary and secondary lethally-irradiated mice, and human CD34+ cells that can repopulate nonobese diabetic-severe combined immunodeficiency (SCID) mice.  AMD3100 synergized with G-CSF to mobilize murine LTR cells and human SCID repopulating cells (SRCs).  Human CD34+ cells isolated after treatment with G-CSF plus AMD3100 expressed a phenotype that was characteristic of highly engrafting mouse HSCs.  Synergy of AMD3100 and G-CSF in mobilization was due to enhanced nos. and perhaps other characteristics of the mobilized cells.  These results support the hypothesis that the CXCL12-CXCR4 axis is involved in marrow retention of HSCs and HPCs, and demonstrate the clin. potential of AMD3100 for HSC mobilization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDUgOByTJX07Vg90H21EOLACvtfcHk0lixiHH9Jr33nA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjs1Citbo%253D&md5=e5942dc81a7687a8b7c10f9542cbf29d</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1084%2Fjem.20041385&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1084%252Fjem.20041385%26sid%3Dliteratum%253Aachs%26aulast%3DBroxmeyer%26aufirst%3DH.%2BE.%26aulast%3DOrschell%26aufirst%3DC.%2BM.%26aulast%3DClapp%26aufirst%3DD.%2BW.%26aulast%3DHangoc%26aufirst%3DG.%26aulast%3DCooper%26aufirst%3DS.%26aulast%3DPlett%26aufirst%3DP.%2BA.%26aulast%3DLiles%26aufirst%3DW.%2BC.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DGraham-Evans%26aufirst%3DB.%26aulast%3DCampbell%26aufirst%3DT.%2BB.%26aulast%3DCalandra%26aufirst%3DG.%26aulast%3DBridger%26aufirst%3DG.%26aulast%3DDale%26aufirst%3DD.%2BC.%26aulast%3DSrour%26aufirst%3DE.%2BF.%26atitle%3DRapid%2520mobilization%2520of%2520murine%2520and%2520human%2520hematopoietic%2520stem%2520and%2520progenitor%2520cells%2520with%2520AMD3100%252C%2520a%2520CXCR4%2520antagonist%26jtitle%3DJ.%2520Exp.%2520Med.%26date%3D2005%26volume%3D201%26spage%3D1307%26epage%3D1318%26doi%3D10.1084%2Fjem.20041385" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span> <span> </span><span class="NLM_article-title">The bicyclam AMD3100 story</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">581</span>– <span class="NLM_lpage">587</span>, <span class="refDoi"> DOI: 10.1038/nrd1134</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1038%2Fnrd1134" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=12815382" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADC%252BD3sXks1Oqsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2003&pages=581-587&author=E.+De+Clercq&title=The+bicyclam+AMD3100+story&doi=10.1038%2Fnrd1134"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Timeline: The bicyclam AMD3100 story</span></div><div class="casAuthors">De Clercq, Erik</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">581-587</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The discovery and development of the bicyclam AMD3100 - a chemokine receptor antagonist - has highlighted the therapeutic potential of such compds. in HIV infection, inflammatory diseases, cancer and stem-cell mobilization.  Here, the author describes the development process of AMD3100, which began about 15 yr ago with the isolation of an impurity, and the basis for the clin. application of AMD3100 and its congeners.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqB-TkHJ79RrbVg90H21EOLACvtfcHk0lixiHH9Jr33nA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXks1Oqsr8%253D&md5=cf8344ba0e19da8ffaadfe8c9b57200c</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1038%2Fnrd1134&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd1134%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BClercq%26aufirst%3DE.%26atitle%3DThe%2520bicyclam%2520AMD3100%2520story%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2003%26volume%3D2%26spage%3D581%26epage%3D587%26doi%3D10.1038%2Fnrd1134" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span> <span> </span><span class="NLM_article-title">The AMD3100 story: The path to the discovery of a stem cell mobilizer (Mozobil)</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">1655</span>– <span class="NLM_lpage">1664</span>, <span class="refDoi"> DOI: 10.1016/j.bcp.2008.12.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1016%2Fj.bcp.2008.12.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=19161986" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADC%252BD1MXkvVSqsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2009&pages=1655-1664&author=E.+De+Clercq&title=The+AMD3100+story%3A+The+path+to+the+discovery+of+a+stem+cell+mobilizer+%28Mozobil%29&doi=10.1016%2Fj.bcp.2008.12.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">The AMD3100 story: The path to the discovery of a stem cell mobilizer (Mozobil)</span></div><div class="casAuthors">De Clercq, Erik</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1655-1664</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  AMD3100 was found to inhibit HIV-1 and HIV-2 within the 1-10 nM concn. range while not being toxic to the host cells at concns. up to 500 μM, thus achieving a selectivity index of approx. 100,000.  The target of action was initially thought to be the viral envelope glycoprotein gp120.  It appeared only to be the indirect target.  The direct target of action turned out to be the co-receptor CXCR4 used by T-lymphotropic HIV strains (now referred to as X4 strains) to enter the cells.  Initial (phase I) clin. trials undertaken with AMD3100, as a prelude to its development as a candidate anti-HIV drug for the treatment of AIDS, showed an unexpected side effect: an increase in the white blood cell counts.  Apparently, AMD3100 specifically increased CD34+ hematopoietic stem cell counts in the peripheral blood.  Stromal derived factor 1 (SDF-1), through its interaction with CXCR4, retains the stem cells in the bone marrow (a process referred to as homing), and AMD3100 specifically antagonizes this interaction.  AMD3100 in combination with granulocyte colony-stimulating factor (G-CSF) resulted in the collection of more progenitor cells than G-CSF alone.  At present, the major indication for clin. use of AMD3100 (Mozobil) is the mobilization of hematopoietic stem cells from the bone marrow into the circulating blood for transplantation in patients with hematol. malignancies such as non-Hodgkin's lymphoma or multiple myeloma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-vof1PYEX37Vg90H21EOLACvtfcHk0lixiHH9Jr33nA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXkvVSqsbc%253D&md5=19d5f76b85ef1c09e41a4d17ffbb2463</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2008.12.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2008.12.014%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BClercq%26aufirst%3DE.%26atitle%3DThe%2520AMD3100%2520story%253A%2520The%2520path%2520to%2520the%2520discovery%2520of%2520a%2520stem%2520cell%2520mobilizer%2520%2528Mozobil%2529%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2009%26volume%3D77%26spage%3D1655%26epage%3D1664%26doi%3D10.1016%2Fj.bcp.2008.12.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span> <span> </span><span class="NLM_article-title">Recent advances on the use of the CXCR4 antagonist plerixafor (AMD3100, Mozobil) and potential of other CXCR4 antagonists as stem cell mobilizers</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>128</i></span>,  <span class="NLM_fpage">509</span>– <span class="NLM_lpage">518</span>, <span class="refDoi"> DOI: 10.1016/j.pharmthera.2010.08.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1016%2Fj.pharmthera.2010.08.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=20826182" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlKhs7zO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2010&pages=509-518&author=E.+De+Clercq&title=Recent+advances+on+the+use+of+the+CXCR4+antagonist+plerixafor+%28AMD3100%2C+Mozobil%29+and+potential+of+other+CXCR4+antagonists+as+stem+cell+mobilizers&doi=10.1016%2Fj.pharmthera.2010.08.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Recent advances on the use of the CXCR4 antagonist plerixafor (AMD3100, Mozobil) and potential of other CXCR4 antagonists as stem cell mobilizers</span></div><div class="casAuthors">De Clercq, Erik</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">128</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">509-518</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  AMD3100 was originally discovered as an anti-HIV agent effective in inhibiting the replication of HIV in vitro at nanomolar concns.  We found it to be a potent and selective antagonist of CXCR4, the receptor for the chemokine SDF-1 (now called CXCL12).  AMD3100 was then developed, and marketed, as a stem cell mobilizer, and renamed plerixafor (Mozobil).  The path to the discovery of Mozobil as a stem cell mobilizer was described in Biochem.  Pharmacol. 77: 1655-1664 (2009).  Here I review the recent advances that have consolidated the role of plerixafor in mobilizing hematopoietic stem cells (HSCs) and hematopoietic progenitor cells (HPCs) from the bone marrow into the blood circulation.  Plerixafor acts synergistically with granulocyte colony-stimulating factor (G-CSF), and its usefulness has been proven particularly for the mobilization of HSCs and HPCs for autologous stem cell transplantation in patients with non-Hodgkin's lymphoma (NHL) or multiple myeloma (MM).  Plerixafor also has great potential for the treatment of hematol. malignancies other than NHL and MM, and non-hematol. malignancies, and, eventually, several other diseases depending on the CXCL12-CXCR4 interaction.  Various AMD3100 analogs have been described (i.e. AMD11070, AMD3465, KRH-3955, T-140, and 4F-benzoyl-TN14003), primarily as potential anti-HIV agents.  They are all strong CXCR4 antagonists.  Their role in stem cell mobilization remains to be assessed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgNBMywfEvpbVg90H21EOLACvtfcHk0lhdsx4XUZdF3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlKhs7zO&md5=cb344c4a5966627126ec462e271e3d9e</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2010.08.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2010.08.009%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BClercq%26aufirst%3DE.%26atitle%3DRecent%2520advances%2520on%2520the%2520use%2520of%2520the%2520CXCR4%2520antagonist%2520plerixafor%2520%2528AMD3100%252C%2520Mozobil%2529%2520and%2520potential%2520of%2520other%2520CXCR4%2520antagonists%2520as%2520stem%2520cell%2520mobilizers%26jtitle%3DPharmacol.%2520Ther.%26date%3D2010%26volume%3D128%26spage%3D509%26epage%3D518%26doi%3D10.1016%2Fj.pharmthera.2010.08.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span> <span> </span><span class="NLM_article-title">AMD3100/CXCR4 inhibitor</span>. <i>Front. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">276</span>, <span class="refDoi"> DOI: 10.3389/fimmu.2015.00276</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.3389%2Ffimmu.2015.00276" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=26106388" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A280%3ADC%252BC2Mbmslaksg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=276&author=E.+De+Clercq&title=AMD3100%2FCXCR4+inhibitor&doi=10.3389%2Ffimmu.2015.00276"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">AMD3100/CXCR4 Inhibitor</span></div><div class="casAuthors">De Clercq Erik</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in immunology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">276</span>
        ISSN:<span class="NLM_cas:issn">1664-3224</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcThQWXPjMQFgkwlCcfExbvbfW6udTcc2eawYtfbtUwWybntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2Mbmslaksg%253D%253D&md5=29bd7fd37dca8c6c43a4c5abdf4b9fe2</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.3389%2Ffimmu.2015.00276&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffimmu.2015.00276%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BClercq%26aufirst%3DE.%26atitle%3DAMD3100%252FCXCR4%2520inhibitor%26jtitle%3DFront.%2520Immunol.%26date%3D2015%26volume%3D6%26spage%3D276%26doi%3D10.3389%2Ffimmu.2015.00276" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span>, <span> </span><span class="NLM_article-title">Mozobil (Plerixafor, AMD3100), 10 years after its approval by the US Food and Drug Administration (FDA)</span>.  <i>Antiviral Chem. Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume">27</span>, <span class="refDoi"> DOI: 10.1177/2040206619829382</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1177%2F2040206619829382" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=30776910" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2019&author=E.+De+Clercq&title=Mozobil+%28Plerixafor%2C+AMD3100%29%2C+10+years+after+its+approval+by+the+US+Food+and+Drug+Administration+%28FDA%29&doi=10.1177%2F2040206619829382"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1177%2F2040206619829382&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F2040206619829382%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BClercq%26aufirst%3DE.%26atitle%3DMozobil%2520%2528Plerixafor%252C%2520AMD3100%2529%252C%252010%2520years%2520after%2520its%2520approval%2520by%2520the%2520US%2520Food%2520and%2520Drug%2520Administration%2520%2528FDA%2529%26jtitle%3DAntiviral%2520Chem.%2520Chemother.%26date%3D2019%26volume%3D27%26doi%3D10.1177%2F2040206619829382" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Balzarini, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holý, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jindrich, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naesens, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snoeck, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schols, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span> <span> </span><span class="NLM_article-title">Differential antiherpesvirus and antiretrovirus effects of the (S) and (R) enantiomers of acyclic nucleoside phosphonates: potent and selective in vitro and in vivo antiretrovirus activities of (R)-9-(2-phosphonomethoxypropyl)-2,6-diaminopurine</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">332</span>– <span class="NLM_lpage">338</span>, <span class="refDoi"> DOI: 10.1128/AAC.37.2.332</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1128%2FAAC.37.2.332" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=8452366" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADyaK3sXhvVakurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=1993&pages=332-338&author=J.+Balzariniauthor=A.+Hol%C3%BDauthor=J.+Jindrichauthor=L.+Naesensauthor=R.+Snoeckauthor=D.+Scholsauthor=E.+De+Clercq&title=Differential+antiherpesvirus+and+antiretrovirus+effects+of+the+%28S%29+and+%28R%29+enantiomers+of+acyclic+nucleoside+phosphonates%3A+potent+and+selective+in+vitro+and+in+vivo+antiretrovirus+activities+of+%28R%29-9-%282-phosphonomethoxypropyl%29-2%2C6-diaminopurine&doi=10.1128%2FAAC.37.2.332"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Differential anti-herpes virus and anti-retrovirus effects of the (S) and (R) enantiomers of acyclic nucleoside phosphonates: potent and selective in vitro and in vivo antiretrovirus activities of (R)-9-(2-phosphonomethoxypropyl)-2,6-diaminopurine</span></div><div class="casAuthors">Balzarini, J.; Holy, A.; Jindrich, J.; Naesens, L.; Snoeck, R.; Schols, D.; De Clercq, E.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">332-8</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    </div><div class="casAbstract">The (S)- and (R)-enantiomers of acyclic purine nucleoside phosphonate analogs [i.e., 3-hydroxy-2-phosphonomethoxypropyl (HPMP) derivs., 3-fluoro-2-phosphonomethoxypropyl (FPMP) derivs., and 2-phosphonomethoxypropyl (PMP) derivs. of adenine (A), 2-aminopurine, 2,6-diaminopurine (DAP), and guanine (G)] were synthesized and evaluated for antiviral activity.  The HPMP derivs. were effective against DNA viruses but not RNA viruses or retroviruses.  In particular, (S)-HPMPA, (S)-HPMPDAP, and (R)- and (S)-HPMPG were exclusively inhibitory to herpes simplex virus type 1 (50% effective concns., 0.63, 0.22, 0.10, and 0.66 μM, resp.).  The FPMP and PMP derivs. showed marked inhibitory activities against retroviruses but not DNA viruses.  The (S)-enantiomer of FPMPA and the (R)-enantiomer of PMPA were ∼30- to 100-fold more effective against human immunodeficiency virus and Moloney murine sarcoma virus (MSV) than their enantiomeric counterparts.  In contrast, both (S)- and (R)-enantiomers of the DAP and G derivs. were equally effective against retroviruses, except for (R)-PMPDAP, which was 15- to 40-fold more inhibitory than (S)-PMPDAP.  (R)-PMPDAP emerged as the most potent and selective inhibitor of MSV-induced transformation of murine C3H/3T3 cells and human immunodeficiency virus-induced cytotoxicity in MT-4 and CEM cells (50% effective concn., ∼0.1 to 0.6 μM).  When administered i.p. in a single dose as low as 2 mg/kg, (R)-PMPDAP efficiently decreased MSV-induced tumor formation in newborn NMRI mice and significantly increased the survival time of MSV-infected mice.  In addn., upon oral administration of MSV-infected mice, (R)-PMPDAP showed marked antiretroviral efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGre_TvFcgxmE7Vg90H21EOLACvtfcHk0ljf0RBFtQ9wvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXhvVakurw%253D&md5=24c89ba7236fd3a24db4d9c9dc7c5f56</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1128%2FAAC.37.2.332&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.37.2.332%26sid%3Dliteratum%253Aachs%26aulast%3DBalzarini%26aufirst%3DJ.%26aulast%3DHol%25C3%25BD%26aufirst%3DA.%26aulast%3DJindrich%26aufirst%3DJ.%26aulast%3DNaesens%26aufirst%3DL.%26aulast%3DSnoeck%26aufirst%3DR.%26aulast%3DSchols%26aufirst%3DD.%26aulast%3DDe%2BClercq%26aufirst%3DE.%26atitle%3DDifferential%2520antiherpesvirus%2520and%2520antiretrovirus%2520effects%2520of%2520the%2520%2528S%2529%2520and%2520%2528R%2529%2520enantiomers%2520of%2520acyclic%2520nucleoside%2520phosphonates%253A%2520potent%2520and%2520selective%2520in%2520vitro%2520and%2520in%2520vivo%2520antiretrovirus%2520activities%2520of%2520%2528R%2529-9-%25282-phosphonomethoxypropyl%2529-2%252C6-diaminopurine%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D1993%26volume%3D37%26spage%3D332%26epage%3D338%26doi%3D10.1128%2FAAC.37.2.332" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Robbins, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srinivas, R. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bischofberger, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fridland, A.</span></span> <span> </span><span class="NLM_article-title">Anti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-<i>R</i>-(2-Phosphonomethoxypropyl)adenine (PMPA), Bis(isopropyloxymethylcarbonyl)PMPA</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">612</span>– <span class="NLM_lpage">617</span>, <span class="refDoi"> DOI: 10.1128/AAC.42.3.612</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1128%2FAAC.42.3.612" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=9517941" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADyaK1cXhvV2ktLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=1998&pages=612-617&author=B.+L.+Robbinsauthor=R.+V.+Srinivasauthor=C.+Kimauthor=N.+Bischofbergerauthor=A.+Fridland&title=Anti-human+immunodeficiency+virus+activity+and+cellular+metabolism+of+a+potential+prodrug+of+the+acyclic+nucleoside+phosphonate+9-R-%282-Phosphonomethoxypropyl%29adenine+%28PMPA%29%2C+Bis%28isopropyloxymethylcarbonyl%29PMPA&doi=10.1128%2FAAC.42.3.612"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2-phosphonomethoxypropyl)adenine (PMPA), bis(isopropyloxymethylcarbonyl)PMPA</span></div><div class="casAuthors">Robbins, Brian L.; Srinivas, Ranga V.; Kim, Choung; Bischofberger, Norbert; Fridland, Arnold</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">612-617</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Bis(isopropyloxymethylcarbonyl) 9-R-(2-phosphonomethoxypropyl)adenine [bis(POC)PMPA] has been identified as a novel prodrug of PMPA.  The anti-human immunodeficiency virus activity of bis(POC)PMPA was >100-fold greater than that of PMPA in both an established T-cell line and primary peripheral blood lymphocytes.  This improved efficacy was shown to be due to a rapid intracellular uptake of the prodrug resulting in an increased intracellular accumulation of PMPA diphosphate (PMPApp), the pharmacol. active metabolite.  PMPApp levels in bis(POC)PMPA-treated cells exceeded by >1000-fold the levels seen in cells treated with unmodified PMPA in both resting and activated peripheral blood lymphocytes.  Significant differences in the intracellular catabolism of PMPA metabolites were noted between the resting and activated lymphocytes.  The half-life for the disappearance of PMPApp, derived from either bis(POC)PMPA or PMPA, was 12 to 15 h in the activated lymphocytes and 33 to 50 h in the resting lymphocytes.  This long persistence of PMPApp, particularly in resting lymphocytes, may be unique to the nucleoside phosphonate analogs and indicates that effective levels of the active metabolite can be achieved and maintained with relatively infrequent administration of the parent drug.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfLivj9uSR77Vg90H21EOLACvtfcHk0ljf0RBFtQ9wvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXhvV2ktLg%253D&md5=15e644a262a5be0b5319dd853d31d2a6</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1128%2FAAC.42.3.612&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.42.3.612%26sid%3Dliteratum%253Aachs%26aulast%3DRobbins%26aufirst%3DB.%2BL.%26aulast%3DSrinivas%26aufirst%3DR.%2BV.%26aulast%3DKim%26aufirst%3DC.%26aulast%3DBischofberger%26aufirst%3DN.%26aulast%3DFridland%26aufirst%3DA.%26atitle%3DAnti-human%2520immunodeficiency%2520virus%2520activity%2520and%2520cellular%2520metabolism%2520of%2520a%2520potential%2520prodrug%2520of%2520the%2520acyclic%2520nucleoside%2520phosphonate%25209-R-%25282-Phosphonomethoxypropyl%2529adenine%2520%2528PMPA%2529%252C%2520Bis%2528isopropyloxymethylcarbonyl%2529PMPA%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D1998%26volume%3D42%26spage%3D612%26epage%3D617%26doi%3D10.1128%2FAAC.42.3.612" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Naesens, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bischofberger, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Augustijns, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Annaert, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van den
Mooter, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arimilli, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, C. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span> <span> </span><span class="NLM_article-title">Antiretroviral efficacy and pharmacokinetics of oral bis(isopropyloxycarbonyloxymethyl)-9-(2-phosphonylmethoxypropyl)adenine in mice</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">1568</span>– <span class="NLM_lpage">1573</span>, <span class="refDoi"> DOI: 10.1128/AAC.42.7.1568</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1128%2FAAC.42.7.1568" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=9660984" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADyaK1cXktlKhtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=1998&pages=1568-1573&author=L.+Naesensauthor=N.+Bischofbergerauthor=P.+Augustijnsauthor=P.+Annaertauthor=G.+Van+den%0AMooterauthor=M.+N.+Arimilliauthor=C.+U.+Kimauthor=E.+De+Clercq&title=Antiretroviral+efficacy+and+pharmacokinetics+of+oral+bis%28isopropyloxycarbonyloxymethyl%29-9-%282-phosphonylmethoxypropyl%29adenine+in+mice&doi=10.1128%2FAAC.42.7.1568"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Antiretroviral efficacy and pharmacokinetics of oral bis(isopropyloxycarbonyloxymethyl)-9-(2-phosphonylmethoxypropyl)adenine in mice</span></div><div class="casAuthors">Naesens, Lieve; Bischofberger, Norbert; Augustijns, Patrick; Annaert, Pieter; Van Den Mooter, Guy; Arimilli, Murty N.; Kim, Choung U.; De Clercq, Erik</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1568-1673</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">To overcome the low oral bioavailability of the highly potent and selective antiretroviral agent (R)-9-(2-phosphonylmethoxypropyl)adenine (PMPA), its lipophilic ester deriv. bis(isopropyloxycarbonyloxymethyl)-ester [bis(POC)-PMPA] was prepd.  The usefulness of bis(POC)-PMPA as an oral prodrug for PMPA was investigated in the intestinal mucosa Caco-2 cell monolayer model.  The total transport of bis(POC)-PMPA was 2.7%, whereas it was <0.1% for PMPA.  Bis(POC)-PMPA was considerably metabolized inside the epithelial cells, since the majority of the compd. was recovered after transport in the form of the monoester metabolite mono(POC)-PMPA.  Bis(POC)-PMPA was relatively resistant to degrdn. at the luminal side of the Caco-2 cells.  Pharmacokinetic studies in mice showed that the oral bioavailability of bis(POC)-PMPA calcd. from the curves of the concn. of free PMPA in blood plasma was 20%.  Neither bis(POC)-PMPA nor mono(POC)-PMPA could be recovered from blood plasma, suggesting the efficient release of the active drug PMPA after oral administration of bis(POC)-PMPA.  Severe combined immunodeficient (SCID) mice infected with Moloney murine sarcoma virus (MSV) and treated orally with bis(POC)-PMPA for 5 or 10 days at dosages of 50, 100, or 200 mg PMPA equiv./kg/day showed a significant delay in MSV-induced tumor appearance and tumor-assocd. death.  The antiviral efficacy of oral bis(POC)-PMPA was related to the dosage and treatment period and was not significantly different from that of s.c. PMPA given at equiv. doses.  The favorable pharmacokinetic profile, marked antiviral efficacy, and low toxicity make bis(POC)-PMPA an attractive oral prodrug of PMPA that should be pursued in clin. studies in patients infected with human immunodeficiency virus or hepatitis B virus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdsnK-h4XpJrVg90H21EOLACvtfcHk0ljf0RBFtQ9wvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXktlKhtbg%253D&md5=1c653e6c96203eed031773867594c223</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1128%2FAAC.42.7.1568&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.42.7.1568%26sid%3Dliteratum%253Aachs%26aulast%3DNaesens%26aufirst%3DL.%26aulast%3DBischofberger%26aufirst%3DN.%26aulast%3DAugustijns%26aufirst%3DP.%26aulast%3DAnnaert%26aufirst%3DP.%26aulast%3DVan%2Bden%2BMooter%26aufirst%3DG.%26aulast%3DArimilli%26aufirst%3DM.%2BN.%26aulast%3DKim%26aufirst%3DC.%2BU.%26aulast%3DDe%2BClercq%26aufirst%3DE.%26atitle%3DAntiretroviral%2520efficacy%2520and%2520pharmacokinetics%2520of%2520oral%2520bis%2528isopropyloxycarbonyloxymethyl%2529-9-%25282-phosphonylmethoxypropyl%2529adenine%2520in%2520mice%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D1998%26volume%3D42%26spage%3D1568%26epage%3D1573%26doi%3D10.1128%2FAAC.42.7.1568" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, C.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Follis, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grant, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bischofberger, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benveniste, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Black, R.</span></span> <span> </span><span class="NLM_article-title">Prevention of SIV infection in macaques by (<i>R</i>)-9-(2-Phosphonylmethoxypropyl)adenine</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>270</i></span>,  <span class="NLM_fpage">1197</span>– <span class="NLM_lpage">1199</span>, <span class="refDoi"> DOI: 10.1126/science.270.5239.1197</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1126%2Fscience.270.5239.1197" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=7502044" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADyaK2MXpsVyktLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=270&publication_year=1995&pages=1197-1199&author=C.-C.+Tsaiauthor=K.+E.+Follisauthor=A.+Saboauthor=T.+W.+Beckauthor=R.+F.+Grantauthor=N.+Bischofbergerauthor=R.+E.+Benvenisteauthor=R.+Black&title=Prevention+of+SIV+infection+in+macaques+by+%28R%29-9-%282-Phosphonylmethoxypropyl%29adenine&doi=10.1126%2Fscience.270.5239.1197"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine</span></div><div class="casAuthors">Tsai, Che-Chung; Follis, Kathryn E.; Sabo, Alexander; Beck, Thomas W.; Grant, Richard F.; Bischofberger, Norbert; Benveniste, Raoul E.; Black, Roberta</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">270</span>
        (<span class="NLM_cas:issue">5239</span>),
    <span class="NLM_cas:pages">1197-9</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The efficacy of pre- and postexposure treatment with the antiviral compd. (R)-9-(2-phosphonylmethoxypropyl)adenine (PMPA) was tested against simian immunodeficiency virus (SIV) in macaques as a model for human immunodeficiency virus (HIV).  PMPA was administered s.c. once daily beginning either 48 h before, 4 h after, or 24 h after virus inoculation.  Treatment continued for 4 wk and the virol., immunol., and clin. status of the macaques was monitored for up to 56 wk.  PMPA prevented SIV infection in all macaques without toxicity, whereas all control macaques became infected.  These results suggest a potential role for PMPA prophylaxis against early HIV infection in cases of known exposure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrv0wYvoJWcxLVg90H21EOLACvtfcHk0ligjcSrEsUqqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXpsVyktLY%253D&md5=ee0ece078305323a3b11a2c792cd88ba</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1126%2Fscience.270.5239.1197&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.270.5239.1197%26sid%3Dliteratum%253Aachs%26aulast%3DTsai%26aufirst%3DC.-C.%26aulast%3DFollis%26aufirst%3DK.%2BE.%26aulast%3DSabo%26aufirst%3DA.%26aulast%3DBeck%26aufirst%3DT.%2BW.%26aulast%3DGrant%26aufirst%3DR.%2BF.%26aulast%3DBischofberger%26aufirst%3DN.%26aulast%3DBenveniste%26aufirst%3DR.%2BE.%26aulast%3DBlack%26aufirst%3DR.%26atitle%3DPrevention%2520of%2520SIV%2520infection%2520in%2520macaques%2520by%2520%2528R%2529-9-%25282-Phosphonylmethoxypropyl%2529adenine%26jtitle%3DScience%26date%3D1995%26volume%3D270%26spage%3D1197%26epage%3D1199%26doi%3D10.1126%2Fscience.270.5239.1197" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Van Damme, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corneli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmed, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agot, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lombaard, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kapiga, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malahleha, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owino, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manongi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Onyango, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Temu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monedi, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mak’Oketch, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makanda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reblin, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makatu, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saylor, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiernan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirkendale, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grant, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kashuba, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nanda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandala, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fransen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deese, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crucitti, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mastro, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, D.</span></span> <span> </span><span class="NLM_article-title">Preexposure prophylaxis for HIV infection among African women</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>367</i></span>,  <span class="NLM_fpage">411</span>– <span class="NLM_lpage">422</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1202614</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1056%2FNEJMoa1202614" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=22784040" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlSltrbL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=367&publication_year=2012&pages=411-422&author=L.+Van+Dammeauthor=A.+Corneliauthor=K.+Ahmedauthor=K.+Agotauthor=J.+Lombaardauthor=S.+Kapigaauthor=M.+Malahlehaauthor=F.+Owinoauthor=R.+Manongiauthor=J.+Onyangoauthor=L.+Temuauthor=M.+C.+Monediauthor=P.+Mak%E2%80%99Oketchauthor=M.+Makandaauthor=I.+Reblinauthor=S.+E.+Makatuauthor=L.+Saylorauthor=H.+Kiernanauthor=S.+Kirkendaleauthor=C.+Wongauthor=R.+F.+Grantauthor=A.+Kashubaauthor=K.+Nandaauthor=J.+Mandalaauthor=K.+Fransenauthor=J.+Deeseauthor=T.+Crucittiauthor=T.+D.+Mastroauthor=D.+Taylor&title=Preexposure+prophylaxis+for+HIV+infection+among+African+women&doi=10.1056%2FNEJMoa1202614"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Preexposure prophylaxis for HIV infection among African women</span></div><div class="casAuthors">Van Damme, Lut; Corneli, Amy; Ahmed, Khatija; Agot, Kawango; Lombaard, Johan; Kapiga, Saidi; Malahleha, Mookho; Owino, Fredrick; Manongi, Rachel; Onyango, Jacob; Temu, Lucky; Monedi, Modie Constance; Mak'Oketch, Paul; Makanda, Mankalimeng; Reblin, Ilse; Makatu, Shumani Elsie; Saylor, Lisa; Kiernan, Haddie; Kirkendale, Stella; Wong, Christina; Grant, Robert; Kashuba, Angela; Nanda, Kavita; Mandala, Justin; Fransen, Katrien; Deese, Jennifer; Crucitti, Tania; Mastro, Timothy D.; Taylor, Douglas</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">367</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">411-422</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: Preexposure prophylaxis with antiretroviral drugs has been effective in the prevention of human immunodeficiency virus (HIV) infection in some trials but not in others.  Methods: In this randomized, double-blind, placebo-controlled trial, we assigned 2120 HIV-neg. women in Kenya, South Africa, and Tanzania to receive either a combination of tenofovir disoproxil fumarate and emtricitabine (TDF-FTC) or placebo once daily.  The primary objective was to assess the effectiveness of TDF-FTC in preventing HIV acquisition and to evaluate safety.  Results: HIV infections occurred in 33 women in the TDF-FTC group (incidence rate, 4.7 per 100 person-years) and in 35 in the placebo group (incidence rate, 5.0 per 100 person-years), for an estd. hazard ratio in the TDF-FTC group of 0.94 (95% confidence interval, 0.59 to 1.52; P = 0.81).  The proportions of women with nausea, vomiting, or elevated alanine aminotransferase levels were significantly higher in the TDF-FTC group (P = 0.04, P<0.001, and P = 0.03, resp.).  Rates of drug discontinuation because of hepatic or renal abnormalities were higher in the TDF-FTC group (4.7%) than in the placebo group (3.0%, P = 0.051).  Less than 40% of the HIV-uninfected women in the TDF-FTC group had evidence of recent pill use at visits that were matched to the HIV-infection window for women with seroconversion.  The study was stopped early, on Apr. 18, 2011, because of lack of efficacy.  Conclusions: Prophylaxis with TDF-FTC did not significantly reduce the rate of HIV infection and was assocd. with increased rates of side effects, as compared with placebo.  Despite substantial counseling efforts, drug adherence appeared to be low.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-zDy6lkjhp7Vg90H21EOLACvtfcHk0lhGp1EvnG4ivA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtlSltrbL&md5=b570dd1c89c2fe20667ddd92f2f1cba0</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1202614&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1202614%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2BDamme%26aufirst%3DL.%26aulast%3DCorneli%26aufirst%3DA.%26aulast%3DAhmed%26aufirst%3DK.%26aulast%3DAgot%26aufirst%3DK.%26aulast%3DLombaard%26aufirst%3DJ.%26aulast%3DKapiga%26aufirst%3DS.%26aulast%3DMalahleha%26aufirst%3DM.%26aulast%3DOwino%26aufirst%3DF.%26aulast%3DManongi%26aufirst%3DR.%26aulast%3DOnyango%26aufirst%3DJ.%26aulast%3DTemu%26aufirst%3DL.%26aulast%3DMonedi%26aufirst%3DM.%2BC.%26aulast%3DMak%25E2%2580%2599Oketch%26aufirst%3DP.%26aulast%3DMakanda%26aufirst%3DM.%26aulast%3DReblin%26aufirst%3DI.%26aulast%3DMakatu%26aufirst%3DS.%2BE.%26aulast%3DSaylor%26aufirst%3DL.%26aulast%3DKiernan%26aufirst%3DH.%26aulast%3DKirkendale%26aufirst%3DS.%26aulast%3DWong%26aufirst%3DC.%26aulast%3DGrant%26aufirst%3DR.%2BF.%26aulast%3DKashuba%26aufirst%3DA.%26aulast%3DNanda%26aufirst%3DK.%26aulast%3DMandala%26aufirst%3DJ.%26aulast%3DFransen%26aufirst%3DK.%26aulast%3DDeese%26aufirst%3DJ.%26aulast%3DCrucitti%26aufirst%3DT.%26aulast%3DMastro%26aufirst%3DT.%2BD.%26aulast%3DTaylor%26aufirst%3DD.%26atitle%3DPreexposure%2520prophylaxis%2520for%2520HIV%2520infection%2520among%2520African%2520women%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2012%26volume%3D367%26spage%3D411%26epage%3D422%26doi%3D10.1056%2FNEJMoa1202614" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marrazzo, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramjee, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomez, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mgodi, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nair, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palanee, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakabiito, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Straten, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noguchi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendrix, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganesh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mkhize, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taljaard, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parikh, U. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piper, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mâsse, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grossman, C. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rooney, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watts, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marzinke, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hillier, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGowan, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chirenje, Z. M.</span></span> <span> </span><span class="NLM_article-title">Tenofovir-based preexposure prophylaxis for HIV infection among African women</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>372</i></span>,  <span class="NLM_fpage">509</span>– <span class="NLM_lpage">518</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1402269</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1056%2FNEJMoa1402269" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=25651245" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADC%252BC2MXisFGkur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=372&publication_year=2015&pages=509-518&author=J.+M.+Marrazzoauthor=G.+Ramjeeauthor=B.+A.+Richardsonauthor=K.+Gomezauthor=N.+M.+Mgodiauthor=G.+Nairauthor=T.+Palaneeauthor=C.+Nakabiitoauthor=A.+van+der+Stratenauthor=L.+Noguchiauthor=C.+W.+Hendrixauthor=J.+Y.+Daiauthor=S.+Ganeshauthor=B.+Mkhizeauthor=M.+Taljaardauthor=U.+M.+Parikhauthor=J.+Piperauthor=B.+M%C3%A2sseauthor=C.+I.+Grossmanauthor=J.+Rooneyauthor=J.+L.+Schwartzauthor=H.+Wattsauthor=M.+A.+Marzinkeauthor=S.+L.+Hillierauthor=I.+M.+McGowanauthor=Z.+M.+Chirenje&title=Tenofovir-based+preexposure+prophylaxis+for+HIV+infection+among+African+women&doi=10.1056%2FNEJMoa1402269"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Tenofovir-based preexposure prophylaxis for HIV infection among African women</span></div><div class="casAuthors">Marrazzo, Jeanne M.; Ramjee, Gita; Richardson, Barbra A.; Gomez, Kailazarid; Mgodi, Nyaradzo; Nair, Gonasagrie; Palanee, Thesla; Nakabiito, Clemensia; van der Straten, Ariane; Noguchi, Lisa; Hendrix, Craig W.; Dai, James Y.; Ganesh, Shayhana; Mkhize, Baningi; Taljaard, Marthinette; Parikh, Urvi M.; Piper, Jeanna; Masse, Benoit; Grossman, Cynthia; Rooney, James; Schwartz, Jill L.; Watts, Heather; Marzinke, Mark A.; Hillier, Sharon L.; McGowan, Ian M.; Chirenje, Z. Mike</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">372</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">509-518/1-509-518/10, 10 pp.</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Reproductive-age women need effective interventions to prevent the acquisition of human immunodeficiency virus type 1 (HIV-1) infection.  We conducted a randomized, placebo-controlled trial to assess daily treatment with oral tenofovir disoproxil fumarate (TDF), oral tenofovir-emtricitabine (TDF-FTC), or 1% tenofovir (TFV) vaginal gel as preexposure prophylaxis against HIV-1 infection in women in South Africa, Uganda, and Zimbabwe.  HIV-1 testing was performed monthly, and plasma TFV levels were assessed quarterly.  Of 12,320 women who were screened, 5029 were enrolled in the study.  The rate of retention in the study was 91% during 5509 person-years of follow-up.  A total of 312 HIV-1 infections occurred; the incidence of HIV-1 infection was 5.7 per 100 person-years.  In the modified intention-to-treat anal., the effectiveness was -49.0% with TDF (hazard ratio for infection, 1.49; 95% confidence interval [CI], 0.97 to 2.29), -4.4% with TDF-FTC (hazard ratio, 1.04; 95% CI, 0.73 to 1.49), and 14.5% with TFV gel (hazard ratio, 0.85; 95% CI, 0.61 to 1.21).  In a random sample, TFV was detected in 30%, 29%, and 25% of available plasma samples from participants randomly assigned to receive TDF, TDF-FTC, and TFV gel, resp.  Independent predictors of TFV detection included being married, being older than 25 years of age, and being multiparous.  Detection of TFV in plasma was neg. assocd. with characteristics predictive of HIV-1 acquisition.  Elevations of serum creatinine levels were seen more frequently among participants randomly assigned to receive oral TDF-FTC than among those assigned to receive oral placebo (1.3% vs. 0.2%, P = 0.004).  We obsd. no significant differences in the frequencies of other adverse events.  None of the drug regimens we evaluated reduced the rates of HIV-1 acquisition in an intention-to-treat anal.  Adherence to study drugs was low.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjwMI6Bbu9d7Vg90H21EOLACvtfcHk0lhGp1EvnG4ivA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXisFGkur4%253D&md5=dfa4a90697a305320dc82815b0d60a1f</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1402269&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1402269%26sid%3Dliteratum%253Aachs%26aulast%3DMarrazzo%26aufirst%3DJ.%2BM.%26aulast%3DRamjee%26aufirst%3DG.%26aulast%3DRichardson%26aufirst%3DB.%2BA.%26aulast%3DGomez%26aufirst%3DK.%26aulast%3DMgodi%26aufirst%3DN.%2BM.%26aulast%3DNair%26aufirst%3DG.%26aulast%3DPalanee%26aufirst%3DT.%26aulast%3DNakabiito%26aufirst%3DC.%26aulast%3Dvan%2Bder%2BStraten%26aufirst%3DA.%26aulast%3DNoguchi%26aufirst%3DL.%26aulast%3DHendrix%26aufirst%3DC.%2BW.%26aulast%3DDai%26aufirst%3DJ.%2BY.%26aulast%3DGanesh%26aufirst%3DS.%26aulast%3DMkhize%26aufirst%3DB.%26aulast%3DTaljaard%26aufirst%3DM.%26aulast%3DParikh%26aufirst%3DU.%2BM.%26aulast%3DPiper%26aufirst%3DJ.%26aulast%3DM%25C3%25A2sse%26aufirst%3DB.%26aulast%3DGrossman%26aufirst%3DC.%2BI.%26aulast%3DRooney%26aufirst%3DJ.%26aulast%3DSchwartz%26aufirst%3DJ.%2BL.%26aulast%3DWatts%26aufirst%3DH.%26aulast%3DMarzinke%26aufirst%3DM.%2BA.%26aulast%3DHillier%26aufirst%3DS.%2BL.%26aulast%3DMcGowan%26aufirst%3DI.%2BM.%26aulast%3DChirenje%26aufirst%3DZ.%2BM.%26atitle%3DTenofovir-based%2520preexposure%2520prophylaxis%2520for%2520HIV%2520infection%2520among%2520African%2520women%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2015%26volume%3D372%26spage%3D509%26epage%3D518%26doi%3D10.1056%2FNEJMoa1402269" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, G.-X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eisenberg, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cihlar, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swaminathan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulato, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cundy, K. C.</span></span> <span> </span><span class="NLM_article-title">Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">1898</span>– <span class="NLM_lpage">1906</span>, <span class="refDoi"> DOI: 10.1128/AAC.49.5.1898-1906.2005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1128%2FAAC.49.5.1898-1906.2005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=15855512" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADC%252BD2MXktFSntL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2005&pages=1898-1906&author=W.+A.+Leeauthor=G.-X.+Heauthor=E.+Eisenbergauthor=T.+Cihlarauthor=S.+Swaminathanauthor=A.+Mulatoauthor=K.+C.+Cundy&title=Selective+intracellular+activation+of+a+novel+prodrug+of+the+human+immunodeficiency+virus+reverse+transcriptase+inhibitor+tenofovir+leads+to+preferential+distribution+and+accumulation+in+lymphatic+tissue&doi=10.1128%2FAAC.49.5.1898-1906.2005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue</span></div><div class="casAuthors">Lee, William A.; He, Gong-Xin; Eisenberg, Eugene; Cihlar, Tomas; Swaminathan, Swami; Mulato, Andrew; Cundy, Kenneth C.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1898-1906</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">An isopropylalaninyl monoamidate Ph monoester prodrug of tenofovir (GS 7340) was prepd., and its in vitro antiviral activity, metab., and pharmacokinetics in dogs were detd.  The 50% effective concn. (EC50) of GS 7340 against human immunodeficiency virus type 1 in MT-2 cells was 0.005 μM compared to an EC50 of 5 μM for the parent drug, tenofovir.  The (L)-alaninyl analog (GS 7340) was >1000-fold more active than the (D)-alaninyl analog.  GS 7340 has a half-life of 90 min in human plasma at 37° and a half-life of 28.3 min in an MT-2 cell ext. at 37°.  The antiviral activity (>10× the EC50) and the metabolic stability in MT-2 cell exts. (>35×) and plasma (>2.5×) were also sensitive to the stereochem. at the phosphorus.  After a single oral dose of GS 7340 (10 mg-eq/kg tenofovir) to male beagle dogs, the plasma bioavailability of tenofovir compared to an i.v. dose of tenofovir was 17%.  The total intracellular concn. of all tenofovir species in isolated peripheral blood mononuclear cells at 24 h was 63 μg-eq/mL compared to 0.2 μg-eq/mL in plasma.  A radiolabeled distribution study with dogs resulted in an increased distribution of tenofovir to tissues of lymphatic origin compared to the com. available prodrug tenofovir DF (Viread).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbOoU4rGP0xrVg90H21EOLACvtfcHk0ljXuXSfbsV4XA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXktFSntL0%253D&md5=b5e724620a1cafa4b473a84aea841282</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1128%2FAAC.49.5.1898-1906.2005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.49.5.1898-1906.2005%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DW.%2BA.%26aulast%3DHe%26aufirst%3DG.-X.%26aulast%3DEisenberg%26aufirst%3DE.%26aulast%3DCihlar%26aufirst%3DT.%26aulast%3DSwaminathan%26aufirst%3DS.%26aulast%3DMulato%26aufirst%3DA.%26aulast%3DCundy%26aufirst%3DK.%2BC.%26atitle%3DSelective%2520intracellular%2520activation%2520of%2520a%2520novel%2520prodrug%2520of%2520the%2520human%2520immunodeficiency%2520virus%2520reverse%2520transcriptase%2520inhibitor%2520tenofovir%2520leads%2520to%2520preferential%2520distribution%2520and%2520accumulation%2520in%2520lymphatic%2520tissue%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2005%26volume%3D49%26spage%3D1898%26epage%3D1906%26doi%3D10.1128%2FAAC.49.5.1898-1906.2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Birkus, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bam, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willkom, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frey, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stray, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yant, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cihlar, T.</span></span> <span> </span><span class="NLM_article-title">Intracellular activation of tenofovir alafenamide and the effect of viral and host protease inhibitors</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">316</span>– <span class="NLM_lpage">322</span>, <span class="refDoi"> DOI: 10.1128/AAC.01834-15</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1128%2FAAC.01834-15" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=26503655" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVCrs7nP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2016&pages=316-322&author=G.+Birkusauthor=R.+A.+Bamauthor=M.+Willkomauthor=C.+R.+Freyauthor=L.+Tsaiauthor=K.+M.+Strayauthor=S.+R.+Yantauthor=T.+Cihlar&title=Intracellular+activation+of+tenofovir+alafenamide+and+the+effect+of+viral+and+host+protease+inhibitors&doi=10.1128%2FAAC.01834-15"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Intracellular activation of tenofovir alafenamide and the effect of viral and host protease inhibitors</span></div><div class="casAuthors">Birkus, Gabriel; Bam, Rujuta A.; Willkom, Madeleine; Frey, Christian R.; Tsai, Luong; Stray, Kirsten M.; Yant, Stephen R.; Cihlar, Tomas</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">316-322</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Tenofovir alafenamide fumarate (TAF) is an oral phosphonoamidate prodrug of the HIV reverse transcriptase nucleotide inhibitor tenofovir (TFV).  Previous studies suggested a principal role for the lysosomal serine protease cathepsin A (CatA) in the intracellular activation of TAF.  Here we further investigated the role of CatA and other human hydrolases in the metab. of TAF.  Overexpression of CatA or liver carboxylesterase 1 (Ces1) in HEK293T cells increased intracellular TAF hydrolysis 2- and 5-fold, resp.  Knockdown of CatA expression with RNA interference (RNAi) in HeLa cells reduced intracellular TAF metab. 5-fold.  Addnl., the anti-HIV activity and the rate of CatA hydrolysis showed good correlation within a large set of TFV phosphonoamidate prodrugs.  The covalent hepatitis C virus (HCV) protease inhibitors (PIs) telaprevir and boceprevir potently inhibited CatA-mediated TAF activation (50% inhibitory concn. [IC50] = 0.27 and 0.16 μM, resp.) in vitro and also reduced its anti-HIV activity in primary human CD4+ T lymphocytes (21- and 3-fold, resp.) at pharmacol. relevant concns.  In contrast, there was no inhibition of CatA or any significant effect on anti-HIV activity of TAF obsd. with cobicistat, noncovalent HIV and HCV PIs, or various prescribed inhibitors of host serine proteases.  Collectively, these studies confirm that CatA plays a pivotal role in the intracellular metab. of TAF, whereas the liver esterase Ces1 likely contributes to the hepatic activation of TAF.  Moreover, this work demonstrates that a wide range of viral and host PIs, with the exception of telaprevir and boceprevir, do not interfere with the antiretroviral activity of TAF.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrn2HFR0GCGELVg90H21EOLACvtfcHk0ljXuXSfbsV4XA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVCrs7nP&md5=2deb35c0d451b36c296d76dc59c5b6d4</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1128%2FAAC.01834-15&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.01834-15%26sid%3Dliteratum%253Aachs%26aulast%3DBirkus%26aufirst%3DG.%26aulast%3DBam%26aufirst%3DR.%2BA.%26aulast%3DWillkom%26aufirst%3DM.%26aulast%3DFrey%26aufirst%3DC.%2BR.%26aulast%3DTsai%26aufirst%3DL.%26aulast%3DStray%26aufirst%3DK.%2BM.%26aulast%3DYant%26aufirst%3DS.%2BR.%26aulast%3DCihlar%26aufirst%3DT.%26atitle%3DIntracellular%2520activation%2520of%2520tenofovir%2520alafenamide%2520and%2520the%2520effect%2520of%2520viral%2520and%2520host%2520protease%2520inhibitors%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2016%26volume%3D60%26spage%3D316%26epage%3D322%26doi%3D10.1128%2FAAC.01834-15" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rose, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crosswell, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bronson, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, J. C.</span></span> <span> </span><span class="NLM_article-title">In vivo antitumor activity of 9-[(2-phosphonylmethoxy)ethyl]-guanine and related phosphonate nucleotide analogues</span>. <i>J. Natl. Cancer Inst.</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>82</i></span>,  <span class="NLM_fpage">510</span>– <span class="NLM_lpage">512</span>, <span class="refDoi"> DOI: 10.1093/jnci/82.6.510</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1093%2Fjnci%2F82.6.510" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=2313724" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADyaK3cXktFOntbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=1990&pages=510-512&author=W.+C.+Roseauthor=A.+R.+Crosswellauthor=J.+J.+Bronsonauthor=J.+C.+Martin&title=In+vivo+antitumor+activity+of+9-%5B%282-phosphonylmethoxy%29ethyl%5D-guanine+and+related+phosphonate+nucleotide+analogues&doi=10.1093%2Fjnci%2F82.6.510"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">In vivo antitumor activity of 9-[(2-phosphonylmethoxy)ethyl]guanine and related phosphonate nucleotide analogs</span></div><div class="casAuthors">Rose, William C.; Crosswell, Alfred R.; Bronson, Joanne J.; Martin, John C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the National Cancer Institute</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">82</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">510-12</span>CODEN:
                <span class="NLM_cas:coden">JNCIEQ</span>;
        ISSN:<span class="NLM_cas:issn">0027-8874</span>.
    </div><div class="casAbstract">Phosphonylmethoxyalkylpurine analogs (I; R = OH or NH2, R1 = H or NH2, and R2 = H or CH2OH) were evaluated for their antitumor activity in murine tumor models.  Three compds., I (R = NH2, R1 = H, and R2 = CH2OH), I (R = NH2, R1 = R2 = H), and PMEG (I; R = OH, R1 = NH2, R2 = H) were modestly active with treated vs. control (T/C) values of 125-175% against i.p. P388 leukemia, but were inactive against i.v.-implanted P388.  The most active and most potent of the 3 was PMEG, which was also evaluated against s.c.-implanted B16 melanoma.  In confirmatory expts., optimal therapy with PMEG yielded reproducible increases in life span (T/C values of 164-170%) and delays in primary tumor growth (7.3- to 13.0-day T-C values).  PMEG is representative of a new class of antitumor antimetabolites heretofore recognized only for their antiviral properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjfTRyf74VPbVg90H21EOLACvtfcHk0ljXuXSfbsV4XA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXktFOntbk%253D&md5=2c9a68cf4dde136414960c030ee77f0a</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2F82.6.510&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252F82.6.510%26sid%3Dliteratum%253Aachs%26aulast%3DRose%26aufirst%3DW.%2BC.%26aulast%3DCrosswell%26aufirst%3DA.%2BR.%26aulast%3DBronson%26aufirst%3DJ.%2BJ.%26aulast%3DMartin%26aufirst%3DJ.%2BC.%26atitle%3DIn%2520vivo%2520antitumor%2520activity%2520of%25209-%255B%25282-phosphonylmethoxy%2529ethyl%255D-guanine%2520and%2520related%2520phosphonate%2520nucleotide%2520analogues%26jtitle%3DJ.%2520Natl.%2520Cancer%2520Inst.%26date%3D1990%26volume%3D82%26spage%3D510%26epage%3D512%26doi%3D10.1093%2Fjnci%2F82.6.510" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Naesens, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatse, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Segers, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verbeken, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balzarini, J.</span></span> <span> </span><span class="NLM_article-title">9-(2-Phosphonylmethoxyethyl)-N6-cyclopropyl-2,6-diaminopurine: a novel prodrug of 9-(2-phosphonylmethoxyethyl)guanine with improved antitumor efficacy and selectivity in choriocarcinoma-bearing rats</span>. <i>Oncol.Res.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">195</span>– <span class="NLM_lpage">203</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10566618" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADC%252BD3cXltFOgurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=1999&pages=195-203&author=L.+Naesensauthor=S.+Hatseauthor=C.+Segersauthor=E.+Verbekenauthor=E.+De+Clercqauthor=M.+Waerauthor=J.+Balzarini&title=9-%282-Phosphonylmethoxyethyl%29-N6-cyclopropyl-2%2C6-diaminopurine%3A+a+novel+prodrug+of+9-%282-phosphonylmethoxyethyl%29guanine+with+improved+antitumor+efficacy+and+selectivity+in+choriocarcinoma-bearing+rats"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">9-(2-Phosphonylmethoxyethyl)-N6-cyclopropyl-2,6-diaminopurine: A novel prodrug of 9-(2-phosphonylmethoxyethyl)guanine with improved antitumor efficacy and selectivity in choriocarcinoma-bearing rats</span></div><div class="casAuthors">Naesens, Lieve; Hatse, Sigrid; Segers, Constant; Verbeken, Erik; De Clercq, Erik; Waer, Mark; Balzarini, Jan</div><div class="citationInfo"><span class="NLM_cas:title">Oncology Research</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">195-203</span>CODEN:
                <span class="NLM_cas:coden">ONREE8</span>;
        ISSN:<span class="NLM_cas:issn">0965-0407</span>.
    
            (<span class="NLM_cas:orgname">Cognizant Communication Corp.</span>)
        </div><div class="casAbstract">The novel acyclic nucleoside phosphonate analog 9-(2-phosphonylmethoxyethyl)-N6-cyclopropyl-2,6-diaminopurine (cPr-PMEDAP) was shown in vitro to act as an intracellular prodrug of 9-(2-phosphonylmethoxyethyl)guanine (PMEG).  We compared the in vivo antitumor efficacy and selectivity of cPr-PMEDAP, its progenitor PMEDAP, and PMEG in a rat choriocarcinoma tumor model.  The rats, inoculated with rat choriocarcinoma (RCHO) cells under the renal capsule, were treated IP during 10 days.  Macroscopical and histol. examn. of the RCHO-inoculated kidneys was performed at two time points (i.e., immediately after the end of treatment or after an addnl. drug-free period of 2 wk).  Complete inhibition of choriocarcinoma tumor development was achieved upon treatment with cPr-PMEDAP, PMEG, and PMEDAP at a daily dose of 10, 1, and 50 mg/kg, resp.  At these doses, all three compds. produced moderate to strong toxicity (evidenced by atrophy of lymphoid organs and reduced body wt. gain).  When compared at the max. tolerated (sublethal) doses (i.e., 0.5, 10, and 50 mg/kg for PMEG, cPr-PMEDAP, and PMEDAP, resp.), cPr-PMEDAP proved superior to PMEG and PMEDAP in achieving a complete inhibition of tumor development.  Also, whereas PMEG was unable to produce a prolonged antitumor effect, the animals treated with cPr-PMEDAP still showed prominent inhibition of tumor development when tumor size was evaluated at 2 wk after end of treatment.  Based on its efficacy and therapeutic safety, cPr-PMEDAP can be regarded as a promising antitumor agent, which merits further in vivo evaluation in addnl. tumor models for human neoplasms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDxQQIWDJUgbVg90H21EOLACvtfcHk0lgrHrKlyE2zVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXltFOgurg%253D&md5=f4b19409d519142f842313078fbaf53a</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNaesens%26aufirst%3DL.%26aulast%3DHatse%26aufirst%3DS.%26aulast%3DSegers%26aufirst%3DC.%26aulast%3DVerbeken%26aufirst%3DE.%26aulast%3DDe%2BClercq%26aufirst%3DE.%26aulast%3DWaer%26aufirst%3DM.%26aulast%3DBalzarini%26aufirst%3DJ.%26atitle%3D9-%25282-Phosphonylmethoxyethyl%2529-N6-cyclopropyl-2%252C6-diaminopurine%253A%2520a%2520novel%2520prodrug%2520of%25209-%25282-phosphonylmethoxyethyl%2529guanine%2520with%2520improved%2520antitumor%2520efficacy%2520and%2520selectivity%2520in%2520choriocarcinoma-bearing%2520rats%26jtitle%3DOncol.Res.%26date%3D1999%26volume%3D11%26spage%3D195%26epage%3D203" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schinkmanová, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Votruba, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holý, A.</span></span> <span> </span><span class="NLM_article-title">N6-Methyl-AMP aminohydrolase activates N6-substituted purine acyclic nucleoside phosphonates</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">1370</span>– <span class="NLM_lpage">1376</span>, <span class="refDoi"> DOI: 10.1016/j.bcp.2006.01.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1016%2Fj.bcp.2006.01.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=16513094" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADC%252BD28XivVOjtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2006&pages=1370-1376&author=M.+Schinkmanov%C3%A1author=I.+Votrubaauthor=A.+Hol%C3%BD&title=N6-Methyl-AMP+aminohydrolase+activates+N6-substituted+purine+acyclic+nucleoside+phosphonates&doi=10.1016%2Fj.bcp.2006.01.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">N6-Methyl-AMP aminohydrolase activates N6-substituted purine acyclic nucleoside phosphonates</span></div><div class="casAuthors">Schinkmanova, Marketa; Votruba, Ivan; Holy, Antonin</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1370-1376</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">In this study the authors present the identification and characterization of the enzyme involved in the N6-cyclopropyl-2,6-diamino-9-[2-(phosphonomethoxy)ethyl]purine (N6-cyclopropyl-PMEDAP) conversion to biol. active 9-[2-(phosphonomethoxy)ethyl]guanine (PMEG) as well as abacavir 5'-phosphate to carbovir 5'-phosphate.  This enzyme was purified from rat liver to homogeneity; it appears to be composed from six 42 kDa subunits and its native form has the mol. wt. 260 kDa.  This so far unknown enzyme catalyzes conversion of both N6-methyl-AMP and N6-methyl-dAMP to IMP and/or dIMP, resp.  The enzyme acts as 6-(N-substituted amino)purine 5'-nucleotide aminohydrolase with the reaction mechanism very similar to AMP deaminase.  The enzyme does not deaminate AMP and dAMP, or the corresponding nucleosides.  It is inhibited by deoxycoformycin 5'-phosphate but not by deoxycoformycin or erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmlkF2bLqPHLVg90H21EOLACvtfcHk0lgrHrKlyE2zVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XivVOjtrs%253D&md5=3cb8a4bc889e5353b069432a04f05614</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2006.01.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2006.01.013%26sid%3Dliteratum%253Aachs%26aulast%3DSchinkmanov%25C3%25A1%26aufirst%3DM.%26aulast%3DVotruba%26aufirst%3DI.%26aulast%3DHol%25C3%25BD%26aufirst%3DA.%26atitle%3DN6-Methyl-AMP%2520aminohydrolase%2520activates%2520N6-substituted%2520purine%2520acyclic%2520nucleoside%2520phosphonates%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2006%26volume%3D71%26spage%3D1370%26epage%3D1376%26doi%3D10.1016%2Fj.bcp.2006.01.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reiser, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ray, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shibata, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birkus, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cihlar, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henne, I. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolfgang, G. H. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desai, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rhodes, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fridland, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plunkett, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vail, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thamm, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeraj, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tumas, D. B.</span></span> <span> </span><span class="NLM_article-title">GS-9219—A Novel acyclic nucleotide analogue with potent antineoplastic activity in dogs with spontaneous non-Hodgkin’s lymphoma</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">2824</span>– <span class="NLM_lpage">2832</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-07-2061</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1158%2F1078-0432.CCR-07-2061" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=18451250" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADC%252BD1cXlsFSjsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=2824-2832&author=H.+Reiserauthor=J.+Wangauthor=L.+Chongauthor=W.+J.+Watkinsauthor=A.+S.+Rayauthor=R.+Shibataauthor=G.+Birkusauthor=T.+Cihlarauthor=S.+Wuauthor=B.+Liauthor=X.+Liuauthor=I.+N.+Henneauthor=G.+H.+I.+Wolfgangauthor=M.+Desaiauthor=G.+R.+Rhodesauthor=A.+Fridlandauthor=W.+A.+Leeauthor=W.+Plunkettauthor=D.+Vailauthor=D.+H.+Thammauthor=R.+Jerajauthor=D.+B.+Tumas&title=GS-9219%E2%80%94A+Novel+acyclic+nucleotide+analogue+with+potent+antineoplastic+activity+in+dogs+with+spontaneous+non-Hodgkin%E2%80%99s+lymphoma&doi=10.1158%2F1078-0432.CCR-07-2061"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">GS-9219-A Novel Acyclic Nucleotide Analogue with Potent Antineoplastic Activity in Dogs with Spontaneous Non-Hodgkin's Lymphoma</span></div><div class="casAuthors">Reiser, Hans; Wang, Jianying; Chong, Lee; Watkins, William J.; Ray, Adrian S.; Shibata, Riri; Birkus, Gabriel; Cihlar, Tomas; Wu, Sylvia; Li, Bei; Liu, Xiaohong; Henne, Ilana N.; Wolfgang, Grushenka H. I.; Desai, Manoj; Rhodes, Gerald R.; Fridland, Arnold; Lee, William A.; Plunkett, William; Vail, David; Thamm, Douglas H.; Jeraj, Robert; Tumas, Daniel B.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2824-2832</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: GS-9219, a novel prodrug of the nucleotide analog 9-(2-phosphonylmethoxyethyl)guanine (PMEG), was designed as a cytotoxic agent that preferentially targets lymphoid cells.  Our objective was to characterize the antiproliferative activity, pharmacokinetics, pharmacodynamics, and safety of GS-9219.  Exptl. Design: GS-9219 was selected through screening in proliferation assays and through pharmacokinetic screening.  The activation pathway of GS-9219 was characterized in lymphocytes, and its cytotoxic activity was evaluated against a panel of hematopoietic and nonhematopoietic cell types.  To test whether the prodrug moieties present in GS-9219 confer an advantage over PMEG in vivo, the pharmacokinetics, pharmacodynamics (lymph node germinal center depletion), and toxicity of equimolar doses of GS-9219 and PMEG were evaluated after i.v. administration to normal beagle dogs.  Finally, proof of concept of the antitumor efficacy of GS-9219 was evaluated in five pet dogs with spontaneous, advanced-stage non-Hodgkin's lymphoma (NHL) following a single i.v. administration of GS-9219 as monotherapy.  RESULTS: In lymphocytes, GS-9219 is converted to its active metabolite, PMEG diphosphate, via enzymic hydrolysis, deamination, and phosphorylation.  GS-9219 has substantial antiproliferative activity against activated lymphocytes and hematopoietic tumor cell lines.  In contrast, resting lymphocytes and solid tumor lines were less sensitive to GS-9219.  GS-9219, but not PMEG, depleted the germinal centers in lymphoid tissues of normal beagle dogs at doses that were tolerated.  In addn., GS-9219 displayed significant in vivo efficacy in five dogs with spontaneous NHL after a single administration, with either no or low-grade adverse events.  CONCLUSION: GS-9219 may have utility for the treatment of NHL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKeCNsKzbneLVg90H21EOLACvtfcHk0lgrHrKlyE2zVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXlsFSjsrs%253D&md5=45263fba4227c41be39117929f6e6cbd</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-07-2061&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-07-2061%26sid%3Dliteratum%253Aachs%26aulast%3DReiser%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DChong%26aufirst%3DL.%26aulast%3DWatkins%26aufirst%3DW.%2BJ.%26aulast%3DRay%26aufirst%3DA.%2BS.%26aulast%3DShibata%26aufirst%3DR.%26aulast%3DBirkus%26aufirst%3DG.%26aulast%3DCihlar%26aufirst%3DT.%26aulast%3DWu%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DHenne%26aufirst%3DI.%2BN.%26aulast%3DWolfgang%26aufirst%3DG.%2BH.%2BI.%26aulast%3DDesai%26aufirst%3DM.%26aulast%3DRhodes%26aufirst%3DG.%2BR.%26aulast%3DFridland%26aufirst%3DA.%26aulast%3DLee%26aufirst%3DW.%2BA.%26aulast%3DPlunkett%26aufirst%3DW.%26aulast%3DVail%26aufirst%3DD.%26aulast%3DThamm%26aufirst%3DD.%2BH.%26aulast%3DJeraj%26aufirst%3DR.%26aulast%3DTumas%26aufirst%3DD.%2BB.%26atitle%3DGS-9219%25E2%2580%2594A%2520Novel%2520acyclic%2520nucleotide%2520analogue%2520with%2520potent%2520antineoplastic%2520activity%2520in%2520dogs%2520with%2520spontaneous%2520non-Hodgkin%25E2%2580%2599s%2520lymphoma%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2008%26volume%3D14%26spage%3D2824%26epage%3D2832%26doi%3D10.1158%2F1078-0432.CCR-07-2061" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span> <span> </span><span class="NLM_article-title">Tanovea® for the treatment of lymphoma in dogs</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>154</i></span>,  <span class="NLM_fpage">265</span>– <span class="NLM_lpage">269</span>, <span class="refDoi"> DOI: 10.1016/j.bcp.2018.05.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1016%2Fj.bcp.2018.05.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=29778492" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADC%252BC1cXpslalur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=154&publication_year=2018&pages=265-269&author=E.+De+Clercq&title=Tanovea%C2%AE+for+the+treatment+of+lymphoma+in+dogs&doi=10.1016%2Fj.bcp.2018.05.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Tanovea for the treatment of lymphoma in dogs</span></div><div class="casAuthors">De Clercq, Erik</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">154</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">265-269</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Tanovea (first named GS-9219, then VDC-1101, generic name: rabacfosadine) is a pro-prodrug or "double" prodrug of PMEG [9-(2-phosphonylmethoxyethyl)guanine], which has been conditionally approved by the US FDA (Food and Drug Administration) for the treatment of lymphoma in dogs.  Tanovea has been demonstrated to be effective against non-Hodgkin's lymphoma (NHL) in dogs, as well as canine cutaneous T-cell lymphoma, spontaneous canine multiple myeloma, naive canine multicentric lymphoma and relapsed canine B-cell lymphoma.  As a double prodrug of PMEG, GS-9219 is first converted intracellularly by hydrolysis to cPr-PMEDAP, then deaminated to PMEG, which is then phosphorylated twice to its active metabolite PMEGpp, acting at the level of the cellular DNA polymerases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGBLgcnzyiebVg90H21EOLACvtfcHk0lhFJ4C042HpxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXpslalur4%253D&md5=b24fa8a7518d2f37d6cdf6f3f9f239d1</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2018.05.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2018.05.010%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BClercq%26aufirst%3DE.%26atitle%3DTanovea%25C2%25AE%2520for%2520the%2520treatment%2520of%2520lymphoma%2520in%2520dogs%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2018%26volume%3D154%26spage%3D265%26epage%3D269%26doi%3D10.1016%2Fj.bcp.2018.05.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McGuigan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barucki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blewett, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carangio, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erichsen, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrei, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snoeck, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balzarini, J.</span></span> <span> </span><span class="NLM_article-title">Highly potent and selective inhibition of varicella-zoster virus by bicyclic furopyrimidine nucleosides bearing an aryl side chain</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">4993</span>– <span class="NLM_lpage">4997</span>, <span class="refDoi"> DOI: 10.1021/jm000210m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm000210m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADC%252BD3cXotFymur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2000&pages=4993-4997&author=C.+McGuiganauthor=H.+Baruckiauthor=S.+Blewettauthor=A.+Carangioauthor=J.+T.+Erichsenauthor=G.+Andreiauthor=R.+Snoeckauthor=E.+De+Clercqauthor=J.+Balzarini&title=Highly+potent+and+selective+inhibition+of+varicella-zoster+virus+by+bicyclic+furopyrimidine+nucleosides+bearing+an+aryl+side+chain&doi=10.1021%2Fjm000210m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Highly Potent and Selective Inhibition of Varicella-Zoster Virus by Bicyclic Furopyrimidine Nucleosides Bearing an Aryl Side Chain</span></div><div class="casAuthors">McGuigan, Christopher; Barucki, Hubert; Blewett, Sally; Carangio, Antonella; Erichsen, Jonathan T.; Andrei, Graciela; Snoeck, Robert; De Clercq, Erik; Balzarini, Jan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">4993-4997</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In addn. to the authors' recent report on the potent anti-varicella-zoster virus (VZV) activity of some unusual bicyclic furopyrimidine nucleosides bearing long alkyl side chains, they herein report the further significant enhancement of the antiviral potency by inclusion of a Ph group in the side chain of these compds.  The target structures were prepd. by the Pd-catalyzed coupling of a series of para-substituted arylacetylenes with 5-iodo-2'-deoxyuridine, to give intermediate 5-alkynyl nucleosides which were cyclized in the presence of Cu to give the desired bicyclic systems.  The compds. display extraordinary potency and selectivity for VZV; the most active are ca. 10,000 times more potent than the ref. compd. acyclovir and ca. 100 times more potent than the alkyl analogs earlier reported by us.  The current compds. show little cytotoxicity, leading to selectivity index values ≥ 1,000,000.  From a range of DNA and RNA viruses tested, only VZV was inhibited by these compds. indicating their extreme selectivity for this target virus.  The novelty of the mols., coupled with their extreme potency and selectivity, their desirable physicochem. properties, and their relative ease of synthesis, makes them of considerable interest for potential drug development for VZV infections.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqu8kNfT53LdrVg90H21EOLACvtfcHk0lhFJ4C042HpxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXotFymur0%253D&md5=15602d44b75b6560024dfdf616fbf23c</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1021%2Fjm000210m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm000210m%26sid%3Dliteratum%253Aachs%26aulast%3DMcGuigan%26aufirst%3DC.%26aulast%3DBarucki%26aufirst%3DH.%26aulast%3DBlewett%26aufirst%3DS.%26aulast%3DCarangio%26aufirst%3DA.%26aulast%3DErichsen%26aufirst%3DJ.%2BT.%26aulast%3DAndrei%26aufirst%3DG.%26aulast%3DSnoeck%26aufirst%3DR.%26aulast%3DDe%2BClercq%26aufirst%3DE.%26aulast%3DBalzarini%26aufirst%3DJ.%26atitle%3DHighly%2520potent%2520and%2520selective%2520inhibition%2520of%2520varicella-zoster%2520virus%2520by%2520bicyclic%2520furopyrimidine%2520nucleosides%2520bearing%2520an%2520aryl%2520side%2520chain%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2000%26volume%3D43%26spage%3D4993%26epage%3D4997%26doi%3D10.1021%2Fjm000210m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Andrei, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sienaert, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGuigan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balzarini, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snoeck, R.</span></span> <span> </span><span class="NLM_article-title">Susceptibilities of several clinical varicella-zoster virus (VZV) isolates and drug-resistant VZV strains to bicyclic furano pyrimidine nucleosides</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">1081</span>– <span class="NLM_lpage">1086</span>, <span class="refDoi"> DOI: 10.1128/AAC.49.3.1081-1086.2005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1128%2FAAC.49.3.1081-1086.2005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=15728906" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADC%252BD2MXit12murs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2005&pages=1081-1086&author=G.+Andreiauthor=R.+Sienaertauthor=C.+McGuiganauthor=E.+De+Clercqauthor=J.+Balzariniauthor=R.+Snoeck&title=Susceptibilities+of+several+clinical+varicella-zoster+virus+%28VZV%29+isolates+and+drug-resistant+VZV+strains+to+bicyclic+furano+pyrimidine+nucleosides&doi=10.1128%2FAAC.49.3.1081-1086.2005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Susceptibilities of several clinical varicella-zoster virus (VZV) isolates and drug-resistant VZV strains to bicyclic furano pyrimidine nucleosides</span></div><div class="casAuthors">Andrei, Graciela; Sienaert, Rebecca; McGuigan, Chris; De Clercq, Erik; Balzarini, Jan; Snoeck, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1081-1086</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Varicella-zoster virus (VZV) is responsible for primary infections as well as reactivations after latency in the dorsal root ganglia.  The treatment of such infections is mandatory for immunocompromised patients and highly recommended for elderly patients with herpes zoster infections (also called zona or shingles).  The treatment of choice is presently based on four mols., acyclovir (ACV), valaciclovir, famciclovir, and (in Europe) brivudine (BVDU).  We present here our data on the antiviral activity of a new class of potent and selective anti-VZV compds., bicyclic pyrimidine nucleoside analogs (BCNAs), against a broad variety of clin. isolates and different drug-resistant virus strains.  The results show that the BCNAs are far more potent inhibitors than ACV and BVDU against clin. VZV isolates as well as the VZV ref. strains Oka and YS.  The BCNAs were not active against ACV- and BVDU-resistant VZV strains bearing mutations in the viral thymidine kinase gene but kept their inhibitory potential against virus strains with mutations in the VZV DNA polymerase gene.  Mutant virus strains selected in the presence of the BCNAs were solely cross-resistant to drugs, such as ACV and BVDU, that depend for their antiviral action on metabolic activation by the viral thymidine kinase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpV5EJqr0qmUbVg90H21EOLACvtfcHk0lhFJ4C042HpxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXit12murs%253D&md5=ef2628333f3beb4e7eb9f728795e20e5</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1128%2FAAC.49.3.1081-1086.2005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.49.3.1081-1086.2005%26sid%3Dliteratum%253Aachs%26aulast%3DAndrei%26aufirst%3DG.%26aulast%3DSienaert%26aufirst%3DR.%26aulast%3DMcGuigan%26aufirst%3DC.%26aulast%3DDe%2BClercq%26aufirst%3DE.%26aulast%3DBalzarini%26aufirst%3DJ.%26aulast%3DSnoeck%26aufirst%3DR.%26atitle%3DSusceptibilities%2520of%2520several%2520clinical%2520varicella-zoster%2520virus%2520%2528VZV%2529%2520isolates%2520and%2520drug-resistant%2520VZV%2520strains%2520to%2520bicyclic%2520furano%2520pyrimidine%2520nucleosides%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2005%26volume%3D49%26spage%3D1081%26epage%3D1086%26doi%3D10.1128%2FAAC.49.3.1081-1086.2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span> <span> </span><span class="NLM_article-title">Highly potent and selective inhibition of varicella-zoster virus replication by bicyclic furo [2,3-d]pyridine nucleoside analogues</span>. <i>Med. Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">253</span>– <span class="NLM_lpage">274</span>, <span class="refDoi"> DOI: 10.1002/med.10035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1002%2Fmed.10035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=12647310" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADC%252BD3sXjsVWitLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2003&pages=253-274&author=E.+De+Clercq&title=Highly+potent+and+selective+inhibition+of+varicella-zoster+virus+replication+by+bicyclic+furo+%5B2%2C3-d%5Dpyridine+nucleoside+analogues&doi=10.1002%2Fmed.10035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Highly potent and selective inhibition of varicella-zoster virus replication by bicyclic furo [2,3-d]pyrimidine nucleoside analogues</span></div><div class="casAuthors">De Clercq, Erik</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">253-274</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  The bicyclic furo[2,3-d]pyrimidine nucleoside analogs represent an entirely new class of fused furopyrimidine derivs. with unprecedented selectivity for varicella-zoster virus (VZV).  From extensive structure-activity relationship (SAR) studies, the 6-(p-alkylphenyl)substituted furopyrimidine derivs. Cf 1742 and Cf 1743 emerged as the most potent inhibitors of VZV replication: they were found to inhibit both lab. VZV strains and clin. VZV isolates at subnanomolar concns., while not being toxic to the host cells at 100,000-fold higher concns.  Although the precise mechanism of action of these compds. remains to be elucidated, it is clear that for their antiviral activity they depend on phosphorylation by the VZV-encoded thymidine kinase.  The furo[2,3-d]pyrimidine nucleoside analogs are not susceptible to degrdn. by human or bacterial thymidine phosphorylase, which may otherwise release the free aglycon.  Also, the latter is not inhibitory to dihydropyrimidine dehydrogenase, an enzyme involved in the degrdn. of thymine, uracil, and the anticancer agent 5-fluorouracil.  Further development of the furo[2,3-d]pyrimidine nucleoside analogs as new therapeutic modalities for the treatment of VZV infections (i.e., varicella and herpes zoster) seems highly justified.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYtL_aPdxa1LVg90H21EOLACvtfcHk0lh8YctFyinLXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXjsVWitLo%253D&md5=d32c87d1553be695e113954baa115808</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1002%2Fmed.10035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.10035%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BClercq%26aufirst%3DE.%26atitle%3DHighly%2520potent%2520and%2520selective%2520inhibition%2520of%2520varicella-zoster%2520virus%2520replication%2520by%2520bicyclic%2520furo%2520%255B2%252C3-d%255Dpyridine%2520nucleoside%2520analogues%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2003%26volume%3D23%26spage%3D253%26epage%3D274%26doi%3D10.1002%2Fmed.10035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McGuigan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pathirana, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Migliore, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adak, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luoni, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Díez-Torrubia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camarasa, M.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Velázquez, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henson, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verbeken, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sienaert, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naesens, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snoeck, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrei, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balzarini, J.</span></span> <span> </span><span class="NLM_article-title">Preclinical development of bicyclic nucleoside analogues as potent and selective inhibitors of varicella zoster virus</span>. <i>J. Antimicrob. Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">1316</span>– <span class="NLM_lpage">1330</span>, <span class="refDoi"> DOI: 10.1093/jac/dkm376</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1093%2Fjac%2Fdkm376" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=17956908" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlKmt7fM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2007&pages=1316-1330&author=C.+McGuiganauthor=R.+N.+Pathiranaauthor=M.+Miglioreauthor=R.+Adakauthor=G.+Luoniauthor=A.+T.+Jonesauthor=A.+D%C3%ADez-Torrubiaauthor=M.-J.+Camarasaauthor=S.+Vel%C3%A1zquezauthor=G.+Hensonauthor=E.+Verbekenauthor=R.+Sienaertauthor=L.+Naesensauthor=R.+Snoeckauthor=G.+Andreiauthor=J.+Balzarini&title=Preclinical+development+of+bicyclic+nucleoside+analogues+as+potent+and+selective+inhibitors+of+varicella+zoster+virus&doi=10.1093%2Fjac%2Fdkm376"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical development of bicyclic nucleoside analogues as potent and selective inhibitors of varicella zoster virus</span></div><div class="casAuthors">McGuigan, Christopher; Pathirana, Ranjith N.; Migliore, Marco; Adak, Rina; Luoni, Giovanna; Jones, Arwyn T.; Diez-Torrubia, Alberto; Camarasa, Maria-Jose; Velazquez, Sonsoles; Henson, Geoffrey; Verbeken, Erik; Sienaert, Rebecca; Naesens, Lieve; Snoeck, Robert; Andrei, Graciela; Balzarini, Jan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Antimicrobial Chemotherapy</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1316-1330</span>CODEN:
                <span class="NLM_cas:coden">JACHDX</span>;
        ISSN:<span class="NLM_cas:issn">0305-7453</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Objectives: To progress the anti-varicella-zoster-virus (VZV) aryl bicyclic nucleoside analogs (BCNAs) to the point of Phase 1 clin. trial for herpes zoster.  Methods: A new chromatog.-free synthetic access to the lead anti-VZV aryl BCNAs is reported.  The anti-VZV activity of lead Cf1743 was evaluated in monolayer cell cultures and organotypic epithelial raft cultures of primary human keratinocytes.  Oral dosing in rodents and preliminary pharmacokinetics assessment was made, followed by an exploration of alternative formulations and the prepn. of pro-drugs.  We also studied uptake into cells of both parent drug and pro-drug using fluorescent microscopy and biol. assays.  Results: Cf1743 proved to be significantly more potent than all ref. anti-VZV compds. as measured either by inhibition of infectious virus particles and/or by viral DNA load.  However, the very low water soly. of this compd. gave poor oral bioavailability (∼14%). A Captisol admixt. and the 5'-monophosphate pro-drug of Cf1743 greatly boosted water soly. but did not significantly improve oral bioavailability.  The most promising pro-drug to emerge was the HCl salt of the 5'-valyl ester, designated as FV-100.  Its uptake into cells studied using fluorescent microscopy and biol. assays indicated that the compd. is taken up by the cells after a short period of incubation and limited exposure to drug in vivo may have beneficial effects.  Conclusions: On the basis of its favorable antiviral and pharmacokinetic properties, FV-100 is now being pursued as the clin. BCNA candidate for the treatment of VZV shingles.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMlVPkcYmb57Vg90H21EOLACvtfcHk0lh8YctFyinLXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlKmt7fM&md5=b8f2aa41ba0035fc69ea892a687bed50</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1093%2Fjac%2Fdkm376&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjac%252Fdkm376%26sid%3Dliteratum%253Aachs%26aulast%3DMcGuigan%26aufirst%3DC.%26aulast%3DPathirana%26aufirst%3DR.%2BN.%26aulast%3DMigliore%26aufirst%3DM.%26aulast%3DAdak%26aufirst%3DR.%26aulast%3DLuoni%26aufirst%3DG.%26aulast%3DJones%26aufirst%3DA.%2BT.%26aulast%3DD%25C3%25ADez-Torrubia%26aufirst%3DA.%26aulast%3DCamarasa%26aufirst%3DM.-J.%26aulast%3DVel%25C3%25A1zquez%26aufirst%3DS.%26aulast%3DHenson%26aufirst%3DG.%26aulast%3DVerbeken%26aufirst%3DE.%26aulast%3DSienaert%26aufirst%3DR.%26aulast%3DNaesens%26aufirst%3DL.%26aulast%3DSnoeck%26aufirst%3DR.%26aulast%3DAndrei%26aufirst%3DG.%26aulast%3DBalzarini%26aufirst%3DJ.%26atitle%3DPreclinical%2520development%2520of%2520bicyclic%2520nucleoside%2520analogues%2520as%2520potent%2520and%2520selective%2520inhibitors%2520of%2520varicella%2520zoster%2520virus%26jtitle%3DJ.%2520Antimicrob.%2520Chemother.%26date%3D2007%26volume%3D60%26spage%3D1316%26epage%3D1330%26doi%3D10.1093%2Fjac%2Fdkm376" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pentikis, H.
S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atiee, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boehlecke, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutchins, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patti, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henson, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, A.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetics and safety of FV-100, a novel oral anti-herpes zoster nucleoside analogue, administered in single and multiple doses to healthy young adult and elderly adult volunteers</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">2847</span>– <span class="NLM_lpage">2854</span>, <span class="refDoi"> DOI: 10.1128/AAC.01446-10</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1128%2FAAC.01446-10" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=21444712" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADC%252BC3MXnt1Kiu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2011&pages=2847-2854&author=H.%0AS.+Pentikisauthor=M.+Matsonauthor=G.+Atieeauthor=B.+Boehleckeauthor=J.+T.+Hutchinsauthor=J.+M.+Pattiauthor=G.+W.+Hensonauthor=A.+Morris&title=Pharmacokinetics+and+safety+of+FV-100%2C+a+novel+oral+anti-herpes+zoster+nucleoside+analogue%2C+administered+in+single+and+multiple+doses+to+healthy+young+adult+and+elderly+adult+volunteers&doi=10.1128%2FAAC.01446-10"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetics and safety of FV-100, a novel oral anti-herpes zoster nucleoside analogue, administered in single and multiple doses to healthy young adult and elderly adult volunteers</span></div><div class="casAuthors">Pentikis, Helen S.; Matson, Mark; Atiee, George; Boehlecke, Brian; Hutchins, Jeff T.; Patti, Joseph M.; Henson, Geoffrey W.; Morris, Amy</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2847-2854</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">FV-100 is the prodrug of the highly potent anti-varicella zoster virus bicyclic nucleoside analog CF-1743.  To characterize the pharmacokinetics and safety of oral FV-100, 3 randomized, double-blind, placebo-controlled clin. trials were conducted: (i) a single-ascending-dose study in 32 healthy subjects aged 18 to 55 years (100-, 200-, 400-, and 800-mg doses) with an evaluation of the food effect in the 400-mg group; (ii) a multiple-ascending-dose study in 48 subjects aged 18 to 55 years (100 mg once daily [QD], 200 mg QD, 400 mg QD, 400 mg twice a day, and 800 mg QD for 7 days); and (iii) a 2-part study in subjects aged 65 years and older with a single 400-mg dose in 15 subjects and a 400-mg QD dosing regimen for 7 days in 12 subjects.  FV-100 was rapidly and extensively converted to CF-1743, the concn. of which remained above that required to reduce viral activity by 50% for the 24-h dosing period.  Renal excretion of CF-1743 was very low.  A high-fat meal reduced exposure to CF-1743; a low-fat meal did not.  Pharmacokinetic parameters for the elderly subjects were comparable to those for the younger subjects.  FV-100 was well tolerated by all subjects.  The pharmacokinetic and safety profiles of FV-100 support its continued investigation for the treatment of herpes zoster and prevention of postherpetic neuralgia with once-daily dosing and without dose modifications for elderly or renally impaired patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYUfzppD_waLVg90H21EOLACvtfcHk0lh8YctFyinLXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXnt1Kiu7w%253D&md5=c74cb28adcd457cca073905cc53ac705</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1128%2FAAC.01446-10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.01446-10%26sid%3Dliteratum%253Aachs%26aulast%3DPentikis%26aufirst%3DH.%2BS.%26aulast%3DMatson%26aufirst%3DM.%26aulast%3DAtiee%26aufirst%3DG.%26aulast%3DBoehlecke%26aufirst%3DB.%26aulast%3DHutchins%26aufirst%3DJ.%2BT.%26aulast%3DPatti%26aufirst%3DJ.%2BM.%26aulast%3DHenson%26aufirst%3DG.%2BW.%26aulast%3DMorris%26aufirst%3DA.%26atitle%3DPharmacokinetics%2520and%2520safety%2520of%2520FV-100%252C%2520a%2520novel%2520oral%2520anti-herpes%2520zoster%2520nucleoside%2520analogue%252C%2520administered%2520in%2520single%2520and%2520multiple%2520doses%2520to%2520healthy%2520young%2520adult%2520and%2520elderly%2520adult%2520volunteers%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2011%26volume%3D55%26spage%3D2847%26epage%3D2854%26doi%3D10.1128%2FAAC.01446-10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wolfgang, G. H. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shibata, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ray, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doerrfler, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reiser, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birkus, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christensen, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrei, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snoeck, R.</span></span> <span> </span><span class="NLM_article-title">GS-9191 Is a novel topical prodrug of the nucleotide analog 9-(2-phosphonylmethoxyethyl)guanine with antiproliferative activity and possible utility in the treatment of human papillomavirus lesions</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">2777</span>– <span class="NLM_lpage">2784</span>, <span class="refDoi"> DOI: 10.1128/AAC.00103-09</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1128%2FAAC.00103-09" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=19398642" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADC%252BD1MXotlWqtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2009&pages=2777-2784&author=G.+H.+I.+Wolfgangauthor=R.+Shibataauthor=J.+Wangauthor=A.+S.+Rayauthor=S.+Wuauthor=E.+Doerrflerauthor=H.+Reiserauthor=W.+A.+Leeauthor=G.+Birkusauthor=N.+D.+Christensenauthor=G.+Andreiauthor=R.+Snoeck&title=GS-9191+Is+a+novel+topical+prodrug+of+the+nucleotide+analog+9-%282-phosphonylmethoxyethyl%29guanine+with+antiproliferative+activity+and+possible+utility+in+the+treatment+of+human+papillomavirus+lesions&doi=10.1128%2FAAC.00103-09"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">GS-9191 is a novel topical prodrug of the nucleotide analog 9-(2-phosphonylmethoxyethyl)guanine with antiproliferative activity and possible utility in the treatment of human papillomavirus lesions</span></div><div class="casAuthors">Wolfgang, Grushenka H. I.; Shibata, Riri; Wang, Jianying; Ray, Adrian S.; Wu, Sylvia; Doerrfler, Edward; Reiser, Hans; Lee, William A.; Birkus, Gabriel; Christensen, Neil D.; Andrei, Graciela; Snoeck, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2777-2784</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">GS-9191 is a novel double prodrug of the nucleotide analog 9-(2-phosphonylmethoxyethyl)guanine (PMEG) designed as a topical agent to permeate skin and be metabolized to the active nucleoside triphosphate analog in the epithelial layer.  The prodrug was shown to be metabolized intracellularly to 9-(2-phosphonylmethoxyethyl)-N6-cyclopropyl-2,6,diaminopurine (cPrPMEDAP) and subsequently deaminated to PMEG.  The active form, PMEG diphosphate, was shown to be a potent inhibitor of DNA polymerase α and β while showing weaker activity against mitochondrial DNA polymerase γ (50% enzyme inhibition obsd. at 2.5, 1.6, and 59.4 μM, resp.).  GS-9191 was markedly more potent than PMEG or cPrPMEDAP in a series of human papillomavirus (HPV)-pos. cell lines, with effective concns. to inhibit 50% cell growth (EC50) as low as 0.03, 207, and 284 nM, resp.  In contrast, GS-9191 was generally less potent in non-HPV-infected cells and primary cells (EC50s between 1 and 15 nM).  DNA synthesis was inhibited by GS-9191 within 24 h of treatment; cells were obsd. to be arrested in S phase by 48 h and to subsequently undergo apoptosis (between 3 and 7 days).  In an animal model (cottontail rabbit papillomavirus), topical GS-9191 was shown to decrease the size of papillomas in a dose-related manner.  At the highest dose (0.1%), cures were evident at the end of 5 wk, and lesions did not recur in a 30-day follow-up period.  These data suggest that GS-9191 may have utility in the treatment of HPV-induced lesions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRJcTRFVb_gbVg90H21EOLACvtfcHk0ljQzBoxH5r5DQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXotlWqtbs%253D&md5=c59462bbf96e4fe32927a905d3f04c03</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1128%2FAAC.00103-09&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00103-09%26sid%3Dliteratum%253Aachs%26aulast%3DWolfgang%26aufirst%3DG.%2BH.%2BI.%26aulast%3DShibata%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DRay%26aufirst%3DA.%2BS.%26aulast%3DWu%26aufirst%3DS.%26aulast%3DDoerrfler%26aufirst%3DE.%26aulast%3DReiser%26aufirst%3DH.%26aulast%3DLee%26aufirst%3DW.%2BA.%26aulast%3DBirkus%26aufirst%3DG.%26aulast%3DChristensen%26aufirst%3DN.%2BD.%26aulast%3DAndrei%26aufirst%3DG.%26aulast%3DSnoeck%26aufirst%3DR.%26atitle%3DGS-9191%2520Is%2520a%2520novel%2520topical%2520prodrug%2520of%2520the%2520nucleotide%2520analog%25209-%25282-phosphonylmethoxyethyl%2529guanine%2520with%2520antiproliferative%2520activity%2520and%2520possible%2520utility%2520in%2520the%2520treatment%2520of%2520human%2520papillomavirus%2520lesions%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2009%26volume%3D53%26spage%3D2777%26epage%3D2784%26doi%3D10.1128%2FAAC.00103-09" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Holý, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Votruba, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masojídková, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrei, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snoeck, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naesens, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balzarini, J.</span></span> <span> </span><span class="NLM_article-title">6-[2-(Phosphonomethoxy)alkoxy]pyrimidines with Antiviral Activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">1918</span>– <span class="NLM_lpage">1929</span>, <span class="refDoi"> DOI: 10.1021/jm011095y</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm011095y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADC%252BD38Xit12mur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2002&pages=1918-1929&author=A.+Hol%C3%BDauthor=I.+Votrubaauthor=M.+Masoj%C3%ADdkov%C3%A1author=G.+Andreiauthor=R.+Snoeckauthor=L.+Naesensauthor=E.+De+Clercqauthor=J.+Balzarini&title=6-%5B2-%28Phosphonomethoxy%29alkoxy%5Dpyrimidines+with+Antiviral+Activity&doi=10.1021%2Fjm011095y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">6-[2-(Phosphonomethoxy)alkoxy]pyrimidines with Antiviral Activity</span></div><div class="casAuthors">Holy, Antonin; Votruba, Ivan; Masojidkova, Milena; Andrei, Graciela; Snoeck, Robert; Naesens, Lieve; De Clercq, Erik; Balzarini, Jan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1918-1929</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">6-Hydroxypyrimidines substituted at positions 2 and 4 by H, Me, amino, cyclopropylamino, dimethylamino, methylthio, or hydroxyl group afford by the reaction with diisopropyl 2-(chloroethoxy)methylphosphonate in the presence of NaH, Cs2CO3, or DBU a mixt. of N1- and O6-[2-(diisopropylphosphorylmethoxy)ethyl] isomers which were converted to the free phosphonic acids by treatment with bromotrimethylsilane followed by hydrolysis.  Analogously, 2,4-diamino-6-hydroxypyrimidine gave on reaction with [(R)- and (S)-2-(diisopropylphosphorylmethoxy)propyl] tosylate, followed by deprotection, the enantiomeric 6-[2-(phosphonomethoxy)propoxy]pyrimidines.  2,4-Diamino-6-sulfanylpyrimidine gave, on treatment with diisopropyl 2-(chloroethoxy)methylphosphonate in the presence of NaH and subsequent deprotection, 2,4-diamino-6-{[2-(phosphonomethoxy)ethyl]thio}pyrimidine.  2-Amino-4-hydroxy-6-[2-(phosphonomethoxy)ethyl]pyrimidine was obtained from the appropriate 2-amino-4-chloropyrimidine deriv. by alk. hydrolysis and ester cleavage.  Direct alkylation of 2-amino-4,6-dihydroxypyrimidine afforded a mixt. of 2-amino-4,6-bis[2-(phosphonomethoxy)ethyl]- and 2-amino-1,4-bis[2-(phosphonomethoxy)ethyl]pyrimidine.  None of the N1-[2-(phosphonomethoxy)ethyl] isomers exhibited any antiviral activity against DNA viruses or RNA viruses tested in vitro.  On the contrary, the O6-isomers, the compds. derived from 2,4-diamino-, 2-amino-4-hydroxy-, or 2-amino-4-[2-(phosphonomethoxy)ethoxy]-6-hydroxypyrimidine, inhibited the replication of herpes viruses [herpes simplex type 1 (HSV-1) and type 2 (HSV-2), varicella-zoster virus (VZV), and cytomegalovirus (CMV)] and retroviruses [Moloney sarcoma virus (MSV) and human immunodeficiency virus type 1 (HIV-1) and type 2 (HIV-2)], their activity being most pronounced against the latter.  The antiviral activity was lower if the O at the position 6 was replaced by a S atom, as in 2,4-diamino-6-[2-(phosphonomethoxy)ethylthio]pyrimidine.  In analogy to N9-[2-(phosphonomethoxy)propyl]-2,6-diaminopurine (PMPDAP), solely the (R)-2,4-diamino-6-[2-(phosphonomethoxy)propoxy]pyrimidine exerted antiviral activity, whereas its (S)-enantiomer was essentially inactive.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZUOLNwoSlNLVg90H21EOLACvtfcHk0ljQzBoxH5r5DQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xit12mur8%253D&md5=f086f0e2cae1cdb319cd23a8d9162052</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1021%2Fjm011095y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm011095y%26sid%3Dliteratum%253Aachs%26aulast%3DHol%25C3%25BD%26aufirst%3DA.%26aulast%3DVotruba%26aufirst%3DI.%26aulast%3DMasoj%25C3%25ADdkov%25C3%25A1%26aufirst%3DM.%26aulast%3DAndrei%26aufirst%3DG.%26aulast%3DSnoeck%26aufirst%3DR.%26aulast%3DNaesens%26aufirst%3DL.%26aulast%3DDe%2BClercq%26aufirst%3DE.%26aulast%3DBalzarini%26aufirst%3DJ.%26atitle%3D6-%255B2-%2528Phosphonomethoxy%2529alkoxy%255Dpyrimidines%2520with%2520Antiviral%2520Activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2002%26volume%3D45%26spage%3D1918%26epage%3D1929%26doi%3D10.1021%2Fjm011095y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref93"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref93'); return false;" data-citation="" class="refNumLink">93</a></strong><div class="NLM_citation" id="cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hocková, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holý, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masojídková, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrei, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snoeck, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balzarini, J.</span></span> <span> </span><span class="NLM_article-title">5-substituted-2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]pyrimidines - acyclic nucleoside phosphonate analogues with antiviral activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">5064</span>– <span class="NLM_lpage">5073</span>, <span class="refDoi"> DOI: 10.1021/jm030932o</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm030932o" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADC%252BD3sXotVKltL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=5064-5073&author=D.+Hockov%C3%A1author=A.+Hol%C3%BDauthor=M.+Masoj%C3%ADdkov%C3%A1author=G.+Andreiauthor=R.+Snoeckauthor=E.+De+Clercqauthor=J.+Balzarini&title=5-substituted-2%2C4-diamino-6-%5B2-%28phosphonomethoxy%29ethoxy%5Dpyrimidines+-+acyclic+nucleoside+phosphonate+analogues+with+antiviral+activity&doi=10.1021%2Fjm030932o"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">5-Substituted-2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]pyrimidines-Acyclic Nucleoside Phosphonate Analogues with Antiviral Activity</span></div><div class="casAuthors">Hockova, Dana; Holy, Antonin; Masojidkova, Milena; Andrei, Graciela; Snoeck, Robert; De Clercq, Erik; Balzarini, Jan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">5064-5073</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">2,4-Diamino-6-hydroxypyrimidines substituted in position 5 by an allyl, benzyl, cyanomethyl, ethoxycarbonylmethyl, Ph, cyclopropyl, or Me group were prepd. either by C5-alkylation or by formation of the pyrimidine ring by cyclization.  Their alkylation with 2-[(diisopropoxyphosphoryl)methoxy]ethyl tosylate afforded N1- and O6-regioisomers that were sepd. and converted to the free phosphonic acids by treatment with bromotrimethylsilane followed by hydrolysis.  Reaction of 2,4-diamino-6-{[(diisopropoxyphosphoryl)methoxy]ethoxy}pyrimidine with elemental bromine, N-chloro-, or N-iodosuccinimide gave the corresponding phosphorus-protected 5-bromo-, 5-chloro-, and 5-iodo derivs., resp.  Their deprotection afforded 2,4-diamino-5-bromo- and -5-chloro-6-[2-(phosphonomethoxy)ethoxy]pyrimidines. 2,4-Diamino-5-methyl-6-[2-(phosphonomethoxy)ethoxy]pyrimidine was synthesized also by cross-coupling of the 5-bromo compd. with AlMe3, followed by deprotection.  The compds. showed poor, if any, inhibitory activity against DNA viruses such as herpes simplex virus type 1 and type 2, cytomegalovirus, varicella-zoster virus, and vaccinia virus.  In contrast, several 5-substituted 2,4-diaminopyrimidine derivs. markedly inhibited retrovirus replication in cell culture.  The 5-Me deriv. was exquisitely inhibitory to human immunodeficiency virus and Moloney murine sarcoma virus-induced cytopathicity in cell culture (EC50 ∼ 0.00018 μmol/mL) but also cytostatic to CEM cell cultures.  In contrast, the 5-halogen-substituted derivs. showed pronounced antiretroviral activity (EC50 = 0.0023-0.0110 μmol/mL), comparable to that of the ref. drugs adefovir and tenofovir, but were devoid of measurable toxicity at 0.3 μmol/mL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9CUljBF1DaLVg90H21EOLACvtfcHk0ljQzBoxH5r5DQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXotVKltL8%253D&md5=5c335da2539c8745e22f10492bab4d48</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1021%2Fjm030932o&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm030932o%26sid%3Dliteratum%253Aachs%26aulast%3DHockov%25C3%25A1%26aufirst%3DD.%26aulast%3DHol%25C3%25BD%26aufirst%3DA.%26aulast%3DMasoj%25C3%25ADdkov%25C3%25A1%26aufirst%3DM.%26aulast%3DAndrei%26aufirst%3DG.%26aulast%3DSnoeck%26aufirst%3DR.%26aulast%3DDe%2BClercq%26aufirst%3DE.%26aulast%3DBalzarini%26aufirst%3DJ.%26atitle%3D5-substituted-2%252C4-diamino-6-%255B2-%2528phosphonomethoxy%2529ethoxy%255Dpyrimidines%2520-%2520acyclic%2520nucleoside%2520phosphonate%2520analogues%2520with%2520antiviral%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D5064%26epage%3D5073%26doi%3D10.1021%2Fjm030932o" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref94"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref94'); return false;" data-citation="" class="refNumLink">94</a></strong><div class="NLM_citation" id="cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrei, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balzarini, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leyssen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naesens, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neyts, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pannecouque, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snoeck, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ying, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hockova, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holý, A.</span></span> <span> </span><span class="NLM_article-title">Antiviral potential of a new generation of acyclic nucleoside phosphonates, the 6-[2-(phosphonomethoxy)alkoxy]-2,4-diaminopyrimidines</span>. <i>Nucleosides, Nucleotides Nucleic Acids</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">331</span>– <span class="NLM_lpage">341</span>, <span class="refDoi"> DOI: 10.1081/NCN-200059772</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1081%2FNCN-200059772" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=16247948" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtFGisb7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2005&pages=331-341&author=E.+De+Clercqauthor=G.+Andreiauthor=J.+Balzariniauthor=P.+Leyssenauthor=L.+Naesensauthor=J.+Neytsauthor=C.+Pannecouqueauthor=R.+Snoeckauthor=C.+Yingauthor=D.+Hockovaauthor=A.+Hol%C3%BD&title=Antiviral+potential+of+a+new+generation+of+acyclic+nucleoside+phosphonates%2C+the+6-%5B2-%28phosphonomethoxy%29alkoxy%5D-2%2C4-diaminopyrimidines&doi=10.1081%2FNCN-200059772"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Antiviral potential of a new generation of acyclic nucleoside phosphonates, the 6-[2-(phosphonomethoxy)alkoxy]-2,4-diaminopyrimidines</span></div><div class="casAuthors">De Clercq, Erik; Andrei, G.; Balzarini, J.; Leyssen, P.; Naesens, L.; Neyts, J.; Pannecouque, C.; Snoeck, R.; Ying, C.; Hockova, D.; Holy, A.</div><div class="citationInfo"><span class="NLM_cas:title">Nucleosides, Nucleotides & Nucleic Acids</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">5-7</span>),
    <span class="NLM_cas:pages">331-341</span>CODEN:
                <span class="NLM_cas:coden">NNNAFY</span>;
        ISSN:<span class="NLM_cas:issn">1525-7770</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis, Inc.</span>)
        </div><div class="casAbstract">A review.  Three acyclic nucleoside phosphonates (ANPs) have been formally approved for clin. use in the treatment of (1) cytomegalovirus retinitis in AIDS patients (cidofovir, by the i.v. route), (2) chronic hepatitis B virus (HBV) infections (adefovir dipivoxil, by the oral route), and (3) human immunodeficiency virus (HIV) infections (tenofovir disoproxil fumarate, by the oral route).  The activity spectrum of cidofovir (S)-1-[3-hydroxy-2-(phosphonomethoxy)propyl]cytosine (S)-HPMPC, like that of (S)-HPMPA (S)-9-[3-hydroxy-2-(phosphonomethoxy)propyl]adenine and (S)-HPMPDAP (S)-9-[3-hydroxy-2-(phosphonomethoxy)propyl]-2,6-diaminopurine, encompasses a broad spectrum of DNA viruses, including polyoma-, papilloma-, adeno-, herpes-, and poxviruses.  Adefovir 9-[2-(phosphonomethoxy)ethyl]adenine (PMEA) and tenofovir (R)-9-[2-(phosphonomethoxy) propyl]adenine (R)-PMPA are particularly active against retroviruses (i.e., HIV) and hepadnaviruses (i.e., HBV); addnl., PMEA also shows activity against herpes- and poxviruses.  We have recently identified a new class of ANPs, namely 6-[2-(phosphonomethoxy)alkoxy]-2,4-diaminopyrimidines, named, in analogy with their alkylpurine counterparts, HPMPO-DAPy, PMEO-DAPy, and (R)-PMPO-DAPy.  These compds. exhibit an antiviral activity spectrum and potency that is similar to that of (S)-HPMPDAP, PMEA, and (R)-PMPA, resp.  Thus, PMEO-DAPy and (R)-PMPO-DAPy, akin to PMEA and (R)-PMPA, proved particularly active against HIV-1, HIV-2, and the murine retrovirus Moloney sarcoma virus (MSV).  PMEO-DAPy and (R)-PMPO-DAPy also showed potent activity against both wild-type and lamivudine-resistant strains of HBV.  HPMPO-DAPy was found to inhibit different poxviruses (i.e., vaccinia, cowpox, and orf) at a similar potency as cidofovir.  HPMPO-DAPy also proved active against adenoviruses.  In vivo, HPMPO-DAPy proved equipotent to cidofovir in suppressing vaccinia virus infection (tail lesion formation) in immunocompetent mice and promoting healing of disseminated vaccinia lesions in athymic-nude mice.  The 6-[2-(phosphonomethoxy)alkoxy]-2,4-diaminopyrimidines offer substantial potential for the treatment of a broad range of retro-, hepadna-, herpes-, adeno-, and poxvirus infections.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpv3hh5tyax17Vg90H21EOLACvtfcHk0liPV3YzghZnkQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtFGisb7I&md5=78c6dbe5b27ddf313792ae64596e0e8a</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1081%2FNCN-200059772&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1081%252FNCN-200059772%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BClercq%26aufirst%3DE.%26aulast%3DAndrei%26aufirst%3DG.%26aulast%3DBalzarini%26aufirst%3DJ.%26aulast%3DLeyssen%26aufirst%3DP.%26aulast%3DNaesens%26aufirst%3DL.%26aulast%3DNeyts%26aufirst%3DJ.%26aulast%3DPannecouque%26aufirst%3DC.%26aulast%3DSnoeck%26aufirst%3DR.%26aulast%3DYing%26aufirst%3DC.%26aulast%3DHockova%26aufirst%3DD.%26aulast%3DHol%25C3%25BD%26aufirst%3DA.%26atitle%3DAntiviral%2520potential%2520of%2520a%2520new%2520generation%2520of%2520acyclic%2520nucleoside%2520phosphonates%252C%2520the%25206-%255B2-%2528phosphonomethoxy%2529alkoxy%255D-2%252C4-diaminopyrimidines%26jtitle%3DNucleosides%252C%2520Nucleotides%2520Nucleic%2520Acids%26date%3D2005%26volume%3D24%26spage%3D331%26epage%3D341%26doi%3D10.1081%2FNCN-200059772" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref95"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref95'); return false;" data-citation="" class="refNumLink">95</a></strong><div class="NLM_citation" id="cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Krečmerová, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holý, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piskala, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masojidková, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrei, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naesens, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neyts, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balzarini, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snoeck, R.</span></span> <span> </span><span class="NLM_article-title">Antiviral activity of triazine analogues of 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]cytosine (cidofovir) and related compounds</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">1069</span>– <span class="NLM_lpage">1077</span>, <span class="refDoi"> DOI: 10.1021/jm061281+</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm061281%2B" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhs1Squ7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=1069-1077&author=M.+Kre%C4%8Dmerov%C3%A1author=A.+Hol%C3%BDauthor=A.+Piskalaauthor=M.+Masojidkov%C3%A1author=G.+Andreiauthor=L.+Naesensauthor=J.+Neytsauthor=J.+Balzariniauthor=E.+De+Clercqauthor=R.+Snoeck&title=Antiviral+activity+of+triazine+analogues+of+1-%28S%29-%5B3-hydroxy-2-%28phosphonomethoxy%29propyl%5Dcytosine+%28cidofovir%29+and+related+compounds&doi=10.1021%2Fjm061281%2B"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Antiviral Activity of Triazine Analogues of 1-(S)-[3-Hydroxy-2-(phosphonomethoxy)propyl]cytosine (Cidofovir) and Related Compounds</span></div><div class="casAuthors">Krecmerova, Marcela; Holy, Antonin; Piskala, Alois; Masojidkova, Milena; Andrei, Graciela; Naesens, Lieve; Neyts, Johan; Balzarini, Jan; De Clercq, Erik; Snoeck, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1069-1077</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Regioselective alkylation of 5-azacytosine sodium salt with diisopropyl [(2-chloroethoxy)methyl]phosphonate followed by removal of ester groups afforded 1-[2-(phosphonomethoxy)ethyl]-5-azacytosine I.  Nucleophilic ring opening of [(trityloxy)methyl]-(2S)-oxirane with 5-azacytosine followed by etherification with diisopropyl (bromomethyl)phosphonate and removal of ester groups gave 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine II.  The analogous synthesis gave 6-azacytosine congener III using N4-benzoyl intermediates.  II was shown to exert strong activity against a broad spectrum of DNA viruses including adenoviruses, poxviruses, and herpesviruses (i.e., herpes simplex viruses, varicella zoster virus, and human cytomegalovirus).  Decompn. of II in alk. solns. resulted in IV and V.  While the N-formylguanidine deriv. IV proved active, the carbamyolguanidine deriv. V was devoid of antiviral activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptgkyvMPA3irVg90H21EOLACvtfcHk0liPV3YzghZnkQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhs1Squ7c%253D&md5=022a4a5039ac36dc3117f72f9e2c0102</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1021%2Fjm061281%2B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm061281%252B%26sid%3Dliteratum%253Aachs%26aulast%3DKre%25C4%258Dmerov%25C3%25A1%26aufirst%3DM.%26aulast%3DHol%25C3%25BD%26aufirst%3DA.%26aulast%3DPiskala%26aufirst%3DA.%26aulast%3DMasojidkov%25C3%25A1%26aufirst%3DM.%26aulast%3DAndrei%26aufirst%3DG.%26aulast%3DNaesens%26aufirst%3DL.%26aulast%3DNeyts%26aufirst%3DJ.%26aulast%3DBalzarini%26aufirst%3DJ.%26aulast%3DDe%2BClercq%26aufirst%3DE.%26aulast%3DSnoeck%26aufirst%3DR.%26atitle%3DAntiviral%2520activity%2520of%2520triazine%2520analogues%2520of%25201-%2528S%2529-%255B3-hydroxy-2-%2528phosphonomethoxy%2529propyl%255Dcytosine%2520%2528cidofovir%2529%2520and%2520related%2520compounds%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D1069%26epage%3D1077%26doi%3D10.1021%2Fjm061281%2B" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref96"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref96'); return false;" data-citation="" class="refNumLink">96</a></strong><div class="NLM_citation" id="cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Krečmerová, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holý, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pohl, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masojidková, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrei, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naesens, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neyts, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balzarini, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snoeck, R.</span></span> <span> </span><span class="NLM_article-title">Ester prodrugs of cyclic 1-(S)- [3-hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine: synthesis and antiviral activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">5765</span>– <span class="NLM_lpage">5772</span>, <span class="refDoi"> DOI: 10.1021/jm0707166</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0707166" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFyhu7rO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=5765-5772&author=M.+Kre%C4%8Dmerov%C3%A1author=A.+Hol%C3%BDauthor=R.+Pohlauthor=M.+Masojidkov%C3%A1author=G.+Andreiauthor=L.+Naesensauthor=J.+Neytsauthor=J.+Balzariniauthor=E.+De+Clercqauthor=R.+Snoeck&title=Ester+prodrugs+of+cyclic+1-%28S%29-+%5B3-hydroxy-2-%28phosphonomethoxy%29propyl%5D-5-azacytosine%3A+synthesis+and+antiviral+activity&doi=10.1021%2Fjm0707166"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">Ester Prodrugs of Cyclic 1-(S)-[3-Hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine: Synthesis and Antiviral Activity</span></div><div class="casAuthors">Krecmerova, Marcela; Holy, Antonin; Pohl, Radek; Masojidkova, Milena; Andrei, Graciela; Naesens, Lieve; Neyts, Johan; Balzarini, Jan; De Clercq, Erik; Snoeck, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">5765-5772</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Reaction of [hydroxy-(phosphonomethoxy)propyl]-azacytosine I with dicyclohexylcarbodiimide and N,N,-dicyclohexyl-4-morpholinocarboxamidine in DMF at elevated temp. afforded the corresponding cyclic phosphonate II (R = H).  Compd. II (R = H) exerts strong in vitro activity against DNA viruses, comparable with activity of parent compd. I.  Transformation of II (R = H) to its tetrabutylammonium salt followed by reaction with alkyl or acyloxyalkyl halogenides enabled us to prep. a series of structurally diverse ester prodrugs: alkyl (octadecyl), alkenyl (erucyl), alkoxyalkyl (hexadecyloxyethyl), and acyloxyalkyl (pivaloyloxymethyl).  The introduction of an alkyl, alkoxyalkyl, or acyloxyalkyl ester group to the mol. resulted in an increase of antiviral activity; the most active compd. was found to be the hexadecyloxyethyl ester II (R = CH2CH2O(CH2)15Me).  The relative configuration of the diastereoisomer trans-II (R = CH2OCO-t-Bu) was detd. using H,H-NOESY NMR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGroxN7W2KAkVLVg90H21EOLACvtfcHk0lgPcH1KVEo2Jw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFyhu7rO&md5=dbd739eec70f6d2e0b16589c006c88d7</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1021%2Fjm0707166&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0707166%26sid%3Dliteratum%253Aachs%26aulast%3DKre%25C4%258Dmerov%25C3%25A1%26aufirst%3DM.%26aulast%3DHol%25C3%25BD%26aufirst%3DA.%26aulast%3DPohl%26aufirst%3DR.%26aulast%3DMasojidkov%25C3%25A1%26aufirst%3DM.%26aulast%3DAndrei%26aufirst%3DG.%26aulast%3DNaesens%26aufirst%3DL.%26aulast%3DNeyts%26aufirst%3DJ.%26aulast%3DBalzarini%26aufirst%3DJ.%26aulast%3DDe%2BClercq%26aufirst%3DE.%26aulast%3DSnoeck%26aufirst%3DR.%26atitle%3DEster%2520prodrugs%2520of%2520cyclic%25201-%2528S%2529-%2520%255B3-hydroxy-2-%2528phosphonomethoxy%2529propyl%255D-5-azacytosine%253A%2520synthesis%2520and%2520antiviral%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D5765%26epage%3D5772%26doi%3D10.1021%2Fjm0707166" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref97"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref97'); return false;" data-citation="" class="refNumLink">97</a></strong><div class="NLM_citation" id="cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Naesens, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrei, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Votruba, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krečmerová, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holý, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neyts, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snoeck, R.</span></span> <span> </span><span class="NLM_article-title">Intracellular metabolism of the new antiviral compound 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">997</span>– <span class="NLM_lpage">1005</span>, <span class="refDoi"> DOI: 10.1016/j.bcp.2008.08.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1016%2Fj.bcp.2008.08.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=18773877" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1Sms7nP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2008&pages=997-1005&author=L.+Naesensauthor=G.+Andreiauthor=I.+Votrubaauthor=M.+Kre%C4%8Dmerov%C3%A1author=A.+Hol%C3%BDauthor=J.+Neytsauthor=E.+De+Clercqauthor=R.+Snoeck&title=Intracellular+metabolism+of+the+new+antiviral+compound+1-%28S%29-%5B3-hydroxy-2-%28phosphonomethoxy%29propyl%5D-5-azacytosine&doi=10.1016%2Fj.bcp.2008.08.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Intracellular metabolism of the new antiviral compound 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine</span></div><div class="casAuthors">Naesens, Lieve; Andrei, Graciela; Votruba, Ivan; Krecmerova, Marcela; Holy, Antonin; Neyts, Johan; De Clercq, Erik; Snoeck, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">997-1005</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine [HPMP-5-azaC], the 5-azacytosine analog of cidofovir (HPMPC), represents a new acyclic nucleoside phosphonate with pronounced activity against DNA viruses, and a selectivity index superior to that of cidofovir.  Here we investigated the intracellular metabolic pathway of [6-3H]-HPMP-5-azaC.  By comparing the metab. in mouse lymphosarcoma S49-wild type (S49-WT) and mutant cells deficient for dCMP deaminase, we identified the mono- and diphosphate metabolites generated from HPMP-5-azaC and its deaminated product HPMP-5-azaU.  In human lung carcinoma A549 cells, the relative formation of the deaminated metabolites was only 6%, implying that deamination plays a minor role in the overall metab. of HPMP-5-azaC.  The diphosphorylated metabolite of HPMP-5-azaC accounted for 60% of the total radioactivity, and reached intracellular levels which were 60-fold higher in abs. value than the corresponding diphosphate levels obtained with cidofovir.  Consequently to its increased activation, HPMP-5-azaC showed about 45-fold higher incorporation into cellular DNA than cidofovir.  Herpes-, pox- or adenovirus infection had no marked influence on the metab. of HPMP-5-azaC.  The HPMP-5-azaC-diphosphate metabolite was shown to have long intracellular stability (half-life: 63 h), suggesting that infrequent administration of HPMP-5-azaC should be possible.  HPMP-5-azaC represents a new acyclic nucleoside phosphonate compd. with promising anti-DNA virus activity and a favorable metabolic profile that is characterized by low sensitivity to catabolic deamination and a high rate of phosphorylation and DNA incorporation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcq-gnygklZLVg90H21EOLACvtfcHk0lgPcH1KVEo2Jw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1Sms7nP&md5=6ac8640f65fdeeb7b0d1bc6e65b0656e</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2008.08.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2008.08.009%26sid%3Dliteratum%253Aachs%26aulast%3DNaesens%26aufirst%3DL.%26aulast%3DAndrei%26aufirst%3DG.%26aulast%3DVotruba%26aufirst%3DI.%26aulast%3DKre%25C4%258Dmerov%25C3%25A1%26aufirst%3DM.%26aulast%3DHol%25C3%25BD%26aufirst%3DA.%26aulast%3DNeyts%26aufirst%3DJ.%26aulast%3DDe%2BClercq%26aufirst%3DE.%26aulast%3DSnoeck%26aufirst%3DR.%26atitle%3DIntracellular%2520metabolism%2520of%2520the%2520new%2520antiviral%2520compound%25201-%2528S%2529-%255B3-hydroxy-2-%2528phosphonomethoxy%2529propyl%255D-5-azacytosine%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2008%26volume%3D76%26spage%3D997%26epage%3D1005%26doi%3D10.1016%2Fj.bcp.2008.08.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88'],'ref89':['cit89'],'ref90':['cit90'],'ref91':['cit91'],'ref92':['cit92'],'ref93':['cit93'],'ref94':['cit94'],'ref95':['cit95'],'ref96':['cit96'],'ref97':['cit97']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 19 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Xi-Rui Zhou, Ye Liu, Zhentao Huang, Qingxin Yao, Fangfei He, <span class="NLM_string-name hlFld-ContribAuthor">Yuan Gao</span>. </span><span class="cited-content_cbyCitation_article-title">Gag Protein Oriented Supramolecular Nets as Potential HIV Traps. </span><span class="cited-content_cbyCitation_journal-name">Bioconjugate Chemistry</span><span> <strong>2021,</strong> <em>32 </em>
                                    (1)
                                     , 106-110. <a href="https://doi.org/10.1021/acs.bioconjchem.0c00706" title="DOI URL">https://doi.org/10.1021/acs.bioconjchem.0c00706</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.bioconjchem.0c00706&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.bioconjchem.0c00706%26sid%3Dliteratum%253Aachs%26jtitle%3DBioconjugate%2520Chemistry%26atitle%3DGag%252BProtein%252BOriented%252BSupramolecular%252BNets%252Bas%252BPotential%252BHIV%252BTraps%26aulast%3DZhou%26aufirst%3DXi-Rui%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D2021%26date%3D23122020%26date%3D04012021%26date%3D06012021%26volume%3D32%26issue%3D1%26spage%3D106%26epage%3D110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Álvaro  Lorente‐Macías</span>, <span class="hlFld-ContribAuthor ">Inmaculada  Iañez</span>, <span class="hlFld-ContribAuthor ">M. Carmen  Jiménez‐López</span>, <span class="hlFld-ContribAuthor ">Manuel  Benítez‐Quesada</span>, <span class="hlFld-ContribAuthor ">Sara  Torres‐Rusillo</span>, <span class="hlFld-ContribAuthor ">Juan J.  Díaz‐Mochón</span>, <span class="hlFld-ContribAuthor ">Ignacio J.  Molina</span>, <span class="hlFld-ContribAuthor ">María J.  Pineda de las Infantas</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and screening of 6‐alkoxy purine analogs as cell type‐selective apoptotic inducers in Jurkat cells. </span><span class="cited-content_cbyCitation_journal-name">Archiv der Pharmazie</span><span> <strong>2021,</strong> <em> </em><a href="https://doi.org/10.1002/ardp.202100095" title="DOI URL">https://doi.org/10.1002/ardp.202100095</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ardp.202100095&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fardp.202100095%26sid%3Dliteratum%253Aachs%26jtitle%3DArchiv%2520der%2520Pharmazie%26atitle%3DSynthesis%252Band%252Bscreening%252Bof%252B6%2525E2%252580%252590alkoxy%252Bpurine%252Banalogs%252Bas%252Bcell%252Btype%2525E2%252580%252590selective%252Bapoptotic%252Binducers%252Bin%252BJurkat%252Bcells%26aulast%3DLorente%25E2%2580%2590Mac%25C3%25ADas%26aufirst%3D%25C3%2581lvaro%26date%3D2021%26date%3D2021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chao  Xia</span>, <span class="hlFld-ContribAuthor ">Dong-Chao  Wang</span>, <span class="hlFld-ContribAuthor ">Gui-Rong  Qu</span>, <span class="hlFld-ContribAuthor ">Hai-Ming  Guo</span>. </span><span class="cited-content_cbyCitation_article-title">Palladium-catalyzed asymmetric allylic amination of a vinylethylene carbonate with N-heteroaromatics. </span><span class="cited-content_cbyCitation_journal-name">Organic Chemistry Frontiers</span><span> <strong>2021,</strong> <em>8 </em>
                                    (11)
                                     , 2569-2575. <a href="https://doi.org/10.1039/D1QO00272D" title="DOI URL">https://doi.org/10.1039/D1QO00272D</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D1QO00272D&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD1QO00272D%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Chemistry%2520Frontiers%26atitle%3DPalladium-catalyzed%252Basymmetric%252Ballylic%252Bamination%252Bof%252Ba%252Bvinylethylene%252Bcarbonate%252Bwith%252BN-heteroaromatics%26aulast%3DXia%26aufirst%3DChao%26date%3D2021%26date%3D2021%26volume%3D8%26issue%3D11%26spage%3D2569%26epage%3D2575" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dohyun  Moon</span>, <span class="hlFld-ContribAuthor ">Sunghwan  Jeon</span>, <span class="hlFld-ContribAuthor ">Woo Taik  Lim</span>, <span class="hlFld-ContribAuthor ">Keon Sang  Ryoo</span>, <span class="hlFld-ContribAuthor ">Jong-Ha  Choi</span>. </span><span class="cited-content_cbyCitation_article-title">Crystal structure of diaqua(3,14-diethyl-2,6,13,17-tetraazatricyclo[16.4.0.0
              7,12
              ]docosane)copper(II) (3,14-diethyl-2,6,13,17-tetraazatricyclo[16.4.0.0
              7,12
              ]docosane)copper(II) tetrabromide dihydrate, [Cu(C
              22
              H
              44
              N
              4
              )(H
              2
              O)
              2
              ][Cu(C
              22
              H
              44
              N
              4
              )]Br
              4
              ·2H
              2
              O. </span><span class="cited-content_cbyCitation_journal-name">Acta Crystallographica Section E Crystallographic Communications</span><span> <strong>2021,</strong> <em>77 </em>
                                    (6)
                                     , 677-680. <a href="https://doi.org/10.1107/S205698902100551X" title="DOI URL">https://doi.org/10.1107/S205698902100551X</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1107/S205698902100551X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1107%2FS205698902100551X%26sid%3Dliteratum%253Aachs%26jtitle%3DActa%2520Crystallographica%2520Section%2520E%2520Crystallographic%2520Communications%26atitle%3DCrystal%252Bstructure%252Bof%252Bdiaqua%2525283%25252C14-diethyl-2%25252C6%25252C13%25252C17-tetraazatricyclo%25255B16.4.0.0%252B7%25252C12%252B%25255Ddocosane%252529copper%252528II%252529%252B%2525283%25252C14-diethyl-2%25252C6%25252C13%25252C17-tetraazatricyclo%25255B16.4.0.0%252B7%25252C12%252B%25255Ddocosane%252529copper%252528II%252529%252Btetrabromide%252Bdihydrate%25252C%252B%25255BCu%252528C%252B22%252BH%252B44%252BN%252B4%252B%252529%252528H%252B2%252BO%252529%252B2%252B%25255D%25255BCu%252528C%252B22%252BH%252B44%252BN%252B4%252B%252529%25255DBr%252B4%252B%2525C2%2525B72H%252B2%252BO%26aulast%3DMoon%26aufirst%3DDohyun%26date%3D2021%26date%3D2021%26volume%3D77%26issue%3D6%26spage%3D677%26epage%3D680" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Claudiu T.  Supuran</span>. </span><span class="cited-content_cbyCitation_article-title">Coronaviruses. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Therapeutic Patents</span><span> <strong>2021,</strong> <em>31 </em>
                                    (4)
                                     , 291-294. <a href="https://doi.org/10.1080/13543776.2021.1901402" title="DOI URL">https://doi.org/10.1080/13543776.2021.1901402</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/13543776.2021.1901402&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F13543776.2021.1901402%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Therapeutic%2520Patents%26atitle%3DCoronaviruses%26aulast%3DSupuran%26aufirst%3DClaudiu%2BT.%26date%3D2021%26date%3D2021%26volume%3D31%26issue%3D4%26spage%3D291%26epage%3D294" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Anne-Laure  Villard</span>, <span class="hlFld-ContribAuthor ">Anne-Marie  Aubertin</span>, <span class="hlFld-ContribAuthor ">Suzanne  Peyrottes</span>, <span class="hlFld-ContribAuthor ">Christian  Périgaud</span>. </span><span class="cited-content_cbyCitation_article-title">An original pronucleotide strategy for the simultaneous delivery of two bioactive drugs. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>216 </em>, 113315. <a href="https://doi.org/10.1016/j.ejmech.2021.113315" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113315</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113315&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113315%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DAn%252Boriginal%252Bpronucleotide%252Bstrategy%252Bfor%252Bthe%252Bsimultaneous%252Bdelivery%252Bof%252Btwo%252Bbioactive%252Bdrugs%26aulast%3DVillard%26aufirst%3DAnne-Laure%26date%3D2021%26volume%3D216%26spage%3D113315" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chao  Feng</span>, <span class="hlFld-ContribAuthor ">Angelique  Cao Minh</span>, <span class="hlFld-ContribAuthor ">Qinliang  Zhao</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and structural analysis of two cyclam derivatives. </span><span class="cited-content_cbyCitation_journal-name">Journal of Molecular Structure</span><span> <strong>2021,</strong> <em>1224 </em>, 128842. <a href="https://doi.org/10.1016/j.molstruc.2020.128842" title="DOI URL">https://doi.org/10.1016/j.molstruc.2020.128842</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.molstruc.2020.128842&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.molstruc.2020.128842%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Molecular%2520Structure%26atitle%3DSynthesis%252Band%252Bstructural%252Banalysis%252Bof%252Btwo%252Bcyclam%252Bderivatives%26aulast%3DFeng%26aufirst%3DChao%26date%3D2021%26volume%3D1224%26spage%3D128842" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Claudio  Curti</span>, <span class="hlFld-ContribAuthor ">Gloria  Rassu</span>, <span class="hlFld-ContribAuthor ">Marco  Lombardo</span>, <span class="hlFld-ContribAuthor ">Vincenzo  Zambrano</span>, <span class="hlFld-ContribAuthor ">Luigi  Pinna</span>, <span class="hlFld-ContribAuthor ">Lucia  Battistini</span>, <span class="hlFld-ContribAuthor ">Andrea  Sartori</span>, <span class="hlFld-ContribAuthor ">Giorgio  Pelosi</span>, <span class="hlFld-ContribAuthor ">Franca  Zanardi</span>. </span><span class="cited-content_cbyCitation_article-title">Unlocking Access to Enantiopure Fused Uracils by Chemodivergent [4+2] Cross‐Cycloadditions: DFT‐Supported Homo‐Synergistic Organocatalytic Approach. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie</span><span> <strong>2020,</strong> <em>132 </em>
                                    (45)
                                     , 20230-20239. <a href="https://doi.org/10.1002/ange.202007509" title="DOI URL">https://doi.org/10.1002/ange.202007509</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ange.202007509&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fange.202007509%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%26atitle%3DUnlocking%252BAccess%252Bto%252BEnantiopure%252BFused%252BUracils%252Bby%252BChemodivergent%252B%25255B4%25252B2%25255D%252BCross%2525E2%252580%252590Cycloadditions%25253A%252BDFT%2525E2%252580%252590Supported%252BHomo%2525E2%252580%252590Synergistic%252BOrganocatalytic%252BApproach%26aulast%3DCurti%26aufirst%3DClaudio%26date%3D2020%26date%3D2020%26volume%3D132%26issue%3D45%26spage%3D20230%26epage%3D20239" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Claudio  Curti</span>, <span class="hlFld-ContribAuthor ">Gloria  Rassu</span>, <span class="hlFld-ContribAuthor ">Marco  Lombardo</span>, <span class="hlFld-ContribAuthor ">Vincenzo  Zambrano</span>, <span class="hlFld-ContribAuthor ">Luigi  Pinna</span>, <span class="hlFld-ContribAuthor ">Lucia  Battistini</span>, <span class="hlFld-ContribAuthor ">Andrea  Sartori</span>, <span class="hlFld-ContribAuthor ">Giorgio  Pelosi</span>, <span class="hlFld-ContribAuthor ">Franca  Zanardi</span>. </span><span class="cited-content_cbyCitation_article-title">Unlocking Access to Enantiopure Fused Uracils by Chemodivergent [4+2] Cross‐Cycloadditions: DFT‐Supported Homo‐Synergistic Organocatalytic Approach. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie International Edition</span><span> <strong>2020,</strong> <em>59 </em>
                                    (45)
                                     , 20055-20064. <a href="https://doi.org/10.1002/anie.202007509" title="DOI URL">https://doi.org/10.1002/anie.202007509</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/anie.202007509&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fanie.202007509%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%2520International%2520Edition%26atitle%3DUnlocking%252BAccess%252Bto%252BEnantiopure%252BFused%252BUracils%252Bby%252BChemodivergent%252B%25255B4%25252B2%25255D%252BCross%2525E2%252580%252590Cycloadditions%25253A%252BDFT%2525E2%252580%252590Supported%252BHomo%2525E2%252580%252590Synergistic%252BOrganocatalytic%252BApproach%26aulast%3DCurti%26aufirst%3DClaudio%26date%3D2020%26date%3D2020%26volume%3D59%26issue%3D45%26spage%3D20055%26epage%3D20064" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Murugesan  Vanangamudi</span>, <span class="hlFld-ContribAuthor ">Sonali  Kurup</span>, <span class="hlFld-ContribAuthor ">Vigneshwaran  Namasivayam</span>. </span><span class="cited-content_cbyCitation_article-title">Non-nucleoside reverse transcriptase inhibitors (NNRTIs): a brief overview of clinically approved drugs and combination regimens. </span><span class="cited-content_cbyCitation_journal-name">Current Opinion in Pharmacology</span><span> <strong>2020,</strong> <em>54 </em>, 179-187. <a href="https://doi.org/10.1016/j.coph.2020.10.009" title="DOI URL">https://doi.org/10.1016/j.coph.2020.10.009</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.coph.2020.10.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.coph.2020.10.009%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Opinion%2520in%2520Pharmacology%26atitle%3DNon-nucleoside%252Breverse%252Btranscriptase%252Binhibitors%252B%252528NNRTIs%252529%25253A%252Ba%252Bbrief%252Boverview%252Bof%252Bclinically%252Bapproved%252Bdrugs%252Band%252Bcombination%252Bregimens%26aulast%3DVanangamudi%26aufirst%3DMurugesan%26date%3D2020%26volume%3D54%26spage%3D179%26epage%3D187" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Songkai  Sun</span>, <span class="hlFld-ContribAuthor ">Boshi  Huang</span>, <span class="hlFld-ContribAuthor ">Zhuo  Li</span>, <span class="hlFld-ContribAuthor ">Zhao  Wang</span>, <span class="hlFld-ContribAuthor ">Lin  Sun</span>, <span class="hlFld-ContribAuthor ">Ping  Gao</span>, <span class="hlFld-ContribAuthor ">Dongwei  Kang</span>, <span class="hlFld-ContribAuthor ">Chin-Ho  Chen</span>, <span class="hlFld-ContribAuthor ">Kuo-Hsiung  Lee</span>, <span class="hlFld-ContribAuthor ">Dirk  Daelemans</span>, <span class="hlFld-ContribAuthor ">Erik  De Clercq</span>, <span class="hlFld-ContribAuthor ">Christophe  Pannecouque</span>, <span class="hlFld-ContribAuthor ">Peng  Zhan</span>, <span class="hlFld-ContribAuthor ">Xinyong  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of potential dual-target prodrugs of HIV-1 reverse transcriptase and nucleocapsid protein 7. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>30 </em>
                                    (16)
                                     , 127287. <a href="https://doi.org/10.1016/j.bmcl.2020.127287" title="DOI URL">https://doi.org/10.1016/j.bmcl.2020.127287</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2020.127287&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2020.127287%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252Bpotential%252Bdual-target%252Bprodrugs%252Bof%252BHIV-1%252Breverse%252Btranscriptase%252Band%252Bnucleocapsid%252Bprotein%252B7%26aulast%3DSun%26aufirst%3DSongkai%26date%3D2020%26volume%3D30%26issue%3D16%26spage%3D127287" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wenxiao  Zheng</span>, <span class="hlFld-ContribAuthor ">Alissa M.  Klammer</span>, <span class="hlFld-ContribAuthor ">Jennifer N.  Naciri</span>, <span class="hlFld-ContribAuthor ">Jason  Yeung</span>, <span class="hlFld-ContribAuthor ">Matthew  Demers</span>, <span class="hlFld-ContribAuthor ">Jadranka  Milosevic</span>, <span class="hlFld-ContribAuthor ">Paul R.  Kinchington</span>, <span class="hlFld-ContribAuthor ">David C.  Bloom</span>, <span class="hlFld-ContribAuthor ">Vishwajit L.  Nimgaonkar</span>, <span class="hlFld-ContribAuthor ">Leonardo  D’Aiuto</span>, . </span><span class="cited-content_cbyCitation_article-title">Patterns of Herpes Simplex Virus 1 Infection in Neural Progenitor Cells. </span><span class="cited-content_cbyCitation_journal-name">Journal of Virology</span><span> <strong>2020,</strong> <em>94 </em>
                                    (16)
                                     <a href="https://doi.org/10.1128/JVI.00994-20" title="DOI URL">https://doi.org/10.1128/JVI.00994-20</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1128/JVI.00994-20&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1128%2FJVI.00994-20%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Virology%26atitle%3DPatterns%252Bof%252BHerpes%252BSimplex%252BVirus%252B1%252BInfection%252Bin%252BNeural%252BProgenitor%252BCells%26aulast%3DZheng%26aufirst%3DWenxiao%26date%3D2020%26volume%3D94%26issue%3D16" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chunlin  Zhuang</span>, <span class="hlFld-ContribAuthor ">Christophe  Pannecouque</span>, <span class="hlFld-ContribAuthor ">Erik  De Clercq</span>, <span class="hlFld-ContribAuthor ">Fener  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Development of non-nucleoside reverse transcriptase inhibitors (NNRTIs): our past twenty years. </span><span class="cited-content_cbyCitation_journal-name">Acta Pharmaceutica Sinica B</span><span> <strong>2020,</strong> <em>10 </em>
                                    (6)
                                     , 961-978. <a href="https://doi.org/10.1016/j.apsb.2019.11.010" title="DOI URL">https://doi.org/10.1016/j.apsb.2019.11.010</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.apsb.2019.11.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.apsb.2019.11.010%26sid%3Dliteratum%253Aachs%26jtitle%3DActa%2520Pharmaceutica%2520Sinica%2520B%26atitle%3DDevelopment%252Bof%252Bnon-nucleoside%252Breverse%252Btranscriptase%252Binhibitors%252B%252528NNRTIs%252529%25253A%252Bour%252Bpast%252Btwenty%252Byears%26aulast%3DZhuang%26aufirst%3DChunlin%26date%3D2020%26volume%3D10%26issue%3D6%26spage%3D961%26epage%3D978" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sun‐A  Lee</span>, <span class="hlFld-ContribAuthor ">Eun Y.  Kim</span>, <span class="hlFld-ContribAuthor ">Sung O.  Chang</span>. </span><span class="cited-content_cbyCitation_article-title">A life where concealment and exposure coexist—The antiretroviral therapy adherence of people living with HIV infection: A phenomenological study. </span><span class="cited-content_cbyCitation_journal-name">Journal of Advanced Nursing</span><span> <strong>2020,</strong> <em>76 </em>
                                    (4)
                                     , 1027-1036. <a href="https://doi.org/10.1111/jan.14309" title="DOI URL">https://doi.org/10.1111/jan.14309</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/jan.14309&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fjan.14309%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Advanced%2520Nursing%26atitle%3DA%252Blife%252Bwhere%252Bconcealment%252Band%252Bexposure%252Bcoexist%2525E2%252580%252594The%252Bantiretroviral%252Btherapy%252Badherence%252Bof%252Bpeople%252Bliving%252Bwith%252BHIV%252Binfection%25253A%252BA%252Bphenomenological%252Bstudy%26aulast%3DLee%26aufirst%3DSun%25E2%2580%2590A%26date%3D2020%26date%3D2020%26volume%3D76%26issue%3D4%26spage%3D1027%26epage%3D1036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yali  Sang</span>, <span class="hlFld-ContribAuthor ">Christophe  Pannecouque</span>, <span class="hlFld-ContribAuthor ">Erik  De Clercq</span>, <span class="hlFld-ContribAuthor ">Chunlin  Zhuang</span>, <span class="hlFld-ContribAuthor ">Fener  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Pharmacophore-fusing design of pyrimidine sulfonylacetanilides as potent non-nucleoside inhibitors of HIV-1 reverse transcriptase. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2020,</strong> <em>96 </em>, 103595. <a href="https://doi.org/10.1016/j.bioorg.2020.103595" title="DOI URL">https://doi.org/10.1016/j.bioorg.2020.103595</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2020.103595&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2020.103595%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DPharmacophore-fusing%252Bdesign%252Bof%252Bpyrimidine%252Bsulfonylacetanilides%252Bas%252Bpotent%252Bnon-nucleoside%252Binhibitors%252Bof%252BHIV-1%252Breverse%252Btranscriptase%26aulast%3DSang%26aufirst%3DYali%26date%3D2020%26volume%3D96%26spage%3D103595" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sheng  Han</span>, <span class="hlFld-ContribAuthor ">Yuan  Lei</span>, <span class="hlFld-ContribAuthor ">Christophe  Pannecouque</span>, <span class="hlFld-ContribAuthor ">Erik  De Clercq</span>, <span class="hlFld-ContribAuthor ">Chunlin  Zhuang</span>, <span class="hlFld-ContribAuthor ">Fener  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Fragment-based discovery of sulfur-containing diarylbenzopyrimidines as novel nonnucleoside reverse transcriptase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Chinese Chemical Letters</span><span> <strong>2020,</strong> <em>31 </em>
                                    (3)
                                     , 764-768. <a href="https://doi.org/10.1016/j.cclet.2019.11.020" title="DOI URL">https://doi.org/10.1016/j.cclet.2019.11.020</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.cclet.2019.11.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.cclet.2019.11.020%26sid%3Dliteratum%253Aachs%26jtitle%3DChinese%2520Chemical%2520Letters%26atitle%3DFragment-based%252Bdiscovery%252Bof%252Bsulfur-containing%252Bdiarylbenzopyrimidines%252Bas%252Bnovel%252Bnonnucleoside%252Breverse%252Btranscriptase%252Binhibitors%26aulast%3DHan%26aufirst%3DSheng%26date%3D2020%26volume%3D31%26issue%3D3%26spage%3D764%26epage%3D768" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Diana M.  Álvarez</span>, <span class="hlFld-ContribAuthor ">Estefanía  Castillo</span>, <span class="hlFld-ContribAuthor ">Luisa F.  Duarte</span>, <span class="hlFld-ContribAuthor ">José  Arriagada</span>, <span class="hlFld-ContribAuthor ">Nicolás  Corrales</span>, <span class="hlFld-ContribAuthor ">Mónica A.  Farías</span>, <span class="hlFld-ContribAuthor ">Adolfo  Henríquez</span>, <span class="hlFld-ContribAuthor ">Cristian  Agurto-Muñoz</span>, <span class="hlFld-ContribAuthor ">Pablo A.  González</span>. </span><span class="cited-content_cbyCitation_article-title">Current Antivirals and Novel Botanical Molecules Interfering With Herpes Simplex Virus Infection. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Microbiology</span><span> <strong>2020,</strong> <em>11 </em><a href="https://doi.org/10.3389/fmicb.2020.00139" title="DOI URL">https://doi.org/10.3389/fmicb.2020.00139</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fmicb.2020.00139&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffmicb.2020.00139%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Microbiology%26atitle%3DCurrent%252BAntivirals%252Band%252BNovel%252BBotanical%252BMolecules%252BInterfering%252BWith%252BHerpes%252BSimplex%252BVirus%252BInfection%26aulast%3D%25C3%2581lvarez%26aufirst%3DDiana%2BM.%26date%3D2020%26date%3D2020%26volume%3D11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sheng  Han</span>, <span class="hlFld-ContribAuthor ">Yali  Sang</span>, <span class="hlFld-ContribAuthor ">Yan  Wu</span>, <span class="hlFld-ContribAuthor ">Yuan  Tao</span>, <span class="hlFld-ContribAuthor ">Christophe  Pannecouque</span>, <span class="hlFld-ContribAuthor ">Erik  De Clercq</span>, <span class="hlFld-ContribAuthor ">Chunlin  Zhuang</span>, <span class="hlFld-ContribAuthor ">Fen-Er  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Fragment hopping-based discovery of novel sulfinylacetamide-diarylpyrimidines (DAPYs) as HIV-1 nonnucleoside reverse transcriptase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>185 </em>, 111874. <a href="https://doi.org/10.1016/j.ejmech.2019.111874" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.111874</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.111874&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.111874%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DFragment%252Bhopping-based%252Bdiscovery%252Bof%252Bnovel%252Bsulfinylacetamide-diarylpyrimidines%252B%252528DAPYs%252529%252Bas%252BHIV-1%252Bnonnucleoside%252Breverse%252Btranscriptase%252Binhibitors%26aulast%3DHan%26aufirst%3DSheng%26date%3D2020%26volume%3D185%26spage%3D111874" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yali  Sang</span>, <span class="hlFld-ContribAuthor ">Sheng  Han</span>, <span class="hlFld-ContribAuthor ">Christophe  Pannecouque</span>, <span class="hlFld-ContribAuthor ">Erik  De Clercq</span>, <span class="hlFld-ContribAuthor ">Chunlin  Zhuang</span>, <span class="hlFld-ContribAuthor ">Fener  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Conformational restriction design of thiophene-biphenyl-DAPY HIV-1 non-nucleoside reverse transcriptase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>182 </em>, 111603. <a href="https://doi.org/10.1016/j.ejmech.2019.111603" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.111603</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.111603&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.111603%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DConformational%252Brestriction%252Bdesign%252Bof%252Bthiophene-biphenyl-DAPY%252BHIV-1%252Bnon-nucleoside%252Breverse%252Btranscriptase%252Binhibitors%26aulast%3DSang%26aufirst%3DYali%26date%3D2019%26volume%3D182%26spage%3D111603" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/medium/jm-2019-00175p_0026.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/large/jm-2019-00175p_0026.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00175&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/medium/jm-2019-00175p_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/large/jm-2019-00175p_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Suramin.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/large/jm-2019-00175p_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00175&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/medium/jm-2019-00175p_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/large/jm-2019-00175p_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. DHPA.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/large/jm-2019-00175p_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00175&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/medium/jm-2019-00175p_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/large/jm-2019-00175p_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. BVDU and BVDU 5′-triphosphate.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/large/jm-2019-00175p_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00175&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/medium/jm-2019-00175p_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/large/jm-2019-00175p_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Valacyclovir (VACV) and ACV triphosphate.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/large/jm-2019-00175p_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00175&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/medium/jm-2019-00175p_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/large/jm-2019-00175p_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (<i>S</i>)-HPMPA or (<i>S</i>)-9-(3-hydroxy-2-phosphonomethoxypropyl)adenine.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/large/jm-2019-00175p_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00175&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/medium/jm-2019-00175p_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/large/jm-2019-00175p_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. PMEA, PMEA dipivoxil, and PMEA diphosphate.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/large/jm-2019-00175p_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00175&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/medium/jm-2019-00175p_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/large/jm-2019-00175p_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. (<i>S</i>)-HPMPC (cidofovir and (<i>S</i>)-HPMPC diphosphate.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/large/jm-2019-00175p_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00175&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/medium/jm-2019-00175p_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/large/jm-2019-00175p_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. d4T Stavudine and d4T 5′-triphosphate.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/large/jm-2019-00175p_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00175&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/medium/jm-2019-00175p_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/large/jm-2019-00175p_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. HEPT and emivirine.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/large/jm-2019-00175p_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00175&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/medium/jm-2019-00175p_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/large/jm-2019-00175p_0010.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. TIBO and rilpivirine.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/large/jm-2019-00175p_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00175&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/medium/jm-2019-00175p_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/large/jm-2019-00175p_0011.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Bicyclam AMD3100, plerixafor.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/large/jm-2019-00175p_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00175&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/medium/jm-2019-00175p_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/large/jm-2019-00175p_0012.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. (<i>R</i>)-PMPA (tenofovir), tenofovir disoproxil fumarate (TDF), (<i>R</i>)-PMPA diphosphate.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/large/jm-2019-00175p_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00175&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/medium/jm-2019-00175p_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/large/jm-2019-00175p_0013.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Tenofovir disoproxil fumarate (TDF) (<a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>) and (−)FTC (emtricitabine).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/large/jm-2019-00175p_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00175&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/medium/jm-2019-00175p_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/large/jm-2019-00175p_0014.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. Tenofovir disoproxil fumarate (TDF) (<a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>), (−)FTC (emtricitabine) (<a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>), and efavirenz.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/large/jm-2019-00175p_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00175&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig15" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/medium/jm-2019-00175p_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/large/jm-2019-00175p_0015.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Tenofovir disoproxil fumarate (TDF) (<a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>), (−)FTC (emtricitabine) (<a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>), and rilpivirine.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/large/jm-2019-00175p_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00175&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig16" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/medium/jm-2019-00175p_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/large/jm-2019-00175p_0016.jpeg" id="rightTab-gr16" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. Tenofovir disoproxil fumarate (TDF) (<a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>), (−)FTC (emtricitabine) (<a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>), elvitegravir, and cobicistat.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/large/jm-2019-00175p_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00175&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig17" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/medium/jm-2019-00175p_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/large/jm-2019-00175p_0017.jpeg" id="rightTab-gr17" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 17. Tenofovir alafenamide (TAF).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/large/jm-2019-00175p_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00175&amp;id=fig17"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig18" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 18</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/medium/jm-2019-00175p_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/large/jm-2019-00175p_0018.jpeg" id="rightTab-gr18" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 18. Tenofovir alafenamide (TAF) (<a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">17</a></a>), (−)FTC (emtricitabine (<a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>), elvitegravir (<a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a></a>), and cobicistat (<a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a></a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/large/jm-2019-00175p_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00175&amp;id=fig18"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig19" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Figure 19</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/medium/jm-2019-00175p_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/large/jm-2019-00175p_0019.jpeg" id="rightTab-gr19" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 19. Tenofovir alafenamide (TAF) (<a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">17</a></a>) and (−)FTC (emtricitabine) (<a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/large/jm-2019-00175p_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00175&amp;id=fig19"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig20" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Figure 20</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/medium/jm-2019-00175p_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/large/jm-2019-00175p_0020.jpeg" id="rightTab-gr20" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 20. Tenofovir alafenamide (TAF) (<a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">17</a></a>), (−)FTC (emtricitabine) (<a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>), and rilpivirine (<a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/large/jm-2019-00175p_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00175&amp;id=fig20"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig21" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Figure 21</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/medium/jm-2019-00175p_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/large/jm-2019-00175p_0021.jpeg" id="rightTab-gr21" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 21. Tenofovir alafenamide (TAF) (<a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">17</a></a>), (−)FTC (emtricitabine) (<a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>), and bictegravir (BIC).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/large/jm-2019-00175p_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00175&amp;id=fig21"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig22" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Figure 22</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/medium/jm-2019-00175p_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/large/jm-2019-00175p_0022.jpeg" id="rightTab-gr22" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 22. Tenofovir alafenamide (TAF) (<a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">17</a></a>), (−)FTC (emtricitabine) (<a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>), darunavir, and cobicistat (<a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a></a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/large/jm-2019-00175p_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00175&amp;id=fig22"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig23" data-index="23" class="article__inlineFigure"><h2 class="fig-label">Figure 23</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/medium/jm-2019-00175p_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/large/jm-2019-00175p_0023.jpeg" id="rightTab-gr23" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 23. GS-9219 (rabacfosadine), cPr-PMEDAP, PMEG, and PMEG diphosphate.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/large/jm-2019-00175p_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00175&amp;id=fig23"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig24" data-index="24" class="article__inlineFigure"><h2 class="fig-label">Figure 24</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/medium/jm-2019-00175p_0024.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/large/jm-2019-00175p_0024.jpeg" id="rightTab-gr24" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 24. Cf1743 and FV100 (5′-valine ester of Cf1743).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/large/jm-2019-00175p_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00175&amp;id=fig24"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig25" data-index="25" class="article__inlineFigure"><h2 class="fig-label">Figure 25</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/medium/jm-2019-00175p_0025.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/large/jm-2019-00175p_0025.jpeg" id="rightTab-gr25" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 25. Acyclic nucleoside phosphonates deserving further exploration.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-16/acs.jmedchem.9b00175/20190815/images/large/jm-2019-00175p_0025.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00175&amp;id=fig25"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i36">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_07056" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_07056" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 97 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Isaacs, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindenmann, J.</span></span> <span> </span><span class="NLM_article-title">Virus interference. I. The interferon</span>. <i>Proc. R. Soc. London, Ser. B</i> <span class="NLM_year" style="font-weight: bold;">1957</span>,  <span class="NLM_volume"><i>147</i></span>,  <span class="NLM_fpage">258</span>– <span class="NLM_lpage">267</span>, <span class="refDoi"> DOI: 10.1098/rspb.1957.0048</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1098%2Frspb.1957.0048" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=13465720" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A280%3ADyaG1c%252FgvVekuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=147&publication_year=1957&pages=258-267&author=A.+Isaacsauthor=J.+Lindenmann&title=Virus+interference.+I.+The+interferon&doi=10.1098%2Frspb.1957.0048"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Virus interference. I. The interferon</span></div><div class="casAuthors">ISAACS A; LINDENMANN J</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the Royal Society of London. Series B, Biological sciences</span>
        (<span class="NLM_cas:date">1957</span>),
    <span class="NLM_cas:volume">147</span>
        (<span class="NLM_cas:issue">927</span>),
    <span class="NLM_cas:pages">258-67</span>
        ISSN:<span class="NLM_cas:issn">0950-1193</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSHJGGj_jKWF5otVjB3IRIyfW6udTcc2eZ05v87OyzLebntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaG1c%252FgvVekuw%253D%253D&md5=c8c357491601f40e87ee3d2bc5ed49c0</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1098%2Frspb.1957.0048&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1098%252Frspb.1957.0048%26sid%3Dliteratum%253Aachs%26aulast%3DIsaacs%26aufirst%3DA.%26aulast%3DLindenmann%26aufirst%3DJ.%26atitle%3DVirus%2520interference.%2520I.%2520The%2520interferon%26jtitle%3DProc.%2520R.%2520Soc.%2520London%252C%2520Ser.%2520B%26date%3D1957%26volume%3D147%26spage%3D258%26epage%3D267%26doi%3D10.1098%2Frspb.1957.0048" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De Somer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Billiau, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schonne, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Claesen, M.</span></span> <span> </span><span class="NLM_article-title">Antiviral activity of polyacrylic and polymethacrylic acids: I. Mode of action in vitro</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">1968</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">878</span>– <span class="NLM_lpage">885</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=4302187" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADyaF1cXkslCksL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=1968&pages=878-885&author=P.+De+Somerauthor=E.+De+Clercqauthor=A.+Billiauauthor=E.+Schonneauthor=M.+Claesen&title=Antiviral+activity+of+polyacrylic+and+polymethacrylic+acids%3A+I.+Mode+of+action+in+vitro"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Antiviral activity of polyacrylic and polymethacrylic acids.  I.  Mode of action in vitro</span></div><div class="casAuthors">De Somer, P.; De Clercq, E.; Billiau, A.; Schonne, E.; Claesen, M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">1968</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">878-85</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    </div><div class="casAbstract">Polyacrylic acid (PAA) and polymethacrylic acid (PMAA) were investigated for their antiviral properties in tissue culture.  Compared to other related polyanions, as dextran sulfate, polystyrene sulfonate, polyvinyl sulfate, and polyphloroglucinol phosphate, PAA and PMAA were more antivirally active and less cytotoxic.  PMAA added 24 hrs. prior to virus inoculation inhibited viral growth most efficiently, but it was also effective when added 3 hrs. after infection.  Neither a direct irreversible action on the virus nor inhibition of virus penetration into the cell could explain the antiviral activity of PMAA.  PMAA inhibited the adsorption of the virus to the host cell and suppressed the one-cycle viral synthesis in tissue cultures inoculated with infectious RNA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJi6VIR5HcoLVg90H21EOLACvtfcHk0lhhze7TcRD8qQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF1cXkslCksL4%253D&md5=88a60981c861fc88ca6113b8751b7a8f</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BSomer%26aufirst%3DP.%26aulast%3DDe%2BClercq%26aufirst%3DE.%26aulast%3DBilliau%26aufirst%3DA.%26aulast%3DSchonne%26aufirst%3DE.%26aulast%3DClaesen%26aufirst%3DM.%26atitle%3DAntiviral%2520activity%2520of%2520polyacrylic%2520and%2520polymethacrylic%2520acids%253A%2520I.%2520Mode%2520of%2520action%2520in%2520vitro%26jtitle%3DJ.%2520Virol.%26date%3D1968%26volume%3D2%26spage%3D878%26epage%3D885" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De Somer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Billiau, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schonne, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Claesen, M.</span></span> <span> </span><span class="NLM_article-title">Antiviral activity of polyacrylic and polymethacrylic acids: II. Mode of action in vivo</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">1968</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">886</span>– <span class="NLM_lpage">893</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=5725320" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADyaF1cXkslGntbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=1968&pages=886-893&author=P.+De+Somerauthor=E.+De+Clercqauthor=A.+Billiauauthor=E.+Schonneauthor=M.+Claesen&title=Antiviral+activity+of+polyacrylic+and+polymethacrylic+acids%3A+II.+Mode+of+action+in+vivo"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Antiviral activity of polyacrylic and polymethacrylic acids.  II.  Mode of action in vivo</span></div><div class="casAuthors">De Somer, P.; De Clercq, E.; Billiau, A.; Schonne, E.; Claesen, M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">1968</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">886-93</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    </div><div class="casAbstract">A marked virus-inhibiting potency is obtained in the serum after i.p. injection of poly(acrylic acid) (PAA) and poly(methacrylic acid) (PMAA) in mice.  Much higher antiviral levels were reached than for other related polymers including dextran sulfate, heparin, poly(vinyl sulfate), pyran copolymer, poly(styrenesulfonate), and macrodex.  The broad antiviral action of PAA and PMAA was attributed both to a direct interference with the virus-cell interaction and the viral RNA metabolism and to the formation of an interferon-like factor.  Both polyanions differed in interferon-inducing ability: highest serum interferon titer was obtained 18 hrs. after the i.p. injection of PAA.  The mechanism of interferon production by PAA and PMAA is discussed.  As described previously for Sindbis virus and endotoxin, the animals also became hyporeactive after injection of PAA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXYc-KBQopz7Vg90H21EOLACvtfcHk0ljwN-yWBjd7fA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF1cXkslGntbg%253D&md5=d3ab37fb7cc556ea3931f81ddbb40aff</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BSomer%26aufirst%3DP.%26aulast%3DDe%2BClercq%26aufirst%3DE.%26aulast%3DBilliau%26aufirst%3DA.%26aulast%3DSchonne%26aufirst%3DE.%26aulast%3DClaesen%26aufirst%3DM.%26atitle%3DAntiviral%2520activity%2520of%2520polyacrylic%2520and%2520polymethacrylic%2520acids%253A%2520II.%2520Mode%2520of%2520action%2520in%2520vivo%26jtitle%3DJ.%2520Virol.%26date%3D1968%26volume%3D2%26spage%3D886%26epage%3D893" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Merigan, T.</span></span> <span> </span><span class="NLM_article-title">Induction of circulating interferon by synthetic anionic polymers of known composition</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1967</span>,  <span class="NLM_volume"><i>214</i></span>,  <span class="NLM_fpage">416</span>– <span class="NLM_lpage">417</span>, <span class="refDoi"> DOI: 10.1038/214416a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1038%2F214416a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=6032855" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADyaF2sXktV2rsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=214&publication_year=1967&pages=416-417&author=T.+Merigan&title=Induction+of+circulating+interferon+by+synthetic+anionic+polymers+of+known+composition&doi=10.1038%2F214416a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Induction of circulating interferon by synthetic anionic polymers of known composition</span></div><div class="casAuthors">Merigan, Thomas C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">1967</span>),
    <span class="NLM_cas:volume">214</span>
        (<span class="NLM_cas:issue">5086</span>),
    <span class="NLM_cas:pages">416-17</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    </div><div class="casAbstract">Maleic anhydride-divinyl ether copolymer (I) injected into mice at 75-500 mg./kg. (i.v. or i.p.) induced the formation of interferon (II) (mol. wt. 70,000; 100-257 units/4 ml.) at peak levels 18 hrs. after injection.  Other structural variations (14) of the maleic acid copolymer were also tested, and those of 40-1250 × 106 mol. wt. were less active and required higher doses to achieve full responses.  Maleic anhydridevinyl Me ether and maleic anhydride-vinyl acetate copolymers could not be distinguished from I in their activities, but the introduction of styrene side chains practically abolished II-inducing ability and increased the toxicity of the copolymer.  Up to 50% Me esterification of the carboxyl group did not block II-inducing capacity, but amidation to the same extent somewhat decreased it.  The most inactive of the polymers, maleic anhydride-vinyl Me ether (50% amidated), was a thick gel and probably did not reach the receptor site.  The serum II produced by these anionic copolymers resembled that produced by statolon in mol. wt. and pattern of production, although the levels produced by the latter were 3-8-fold greater.  The failure of these compds. to be metabolized by the animal, which could lead to their deposition in the reticuloendothelial system, is the major drawback against the therapeutic use of such compds.  19 references.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0pF6GWWCvbLVg90H21EOLACvtfcHk0ljwN-yWBjd7fA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF2sXktV2rsb8%253D&md5=3de06a4b45c1bb421df859edb0a7bbbb</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2F214416a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F214416a0%26sid%3Dliteratum%253Aachs%26aulast%3DMerigan%26aufirst%3DT.%26atitle%3DInduction%2520of%2520circulating%2520interferon%2520by%2520synthetic%2520anionic%2520polymers%2520of%2520known%2520composition%26jtitle%3DNature%26date%3D1967%26volume%3D214%26spage%3D416%26epage%3D417%26doi%3D10.1038%2F214416a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Merigan, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Regelson, W.</span></span> <span> </span><span class="NLM_article-title">Interferon induction in man by a synthetic polyanion of defined composition</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">1967</span>,  <span class="NLM_volume"><i>277</i></span>,  <span class="NLM_fpage">1283</span>– <span class="NLM_lpage">1287</span>, <span class="refDoi"> DOI: 10.1056/NEJM196712142772403</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1056%2FNEJM196712142772403" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=6073272" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADyaF1cXivVChsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=277&publication_year=1967&pages=1283-1287&author=T.+C.+Meriganauthor=W.+Regelson&title=Interferon+induction+in+man+by+a+synthetic+polyanion+of+defined+composition&doi=10.1056%2FNEJM196712142772403"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Interferon induction in man by a synthetic polyanion of defined composition</span></div><div class="casAuthors">Merigan, Thomas C.; Regelson, William</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">1967</span>),
    <span class="NLM_cas:volume">277</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">1283-7</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    </div><div class="casAbstract">Ten patients with advanced cancer not amenable to other forms of therapy received pyran copolymer.  A single i.v. injection of pyran at a dose level of 12 mg./kg. produced antiviral activity in the serum of only 1 of 4 patients, but higher doses (15-16 mg./kg.) were consistently effective in 3 patients.  Antiviral responses were regularly observed when a dose of 12 mg./kg. was given on 2 successive days.  This antiviral activity was similar to that of human interferon found in the serum after vaccination with primary live virus or with naturally occurring virus infection.  Thrombocytopenia and fever (>101°F) were the major side effects, the former appeared in all patients at the dose of 8 mg./kg. or higher and the latter was seen in 10 of 13 patients at doses >8 mg./kg.  Autopsies revealed reticuloendothelial stimulation as demonstrated by splenic and hepatic phagocytic activity.  32 references.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKwD8Ot84BPbVg90H21EOLACvtfcHk0ljwN-yWBjd7fA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF1cXivVChsQ%253D%253D&md5=e80705e09258761ab78b00108aad9217</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1056%2FNEJM196712142772403&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM196712142772403%26sid%3Dliteratum%253Aachs%26aulast%3DMerigan%26aufirst%3DT.%2BC.%26aulast%3DRegelson%26aufirst%3DW.%26atitle%3DInterferon%2520induction%2520in%2520man%2520by%2520a%2520synthetic%2520polyanion%2520of%2520defined%2520composition%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D1967%26volume%3D277%26spage%3D1283%26epage%3D1287%26doi%3D10.1056%2FNEJM196712142772403" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lampson, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tytell, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Field, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nemes, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hilleman, M. R.</span></span> <span> </span><span class="NLM_article-title">Inducers of interferon and host resistance. I. Double-stranded RNA from extracts of Penicillium funiculosum</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1967</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">782</span>– <span class="NLM_lpage">789</span>, <span class="refDoi"> DOI: 10.1073/pnas.58.2.782</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1073%2Fpnas.58.2.782" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=5233474" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADyaF2sXkvVSktL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=1967&pages=782-789&author=G.+P.+Lampsonauthor=A.+A.+Tytellauthor=A.+K.+Fieldauthor=M.+M.+Nemesauthor=M.+R.+Hilleman&title=Inducers+of+interferon+and+host+resistance.+I.+Double-stranded+RNA+from+extracts+of+Penicillium+funiculosum&doi=10.1073%2Fpnas.58.2.782"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Inducers of interferon and host resisance. I.  Double-stranded RNA from extracts of Penicillium funiculosum</span></div><div class="casAuthors">Lampson, George P.; Tytell, Alfred A.; Field, A. K.; Nemes, Marjorie M.; Hilleman, Maurice R.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1967</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">782-9</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    </div><div class="casAbstract">A highly purified double-stranded RNA termed HeI-RNA (I) which was active in μg. amts. in inducing interferon in rabbits and resistance to virus infection in vivo in mice and in vitro was recovered from P. funiculosum mycelial exts.  The biol., chem., and phys. properties of the RNA and the interferon induced by it were given.  I induced resistance to both PVM (pneumonia virus of mice) and to Columbia SK viruses in mice.  The uv absorption spectrum of the purified I was typical for nucleic acid.  The I contained 38% ribose, 8.4% P, plus purine and pyrimidine bases.  Protein, polysaccharide, and deoxyribose were absent.  The interferon-inducing activity was resistant to DNase, HIO4, and HCHO, but was destroyed by RNase at 56°.  I had a high level of thermal stability.  The sedimentation coeff. was 12.1 s.  The finding of the requirement of double-strandedness for activity is new and adds to the understanding of some of the requirements for induction of interferon and host resistance by RNA.  30 references.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5QuyjUD-r7bVg90H21EOLACvtfcHk0ljwN-yWBjd7fA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF2sXkvVSktL4%253D&md5=82fecd273fc849b62e42287220695a13</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1073%2Fpnas.58.2.782&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.58.2.782%26sid%3Dliteratum%253Aachs%26aulast%3DLampson%26aufirst%3DG.%2BP.%26aulast%3DTytell%26aufirst%3DA.%2BA.%26aulast%3DField%26aufirst%3DA.%2BK.%26aulast%3DNemes%26aufirst%3DM.%2BM.%26aulast%3DHilleman%26aufirst%3DM.%2BR.%26atitle%3DInducers%2520of%2520interferon%2520and%2520host%2520resistance.%2520I.%2520Double-stranded%2520RNA%2520from%2520extracts%2520of%2520Penicillium%2520funiculosum%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1967%26volume%3D58%26spage%3D782%26epage%3D789%26doi%3D10.1073%2Fpnas.58.2.782" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Field, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tytell, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lampson, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hilleman, M. R.</span></span> <span> </span><span class="NLM_article-title">Inducers of interferon and host resistance. II. Multistranded synthetic polynucleotide complexes</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1967</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">1004</span>– <span class="NLM_lpage">1010</span>, <span class="refDoi"> DOI: 10.1073/pnas.58.3.1004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1073%2Fpnas.58.3.1004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=5233831" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADyaF2sXltFGltLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=1967&pages=1004-1010&author=A.+K.+Fieldauthor=A.+A.+Tytellauthor=G.+P.+Lampsonauthor=M.+R.+Hilleman&title=Inducers+of+interferon+and+host+resistance.+II.+Multistranded+synthetic+polynucleotide+complexes&doi=10.1073%2Fpnas.58.3.1004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Inducers of interferon and host resistance.  II.  Multistranded synthetic polynucleotide complexes</span></div><div class="casAuthors">Field, A. K.; Tytell, Alfred A.; Lampson, George P.; Hilleman, Maurice R.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1967</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1004-10</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    </div><div class="casAbstract">cf. CA 67: 80760u.  A complex of polyinosinic acid and polycytidylic acid, a complex of polyadenylic acid and polyuridylic acid, and a mixt. of polyinosinic acid and cytidylyl-cytidine were active in microgram amts. in inducing interferon in rabbits.  A variety of homopolymers and copolymers tested singly and in combination were inactive, as were a large no. of oligonucleotides, dinucleotides, nucleotides, nucleosides, and free bases.  A complex of polyinosinic acid and polycytidylic acid also induced resistance to viral infection in mice and induced interferon and evoked resistance to viruses in cell culture.  This was the first reported demonstration of the biol. activity of complexed homopolynucleotides.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkyEErWzAE-LVg90H21EOLACvtfcHk0liZSqLEPZ2PEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF2sXltFGltLs%253D&md5=e3ad73f4fadf5f8e0062e5630b64d63f</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1073%2Fpnas.58.3.1004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.58.3.1004%26sid%3Dliteratum%253Aachs%26aulast%3DField%26aufirst%3DA.%2BK.%26aulast%3DTytell%26aufirst%3DA.%2BA.%26aulast%3DLampson%26aufirst%3DG.%2BP.%26aulast%3DHilleman%26aufirst%3DM.%2BR.%26atitle%3DInducers%2520of%2520interferon%2520and%2520host%2520resistance.%2520II.%2520Multistranded%2520synthetic%2520polynucleotide%2520complexes%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1967%26volume%3D58%26spage%3D1004%26epage%3D1010%26doi%3D10.1073%2Fpnas.58.3.1004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tytell, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lampson, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Field, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hilleman, M. R.</span></span> <span> </span><span class="NLM_article-title">Inducers of interferon and host resistance. 3. Double-stranded RNA from reovirus type 3 virions (reo 3-RNA)</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1967</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">1719</span>– <span class="NLM_lpage">1722</span>, <span class="refDoi"> DOI: 10.1073/pnas.58.4.1719</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1073%2Fpnas.58.4.1719" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=4295834" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADyaF1cXitVGguw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=1967&pages=1719-1722&author=A.+A.+Tytellauthor=G.+P.+Lampsonauthor=A.+K.+Fieldauthor=M.+R.+Hilleman&title=Inducers+of+interferon+and+host+resistance.+3.+Double-stranded+RNA+from+reovirus+type+3+virions+%28reo+3-RNA%29&doi=10.1073%2Fpnas.58.4.1719"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Inducers of interferon and host resistance.  III.  Double-stranded RNA from reovirus type 3 virions (Reo 3-RNA)</span></div><div class="casAuthors">Tytell, Alfred A.; Lampson, George P.; Field, A. K.; Hilleman, Maurice R.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1967</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1719-22</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    </div><div class="casAbstract">A purified double-stranded RNA obtained from reovirus 3 virions and designated Reo 3-RNA was active in μg. amts. in inducing interferon in vivo and resistance to viral infection in vitro.  The induction period of Reo 3-RNA was 1 hr. or less in contrast to 5-6 hrs. for the whole infectious virus; this may be related to the time requirement for removal of the capsid from the RNA before induction can occur.  The induced interferon exhibited a host species-specificity of inhibitory titers of 128-256 in homologous rabbit kidney cells and <32 in heterologous mouse and chick embryo cells in culture, a redn. in titer from 32 to <5 by treatment for 4 hrs. at 35° with 50 μg. trypsin/ml., a mol. wt. of 40,000 based on Sephadex G-200 gel filtration, and an isoelec. point of 7.0 measured by chromatog. on CM-Sephadex.  The Reo 3-RNA exhibited uv absorption spectrum max. and min. of 260 and 232 mμ., resp., a thermal transition midpoint of 110°, and a significantly lower sensitivity to RNase than was observed with single-stranded yeast RNA.  The requirement for double stranding of viral RNA in order to induce interferon and host resistance to viral infection is consistent with the previously observed necessity of double-stranding for similar activities of the RNA from Penicillium funiculosum (HeI-RNA) and for active complexes of polynucleotides.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJusmiznSvuLVg90H21EOLACvtfcHk0liZSqLEPZ2PEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF1cXitVGguw%253D%253D&md5=a2f9181daccec07c154d534fcbcc62c2</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1073%2Fpnas.58.4.1719&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.58.4.1719%26sid%3Dliteratum%253Aachs%26aulast%3DTytell%26aufirst%3DA.%2BA.%26aulast%3DLampson%26aufirst%3DG.%2BP.%26aulast%3DField%26aufirst%3DA.%2BK.%26aulast%3DHilleman%26aufirst%3DM.%2BR.%26atitle%3DInducers%2520of%2520interferon%2520and%2520host%2520resistance.%25203.%2520Double-stranded%2520RNA%2520from%2520reovirus%2520type%25203%2520virions%2520%2528reo%25203-RNA%2529%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1967%26volume%3D58%26spage%3D1719%26epage%3D1722%26doi%3D10.1073%2Fpnas.58.4.1719" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Field, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lampson, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tytell, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nemes, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hilleman, M. R.</span></span> <span> </span><span class="NLM_article-title">Inducers of interferon and host resistance, IV. Double-stranded replicative form RNA (MS2-Ff-RNA) from E. coli infected with MS2 coliphage</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1967</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">2102</span>– <span class="NLM_lpage">2108</span>, <span class="refDoi"> DOI: 10.1073/pnas.58.5.2102</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1073%2Fpnas.58.5.2102" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=4295588" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADyaF1cXitVGnsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=1967&pages=2102-2108&author=A.+K.+Fieldauthor=G.+P.+Lampsonauthor=A.+A.+Tytellauthor=M.+M.+Nemesauthor=M.+R.+Hilleman&title=Inducers+of+interferon+and+host+resistance%2C+IV.+Double-stranded+replicative+form+RNA+%28MS2-Ff-RNA%29+from+E.+coli+infected+with+MS2+coliphage&doi=10.1073%2Fpnas.58.5.2102"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Inducers of interferon and host resistance.  IV.  Double-stranded replicative form RNA (MS2-RF-RNA) from Escherichia coli infected with MS2 coliphage</span></div><div class="casAuthors">Field, A. K.; Lampson, George P.; Tytell, Alfred A.; Nemes, Marjorie M.; Hilleman, Maurice R.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1967</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2102-8</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    </div><div class="casAbstract">A purified double-stranded replicative form of RNA (I) obtained from Escherichia coli infected with MS2 coliphage was active in inducing interferon in rabbits, with as little as 0.5 mg. of I inducing resistance to viral infection in vivo and in vitro.  Single-stranded RNA derived from the MS2 virion was inactive.  Data relating to the biol., chem., and phys. properties of I and the interferon induced by it was presented.  The finding of the requirements of double-stranding of viral RNA for induction of interferon and host resistance to viral infection is consistent with previous findings.  16 references.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZAeKrTXiCyLVg90H21EOLACvtfcHk0liZSqLEPZ2PEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF1cXitVGnsg%253D%253D&md5=e89f37be863e724ea0865cde51abdd3e</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1073%2Fpnas.58.5.2102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.58.5.2102%26sid%3Dliteratum%253Aachs%26aulast%3DField%26aufirst%3DA.%2BK.%26aulast%3DLampson%26aufirst%3DG.%2BP.%26aulast%3DTytell%26aufirst%3DA.%2BA.%26aulast%3DNemes%26aufirst%3DM.%2BM.%26aulast%3DHilleman%26aufirst%3DM.%2BR.%26atitle%3DInducers%2520of%2520interferon%2520and%2520host%2520resistance%252C%2520IV.%2520Double-stranded%2520replicative%2520form%2520RNA%2520%2528MS2-Ff-RNA%2529%2520from%2520E.%2520coli%2520infected%2520with%2520MS2%2520coliphage%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1967%26volume%3D58%26spage%3D2102%26epage%3D2108%26doi%3D10.1073%2Fpnas.58.5.2102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Field, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tytell, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lampson, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hilleman, M. R.</span></span> <span> </span><span class="NLM_article-title">Inducers of interferon and host resistance, V. In vitro studies</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1968</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">340</span>– <span class="NLM_lpage">346</span>, <span class="refDoi"> DOI: 10.1073/pnas.61.1.340</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1073%2Fpnas.61.1.340" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=4301592" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADyaF1cXltVCksLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=1968&pages=340-346&author=A.+K.+Fieldauthor=A.+A.+Tytellauthor=G.+P.+Lampsonauthor=M.+R.+Hilleman&title=Inducers+of+interferon+and+host+resistance%2C+V.+In+vitro+studies&doi=10.1073%2Fpnas.61.1.340"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Inducers of interferon and host resistance.  V.  In vitro studies</span></div><div class="casAuthors">Field, A. K.; Tytell, A. A.; Lampson, G. P.; Hilleman, M. R.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1968</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">340-6</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    </div><div class="casAbstract">The induction of resistance against several viruses (vesicular stomatitis, vaccinia, herpes simplex, and rhinovirus) in a variety of cell cultures (including rabbit, dog, and calf kidney and mouse embryo) by the poly(riboinosinic acid)-poly(ribocytidylic acid) complex was studied.  The complex was highly active in inducing the resistance to viral infection in cell culture.  Such resistance was broad-spectrum with respect to kinds of viruses, but the amt. of the complex required for induction varied considerably for different cells and was not always consistent for a particular kind of cell.  Single-stranded poly(riboinosinic acid) and poly(ribocytidylic acid) were inactive in vitro, and the purported activity of such materials was due to the presence of a contaminant that was double-stranded.  The development of resistance to viral infection following treatment with the complex was accompanied by production of interferon.  The induction of interferon by the poly(riboinosinic acid)-poly(ribocytidylic acid) complex in vitro was prevented by prior treatment of cells with actinomycin D (0.5 μg./ml.), indicating an apparent requirement for DNA-dependent RNA synthesis.  16 references.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzp4zYnlnQwLVg90H21EOLACvtfcHk0liMHyVASr3nLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF1cXltVCksLg%253D&md5=118d17852907d9bc15aaad0073eba4aa</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1073%2Fpnas.61.1.340&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.61.1.340%26sid%3Dliteratum%253Aachs%26aulast%3DField%26aufirst%3DA.%2BK.%26aulast%3DTytell%26aufirst%3DA.%2BA.%26aulast%3DLampson%26aufirst%3DG.%2BP.%26aulast%3DHilleman%26aufirst%3DM.%2BR.%26atitle%3DInducers%2520of%2520interferon%2520and%2520host%2520resistance%252C%2520V.%2520In%2520vitro%2520studies%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1968%26volume%3D61%26spage%3D340%26epage%3D346%26doi%3D10.1073%2Fpnas.61.1.340" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De
Clercq, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merigan, T.</span></span> <span> </span><span class="NLM_article-title">Requirement of a stable secondary structure for the antiviral activity of polynucleotides</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1969</span>,  <span class="NLM_volume"><i>222</i></span>,  <span class="NLM_fpage">1148</span>– <span class="NLM_lpage">1152</span>, <span class="refDoi"> DOI: 10.1038/2221148a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1038%2F2221148a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=4307027" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADyaF1MXkvVyru74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=222&publication_year=1969&pages=1148-1152&author=E.+De%0AClercqauthor=T.+Merigan&title=Requirement+of+a+stable+secondary+structure+for+the+antiviral+activity+of+polynucleotides&doi=10.1038%2F2221148a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Requirement of a stable secondary structure for the antiviral activity of polynucleotides</span></div><div class="casAuthors">De Clercq, E.; Merigan, T. C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">1969</span>),
    <span class="NLM_cas:volume">222</span>
        (<span class="NLM_cas:issue">5199</span>),
    <span class="NLM_cas:pages">1148-52</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    </div><div class="casAbstract">Homopolymer pairs with higher melting temp. (Tm) values were more active against bovine vesicular stomatitis virus (BVSV) in tissue culture.  Both Tm and antiviral activity increased in the order A/I, U/X, A/U, and I/C.  I/X induced a higher resistance against BVSV than U/X and A/I.  The activity of I/X was a summation of the antiviral effects of the individual homopolymers sep.  Differences in antiviral activity between homopolynucleotide complexes were accounted for by the differences in melting behavior and helical stability of the complex.  The 3-stranded complex A/2X gave min. antiviral activity.  With the homopolymer pairs U/X and A/I, the addn. of Mg2+ and decrease in pH increased thermal stability and antiviral activity of A/I.  The addn. of Mg2+ at pH 7 or 7.5 caused a minor shift in both Tm and viral inhibition of U/X; at pH 6 Mg2+ caused a redn. of both Tm and antiviral affect.  A decrease in pH and addn. of Mg2+ did not enhance interferon induction by I/C and A/U.  At 40 γ/ml., G, I, and X induced significant cellular resistance to BVSV; U, C, and A did not induce any activity but slightly stimulated virus plaque formation.  Hypochromicity was greatest for G, I, and X.  Mg2+ had little effect on antiviral activity of U, G, I, or X; C and A became more active in the presence of mg2+.  Both C and A became active at pH <7.5, and antiviral activity increased with decreasing pH.  The antiviral capacity or U, C, and A at pH 6 increased in the same order as their degree of hypochromicity.  The antiviral activity of single homopolymers was due to the homopolynucleotide itself and not to foreign double-stranded contaminants.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFW9g91t5VxLVg90H21EOLACvtfcHk0liMHyVASr3nLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF1MXkvVyru74%253D&md5=bd38006fb6d491f923053e3cc3a41c5d</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2F2221148a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F2221148a0%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BClercq%26aufirst%3DE.%26aulast%3DMerigan%26aufirst%3DT.%26atitle%3DRequirement%2520of%2520a%2520stable%2520secondary%2520structure%2520for%2520the%2520antiviral%2520activity%2520of%2520polynucleotides%26jtitle%3DNature%26date%3D1969%26volume%3D222%26spage%3D1148%26epage%3D1152%26doi%3D10.1038%2F2221148a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merigan, T.</span></span> <span> </span><span class="NLM_article-title">Increase in antiviral activity of polynucleotides by thermal activation</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1970</span>,  <span class="NLM_volume"><i>226</i></span>,  <span class="NLM_fpage">364</span>– <span class="NLM_lpage">366</span>, <span class="refDoi"> DOI: 10.1038/226364a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1038%2F226364a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=4314782" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADyaE3cXktFWltLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=226&publication_year=1970&pages=364-366&author=E.+De+Clercqauthor=R.+Wellsauthor=T.+Merigan&title=Increase+in+antiviral+activity+of+polynucleotides+by+thermal+activation&doi=10.1038%2F226364a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Increase in antiviral activity of polynucleotides by thermal activation</span></div><div class="casAuthors">De Clercq, Erik; Wells, Robert D.; Merigan, Thomas C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">1970</span>),
    <span class="NLM_cas:volume">226</span>
        (<span class="NLM_cas:issue">5243</span>),
    <span class="NLM_cas:pages">364-6</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    </div><div class="casAbstract">Incubation of several synthetic polynucleotides at 37° for 5 min-2 hr increased their antiviral activity in subsequent in vitro and in vivo tests.  Thermal activation occurred with both alternating copolymer and homopolymer pairs of either the RNA or DNA types, but this effect was greatest for poly(A-U).  Thus, 5-min incubation at 37° increased the antiviral activity of poly(A-U) by >106-fold, as judged by the concn. required to decrease viral plaque formation 50% in cultures of human skin fibroblasts inoculated with bovine vesicular stomatitis virus.  Heat treatment of poly(A-U) also increased its ability to induce interferon formation in fibroblasts cultures and in mice after i.v. injection.  Incubation at 32 or 56° increased the antiviral activity of poly(A-U) as efficiently as at 37°, but there was no activation at 25°, and 90° destroyed activity.  The random copolymer poly(A,U) was devoid of antiviral activity at the highest concn. tested (10 μg/ml), and incubation at 37° did not activate it.  Moderate heating apparently increases the antiviral activity of some polynucleotides by stabilizing their double-stranded structure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprWvaSx4Lm8LVg90H21EOLACvtfcHk0liMHyVASr3nLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE3cXktFWltLg%253D&md5=d76282f00bfc77be3db88f9e5ec15f79</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1038%2F226364a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F226364a0%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BClercq%26aufirst%3DE.%26aulast%3DWells%26aufirst%3DR.%26aulast%3DMerigan%26aufirst%3DT.%26atitle%3DIncrease%2520in%2520antiviral%2520activity%2520of%2520polynucleotides%2520by%2520thermal%2520activation%26jtitle%3DNature%26date%3D1970%26volume%3D226%26spage%3D364%26epage%3D366%26doi%3D10.1038%2F226364a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eckstein, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merigan, T. C.</span></span> <span> </span><span class="NLM_article-title">Interferon induction increased through chemical modification of a synthetic polyribonucleotide</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1969</span>,  <span class="NLM_volume"><i>165</i></span>,  <span class="NLM_fpage">1137</span>– <span class="NLM_lpage">1139</span>, <span class="refDoi"> DOI: 10.1126/science.165.3898.1137</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1126%2Fscience.165.3898.1137" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=5801596" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADyaF1MXkvFyhtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=165&publication_year=1969&pages=1137-1139&author=E.+De+Clercqauthor=F.+Ecksteinauthor=T.+C.+Merigan&title=Interferon+induction+increased+through+chemical+modification+of+a+synthetic+polyribonucleotide&doi=10.1126%2Fscience.165.3898.1137"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Interferon induction increased through chemical modification of a synthetic polyribonucleotide</span></div><div class="casAuthors">De Clercq, Erik; Eckstein, F.; Merigan, T. C.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">1969</span>),
    <span class="NLM_cas:volume">165</span>
        (<span class="NLM_cas:issue">3898</span>),
    <span class="NLM_cas:pages">1137-9</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    </div><div class="casAbstract">The alternating copolymer riboadenylic-ribouridylic acid gained a significant increase in ability to stimulate interferon production (2-20-fold) and cellular resistance (100-10,000-fold) both in vitro and in vivo upon substitution of phosphate by thiophosphate groups.  The resulting nucleotide analog was also 10-100 times less sensitive to degradation by pancreatic RNase, as detd. by residual antiviral activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRvxIdM6f5abVg90H21EOLACvtfcHk0lha4erj573Q-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF1MXkvFyhtLc%253D&md5=0fd2a4047a3edf7602e14884af43f58a</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1126%2Fscience.165.3898.1137&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.165.3898.1137%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BClercq%26aufirst%3DE.%26aulast%3DEckstein%26aufirst%3DF.%26aulast%3DMerigan%26aufirst%3DT.%2BC.%26atitle%3DInterferon%2520induction%2520increased%2520through%2520chemical%2520modification%2520of%2520a%2520synthetic%2520polyribonucleotide%26jtitle%3DScience%26date%3D1969%26volume%3D165%26spage%3D1137%26epage%3D1139%26doi%3D10.1126%2Fscience.165.3898.1137" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Somer, P.</span></span> <span> </span><span class="NLM_article-title">Antiviral activity of polyribocytidylic acid in cells primed with polyriboinosinic acid</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1971</span>,  <span class="NLM_volume"><i>173</i></span>,  <span class="NLM_fpage">260</span>– <span class="NLM_lpage">262</span>, <span class="refDoi"> DOI: 10.1126/science.173.3993.260</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1126%2Fscience.173.3993.260" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=4325867" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADyaE3MXkvFOjsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=173&publication_year=1971&pages=260-262&author=E.+De+Clercqauthor=P.+De+Somer&title=Antiviral+activity+of+polyribocytidylic+acid+in+cells+primed+with+polyriboinosinic+acid&doi=10.1126%2Fscience.173.3993.260"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Antiviral activity of polyribocytidylic acid in cells primed with polyriboinosinic acid</span></div><div class="casAuthors">De Clercq, E.; De Somer, P.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">1971</span>),
    <span class="NLM_cas:volume">173</span>
        (<span class="NLM_cas:issue">3993</span>),
    <span class="NLM_cas:pages">260-2</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    </div><div class="casAbstract">Polyribocytylic acid [poly(rC)] or polyriboinosinic acid [poly(rI)] added separately to 7 different cell cultures challenged with different viruses induced antiviral activity which was identical to or greater than that resulting from addn. of the poly(rI).poly(rC) complex.  Poly(rI) priming of cells, followed by treatment with poly(rC), gave consistently greater antiviral activity than poly(rI).poly(rC) itself.  When poly(rI) and poly(rC) were injected (i.v. and i.p.) successively into mice, lower interferon levels resulted than with injection of the poly(rI).poly(rC) complex.  Prior injection of poly(rI) proved superior in restoring the interferon inducing capacity of poly(rI).poly(rC) in vivo, as compared to prior injection of poly(rC).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjofojGG9IsLVg90H21EOLACvtfcHk0lha4erj573Q-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE3MXkvFOjsbc%253D&md5=151c0998e043025a77a8c95da8fb1e48</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1126%2Fscience.173.3993.260&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.173.3993.260%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BClercq%26aufirst%3DE.%26aulast%3DDe%2BSomer%26aufirst%3DP.%26atitle%3DAntiviral%2520activity%2520of%2520polyribocytidylic%2520acid%2520in%2520cells%2520primed%2520with%2520polyriboinosinic%2520acid%26jtitle%3DScience%26date%3D1971%26volume%3D173%26spage%3D260%26epage%3D262%26doi%3D10.1126%2Fscience.173.3993.260" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span> <span> </span><span class="NLM_article-title">Synthetic interferon inducers</span>. <i>Top. Curr. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1974</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">173</span>– <span class="NLM_lpage">208</span>, <span class="refDoi"> DOI: 10.1007/3-540-06873-2_17</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1007%2F3-540-06873-2_17" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=4617338" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADyaE2MXltFagsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=1974&pages=173-208&author=E.+De+Clercq&title=Synthetic+interferon+inducers&doi=10.1007%2F3-540-06873-2_17"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic interferon inducers</span></div><div class="casAuthors">De Clercq, Erik</div><div class="citationInfo"><span class="NLM_cas:title">Topics in Current Chemistry</span>
        (<span class="NLM_cas:date">1974</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">173-208</span>CODEN:
                <span class="NLM_cas:coden">TPCCAQ</span>;
        ISSN:<span class="NLM_cas:issn">0340-1022</span>.
    </div><div class="casAbstract">A review emphasizing the structure-activity relationships of synthetic interferon inducers; 202 refs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBiLSHqFUQibVg90H21EOLACvtfcHk0lha4erj573Q-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE2MXltFagsg%253D%253D&md5=e25e1bfbb5d65053912290a638eb32ed</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1007%2F3-540-06873-2_17&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F3-540-06873-2_17%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BClercq%26aufirst%3DE.%26atitle%3DSynthetic%2520interferon%2520inducers%26jtitle%3DTop.%2520Curr.%2520Chem.%26date%3D1974%26volume%3D52%26spage%3D173%26epage%3D208%26doi%3D10.1007%2F3-540-06873-2_17" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Carter, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span> <span> </span><span class="NLM_article-title">Viral infection and host defense</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1974</span>,  <span class="NLM_volume"><i>186</i></span>,  <span class="NLM_fpage">1172</span>– <span class="NLM_lpage">1178</span>, <span class="refDoi"> DOI: 10.1126/science.186.4170.1172</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1126%2Fscience.186.4170.1172" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=4610750" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADyaE2MXotl2ntQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=186&publication_year=1974&pages=1172-1178&author=W.+A.+Carterauthor=E.+De+Clercq&title=Viral+infection+and+host+defense&doi=10.1126%2Fscience.186.4170.1172"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Viral infection and host defense</span></div><div class="casAuthors">Carter, William A.; De Clercq, Erik</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">1974</span>),
    <span class="NLM_cas:volume">186</span>
        (<span class="NLM_cas:issue">4170</span>),
    <span class="NLM_cas:pages">1172-8</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    </div><div class="casAbstract">A review with 61 refs. of interferon induction by double-stranded RNA (dsRNA), intrinsic toxicity of dsRNA, dsRNA in acute infections, host defense mechanism and recovery from acute virus infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmJsNvFei7oLVg90H21EOLACvtfcHk0lgW6dSkOd94ig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE2MXotl2ntQ%253D%253D&md5=83c9d2eaf12de0f3c9689e811491f36b</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1126%2Fscience.186.4170.1172&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.186.4170.1172%26sid%3Dliteratum%253Aachs%26aulast%3DCarter%26aufirst%3DW.%2BA.%26aulast%3DDe%2BClercq%26aufirst%3DE.%26atitle%3DViral%2520infection%2520and%2520host%2520defense%26jtitle%3DScience%26date%3D1974%26volume%3D186%26spage%3D1172%26epage%3D1178%26doi%3D10.1126%2Fscience.186.4170.1172" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Derynck, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Content, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volckaert, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tavernier, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devos, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiers, W.</span></span> <span> </span><span class="NLM_article-title">Isolation and structure of a human fibroblast interferon gene</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1980</span>,  <span class="NLM_volume"><i>285</i></span>,  <span class="NLM_fpage">542</span>– <span class="NLM_lpage">547</span>, <span class="refDoi"> DOI: 10.1038/285542a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1038%2F285542a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=6157094" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADyaL3cXls1GrsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=285&publication_year=1980&pages=542-547&author=R.+Derynckauthor=J.+Contentauthor=E.+De+Clercqauthor=G.+Volckaertauthor=J.+Tavernierauthor=R.+Devosauthor=W.+Fiers&title=Isolation+and+structure+of+a+human+fibroblast+interferon+gene&doi=10.1038%2F285542a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Isolation and structure of a human fibroblast interferon gene</span></div><div class="casAuthors">Derynck, Rik; Content, Jean; De Clercq, Erik; Volckaert, Guido; Tavernier, Jan; Devos, Rene; Fiers, Walter</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">1980</span>),
    <span class="NLM_cas:volume">285</span>
        (<span class="NLM_cas:issue">5766</span>),
    <span class="NLM_cas:pages">542-7</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    </div><div class="casAbstract">An RNA selection method was used to screen chimeric plasmids contg. double-stranded complementary DNA copies of mRNA induced in human fibroblasts by poly I·C.  A series of clones to which human fibroblast interferon mRNA selectively hybridized was identified.  From the nucleotide sequence of the gene, the complete amino acid sequence was deduced.  The protein was 166 amino acids long and was preceded by a 21-amino acid signal sequence.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbKnjBREPEWLVg90H21EOLACvtfcHk0lgW6dSkOd94ig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3cXls1GrsLg%253D&md5=49da061868df75ab6153c8ac67a4c353</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1038%2F285542a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F285542a0%26sid%3Dliteratum%253Aachs%26aulast%3DDerynck%26aufirst%3DR.%26aulast%3DContent%26aufirst%3DJ.%26aulast%3DDe%2BClercq%26aufirst%3DE.%26aulast%3DVolckaert%26aufirst%3DG.%26aulast%3DTavernier%26aufirst%3DJ.%26aulast%3DDevos%26aufirst%3DR.%26aulast%3DFiers%26aufirst%3DW.%26atitle%3DIsolation%2520and%2520structure%2520of%2520a%2520human%2520fibroblast%2520interferon%2520gene%26jtitle%3DNature%26date%3D1980%26volume%3D285%26spage%3D542%26epage%3D547%26doi%3D10.1038%2F285542a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Derynck, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Remaut, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saman, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stanssens, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Content, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiers, W.</span></span> <span> </span><span class="NLM_article-title">Expression of human fibroblast interferon gene in <i>Escherichia coli</i></span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1980</span>,  <span class="NLM_volume"><i>287</i></span>,  <span class="NLM_fpage">193</span>– <span class="NLM_lpage">197</span>, <span class="refDoi"> DOI: 10.1038/287193a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1038%2F287193a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=6159534" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADyaL3MXht1Khtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=287&publication_year=1980&pages=193-197&author=R.+Derynckauthor=E.+Remautauthor=E.+Samanauthor=P.+Stanssensauthor=E.+De+Clercqauthor=J.+Contentauthor=W.+Fiers&title=Expression+of+human+fibroblast+interferon+gene+in+Escherichia+coli&doi=10.1038%2F287193a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Expression of human fibroblast interferon gene in Escherichia coli</span></div><div class="casAuthors">Derynck, Rik; Remaut, Erik; Saman, Erik; Stanssens, Patrick; De Clercq, Erik; Content, Jean; Fiers, Walter</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">1980</span>),
    <span class="NLM_cas:volume">287</span>
        (<span class="NLM_cas:issue">5779</span>),
    <span class="NLM_cas:pages">193-7</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    </div><div class="casAbstract">The human fibroblast interferon gene was inserted in a thermoinducible expression plasmid under control of the strong leftward promoter (PL) of bacteriophage λ.  The functioning of the promoter could be controlled by using host strains which formed a temp.-sensitive repressor.  The primary translation products predicted on the basis of the plasmid constructions were hybrid proteins starting with β-lactamase or phage MS2 polymerase information followed by the total preinterferon.  On induction, antiviral activity, whose physico-chem., immunol., and biol. characteristics closely corresponded to those of authentic human fibroblast interferon, was formed (titer of ∼100 units/5 × 108 cells/mL).  Processing to a size compatible with mature but unglycosylated authentic product was obsd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfJrm5cXhc_rVg90H21EOLACvtfcHk0lgW6dSkOd94ig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3MXht1Khtw%253D%253D&md5=fed9c6436634d0530a97944a5027d036</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1038%2F287193a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F287193a0%26sid%3Dliteratum%253Aachs%26aulast%3DDerynck%26aufirst%3DR.%26aulast%3DRemaut%26aufirst%3DE.%26aulast%3DSaman%26aufirst%3DE.%26aulast%3DStanssens%26aufirst%3DP.%26aulast%3DDe%2BClercq%26aufirst%3DE.%26aulast%3DContent%26aufirst%3DJ.%26aulast%3DFiers%26aufirst%3DW.%26atitle%3DExpression%2520of%2520human%2520fibroblast%2520interferon%2520gene%2520in%2520Escherichia%2520coli%26jtitle%3DNature%26date%3D1980%26volume%3D287%26spage%3D193%26epage%3D197%26doi%3D10.1038%2F287193a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Temin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizutani, S.</span></span> <span> </span><span class="NLM_article-title">RNA-dependent DNA polymerase in virions of Rous sarcoma virus</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1970</span>,  <span class="NLM_volume"><i>226</i></span>,  <span class="NLM_fpage">1211</span>– <span class="NLM_lpage">1213</span>, <span class="refDoi"> DOI: 10.1038/2261211a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1038%2F2261211a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=4316301" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADyaE3cXkvVCru70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=226&publication_year=1970&pages=1211-1213&author=H.+Teminauthor=S.+Mizutani&title=RNA-dependent+DNA+polymerase+in+virions+of+Rous+sarcoma+virus&doi=10.1038%2F2261211a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">RNA-dependent DNA polymerase in virions of Rous sarcoma virus</span></div><div class="casAuthors">Temin, Howard M.; Mizutani, Satoshi</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">1970</span>),
    <span class="NLM_cas:volume">226</span>
        (<span class="NLM_cas:issue">5252</span>),
    <span class="NLM_cas:pages">1211-13</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    </div><div class="casAbstract">A new polymerase was demonstrated inside the virions of Rous sarcoma virus but was not present in supernatants from normal host cells.  The polymerase seems to catalyze the incorporation of deoxyribonucleotide triphosphates into DNA from a RNA template.  If the present results and those of Baltimore (1970) are upheld they will constitute strong evidence that the DNA provirus hypothesis is correct and that RNA tumor viruses have a DNA genome when they are in cells and a RNA genome when they are virions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpinyJgw88blbVg90H21EOLACvtfcHk0lgW6dSkOd94ig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE3cXkvVCru70%253D&md5=cb9fb0bce2dfea6e8f060d953c2a1493</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1038%2F2261211a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F2261211a0%26sid%3Dliteratum%253Aachs%26aulast%3DTemin%26aufirst%3DH.%26aulast%3DMizutani%26aufirst%3DS.%26atitle%3DRNA-dependent%2520DNA%2520polymerase%2520in%2520virions%2520of%2520Rous%2520sarcoma%2520virus%26jtitle%3DNature%26date%3D1970%26volume%3D226%26spage%3D1211%26epage%3D1213%26doi%3D10.1038%2F2261211a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baltimore, D.</span></span> <span> </span><span class="NLM_article-title">RNA-dependent DNA polymerase in virions of RNA tumour viruses</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1970</span>,  <span class="NLM_volume"><i>226</i></span>,  <span class="NLM_fpage">1209</span>– <span class="NLM_lpage">1211</span>, <span class="refDoi"> DOI: 10.1038/2261209a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1038%2F2261209a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=4316300" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADyaE3cXkvVCru7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=226&publication_year=1970&pages=1209-1211&author=D.+Baltimore&title=RNA-dependent+DNA+polymerase+in+virions+of+RNA+tumour+viruses&doi=10.1038%2F2261209a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Viral RNA-dependent DNA polymerase</span></div><div class="casAuthors">Baltimore, David</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">1970</span>),
    <span class="NLM_cas:volume">226</span>
        (<span class="NLM_cas:issue">5252</span>),
    <span class="NLM_cas:pages">1209-11</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    </div><div class="casAbstract">A RNA-dependent DNA polymerase was present in the virions of 2 RNA tumor viruses, Rauscher mouse leukemia virus and Rous sarcoma virus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyV2nIllstQbVg90H21EOLACvtfcHk0liGajNCZPbSVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE3cXkvVCru7o%253D&md5=043600fe8afa5bf080e8528d595e3874</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1038%2F2261209a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F2261209a0%26sid%3Dliteratum%253Aachs%26aulast%3DBaltimore%26aufirst%3DD.%26atitle%3DRNA-dependent%2520DNA%2520polymerase%2520in%2520virions%2520of%2520RNA%2520tumour%2520viruses%26jtitle%3DNature%26date%3D1970%26volume%3D226%26spage%3D1209%26epage%3D1211%26doi%3D10.1038%2F2261209a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span> <span> </span><span class="NLM_article-title">Suramin: a potent inhibitor of the reverse transcriptase of RNA tumor viruses</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">1979</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">9</span>– <span class="NLM_lpage">22</span>, <span class="refDoi"> DOI: 10.1016/0304-3835(79)90017-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1016%2F0304-3835%2879%2990017-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=92362" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADyaL3cXjtl2gsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=1979&pages=9-22&author=E.+De+Clercq&title=Suramin%3A+a+potent+inhibitor+of+the+reverse+transcriptase+of+RNA+tumor+viruses&doi=10.1016%2F0304-3835%2879%2990017-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Suramin:  a potent inhibitor of the reverse transcriptase of RNA tumor viruses</span></div><div class="casAuthors">De Clercq, Erik</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (Shannon, Ireland)</span>
        (<span class="NLM_cas:date">1979</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">9-22</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    </div><div class="casAbstract">Moranyl (suramin hexasodium)(I)  [129-46-4] exerted a strong inhibitory effect on the RNA-directed DNA polymerase (reverse transcriptase)  [9012-90-2] activity of several oncornaviruses such as Moloney murine leukemia virus, murine Rauscher leukemia viruses, Moloney murine sarcoma virus and avian myeloblastosis virus.  Inhibition of enzyme activity was obtained with both endogenous viral RNA and (A)n · oligo(dT) as the template primer.  I effected a 50% inhibition of the reverse transcriptase activity of oncornaviruses at a concn. range of 0.1-1 μg/mL.  In this aspect I compared favorably to ethidium bromide, another trypanocide drug which is considered as one of the most powerful inhibitors of oncornavirus DNA polymerases.  The inhibition of reverse transcriptase activity by I was competitive with the template-primer, (A)n · oligo(dT), suggesting that the drug may interact with the template-primer binding site of the enzyme.  The possibility of I being an antitumor agent is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofyfy4FtJC6rVg90H21EOLACvtfcHk0liGajNCZPbSVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3cXjtl2gsg%253D%253D&md5=3d0cf6a877be7a2a910081415791f0c7</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2F0304-3835%2879%2990017-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0304-3835%252879%252990017-X%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BClercq%26aufirst%3DE.%26atitle%3DSuramin%253A%2520a%2520potent%2520inhibitor%2520of%2520the%2520reverse%2520transcriptase%2520of%2520RNA%2520tumor%2520viruses%26jtitle%3DCancer%2520Lett.%26date%3D1979%26volume%3D8%26spage%3D9%26epage%3D22%26doi%3D10.1016%2F0304-3835%2879%2990017-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mitsuya, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Popovic, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yarchoan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsushita, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broder, S.</span></span> <span> </span><span class="NLM_article-title">Suramin protection of T cells in vitro against infectivity and cytopathic effect of HTLV-III</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1984</span>,  <span class="NLM_volume"><i>226</i></span>,  <span class="NLM_fpage">172</span>– <span class="NLM_lpage">174</span>, <span class="refDoi"> DOI: 10.1126/science.6091268</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1126%2Fscience.6091268" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=6091268" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADyaL2cXmtVeqtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=226&publication_year=1984&pages=172-174&author=H.+Mitsuyaauthor=M.+Popovicauthor=R.+Yarchoanauthor=S.+Matsushitaauthor=R.+Galloauthor=S.+Broder&title=Suramin+protection+of+T+cells+in+vitro+against+infectivity+and+cytopathic+effect+of+HTLV-III&doi=10.1126%2Fscience.6091268"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Suramin protection of T cells in vitro against infectivity and cytopathic effect of HTLV-III</span></div><div class="casAuthors">Mitsuya, Hiroaki; Popovic, Mikulas; Yarchoan, Robert; Matsushita, Shuzo; Gallo, Robert C.; Broder, Samuel</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">1984</span>),
    <span class="NLM_cas:volume">226</span>
        (<span class="NLM_cas:issue">4671</span>),
    <span class="NLM_cas:pages">172-4</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    </div><div class="casAbstract">A recently discovered member of the human T-cell leukemia virus (HTLV) family of retroviruses has been etiol. linked to the acquired immune deficiency syndrome (AIDS).  This virus, which has been designated HTLV-III, is tropic for OKT4-bearing (helper-inducer) T cells.  Moreover, the virus is cytopathic for these cells.  Suramin  [145-63-1] is a drug used in the therapy of Rhodesian trypanosomiasis and onchocerciasis, and it is known to inhibit the reverse transcriptase of a no. of retroviruses.  Suramin has now been found to block in vitro the infectivity and cytopathic effect of HTLV-III at concns. that are clin. attainable in human beings.  The possible use of suramin in the treatment of AIDS is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWci4wMb_TXrVg90H21EOLACvtfcHk0liGajNCZPbSVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2cXmtVeqtrs%253D&md5=e6ac09c4226b01f517940421695584de</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1126%2Fscience.6091268&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.6091268%26sid%3Dliteratum%253Aachs%26aulast%3DMitsuya%26aufirst%3DH.%26aulast%3DPopovic%26aufirst%3DM.%26aulast%3DYarchoan%26aufirst%3DR.%26aulast%3DMatsushita%26aufirst%3DS.%26aulast%3DGallo%26aufirst%3DR.%26aulast%3DBroder%26aufirst%3DS.%26atitle%3DSuramin%2520protection%2520of%2520T%2520cells%2520in%2520vitro%2520against%2520infectivity%2520and%2520cytopathic%2520effect%2520of%2520HTLV-III%26jtitle%3DScience%26date%3D1984%26volume%3D226%26spage%3D172%26epage%3D174%26doi%3D10.1126%2Fscience.6091268" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Broder, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Markham, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Redfield, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoth, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groopman, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallo, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yarchoan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clifford
Lane, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klecker, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitsuya, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelmann, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Resnick, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myers, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fauci, A. S.</span></span> <span> </span><span class="NLM_article-title">Effects of suramin on HTLV-III/LAV infection presenting as Kaposi’s sarcoma or AIDS-related complex: clinical pharmacology and suppression of virus replication <i>in vivo</i></span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">1985</span>,  <span class="NLM_volume"><i>326</i></span>,  <span class="NLM_fpage">627</span>– <span class="NLM_lpage">630</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(85)90002-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1016%2FS0140-6736%2885%2990002-9" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=326&publication_year=1985&pages=627-630&author=S.+Broderauthor=J.+M.+Collinsauthor=P.+D.+Markhamauthor=R.+R.+Redfieldauthor=D.+F.+Hothauthor=J.+E.+Groopmanauthor=R.+C.+Galloauthor=R.+Yarchoanauthor=H.+Clifford%0ALaneauthor=R.+W.+Kleckerauthor=H.+Mitsuyaauthor=E.+Gelmannauthor=L.+Resnickauthor=C.+E.+Myersauthor=A.+S.+Fauci&title=Effects+of+suramin+on+HTLV-III%2FLAV+infection+presenting+as+Kaposi%E2%80%99s+sarcoma+or+AIDS-related+complex%3A+clinical+pharmacology+and+suppression+of+virus+replication+in+vivo&doi=10.1016%2FS0140-6736%2885%2990002-9"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2885%2990002-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252885%252990002-9%26sid%3Dliteratum%253Aachs%26aulast%3DBroder%26aufirst%3DS.%26aulast%3DCollins%26aufirst%3DJ.%2BM.%26aulast%3DMarkham%26aufirst%3DP.%2BD.%26aulast%3DRedfield%26aufirst%3DR.%2BR.%26aulast%3DHoth%26aufirst%3DD.%2BF.%26aulast%3DGroopman%26aufirst%3DJ.%2BE.%26aulast%3DGallo%26aufirst%3DR.%2BC.%26aulast%3DYarchoan%26aufirst%3DR.%26aulast%3DClifford%2BLane%26aufirst%3DH.%26aulast%3DKlecker%26aufirst%3DR.%2BW.%26aulast%3DMitsuya%26aufirst%3DH.%26aulast%3DGelmann%26aufirst%3DE.%26aulast%3DResnick%26aufirst%3DL.%26aulast%3DMyers%26aufirst%3DC.%2BE.%26aulast%3DFauci%26aufirst%3DA.%2BS.%26atitle%3DEffects%2520of%2520suramin%2520on%2520HTLV-III%252FLAV%2520infection%2520presenting%2520as%2520Kaposi%25E2%2580%2599s%2520sarcoma%2520or%2520AIDS-related%2520complex%253A%2520clinical%2520pharmacology%2520and%2520suppression%2520of%2520virus%2520replication%2520in%2520vivo%26jtitle%3DLancet%26date%3D1985%26volume%3D326%26spage%3D627%26epage%3D630%26doi%3D10.1016%2FS0140-6736%2885%2990002-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mitsuya, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinhold, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furman, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">St Clair, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehrman, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallo, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolognesi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barry, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broder, S.</span></span> <span> </span><span class="NLM_article-title">3′-Azido-3′-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1985</span>,  <span class="NLM_volume"><i>82</i></span>,  <span class="NLM_fpage">7096</span>– <span class="NLM_lpage">7100</span>, <span class="refDoi"> DOI: 10.1073/pnas.82.20.7096</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1073%2Fpnas.82.20.7096" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=2413459" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADyaL2MXlvV2htbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=1985&pages=7096-7100&author=H.+Mitsuyaauthor=K.+J.+Weinholdauthor=P.+A.+Furmanauthor=M.+H.+St+Clairauthor=S.+N.+Lehrmanauthor=R.+C.+Galloauthor=D.+Bolognesiauthor=D.+W.+Barryauthor=S.+Broder&title=3%E2%80%B2-Azido-3%E2%80%B2-deoxythymidine+%28BW+A509U%29%3A+an+antiviral+agent+that+inhibits+the+infectivity+and+cytopathic+effect+of+human+T-lymphotropic+virus+type+III%2Flymphadenopathy-associated+virus+in+vitro&doi=10.1073%2Fpnas.82.20.7096"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">3'-Azido-3'-deoxythymidine (BW A509U):  an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro</span></div><div class="casAuthors">Mitsuya, Hiroaki; Weinhold, Kent J.; Furman, Phillip A.; St. Clair, Marty H.; Lehrman, Sandra Nusinoff; Gallo, Robert C.; Bolognesi, Dani; Barry, David W.; Broder, Samuel</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1985</span>),
    <span class="NLM_cas:volume">82</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">7096-100</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    </div><div class="casAbstract">The antiviral effects of a thymidine analog, 3'-azido-3'-deoxythymidine (BW A509U)(I)  [30516-87-1], which, as a triphosphate, inhibits the reverse transcriptase of human T-lymphotropic virus type III (HTLV-III)/lymphadenopathy-assocd. virus (LAV) was detd.  This agent blocked the expression of the p24 gag protein of HTLV-III/LAV in H9 cells following exposure to virus.  The drug also inhibited the cytopathic effect of HTLV-IIIB (a virus derived from a pool of American patients) and HTLV-III/RF-II (an isolate obtained from a Haitian patient that differs by about 20% in the amino acid sequence of the envelope gene from several isolates of HTLV-III/LAV, including HTLV-IIIB, analyzed so far).  3'-Azido-3'-deoxythymidine also completely blocked viral replication as assessed by reverse transcriptase prodn. in normal human peripheral blood mononuclear cells exposed to HTLV-III.  Finally, at concns. of 3'-azido-3'-deoxythymidine that block the in vitro infectively and cytopathic effect of HTLV-IIIB, the in vitro immune functions of normal T cells remain basically intact.  These results are relevant to the treatment of AIDS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6ef2jfFgGQbVg90H21EOLACvtfcHk0lhWUl_vKvkrhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2MXlvV2htbk%253D&md5=f56aaaed3c081c9a393e5fa8893f769c</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1073%2Fpnas.82.20.7096&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.82.20.7096%26sid%3Dliteratum%253Aachs%26aulast%3DMitsuya%26aufirst%3DH.%26aulast%3DWeinhold%26aufirst%3DK.%2BJ.%26aulast%3DFurman%26aufirst%3DP.%2BA.%26aulast%3DSt%2BClair%26aufirst%3DM.%2BH.%26aulast%3DLehrman%26aufirst%3DS.%2BN.%26aulast%3DGallo%26aufirst%3DR.%2BC.%26aulast%3DBolognesi%26aufirst%3DD.%26aulast%3DBarry%26aufirst%3DD.%2BW.%26aulast%3DBroder%26aufirst%3DS.%26atitle%3D3%25E2%2580%25B2-Azido-3%25E2%2580%25B2-deoxythymidine%2520%2528BW%2520A509U%2529%253A%2520an%2520antiviral%2520agent%2520that%2520inhibits%2520the%2520infectivity%2520and%2520cytopathic%2520effect%2520of%2520human%2520T-lymphotropic%2520virus%2520type%2520III%252Flymphadenopathy-associated%2520virus%2520in%2520vitro%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1985%26volume%3D82%26spage%3D7096%26epage%3D7100%26doi%3D10.1073%2Fpnas.82.20.7096" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balzarini, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Descamps, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eckstein, F.</span></span> <span> </span><span class="NLM_article-title">Antiviral, antimetabolic and antineoplastic activities of 2′- or 3′-amino or -azido-substituted deoxyribonucleosides</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1980</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">1849</span>– <span class="NLM_lpage">1851</span>, <span class="refDoi"> DOI: 10.1016/0006-2952(80)90149-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1016%2F0006-2952%2880%2990149-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=7406907" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADyaL3cXmtFGhtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=1980&pages=1849-1851&author=E.+De+Clercqauthor=J.+Balzariniauthor=J.+Descampsauthor=F.+Eckstein&title=Antiviral%2C+antimetabolic+and+antineoplastic+activities+of+2%E2%80%B2-+or+3%E2%80%B2-amino+or+-azido-substituted+deoxyribonucleosides&doi=10.1016%2F0006-2952%2880%2990149-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Antiviral, antimetabolic, antineoplastic activities of 2'- or 3'-amino or -azido-substituted deoxyribonucleosides</span></div><div class="casAuthors">De Clercq, Erik; Balzarini, Jan; Descamps, Johan; Eckstein, Fritz</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology</span>
        (<span class="NLM_cas:date">1980</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1849-51</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    </div><div class="casAbstract">None of the nucleoside analogs tested inhibited herpes simplex virus or vesicular stomatitis virus replication in primary rabbit kidney cell culture, but vaccinia virus replication was inhibited by several compds. at 4 μg/mL; cytotoxicity was obsd. at 40 μg/mL.  3'-Azido-3'-deoxyaraadenosine  [29411-70-9] was effective at 20 μg/mL and not cytotoxic at 200 μg/mL, but generally antiviral activity correlated with cytotoxicity.  Thus, antiviral activity was probably mediated via host cell DNA formation inhibition.  L1210 cell growth was inhibited specifically by 3'-amino-2',3'-dideoxyadenosine  [7403-25-0], 3'-azido-2',3'-dideoxyguanosine  [66323-46-4], and 2'-amino-2'-deoxyguanosine  [60966-26-9].</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoetUIei8s0o7Vg90H21EOLACvtfcHk0lhWUl_vKvkrhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3cXmtFGhtLg%253D&md5=c6ba754f83e2476edd2d2b7beaba93ab</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2F0006-2952%2880%2990149-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0006-2952%252880%252990149-5%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BClercq%26aufirst%3DE.%26aulast%3DBalzarini%26aufirst%3DJ.%26aulast%3DDescamps%26aufirst%3DJ.%26aulast%3DEckstein%26aufirst%3DF.%26atitle%3DAntiviral%252C%2520antimetabolic%2520and%2520antineoplastic%2520activities%2520of%25202%25E2%2580%25B2-%2520or%25203%25E2%2580%25B2-amino%2520or%2520-azido-substituted%2520deoxyribonucleosides%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D1980%26volume%3D29%26spage%3D1849%26epage%3D1851%26doi%3D10.1016%2F0006-2952%2880%2990149-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Furman, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fyfe, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">St Clair, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinhold, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rideout, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freeman, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehrman, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolognesi, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broder, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitsuya, H.</span></span> <span> </span><span class="NLM_article-title">Phosphorylation of 3′-azido-3′-deoxythymidine and selective interaction of the 5′-triphosphate with human immunodeficiency virus reverse transcriptase</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1986</span>,  <span class="NLM_volume"><i>83</i></span>,  <span class="NLM_fpage">8333</span>– <span class="NLM_lpage">8337</span>, <span class="refDoi"> DOI: 10.1073/pnas.83.21.8333</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1073%2Fpnas.83.21.8333" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=2430286" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADyaL2sXktlCqug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=1986&pages=8333-8337&author=P.+A.+Furmanauthor=J.+A.+Fyfeauthor=M.+H.+St+Clairauthor=K.+Weinholdauthor=J.+L.+Rideoutauthor=G.+A.+Freemanauthor=S.+N.+Lehrmanauthor=D.+P.+Bolognesiauthor=S.+Broderauthor=H.+Mitsuya&title=Phosphorylation+of+3%E2%80%B2-azido-3%E2%80%B2-deoxythymidine+and+selective+interaction+of+the+5%E2%80%B2-triphosphate+with+human+immunodeficiency+virus+reverse+transcriptase&doi=10.1073%2Fpnas.83.21.8333"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase</span></div><div class="casAuthors">Furman, Phillip A.; Fyfe, James A.; St. Clair, Marty H.; Weinhold, Kent; Rideout, Janet L.; Freeman, George A.; Lehrman, Sandra Nusinoff; Bolognesi, Dani P.; Broder, Samuel; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1986</span>),
    <span class="NLM_cas:volume">83</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">8333-7</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    </div><div class="casAbstract">The thymidine analog 3'-azido-3'-deoxythymidine (azidothymidine)  [30516-87-1] was previously shown to inhibit human immunodeficiency virus (HIV) replication effectively in the 50-500 nM range.  In contrast, inhibition of the growth of uninfected human fibroblasts and lymphocytes was obsd. only at concns. above 1 mM.  The nature of this selectivity was investigated.  Azidothymidine anabolism to the 5'-mono-  [29706-85-2], -di-  [106060-89-3], and -triphosphate  [92586-35-1] derivs. was similar in uninfected and HIV-infected cells.  The level of azidothymidine monophosphate was high, whereas the levels of the di- and triphosphate were low (≤5 μM and ≤2 μM, resp.).  Cytosolic thymidine kinase (EC 2.7.1.21)  [9002-06-6] was responsible for phosphorylation of azidothymidine to its monophosphate.  Purified thymidine kinase catalyzed the phosphorylations of thymidine  [50-89-5] and azidothymidine with apparent Km values of 2.9 μM and 3.0 μM.  The maximal rate of phosphorylation with azidothymidine was equal to 60% of the rate with thymidine.  Phosphorylation of azidothymidine monophosphate to the diphosphate also appeared to be catalyzed by a host-cell enzyme, thymidylate kinase (EC 2.7.4.9)  [9014-43-1].  The apparent Km value for azidothymidine monophosphate was 2-fold greater than the value for dTMP  [365-07-1] (8.6 μM vs. 4.1 μM), but the maximal phosphorylation rate was only 0.3% of the dTMP rate.  These kinetic consts. were consistent with the anabolism results and indicated that azidothymidine monophosphate is an alternative-substrate inhibitor of thymidylate kinase.  This conclusion was reflected in the observation that cell incubated with azidothymidine had reduced intracellular levels of dTTP  [365-08-2].  IC50 (concn. of inhibitor that inhibits enzyme activity 50%) values were detd. for azidothymidine triphosphate with reverse transcriptase  [9068-38-6] and with immortalized human lymphocyte (H9 cell) DNA polymerase  [9012-90-2] α .  Azidothymidine triphosphate competed about 100-fold better for the HIV reverse transcriptase than for the cellular DNA polymerase α.  These results suggest that azidothymidine is nonselectively phosphorylated but that the triphosphate deriv. efficiently and selectively binds to the HIV reverse transcriptase.  Incorporation of azidothymidylate into a growing DNA strand should terminate DNA elongation and thus inhibit DNA synthesis.  These results may have relevance to the antiviral action mechanism for azidothymidine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1_5UurNpyQrVg90H21EOLACvtfcHk0lhNp_ttiKICnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2sXktlCqug%253D%253D&md5=2dcdd98db3c5708b2c31058cc47eeb41</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1073%2Fpnas.83.21.8333&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.83.21.8333%26sid%3Dliteratum%253Aachs%26aulast%3DFurman%26aufirst%3DP.%2BA.%26aulast%3DFyfe%26aufirst%3DJ.%2BA.%26aulast%3DSt%2BClair%26aufirst%3DM.%2BH.%26aulast%3DWeinhold%26aufirst%3DK.%26aulast%3DRideout%26aufirst%3DJ.%2BL.%26aulast%3DFreeman%26aufirst%3DG.%2BA.%26aulast%3DLehrman%26aufirst%3DS.%2BN.%26aulast%3DBolognesi%26aufirst%3DD.%2BP.%26aulast%3DBroder%26aufirst%3DS.%26aulast%3DMitsuya%26aufirst%3DH.%26atitle%3DPhosphorylation%2520of%25203%25E2%2580%25B2-azido-3%25E2%2580%25B2-deoxythymidine%2520and%2520selective%2520interaction%2520of%2520the%25205%25E2%2580%25B2-triphosphate%2520with%2520human%2520immunodeficiency%2520virus%2520reverse%2520transcriptase%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1986%26volume%3D83%26spage%3D8333%26epage%3D8337%26doi%3D10.1073%2Fpnas.83.21.8333" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Descamps, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Somer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holý, A.</span></span> <span> </span><span class="NLM_article-title">(S)-9-(2,3-dihydroxypropyl)adenine: an aliphatic nucleoside analog with broad-spectrum antiviral activity</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1978</span>,  <span class="NLM_volume"><i>200</i></span>,  <span class="NLM_fpage">563</span>– <span class="NLM_lpage">565</span>, <span class="refDoi"> DOI: 10.1126/science.200.4341.563</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1126%2Fscience.200.4341.563" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=17839440" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADyaE1cXkvF2qtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=200&publication_year=1978&pages=563-565&author=E.+De+Clercqauthor=J.+Descampsauthor=P.+De+Somerauthor=A.+Hol%C3%BD&title=%28S%29-9-%282%2C3-dihydroxypropyl%29adenine%3A+an+aliphatic+nucleoside+analog+with+broad-spectrum+antiviral+activity&doi=10.1126%2Fscience.200.4341.563"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">(S)-9-(2,3-Dihydroxypropyl)adenine:  an aliphatic nucleoside analog with broad-spectrum antiviral activity</span></div><div class="casAuthors">De Clercq, Erik; Descamps, Johan; De Somer, Pierre; Holy, Antonin</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">1978</span>),
    <span class="NLM_cas:volume">200</span>
        (<span class="NLM_cas:issue">4341</span>),
    <span class="NLM_cas:pages">563-5</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    </div><div class="casAbstract">(S)-9-(2,3-Dihydroxypropyl)adenine (I)  [54262-83-8], a novel nucleoside analog, the sugar moiety of which is replaced by an aliph. chain, inhibited the replication in vitro of several DNA and RNA viruses, including vaccinia, herpes simplex (types 1 and 2), measles, and vesicular stomatitis.  It was also effective in vivo in reducing the mortality rate of mice inoculated intranasally with vesicular stomatitis virus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkW_-BORiddbVg90H21EOLACvtfcHk0lhNp_ttiKICnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE1cXkvF2qtbk%253D&md5=fdeb3a0d1bf06684d4fd995f6879fae2</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1126%2Fscience.200.4341.563&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.200.4341.563%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BClercq%26aufirst%3DE.%26aulast%3DDescamps%26aufirst%3DJ.%26aulast%3DDe%2BSomer%26aufirst%3DP.%26aulast%3DHol%25C3%25BD%26aufirst%3DA.%26atitle%3D%2528S%2529-9-%25282%252C3-dihydroxypropyl%2529adenine%253A%2520an%2520aliphatic%2520nucleoside%2520analog%2520with%2520broad-spectrum%2520antiviral%2520activity%26jtitle%3DScience%26date%3D1978%26volume%3D200%26spage%3D563%26epage%3D565%26doi%3D10.1126%2Fscience.200.4341.563" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schaeffer, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beauchamp, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Miranda, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elion, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, P.</span></span> <span> </span><span class="NLM_article-title">9-(2-Hydroxyethoxymethyl)guanine activity against viruses of the herpes group</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1978</span>,  <span class="NLM_volume"><i>272</i></span>,  <span class="NLM_fpage">583</span>– <span class="NLM_lpage">585</span>, <span class="refDoi"> DOI: 10.1038/272583a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1038%2F272583a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=205792" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADyaE1cXltVSjsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=272&publication_year=1978&pages=583-585&author=H.+Schaefferauthor=L.+Beauchampauthor=P.+De+Mirandaauthor=G.+Elionauthor=D.+Bauerauthor=P.+Collins&title=9-%282-Hydroxyethoxymethyl%29guanine+activity+against+viruses+of+the+herpes+group&doi=10.1038%2F272583a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">9-(2-Hydroxyethoxymethyl)guanine activity against viruses of the herpes group</span></div><div class="casAuthors">Schaeffer, H. J.; Beauchamp, Lilia; De Miranda, P.; Elion, Gertrude B.; Bauer, D. J.; Collins, P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">1978</span>),
    <span class="NLM_cas:volume">272</span>
        (<span class="NLM_cas:issue">5654</span>),
    <span class="NLM_cas:pages">583-5</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    </div><div class="casAbstract">Of a series of nucleoside analogs synthesized, 9-(2-hydroxyethoxymethyl)guanine (I)  [59277-89-3] had marked antiviral activity with low toxicity in animal models of herpes virus infections.  In mice the oral and i.p. LD50 values for I were >10,000 and 1000 mg/kg, resp.; no toxicity was obsd. in mice given oral I (450 mg/kg) daily for 30 days.  In mice given I, 14C-labeled at the 8-position of the guanine nucleus, 82 and 94% of label was excreted in urine by 4 and 24 h, resp., essentially as unmetabolized I.  No appreciable I binding to plasma or tissues was obsd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3OmyVfempg7Vg90H21EOLACvtfcHk0lhNp_ttiKICnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE1cXltVSjsr0%253D&md5=383b527f72528e860c4b21f2fdb7fccd</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1038%2F272583a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F272583a0%26sid%3Dliteratum%253Aachs%26aulast%3DSchaeffer%26aufirst%3DH.%26aulast%3DBeauchamp%26aufirst%3DL.%26aulast%3DDe%2BMiranda%26aufirst%3DP.%26aulast%3DElion%26aufirst%3DG.%26aulast%3DBauer%26aufirst%3DD.%26aulast%3DCollins%26aufirst%3DP.%26atitle%3D9-%25282-Hydroxyethoxymethyl%2529guanine%2520activity%2520against%2520viruses%2520of%2520the%2520herpes%2520group%26jtitle%3DNature%26date%3D1978%26volume%3D272%26spage%3D583%26epage%3D585%26doi%3D10.1038%2F272583a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Elion, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furman, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fyfe, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Miranda, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beauchamp, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaeffer, H. J.</span></span> <span> </span><span class="NLM_article-title">Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl)guanine</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1977</span>,  <span class="NLM_volume"><i>74</i></span>,  <span class="NLM_fpage">5716</span>– <span class="NLM_lpage">5720</span>, <span class="refDoi"> DOI: 10.1073/pnas.74.12.5716</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1073%2Fpnas.74.12.5716" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=202961" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADyaE1cXhvVanurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=1977&pages=5716-5720&author=G.+B.+Elionauthor=P.+A.+Furmanauthor=J.+A.+Fyfeauthor=P.+de+Mirandaauthor=L.+Beauchampauthor=H.+J.+Schaeffer&title=Selectivity+of+action+of+an+antiherpetic+agent%2C+9-%282-hydroxyethoxymethyl%29guanine&doi=10.1073%2Fpnas.74.12.5716"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl)guanine</span></div><div class="casAuthors">Elion, Gertrude B.; Furman, Phillip A.; Fyfe, James A.; De Miranda, Paulo; Beauchamp, Lilia; Schaeffer, Howard J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1977</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5716-20</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    </div><div class="casAbstract">Acycloguanosine (I)  [59277-89-3] had potent antiviral activity (ED50 = 0.1 μM) against herpes simplex virus type I.  I was converted to a monophosphate  [66341-16-0] by a virus-specified thymidine kinase  [9002-06-6] and was subsequently converted to I di-  [66341-17-1] and I triphosphates  [66341-18-2].  In the uninfected host cell (Vero), these phosphorylations of I occurred at only a very limited extent.  I triphosphate inhibited herpes simplex virus DNA nucleotidyltransferase  [9012-90-2] 10-30 times more effectively than cellular (HeLa S3) DNA nucleotidyltransferase.  These factors contribute to I selectivity; inhibition of growth of the host cell requires a 3000-fold greater concn. of drug than does the inhibition of viral multiplication.  The identify of the kinase that phosphorylates I was detd. after sepn. of the cellular and virus-specified thymidine kinase activities by affinity chromatog., by reversal studies with thymidine, and by the lack of monophosphate formation in a temp.-sensitive, thymidine kinase-deficient mutant of the KOS strain of herpes simplex virus type 1 (tsA1).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4WWPCnssW2bVg90H21EOLACvtfcHk0lhNp_ttiKICnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE1cXhvVanurw%253D&md5=ed4071cc91116c4f97715e203614b005</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1073%2Fpnas.74.12.5716&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.74.12.5716%26sid%3Dliteratum%253Aachs%26aulast%3DElion%26aufirst%3DG.%2BB.%26aulast%3DFurman%26aufirst%3DP.%2BA.%26aulast%3DFyfe%26aufirst%3DJ.%2BA.%26aulast%3Dde%2BMiranda%26aufirst%3DP.%26aulast%3DBeauchamp%26aufirst%3DL.%26aulast%3DSchaeffer%26aufirst%3DH.%2BJ.%26atitle%3DSelectivity%2520of%2520action%2520of%2520an%2520antiherpetic%2520agent%252C%25209-%25282-hydroxyethoxymethyl%2529guanine%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1977%26volume%3D74%26spage%3D5716%26epage%3D5720%26doi%3D10.1073%2Fpnas.74.12.5716" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span> <span> </span><span class="NLM_article-title"><i>S</i>-Adenosylhomocysteine hydrolase inhibitors as broad-spectrum antiviral agents</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1987</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">2567</span>– <span class="NLM_lpage">2575</span>, <span class="refDoi"> DOI: 10.1016/0006-2952(87)90533-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1016%2F0006-2952%2887%2990533-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=3300656" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADyaL2sXltVylurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=1987&pages=2567-2575&author=E.+De+Clercq&title=S-Adenosylhomocysteine+hydrolase+inhibitors+as+broad-spectrum+antiviral+agents&doi=10.1016%2F0006-2952%2887%2990533-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">S-Adenosylhomocysteine hydrolase inhibitors as broad-spectrum antiviral agents</span></div><div class="casAuthors">De Clercq, Erik</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology</span>
        (<span class="NLM_cas:date">1987</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">2567-75</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    </div><div class="casAbstract">A review with 99 refs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9PnsyZJUH4bVg90H21EOLACvtfcHk0lgJCJAwAJB2yQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2sXltVylurs%253D&md5=52d6b2b153b1757d03d6ea98836fccb5</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2F0006-2952%2887%2990533-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0006-2952%252887%252990533-8%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BClercq%26aufirst%3DE.%26atitle%3DS-Adenosylhomocysteine%2520hydrolase%2520inhibitors%2520as%2520broad-spectrum%2520antiviral%2520agents%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D1987%26volume%3D36%26spage%3D2567%26epage%3D2575%26doi%3D10.1016%2F0006-2952%2887%2990533-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span> <span> </span><span class="NLM_article-title">John Montgomery’s Legacy: Carbocyclic adenosine analogues as SAH hydrolase inhibitors with broad-spectrum antiviral activity</span>. <i>Nucleosides, Nucleotides Nucleic Acids</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">1395</span>– <span class="NLM_lpage">1415</span>, <span class="refDoi"> DOI: 10.1080/15257770500265638</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1080%2F15257770500265638" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=16438025" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlakt7jL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2005&pages=1395-1415&author=E.+De+Clercq&title=John+Montgomery%E2%80%99s+Legacy%3A+Carbocyclic+adenosine+analogues+as+SAH+hydrolase+inhibitors+with+broad-spectrum+antiviral+activity&doi=10.1080%2F15257770500265638"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">John Montgomery's Legacy: Carbocyclic Adenosine Analogues as Sah Hydrolase Inhibitors with Broad-Spectrum Antiviral Activity</span></div><div class="casAuthors">De Clercq, E.</div><div class="citationInfo"><span class="NLM_cas:title">Nucleosides, Nucleotides & Nucleic Acids</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">10-12</span>),
    <span class="NLM_cas:pages">1395-1415</span>CODEN:
                <span class="NLM_cas:coden">NNNAFY</span>;
        ISSN:<span class="NLM_cas:issn">1525-7770</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis, Inc.</span>)
        </div><div class="casAbstract">A review.  Ever since the S-adenosylhomocysteine (AdoHcy, SAH) hydrolase was recognized as a pharmacol. target for antiviral agents (J. A. Montgomery et al., J. Med. Chem. 25:626-629, 1982), an increasing no. of adenosine, acyclic adenosine, and carbocyclic adenosine analogs have been described as potent SAH hydrolase inhibitors endowed with broad-spectrum antiviral activity.  The antiviral activity spectrum of the SAH hydrolase inhibitors include pox-, rhabdo-, filo-, arena-, paramyxo-, reo-, and retroviruses.  Among the most potent SAH hydrolase inhibitors and antiviral agents rank carbocyclic 3-deazaadenosine (C-c3 Ado), neplanocin A, 3-deazaneplanocin A, the 5'-nor derivs. of carbocyclic adenosine (C-Ado, aristeromycin), and the 2-halo (i.e., 2-fluoro) and 6'-R-alkyl (i.e., 6'-R-methyl) derivs. of neplanocin A.  These compds. are particularly active against poxviruses (i.e., vaccinia virus), and rhabdoviruses (i.e., vesicular stomatitis virus).  The in vivo efficacy of C-c3 Ado and 3-deazaneplanocin A has been established in mouse models for vaccinia virus, vesicular stomatitis virus, and Ebola virus.  SAH hydrolase inhibitors such as C-c3 Ado and 3-deazaneplanocin A should in the first place be considered for therapeutic (or prophylactic) use against poxvirus infections, including smallpox, and hemorrhagic fever virus infections such as Ebola.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmm33arKaCVLVg90H21EOLACvtfcHk0lgJCJAwAJB2yQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlakt7jL&md5=342541d1bd112f9ee6f1b04faddd2958</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1080%2F15257770500265638&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F15257770500265638%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BClercq%26aufirst%3DE.%26atitle%3DJohn%2520Montgomery%25E2%2580%2599s%2520Legacy%253A%2520Carbocyclic%2520adenosine%2520analogues%2520as%2520SAH%2520hydrolase%2520inhibitors%2520with%2520broad-spectrum%2520antiviral%2520activity%26jtitle%3DNucleosides%252C%2520Nucleotides%2520Nucleic%2520Acids%26date%3D2005%26volume%3D24%26spage%3D1395%26epage%3D1415%26doi%3D10.1080%2F15257770500265638" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Montgomery, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clayton, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shannon, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnett, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bodner, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kion, I. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantoni, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiang, P.</span></span> <span> </span><span class="NLM_article-title">Carbocyclic analogue of 3-deazaadenosine: A novel antiviral agent using S-adenosylhomocysteine hydrolase as a pharmacological target</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1982</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">626</span>– <span class="NLM_lpage">629</span>, <span class="refDoi"> DOI: 10.1021/jm00348a004</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00348a004" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADyaL38XhvFaqtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=1982&pages=626-629&author=J.+Montgomeryauthor=S.+Claytonauthor=H.+Thomasauthor=W.+Shannonauthor=G.+Arnettauthor=A.+Bodnerauthor=I.+K.+Kionauthor=G.+L.+Cantoniauthor=P.+Chiang&title=Carbocyclic+analogue+of+3-deazaadenosine%3A+A+novel+antiviral+agent+using+S-adenosylhomocysteine+hydrolase+as+a+pharmacological+target&doi=10.1021%2Fjm00348a004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Carbocyclic analog of 3-deazaadenosine:  a novel antiviral agent using S-adenosylhomocysteine hydrolase as a pharmacological target</span></div><div class="casAuthors">Montgomery, John A.; Clayton, Sarah J.; Thomas, H. Jeanette; Shannon, William M.; Arnett, Gussie; Bodner, Anne J.; Kion, In Kyung; Cantoni, Giulio L.; Chiang, Peter K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1982</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">626-9</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    </div><div class="casAbstract">The carbocyclic analog of 3-deazaadenosine (3-deaza-C-Ado)(I)  [81601-33-4] has been synthesized and found to have antiviral activity in cell culture against herpes simplex virus type 1, vaccinia virus, and HL-23 C-type virus.  It is relatively noncytotoxic at effective antiviral concns. and is not subject to deamination or phosphorylation.  It acts as a competitive inhibitor of S-adenosyl-L-homocysteine hydrolase  [9025-54-1], is at best a poor substrate, and does not inactivate the enzyme significantly.  3-Deaza-C-Ado may cause a selective inhibition of the methylation of the polynucleotide 5' cap of viral mRNA via the higher cellular concns. of S-adenosyl-L-homocysteine resulting from the inhibition of S-adenosylhomocysteine hydrolase in infected cells, since increases in the intracellular level of S-adenosylhomocysteine, but no effects on DNA or RNA synthesis, were obsd. after incubation of these cells with it.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpA2CkZFy7L3bVg90H21EOLACvtfcHk0lgJCJAwAJB2yQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL38XhvFaqtbw%253D&md5=f27c8e7dc8c7dfd829bd75085bbbd007</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Fjm00348a004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00348a004%26sid%3Dliteratum%253Aachs%26aulast%3DMontgomery%26aufirst%3DJ.%26aulast%3DClayton%26aufirst%3DS.%26aulast%3DThomas%26aufirst%3DH.%26aulast%3DShannon%26aufirst%3DW.%26aulast%3DArnett%26aufirst%3DG.%26aulast%3DBodner%26aufirst%3DA.%26aulast%3DKion%26aufirst%3DI.%2BK.%26aulast%3DCantoni%26aufirst%3DG.%2BL.%26aulast%3DChiang%26aufirst%3DP.%26atitle%3DCarbocyclic%2520analogue%2520of%25203-deazaadenosine%253A%2520A%2520novel%2520antiviral%2520agent%2520using%2520S-adenosylhomocysteine%2520hydrolase%2520as%2520a%2520pharmacological%2520target%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1982%26volume%3D25%26spage%3D626%26epage%3D629%26doi%3D10.1021%2Fjm00348a004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Descamps, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Somer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barr, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, R. T.</span></span> <span> </span><span class="NLM_article-title">(<i>E</i>)-5-(2-Bromovinyl)-2′-deoxyuridine: a potent and selective anti-herpes agent</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1979</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">2947</span>– <span class="NLM_lpage">2951</span>, <span class="refDoi"> DOI: 10.1073/pnas.76.6.2947</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1073%2Fpnas.76.6.2947" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=223163" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADyaE1MXltlersbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=1979&pages=2947-2951&author=E.+De+Clercqauthor=J.+Descampsauthor=P.+De+Somerauthor=P.+J.+Barrauthor=A.+S.+Jonesauthor=R.+T.+Walker&title=%28E%29-5-%282-Bromovinyl%29-2%E2%80%B2-deoxyuridine%3A+a+potent+and+selective+anti-herpes+agent&doi=10.1073%2Fpnas.76.6.2947"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">(E)-5-(2-bromovinyl)-2'-deoxyuridine:  A potent and selective anti-herpes agent</span></div><div class="casAuthors">De Clercq, E.; Descamps, J.; De Somer, P.; Barr, P. J.; Jones, A. S.; Walker, R. T.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1979</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2947-51</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    </div><div class="casAbstract">Of a series of 5 newly synthesized 2'-deoxyuridine derivs., including 5-vinyl-dUrd  [55520-67-7], 5-ethynyl-dUrd  [61135-33-9], 5-(1-chlorovinyl)-dUrd  [69304-46-7], (E)-5-(2-bromovinyl)-dUrd (I)  [69304-47-8], and (E)-5-(2-iodovinyl)-dUrd (II)  [69304-48-9], the last 2 compds. exerted a marked inhibitory effect on the replication of herpes simplex virus type 1 [ID50 (mean inhibitory dose), 0.004-0.02 μg/mL].  Both I and II were highly selective in their antiherpes activity in that they did not affect the growth or metab. of the host (primary rabbit kidney) cells unless drug concns. were used that were 5,000- to 10,000-fold greater than those required to inhibit virus multiplication.  In this sense I and II proved more selective in their activity against herpes simplex virus type 1 than all other antiherpes compds. that have been described so far.  In animal model systems (namely, cutaneous herpes infections of athymic nude mice), I suppressed the development of herpetic skin lesions and mortality therewith assocd., whether the compd. was administered topically or systemically.  Under the same conditions, the std. antiherpes drug 5-iodo-dUrd (Idoxuridine) offered little, if any, protection.  Although the precise mechanism of action of I and II remains to be established, preliminary findings indicate that they do not specifically act at the thymidylate synthetase step.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdVSomZVeCh7Vg90H21EOLACvtfcHk0lhB7OzDCVpaXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE1MXltlersbg%253D&md5=5e18394296c56142473f8d539855deb8</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1073%2Fpnas.76.6.2947&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.76.6.2947%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BClercq%26aufirst%3DE.%26aulast%3DDescamps%26aufirst%3DJ.%26aulast%3DDe%2BSomer%26aufirst%3DP.%26aulast%3DBarr%26aufirst%3DP.%2BJ.%26aulast%3DJones%26aufirst%3DA.%2BS.%26aulast%3DWalker%26aufirst%3DR.%2BT.%26atitle%3D%2528E%2529-5-%25282-Bromovinyl%2529-2%25E2%2580%25B2-deoxyuridine%253A%2520a%2520potent%2520and%2520selective%2520anti-herpes%2520agent%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1979%26volume%3D76%26spage%3D2947%26epage%3D2951%26doi%3D10.1073%2Fpnas.76.6.2947" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span> <span> </span><span class="NLM_article-title">Discovery and development of BVDU (brivudin) as a therapeutic for the treatment of herpes zoster</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">2301</span>– <span class="NLM_lpage">2315</span>, <span class="refDoi"> DOI: 10.1016/j.bcp.2004.07.039</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1016%2Fj.bcp.2004.07.039" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=15548377" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVWjsLzN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2004&pages=2301-2315&author=E.+De+Clercq&title=Discovery+and+development+of+BVDU+%28brivudin%29+as+a+therapeutic+for+the+treatment+of+herpes+zoster&doi=10.1016%2Fj.bcp.2004.07.039"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and development of BVDU (brivudine) as a therapeutic for the treatment of herpes zoster</span></div><div class="casAuthors">De Clercq, E.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2301-2315</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  This commentary is dedicated to the memory of Dr. Jacques Gielen, the late Editor of Biochem. Pharmacol., whom I have known as both an author and reviewer for the Journal for about 25 years.  This is, quite incidentally, about the time it took for bringing brivudine (BVDU) [(E)-5-(2-bromovinyl)-2'-deoxyuridine] from its original description as an antiviral agent to the market place (in a no. of European countries, including Germany and Italy) for the treatment of herpes zoster in immunocompetent persons.  BVDU is exquisitely active and selective against varicella-zoster virus (VZV) and herpes simplex virus type 1 (HSV-1).  BVDU owes this high selectivity and activity profile to a specific phosphorylation by the virus-encoded thymidine kinase, followed by a potent interaction with the viral DNA polymerase.  The (E)-5-(2-bromovinyl)-substituent can be considered as the hallmark for the activity of BVDU against VZV and HSV-1.  Extensive clin. studies have indicated that BVDU as a single (oral) daily dose of 125 mg (for no more than 7 days) is effective in the treatment of herpes zoster, as regards both short-term (suppression of new lesion formation) and long-term effects (prevention of post-herpetic neuralgia).  In this sense, BVDU is as efficient and/or convenient, if not more so, than the other drugs (acyclovir, valaciclovir, famciclovir) that have been licensed for the treatment of herpes zoster.  There is one caveat; however, BVDU should not be given to patients under 5-fluorouracil therapy, as the degrdn. product of BVDU, namely (E)-5-(2-bromovinyl)uracil (BVU), may potentiate the toxicity of 5-fluorouracil, due to inhibition of dihydropyrimidine dehydrogenase, the enzyme involved in the catabolism of 5-fluorouracil.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqklZzJgQDBq7Vg90H21EOLACvtfcHk0lhB7OzDCVpaXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVWjsLzN&md5=c43449f70ae0d4d31a17f4c34bf4db06</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2004.07.039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2004.07.039%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BClercq%26aufirst%3DE.%26atitle%3DDiscovery%2520and%2520development%2520of%2520BVDU%2520%2528brivudin%2529%2520as%2520a%2520therapeutic%2520for%2520the%2520treatment%2520of%2520herpes%2520zoster%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2004%26volume%3D68%26spage%3D2301%26epage%3D2315%26doi%3D10.1016%2Fj.bcp.2004.07.039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Degreef, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wildiers, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Jonge, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drochmans, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Descamps, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Somer, P.</span></span> <span> </span><span class="NLM_article-title">Oral (E)-5-(2-bromovinyl)-2′-deoxyuridine in severe herpes zoster</span>. <i>Br. Med. J.</i> <span class="NLM_year" style="font-weight: bold;">1980</span>,  <span class="NLM_volume"><i>281</i></span>,  <span class="NLM_fpage">1178</span>– <span class="NLM_lpage">1178</span>, <span class="refDoi"> DOI: 10.1136/bmj.281.6249.1178</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1136%2Fbmj.281.6249.1178" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=7427624" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A280%3ADyaL3M%252FktFCksw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=281&publication_year=1980&pages=1178-1178&author=E.+De+Clercqauthor=H.+Degreefauthor=J.+Wildiersauthor=G.+De+Jongeauthor=A.+Drochmansauthor=J.+Descampsauthor=P.+De+Somer&title=Oral+%28E%29-5-%282-bromovinyl%29-2%E2%80%B2-deoxyuridine+in+severe+herpes+zoster&doi=10.1136%2Fbmj.281.6249.1178"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Oral (E)-5-(2-bromovinyl)-2'-deoxyuridine in severe herpes zoster</span></div><div class="casAuthors">de Clercq E; Degreef H; Wildiers J; de Jonge G; Drochmans A; Descamps J; de Somer P</div><div class="citationInfo"><span class="NLM_cas:title">British medical journal</span>
        (<span class="NLM_cas:date">1980</span>),
    <span class="NLM_cas:volume">281</span>
        (<span class="NLM_cas:issue">6249</span>),
    <span class="NLM_cas:pages">1178</span>
        ISSN:<span class="NLM_cas:issn">0007-1447</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSk7obhVLONGnT4ugvCDgnZfW6udTcc2eb8EZHsQ7swgLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL3M%252FktFCksw%253D%253D&md5=1009f624f16c0a5a759041c639820103</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1136%2Fbmj.281.6249.1178&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fbmj.281.6249.1178%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BClercq%26aufirst%3DE.%26aulast%3DDegreef%26aufirst%3DH.%26aulast%3DWildiers%26aufirst%3DJ.%26aulast%3DDe%2BJonge%26aufirst%3DG.%26aulast%3DDrochmans%26aufirst%3DA.%26aulast%3DDescamps%26aufirst%3DJ.%26aulast%3DDe%2BSomer%26aufirst%3DP.%26atitle%3DOral%2520%2528E%2529-5-%25282-bromovinyl%2529-2%25E2%2580%25B2-deoxyuridine%2520in%2520severe%2520herpes%2520zoster%26jtitle%3DBr.%2520Med.%2520J.%26date%3D1980%26volume%3D281%26spage%3D1178%26epage%3D1178%26doi%3D10.1136%2Fbmj.281.6249.1178" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Whitley, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ch’ien, L. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dolin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galasso, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alford, C. A.</span></span> <span> </span><span class="NLM_article-title">Adenine arabinoside therapy of herpes zoster in the immunosuppressed</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">1976</span>,  <span class="NLM_volume"><i>294</i></span>,  <span class="NLM_fpage">1193</span>– <span class="NLM_lpage">1199</span>, <span class="refDoi"> DOI: 10.1056/NEJM197605272942201</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1056%2FNEJM197605272942201" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=177866" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A280%3ADyaE287nsVeitw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=294&publication_year=1976&pages=1193-1199&author=R.+J.+Whitleyauthor=L.+T.+Ch%E2%80%99ienauthor=R.+Dolinauthor=G.+J.+Galassoauthor=C.+A.+Alford&title=Adenine+arabinoside+therapy+of+herpes+zoster+in+the+immunosuppressed&doi=10.1056%2FNEJM197605272942201"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Adenine arabinoside therapy of herpes zoster in the immunosuppressed. NIAID collaborative antiviral study</span></div><div class="casAuthors">Whitley R J; Ch'ien L T; Dolin R; Galasso G J; Alford C A Jr</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">1976</span>),
    <span class="NLM_cas:volume">294</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">1193-9</span>
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    </div><div class="casAbstract">We evaluated adenine arabinoside treatment of herpes zoster in immunodeficient patients in a randomized, controlled crossover study.  The two study groups had similar characteristics.  In spite of rapid natural healing, those receiving adenine arabinoside over the first five days had accelerated clearance of virus from vesicles (P = 0.01), and cessation of new vesicle formation (P = 0.004), and a shorter time to total pustulation (P = 0.001).  Factors modifying the response to therapy included age, underlying disease, and the duration of zoster prior to therapy.  Clinical toxicity was minimal.  Laboratory assessment of bone-marrow, liver and renal function showed insignificant alterations as a result of therapy.  These studies show that adenine arabinoside is a drug with promise for therapy of systemic herpes zoster in immunocompromised patients.  It is most efficacious when administered during the first six days of disease (P = 0.001) to those who have reticuloendothelial neoplasia (P = 0.001) and are less than 38 years of age (P = 0.001).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ7E33NyFJ7Xf6BottYdIAWfW6udTcc2eZs5OKy_PJR27ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaE287nsVeitw%253D%253D&md5=c3d727ec1f540969574e7e42ac55e0ac</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1056%2FNEJM197605272942201&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM197605272942201%26sid%3Dliteratum%253Aachs%26aulast%3DWhitley%26aufirst%3DR.%2BJ.%26aulast%3DCh%25E2%2580%2599ien%26aufirst%3DL.%2BT.%26aulast%3DDolin%26aufirst%3DR.%26aulast%3DGalasso%26aufirst%3DG.%2BJ.%26aulast%3DAlford%26aufirst%3DC.%2BA.%26atitle%3DAdenine%2520arabinoside%2520therapy%2520of%2520herpes%2520zoster%2520in%2520the%2520immunosuppressed%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D1976%26volume%3D294%26spage%3D1193%26epage%3D1199%26doi%3D10.1056%2FNEJM197605272942201" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Colla, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Busson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanderhaeghe, H.</span></span> <span> </span><span class="NLM_article-title">Synthesis and antiviral activity of water-soluble esters of acyclovir [9-[(2-hydroxyethoxy)methyl]guanine]</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1983</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">602</span>– <span class="NLM_lpage">604</span>, <span class="refDoi"> DOI: 10.1021/jm00358a029</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00358a029" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADyaL3sXhtF2hs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=1983&pages=602-604&author=L.+Collaauthor=E.+De+Clercqauthor=R.+Bussonauthor=H.+Vanderhaeghe&title=Synthesis+and+antiviral+activity+of+water-soluble+esters+of+acyclovir+%5B9-%5B%282-hydroxyethoxy%29methyl%5Dguanine%5D&doi=10.1021%2Fjm00358a029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and antiviral activity of water-soluble esters of acyclovir [9-[(2-hydroxyethoxy)methyl]guanine)</span></div><div class="casAuthors">Colla, Leon; De Clercq, Erik; Busson, Roger; Vanderhaeghe, Hubert</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1983</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">602-4</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    </div><div class="casAbstract">The title compds. I (R = COCH2NH2, COCHMeNH2, COCH2CH2NH2, COCH2CH2CO2H, and COCH2N3) as the HCl and Na salts were prepd. by direct esterification of acyclovir  [59277-89-3] and evaluated for virucidal activity in vitro.  The compds. were as active or slightly less active than acyclovir itself against herpes simplex virus type 1 and type 2 in primary rabbit kidney cells, showed little activity against vaccinia virus and no activity against stomatitits virus, and no cytotoxicity.  9-[2-(glycyloxy)ethoxymethyl]guanine-HCl  [84499-61-6] Effectively suppressed the development of both epithelial and stromal keratitis and iritis.  I was stable at room temp. for 6 days in isotonic borate buffer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvzWgI3CTaYLVg90H21EOLACvtfcHk0lhNUjcE0155vw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3sXhtF2hs78%253D&md5=e3b4f5cf614b82a1befcff949a246e30</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Fjm00358a029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00358a029%26sid%3Dliteratum%253Aachs%26aulast%3DColla%26aufirst%3DL.%26aulast%3DDe%2BClercq%26aufirst%3DE.%26aulast%3DBusson%26aufirst%3DR.%26aulast%3DVanderhaeghe%26aufirst%3DH.%26atitle%3DSynthesis%2520and%2520antiviral%2520activity%2520of%2520water-soluble%2520esters%2520of%2520acyclovir%2520%255B9-%255B%25282-hydroxyethoxy%2529methyl%255Dguanine%255D%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1983%26volume%3D26%26spage%3D602%26epage%3D604%26doi%3D10.1021%2Fjm00358a029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maudgal, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Descamps, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Missotten, L.</span></span> <span> </span><span class="NLM_article-title">Topical treatment of experimental herpes simplex keratouveitis with 2′-O-glycylacyclovir</span>. <i>Arch. Ophthalmol.</i> <span class="NLM_year" style="font-weight: bold;">1984</span>,  <span class="NLM_volume"><i>102</i></span>,  <span class="NLM_fpage">140</span>– <span class="NLM_lpage">142</span>, <span class="refDoi"> DOI: 10.1001/archopht.1984.01040030118049</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1001%2Farchopht.1984.01040030118049" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=6703958" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A280%3ADyaL2c7ltlCisA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=1984&pages=140-142&author=P.+C.+Maudgalauthor=E.+De+Clercqauthor=J.+Descampsauthor=L.+Missotten&title=Topical+treatment+of+experimental+herpes+simplex+keratouveitis+with+2%E2%80%B2-O-glycylacyclovir&doi=10.1001%2Farchopht.1984.01040030118049"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Topical treatment of experimental herpes simplex keratouveitis with 2'-O-glycylacyclovir. A water-soluble ester of acyclovir</span></div><div class="casAuthors">Maudgal P C; De Clercq K; Descamps J; Missotten L</div><div class="citationInfo"><span class="NLM_cas:title">Archives of ophthalmology (Chicago, Ill. : 1960)</span>
        (<span class="NLM_cas:date">1984</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">140-2</span>
        ISSN:<span class="NLM_cas:issn">0003-9950</span>.
    </div><div class="casAbstract">2'-O-glycylacyclovir, a water-soluble ester derivative of acyclovir, has proved efficacious in the topical treatment of epithelial and stromal herpes simplex keratitis, and iritis therewith associated, when administered as a 1% eyedrop formulation to rabbits.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRSmFpK9ihjY-b6AVA-44PTfW6udTcc2eZs5OKy_PJR27ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL2c7ltlCisA%253D%253D&md5=7882ab70d2f929d8cdb4b4268d30cc4d</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1001%2Farchopht.1984.01040030118049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Farchopht.1984.01040030118049%26sid%3Dliteratum%253Aachs%26aulast%3DMaudgal%26aufirst%3DP.%2BC.%26aulast%3DDe%2BClercq%26aufirst%3DE.%26aulast%3DDescamps%26aufirst%3DJ.%26aulast%3DMissotten%26aufirst%3DL.%26atitle%3DTopical%2520treatment%2520of%2520experimental%2520herpes%2520simplex%2520keratouveitis%2520with%25202%25E2%2580%25B2-O-glycylacyclovir%26jtitle%3DArch.%2520Ophthalmol.%26date%3D1984%26volume%3D102%26spage%3D140%26epage%3D142%26doi%3D10.1001%2Farchopht.1984.01040030118049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beauchamp, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orr, G. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Miranda, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bumette, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krenitsky, T. A.</span></span> <span> </span><span class="NLM_article-title">Amino acid ester prodrugs of acyclovir</span>. <i>Antiviral Chem. Chemother.</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">157</span>– <span class="NLM_lpage">164</span>, <span class="refDoi"> DOI: 10.1177/095632029200300305</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1177%2F095632029200300305" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADyaK38XltVelsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=1992&pages=157-164&author=L.+M.+Beauchampauthor=G.+F.+Orrauthor=P.+de+Mirandaauthor=T.+Bumetteauthor=T.+A.+Krenitsky&title=Amino+acid+ester+prodrugs+of+acyclovir&doi=10.1177%2F095632029200300305"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Amino acid ester prodrugs of acyclovir</span></div><div class="casAuthors">Beauchamp, L. M.; Orr, G. F.; De Miranda, P.; Burnette, T.; Krenitsky, T. A.</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Chemistry & Chemotherapy</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">157-64</span>CODEN:
                <span class="NLM_cas:coden">ACCHEH</span>;
        ISSN:<span class="NLM_cas:issn">0956-3202</span>.
    </div><div class="casAbstract">Eighteen amino acid esters of the antiherpetic drug, acyclovir, were synthesized as potential prodrugs for oral administration.  The esters were examd. for in vitro antiviral activity against herpes simplex virus Type 1 (HSV-1).  They had less potency than the parent compd.  Their efficiencies as prodrugs were evaluated in rats by measuring the urinary recovery of acyclovir.  Ten prodrugs produced greater amts. of the parent drug in the urine.  The L-amino acid esters were better prodrugs than the corresponding D- or D,L-isomers, suggesting the involvement of a stereoselective transporter.  The L-valyl ester, 256U87, was the best prodrug.  Sixty-three percent of its administered dose was excreted as acyclovir in the urine, a considerable improvement over acyclovir itself, for which this value was 19%.  Since 256U87 was stable in aq. solns., its conversion to acyclovir in vivo was probably enzyme catalyzed.  This L-valyl ester prodrug of acyclovir is now undergoing clin. evaluation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriTQ5TOWVr3LVg90H21EOLACvtfcHk0lhCHAcBD6pdNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38XltVelsbw%253D&md5=a1befed5efcf119abf7ce4660a133fc8</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1177%2F095632029200300305&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F095632029200300305%26sid%3Dliteratum%253Aachs%26aulast%3DBeauchamp%26aufirst%3DL.%2BM.%26aulast%3DOrr%26aufirst%3DG.%2BF.%26aulast%3Dde%2BMiranda%26aufirst%3DP.%26aulast%3DBumette%26aufirst%3DT.%26aulast%3DKrenitsky%26aufirst%3DT.%2BA.%26atitle%3DAmino%2520acid%2520ester%2520prodrugs%2520of%2520acyclovir%26jtitle%3DAntiviral%2520Chem.%2520Chemother.%26date%3D1992%26volume%3D3%26spage%3D157%26epage%3D164%26doi%3D10.1177%2F095632029200300305" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Purifoy, D. J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beauchamp, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Miranda, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ertl, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lacey, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahim, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darby, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krenitsky, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, K. L.</span></span> <span> </span><span class="NLM_article-title">Review of research leading to new anti-herpesvirus agents in clinical development: valaciclovir hydrochloride (256U, the L-valyl ester of acyclovir) and 882C, a specific agent for varicella zoster virus</span>. <i>J. Med. Virol.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">139</span>– <span class="NLM_lpage">145</span>, <span class="refDoi"> DOI: 10.1002/jmv.1890410527</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1002%2Fjmv.1890410527" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=1993&pages=139-145&author=D.+J.+M.+Purifoyauthor=L.+M.+Beauchampauthor=P.+de+Mirandaauthor=P.+Ertlauthor=S.+Laceyauthor=G.+Robertsauthor=S.+G.+Rahimauthor=G.+Darbyauthor=T.+A.+Krenitskyauthor=K.+L.+Powell&title=Review+of+research+leading+to+new+anti-herpesvirus+agents+in+clinical+development%3A+valaciclovir+hydrochloride+%28256U%2C+the+L-valyl+ester+of+acyclovir%29+and+882C%2C+a+specific+agent+for+varicella+zoster+virus&doi=10.1002%2Fjmv.1890410527"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1002%2Fjmv.1890410527&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjmv.1890410527%26sid%3Dliteratum%253Aachs%26aulast%3DPurifoy%26aufirst%3DD.%2BJ.%2BM.%26aulast%3DBeauchamp%26aufirst%3DL.%2BM.%26aulast%3Dde%2BMiranda%26aufirst%3DP.%26aulast%3DErtl%26aufirst%3DP.%26aulast%3DLacey%26aufirst%3DS.%26aulast%3DRoberts%26aufirst%3DG.%26aulast%3DRahim%26aufirst%3DS.%2BG.%26aulast%3DDarby%26aufirst%3DG.%26aulast%3DKrenitsky%26aufirst%3DT.%2BA.%26aulast%3DPowell%26aufirst%3DK.%2BL.%26atitle%3DReview%2520of%2520research%2520leading%2520to%2520new%2520anti-herpesvirus%2520agents%2520in%2520clinical%2520development%253A%2520valaciclovir%2520hydrochloride%2520%2528256U%252C%2520the%2520L-valyl%2520ester%2520of%2520acyclovir%2529%2520and%2520882C%252C%2520a%2520specific%2520agent%2520for%2520varicella%2520zoster%2520virus%26jtitle%3DJ.%2520Med.%2520Virol.%26date%3D1993%26volume%3D41%26spage%3D139%26epage%3D145%26doi%3D10.1002%2Fjmv.1890410527" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holý, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenberg, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakuma, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balzarini, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maudgal, P. C.</span></span> <span> </span><span class="NLM_article-title">A novel selective broad-spectrum anti-DNA virus agent</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1986</span>,  <span class="NLM_volume"><i>323</i></span>,  <span class="NLM_fpage">464</span>– <span class="NLM_lpage">467</span>, <span class="refDoi"> DOI: 10.1038/323464a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1038%2F323464a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=3762696" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADyaL28XmtFygtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=323&publication_year=1986&pages=464-467&author=E.+De+Clercqauthor=A.+Hol%C3%BDauthor=I.+Rosenbergauthor=T.+Sakumaauthor=J.+Balzariniauthor=P.+C.+Maudgal&title=A+novel+selective+broad-spectrum+anti-DNA+virus+agent&doi=10.1038%2F323464a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">A novel selective broad-spectrum anti-DNA virus agent</span></div><div class="casAuthors">De Clercq, Erik; Holy, Antonin; Rosenberg, Ivan; Sakuma, Takashi; Balzarini, Jan; Maudgal, Prabhat C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">1986</span>),
    <span class="NLM_cas:volume">323</span>
        (<span class="NLM_cas:issue">6087</span>),
    <span class="NLM_cas:pages">464-7</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    </div><div class="casAbstract">A new compd. was found, (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine (I)  [92999-29-6], that has potent and selective activity against a broad spectrum of DNA viruses, including herpes simplex virus (types 1 and 2), varicella zoster virus, thymidine kinase-deficient (TK-) mutants of herpes simplex and varicella zoster virus, human cytomegalovirus, phocid, simian, suid, bovid, and equid herpes viruses, African swine fever virus, vaccinia virus, and human adenoviruses.  It is also active against retroviruses.  In mice and rabbits in vivo, the compd. is effective against both local and systemic infections with herpes simplex virus type 1, including herpetic keratitis caused by a TK- mutant which is resistant to the classical anti-herpes drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHvD011SupIbVg90H21EOLACvtfcHk0lhCHAcBD6pdNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL28XmtFygtrY%253D&md5=774d0545b43b01b98d46406674e16f0d</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1038%2F323464a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F323464a0%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BClercq%26aufirst%3DE.%26aulast%3DHol%25C3%25BD%26aufirst%3DA.%26aulast%3DRosenberg%26aufirst%3DI.%26aulast%3DSakuma%26aufirst%3DT.%26aulast%3DBalzarini%26aufirst%3DJ.%26aulast%3DMaudgal%26aufirst%3DP.%2BC.%26atitle%3DA%2520novel%2520selective%2520broad-spectrum%2520anti-DNA%2520virus%2520agent%26jtitle%3DNature%26date%3D1986%26volume%3D323%26spage%3D464%26epage%3D467%26doi%3D10.1038%2F323464a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakuma, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baba, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pauwels, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balzarini, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenberg, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holý, A.</span></span> <span> </span><span class="NLM_article-title">Antiviral activity of phosphonylmethoxyalkyl derivatives of purine and pyrimidines</span>. <i>Antiviral Res.</i> <span class="NLM_year" style="font-weight: bold;">1987</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">261</span>– <span class="NLM_lpage">272</span>, <span class="refDoi"> DOI: 10.1016/S0166-3542(87)80004-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1016%2FS0166-3542%2887%2980004-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=3451698" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADyaL1cXhsl2lsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=1987&pages=261-272&author=E.+De+Clercqauthor=T.+Sakumaauthor=M.+Babaauthor=R.+Pauwelsauthor=J.+Balzariniauthor=I.+Rosenbergauthor=A.+Hol%C3%BD&title=Antiviral+activity+of+phosphonylmethoxyalkyl+derivatives+of+purine+and+pyrimidines&doi=10.1016%2FS0166-3542%2887%2980004-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Antiviral activity of phosphonylmethoxyalkyl derivatives of purines and pyrimidines</span></div><div class="casAuthors">De Clercq, Erik; Sakuma, Takashi; Baba, Masanori; Pauwels, Rudi; Balzarini, Jan; Rosenberg, Ivan; Holy, Antonin</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">1987</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5-6</span>),
    <span class="NLM_cas:pages">261-72</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    </div><div class="casAbstract">Various 3-hydroxy-2-phosphonylmethoxypropyl (HPMP) and 2-phosphonylmethoxyethyl (PME) derivs. of purines [adenine (A), guanine (G), 2,6-diaminopurine (DAP), 2-monoaminopurine (MAP), hypoxanthine (HX)] and pyrimidines [cytosine (C), uracil (U), thymine (T)] were evaluated for their antiviral properties.  PMEDAP, (S)-HPMPA [and the cyclic phosphonate thereof, (S)-cHPMPA)], (S)-HPMPC, PMEG, PMEA, HPMPG, and HPMPDAP were effective inhibitors of herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2).  (S)-HPMPA and (S)-cHPMPA were the most effective inhibitors of varicella-zoster virus (VZV), and (s)-HPMPC was the most effective inhibitor of cytomegalovirus (CMV).  (S)-HPMPA and (S)-cHPMPA showed the greatest inhibitory activity against adenovirus (types 2, 3, and 4) and vaccinia virus.  The PME derivs. were much less inhibitory to VZV, CMV, vaccinia and adenovirus than the HPMP derivs.  However, PMEA, PMEDAP, and PMEMAP showed marked and selective activity against the human immunodeficiency virus.  (S)-HPMPA proved efficacious in the topical treatment of HSV-1 keratitis in rabbits and cutaneous HSV-1 infection in hairless mice, and in the systemic treatment of both HSV-1 and vaccinia virus infections in mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzijl5gXLtPbVg90H21EOLACvtfcHk0lhCHAcBD6pdNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1cXhsl2lsbg%253D&md5=aaf3aa204ab0a5fc34e6557c6158313b</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2FS0166-3542%2887%2980004-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0166-3542%252887%252980004-9%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BClercq%26aufirst%3DE.%26aulast%3DSakuma%26aufirst%3DT.%26aulast%3DBaba%26aufirst%3DM.%26aulast%3DPauwels%26aufirst%3DR.%26aulast%3DBalzarini%26aufirst%3DJ.%26aulast%3DRosenberg%26aufirst%3DI.%26aulast%3DHol%25C3%25BD%26aufirst%3DA.%26atitle%3DAntiviral%2520activity%2520of%2520phosphonylmethoxyalkyl%2520derivatives%2520of%2520purine%2520and%2520pyrimidines%26jtitle%3DAntiviral%2520Res.%26date%3D1987%26volume%3D8%26spage%3D261%26epage%3D272%26doi%3D10.1016%2FS0166-3542%2887%2980004-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mitsuya, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broder, S.</span></span> <span> </span><span class="NLM_article-title">Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2′,3′-dideoxynucleosides</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1986</span>,  <span class="NLM_volume"><i>83</i></span>,  <span class="NLM_fpage">1911</span>– <span class="NLM_lpage">1915</span>, <span class="refDoi"> DOI: 10.1073/pnas.83.6.1911</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1073%2Fpnas.83.6.1911" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=3006077" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADyaL28XhvVehs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=1986&pages=1911-1915&author=H.+Mitsuyaauthor=S.+Broder&title=Inhibition+of+the+in+vitro+infectivity+and+cytopathic+effect+of+human+T-lymphotrophic+virus+type+III%2Flymphadenopathy-associated+virus+%28HTLV-III%2FLAV%29+by+2%E2%80%B2%2C3%E2%80%B2-dideoxynucleosides&doi=10.1073%2Fpnas.83.6.1911"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2',3'-dideoxynucleosides</span></div><div class="casAuthors">Mitsuya, Hiroaki; Broder, Samuel</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1986</span>),
    <span class="NLM_cas:volume">83</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1911-15</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    </div><div class="casAbstract">Human T-lymphotropic virus type III (HTLV-III)/lymphadenopathy-assocd. virus (LAV) is a newly discovered lymphotropic retrovirus that is cytopathic for helper/inducer T cells in vitro.  This virus is the etiol. agent of the acquired immunodeficiency syndrome and related diseases.  In the current study, the capacity of purine and pyrimidine nucleoside derivs. to inhibit the infectivity and cytopathic effect of human T-lymphotropic virus type III in vitro was detd.  With the ribose moiety of the mol. in a 2',3'-dideoxy configuration, every purine (adenosine, guanosine, and inosine) and pyrimidine (cytidine and thymidine) nucleoside tested suppressed the virus, although the thymidine deriv. seemed to have substantially less activity in our system than the others.  In general, essentially complete suppression of the virus were obsd. at doses that were lower by a factor of 10 to 20 than those needed to inhibit the proliferation of the target T cells and the immune reactivity of normal T cells in vitro.  An anal. of 5 adenosine congeners, which differed only in the sugar moiety, revealed that redn. (an absence of hydroxyl determinants) at both the 2' and 3' carbons of the ribose was necessary for an anti-viral effect, and an addnl. redn. at the 5' carbon nullified the anti-viral activity.  These observations may be of value in developing a new class of exptl. drugs for the therapy of human T-lymphotropic virus type III infections.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqd8dTpxg1q8LVg90H21EOLACvtfcHk0lg3B3ISj0AhHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL28XhvVehs7g%253D&md5=d2541c7e2684dfa6563c44db18186755</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1073%2Fpnas.83.6.1911&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.83.6.1911%26sid%3Dliteratum%253Aachs%26aulast%3DMitsuya%26aufirst%3DH.%26aulast%3DBroder%26aufirst%3DS.%26atitle%3DInhibition%2520of%2520the%2520in%2520vitro%2520infectivity%2520and%2520cytopathic%2520effect%2520of%2520human%2520T-lymphotrophic%2520virus%2520type%2520III%252Flymphadenopathy-associated%2520virus%2520%2528HTLV-III%252FLAV%2529%2520by%25202%25E2%2580%25B2%252C3%25E2%2580%25B2-dideoxynucleosides%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1986%26volume%3D83%26spage%3D1911%26epage%3D1915%26doi%3D10.1073%2Fpnas.83.6.1911" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baba, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pauwels, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herdewijn, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desmyter, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vandeputte, M.</span></span> <span> </span><span class="NLM_article-title">Both 2′,3′-dideoxythymidine and its 2′,3′-unsaturated derivative (2′,3′-dideoxythymidinene) are potent and selective inhibitors of human immunodeficiency virus replication in vitro</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">1987</span>,  <span class="NLM_volume"><i>142</i></span>,  <span class="NLM_fpage">128</span>– <span class="NLM_lpage">134</span>, <span class="refDoi"> DOI: 10.1016/0006-291X(87)90460-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1016%2F0006-291X%2887%2990460-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=3028398" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADyaL2sXhs1yms7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=142&publication_year=1987&pages=128-134&author=M.+Babaauthor=R.+Pauwelsauthor=P.+Herdewijnauthor=E.+De+Clercqauthor=J.+Desmyterauthor=M.+Vandeputte&title=Both+2%E2%80%B2%2C3%E2%80%B2-dideoxythymidine+and+its+2%E2%80%B2%2C3%E2%80%B2-unsaturated+derivative+%282%E2%80%B2%2C3%E2%80%B2-dideoxythymidinene%29+are+potent+and+selective+inhibitors+of+human+immunodeficiency+virus+replication+in+vitro&doi=10.1016%2F0006-291X%2887%2990460-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Both 2',3'-dideoxythymidine and its 2',3'-unsaturated derivative (2',3'-dideoxythymidinene) are potent and selective inhibitors of human immunodeficiency virus replication in vitro</span></div><div class="casAuthors">Baba, Masanori; Pauwels, Rudi; Herdewijn, Piet; De Clercq, Erik; Desmyter, Jan; Vandeputte, Michel</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical and Biophysical Research Communications</span>
        (<span class="NLM_cas:date">1987</span>),
    <span class="NLM_cas:volume">142</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">128-34</span>CODEN:
                <span class="NLM_cas:coden">BBRCA9</span>;
        ISSN:<span class="NLM_cas:issn">0006-291X</span>.
    </div><div class="casAbstract">2',3'-Dideoxythymidine (ddThd)  [3416-05-5] and its 2',3'-unsatd. deriv., 2',3'-dideoxythymidinene (ddeThd)  [3056-17-5], are potent and selective inhibitors of human immunodeficiency virus (HIV) in vitro.  When evaluated for their inhibitory effects on the cytopathogenicity of HIV in MT-4 cells, ddThd and ddeThd completely protected the cells against destruction by the virus at a concn. of 1 and 0.04 μM, resp.  In this aspect, ddeThd was ∼5-fold more potent than 2',3'-dideoxycytidine (ddCyd)  [7481-89-2], one of the most potent and selective anti-HIV compds. now pursued for its therapeutic potential in the treatment of AIDS.  Both ddThd and ddeThd also suppressed HIV antigen expression at 1 and 0.04 μM, resp.  Their selectivity indexes, as based on the ratio of the 50% cytotoxic dose to the 50% antiviral ED, were 120 (ddeThd) and >625 (ddThd).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDUfA6sIjZ_rVg90H21EOLACvtfcHk0lg3B3ISj0AhHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2sXhs1yms7c%253D&md5=8859861892f9d739d191e1934a34c27f</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2F0006-291X%2887%2990460-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0006-291X%252887%252990460-8%26sid%3Dliteratum%253Aachs%26aulast%3DBaba%26aufirst%3DM.%26aulast%3DPauwels%26aufirst%3DR.%26aulast%3DHerdewijn%26aufirst%3DP.%26aulast%3DDe%2BClercq%26aufirst%3DE.%26aulast%3DDesmyter%26aufirst%3DJ.%26aulast%3DVandeputte%26aufirst%3DM.%26atitle%3DBoth%25202%25E2%2580%25B2%252C3%25E2%2580%25B2-dideoxythymidine%2520and%2520its%25202%25E2%2580%25B2%252C3%25E2%2580%25B2-unsaturated%2520derivative%2520%25282%25E2%2580%25B2%252C3%25E2%2580%25B2-dideoxythymidinene%2529%2520are%2520potent%2520and%2520selective%2520inhibitors%2520of%2520human%2520immunodeficiency%2520virus%2520replication%2520in%2520vitro%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D1987%26volume%3D142%26spage%3D128%26epage%3D134%26doi%3D10.1016%2F0006-291X%2887%2990460-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, T.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schinazi, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prusoff, W. H.</span></span> <span> </span><span class="NLM_article-title">Potent and selective in vitro activity of 3′-deoxythymidin-2′-ene (3′-deoxy-2′,3′-didehydrothymidine) against human immunodeficiency virus</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1987</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">2713</span>– <span class="NLM_lpage">2718</span>, <span class="refDoi"> DOI: 10.1016/0006-2952(87)90253-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1016%2F0006-2952%2887%2990253-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=2443141" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADyaL2sXmtFWnurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=1987&pages=2713-2718&author=T.-S.+Linauthor=R.+F.+Schinaziauthor=W.+H.+Prusoff&title=Potent+and+selective+in+vitro+activity+of+3%E2%80%B2-deoxythymidin-2%E2%80%B2-ene+%283%E2%80%B2-deoxy-2%E2%80%B2%2C3%E2%80%B2-didehydrothymidine%29+against+human+immunodeficiency+virus&doi=10.1016%2F0006-2952%2887%2990253-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Potent and selective in vitro activity of 3'-deoxythymidin-2'-ene (3'-deoxy-2',3'-didehydrothymidine) against human immunodeficiency virus</span></div><div class="casAuthors">Lin, Tai Shun; Schinazi, Raymond F.; Prusoff, William H.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology</span>
        (<span class="NLM_cas:date">1987</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">2713-18</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    </div><div class="casAbstract">3'-Deoxy-2',3'-didehydrothymidine (d4T) is a more potent inhibitor of human immunodeficiency virus (HIV) than 3'-deoxythymidine (d2T) in human peripheral blood mononuclear cells in vitro.  Although d2T was at least 10-fold less toxic than d4T to uninfected cells, the unsatd. analog (d4T) was about 19 times more potent as an antiviral agent.  D4T (0.1 μM) was markedly more effective in inhibiting viral replication than d2T (1.0 μM) when treatment was delayed by 1 or 2 days after infection.  The therapeutic index of d4T appears to be close to 5000.  The potent activity of d4T against HIV-1 and its very high therapeutic index make it to be a potentially useful agent for control of AIDS and related disorders.  A review is also presented on the compds. which have shown activity against HIV.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrF9l_kho8bdrVg90H21EOLACvtfcHk0lg3B3ISj0AhHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2sXmtFWnurg%253D&md5=7de431cda4747fb43a9e5840c75a9001</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1016%2F0006-2952%2887%2990253-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0006-2952%252887%252990253-X%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DT.-S.%26aulast%3DSchinazi%26aufirst%3DR.%2BF.%26aulast%3DPrusoff%26aufirst%3DW.%2BH.%26atitle%3DPotent%2520and%2520selective%2520in%2520vitro%2520activity%2520of%25203%25E2%2580%25B2-deoxythymidin-2%25E2%2580%25B2-ene%2520%25283%25E2%2580%25B2-deoxy-2%25E2%2580%25B2%252C3%25E2%2580%25B2-didehydrothymidine%2529%2520against%2520human%2520immunodeficiency%2520virus%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D1987%26volume%3D36%26spage%3D2713%26epage%3D2718%26doi%3D10.1016%2F0006-2952%2887%2990253-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hamamoto, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakashima, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsui, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsuda, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, N.</span></span> <span> </span><span class="NLM_article-title">Inhibitory effect of 2′,3′-didehydro-2′,3′-dideoxynucleosides on infectivity, cytopathic effects, and replication of human immunodeficiency virus</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">1987</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">907</span>– <span class="NLM_lpage">910</span>, <span class="refDoi"> DOI: 10.1128/AAC.31.6.907</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1128%2FAAC.31.6.907" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=3039911" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADyaL2sXkslSgs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=1987&pages=907-910&author=Y.+Hamamotoauthor=H.+Nakashimaauthor=T.+Matsuiauthor=A.+Matsudaauthor=T.+Uedaauthor=N.+Yamamoto&title=Inhibitory+effect+of+2%E2%80%B2%2C3%E2%80%B2-didehydro-2%E2%80%B2%2C3%E2%80%B2-dideoxynucleosides+on+infectivity%2C+cytopathic+effects%2C+and+replication+of+human+immunodeficiency+virus&doi=10.1128%2FAAC.31.6.907"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitory effect of 2',3'-didehydro-2',3'-dideoxynucleosides on infectivity, cytopathic effects, and replication of human immunodeficiency virus</span></div><div class="casAuthors">Hamamoto, Yoshiaki; Nakashima, Hideki; Matsui, Toshio; Matsuda, Akira; Ueda, Toru; Yamamoto, Naoki</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">1987</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">907-10</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    </div><div class="casAbstract">It is generally accepted that human immunodeficiency virus (HIV) is the etiol. agent of the acquired immunodeficiency syndrome and related diseases.  This report demonstrates the antiviral effect of the nucleoside analogs 2',3'-didehydro-2'-3'-dideoxythymidine (DHT) (I) and 2',3'-didehydro-2',3'-dideoxycytidine (DHC) (II) by using human T-cell lymphotropic virus type I-carrying MT-4 cells, which are extremely susceptible to HIV infection.  These agents efficiently inhibited the cytopathic effects and expression of HIV-specific antigens in MT-4 cells after infection of the virus.  Both DHT and DHC also strongly blocked viral replication as detd. by a quant. bioassay system using a plaque-forming assay.  These antiviral effects were obtained at concns. at which the drugs produced little or no toxicity and were comparable to those with 3'-azido-3'-deoxythymidine and 2',3'-dideoxynucleosides.  These findings warrant further investigation of the use of DHT and DHC for the treatment of the acquired immunodeficiency syndrome and related diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSgD_l_EHcSrVg90H21EOLACvtfcHk0lhDXTh91Qd7hw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2sXkslSgs7c%253D&md5=cee133f0b41bc0ce51882949d808cee5</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1128%2FAAC.31.6.907&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.31.6.907%26sid%3Dliteratum%253Aachs%26aulast%3DHamamoto%26aufirst%3DY.%26aulast%3DNakashima%26aufirst%3DH.%26aulast%3DMatsui%26aufirst%3DT.%26aulast%3DMatsuda%26aufirst%3DA.%26aulast%3DUeda%26aufirst%3DT.%26aulast%3DYamamoto%26aufirst%3DN.%26atitle%3DInhibitory%2520effect%2520of%25202%25E2%2580%25B2%252C3%25E2%2580%25B2-didehydro-2%25E2%2580%25B2%252C3%25E2%2580%25B2-dideoxynucleosides%2520on%2520infectivity%252C%2520cytopathic%2520effects%252C%2520and%2520replication%2520of%2520human%2520immunodeficiency%2520virus%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D1987%26volume%3D31%26spage%3D907%26epage%3D910%26doi%3D10.1128%2FAAC.31.6.907" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baba, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pauwels, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balzarini, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schols, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakashima, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perno, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyasaka, T.</span></span> <span> </span><span class="NLM_article-title">Highly specific inhibition of human immunodeficiency virus type 1 by a novel 6-substituted acyclouridine derivative</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">1989</span>,  <span class="NLM_volume"><i>165</i></span>,  <span class="NLM_fpage">1375</span>– <span class="NLM_lpage">1381</span>, <span class="refDoi"> DOI: 10.1016/0006-291X(89)92756-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1016%2F0006-291X%2889%2992756-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=2575380" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADyaK3cXptFaktw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=165&publication_year=1989&pages=1375-1381&author=M.+Babaauthor=H.+Tanakaauthor=E.+De+Clercqauthor=R.+Pauwelsauthor=J.+Balzariniauthor=D.+Scholsauthor=H.+Nakashimaauthor=C.+F.+Pernoauthor=R.+T.+Walkerauthor=T.+Miyasaka&title=Highly+specific+inhibition+of+human+immunodeficiency+virus+type+1+by+a+novel+6-substituted+acyclouridine+derivative&doi=10.1016%2F0006-291X%2889%2992756-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Highly specific inhibition of human immunodeficiency virus type 1 by a novel 6-substituted acyclouridine derivative</span></div><div class="casAuthors">Baba, M.; Tanaka, H.; De Clercq, E.; Pauwels, R.; Balzarini, J.; Schols, D.; Nakashima, H.; Perno, C. F.; Walker, R. T.; Miyasaka, T.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical and Biophysical Research Communications</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">165</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1375-81</span>CODEN:
                <span class="NLM_cas:coden">BBRCA9</span>;
        ISSN:<span class="NLM_cas:issn">0006-291X</span>.
    </div><div class="casAbstract">A 6-substituted acyclouridine deriv., 1-[(2-hydroxyethoxy)methyl]-6-phenylthiothymine (HEPT) (I), was a potent and selective inhibitor of human immunodeficiency virus type 1 (HIV-1) in vitro.  HEPT inhibited HIV-1 replication in various T4 cell cultures as well as peripheral blood lymphocytes and macrophages.  The 50% antiviral concn. for HIV-1 in MT-4 cells was 7.0 μM, while the 0% cytotoxic concn. for mock-infected MT-4 cells was 740 μM.  Although HEPT was inhibitory to various strains of HIV-1, it had no effect on the replication of other retroviruses, including HIV type 2.  In contrast with the dideoxynucleoside (i.e., azidothymidine) 5'-triphosphates, the triphosphate of HEPT did not interact with HIV-1 reverse transcriptase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqoXXr46wZ9Z7Vg90H21EOLACvtfcHk0ljwVWvFGse-UQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXptFaktw%253D%253D&md5=f4d0802cedbe7e906378fb1ece9da4bb</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1016%2F0006-291X%2889%2992756-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0006-291X%252889%252992756-3%26sid%3Dliteratum%253Aachs%26aulast%3DBaba%26aufirst%3DM.%26aulast%3DTanaka%26aufirst%3DH.%26aulast%3DDe%2BClercq%26aufirst%3DE.%26aulast%3DPauwels%26aufirst%3DR.%26aulast%3DBalzarini%26aufirst%3DJ.%26aulast%3DSchols%26aufirst%3DD.%26aulast%3DNakashima%26aufirst%3DH.%26aulast%3DPerno%26aufirst%3DC.%2BF.%26aulast%3DWalker%26aufirst%3DR.%2BT.%26aulast%3DMiyasaka%26aufirst%3DT.%26atitle%3DHighly%2520specific%2520inhibition%2520of%2520human%2520immunodeficiency%2520virus%2520type%25201%2520by%2520a%2520novel%25206-substituted%2520acyclouridine%2520derivative%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D1989%26volume%3D165%26spage%3D1375%26epage%3D1381%26doi%3D10.1016%2F0006-291X%2889%2992756-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miyasaka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baba, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayakawa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balzarini, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span> <span> </span><span class="NLM_article-title">A novel lead for specific anti-HIV-1 agents: 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1989</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">2507</span>– <span class="NLM_lpage">2509</span>, <span class="refDoi"> DOI: 10.1021/jm00132a002</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00132a002" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADyaL1MXlvFGgs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=1989&pages=2507-2509&author=T.+Miyasakaauthor=H.+Tanakaauthor=M.+Babaauthor=H.+Hayakawaauthor=R.+T.+Walkerauthor=J.+Balzariniauthor=E.+De+Clercq&title=A+novel+lead+for+specific+anti-HIV-1+agents%3A+1-%5B%282-hydroxyethoxy%29methyl%5D-6-%28phenylthio%29thymine&doi=10.1021%2Fjm00132a002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">A novel lead for specific anti-HIV-1 agents:  1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine</span></div><div class="casAuthors">Miyasaka, Tadashi; Tanaka, Hiromichi; Baba, Masanori; Hayakawa, Hiroyuki; Walker, Richard T.; Balzarini, Jan; De Clercq, Erik</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2507-9</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    </div><div class="casAbstract">Uracil acyclonucleosides I (R = H; R1 = H, F, Cl, Br, Me; R2 = SPh, iodo) were synthesized via lithiation of I (R = SiMe2CMe3; R1 = H, F, Cl; R2 = H) and reaction of the C-6 lithiated species with I2 or PhSSPh.  Among the compds. synthesized, I (R = H, R1 = Me, R2 = SPh) was a highly specific anti-HIV-1 agent with a selectivity index comparable to that of 2',3'-dideoxyadenosine.  The compd. showed no activity against HIV-2 and its triphosphate did not inhibit HIV-1 reverse transcriptase.  This suggests that this compd. manifests its activity through a mechanism different from that so far known for other nucleoside analogs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGos-Y3AIQxUPbVg90H21EOLACvtfcHk0ljwVWvFGse-UQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXlvFGgs70%253D&md5=fb74b02b0fdd8de1c5cc0486d550b4c6</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1021%2Fjm00132a002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00132a002%26sid%3Dliteratum%253Aachs%26aulast%3DMiyasaka%26aufirst%3DT.%26aulast%3DTanaka%26aufirst%3DH.%26aulast%3DBaba%26aufirst%3DM.%26aulast%3DHayakawa%26aufirst%3DH.%26aulast%3DWalker%26aufirst%3DR.%2BT.%26aulast%3DBalzarini%26aufirst%3DJ.%26aulast%3DDe%2BClercq%26aufirst%3DE.%26atitle%3DA%2520novel%2520lead%2520for%2520specific%2520anti-HIV-1%2520agents%253A%25201-%255B%25282-hydroxyethoxy%2529methyl%255D-6-%2528phenylthio%2529thymine%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1989%26volume%3D32%26spage%3D2507%26epage%3D2509%26doi%3D10.1021%2Fjm00132a002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pauwels, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andries, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desmyter, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schols, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kukla, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breslin, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raeymaeckers, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Gelder, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woestenborghs, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heykants, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schellekens, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janssen, M. A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janssen, P. A. J.</span></span> <span> </span><span class="NLM_article-title">Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>343</i></span>,  <span class="NLM_fpage">470</span>– <span class="NLM_lpage">474</span>, <span class="refDoi"> DOI: 10.1038/343470a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1038%2F343470a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1689015" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADyaK3cXhslGntL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=343&publication_year=1990&pages=470-474&author=R.+Pauwelsauthor=K.+Andriesauthor=J.+Desmyterauthor=D.+Scholsauthor=M.+J.+Kuklaauthor=H.+J.+Breslinauthor=A.+Raeymaeckersauthor=J.+Van+Gelderauthor=R.+Woestenborghsauthor=J.+Heykantsauthor=K.+Schellekensauthor=M.+A.+C.+Janssenauthor=E.+De+Clercqauthor=P.+A.+J.+Janssen&title=Potent+and+selective+inhibition+of+HIV-1+replication+in+vitro+by+a+novel+series+of+TIBO+derivatives&doi=10.1038%2F343470a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives</span></div><div class="casAuthors">Pauwels, Rudi; Andries, Koen; Desmyter, Jan; Schols, Dominique; Kukla, Michael J.; Breslin, Henry J.; Raeymaeckers, Alfons; Van Gelder, Jozef; Woestenborghs, Robert; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">343</span>
        (<span class="NLM_cas:issue">6257</span>),
    <span class="NLM_cas:pages">470-4</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    </div><div class="casAbstract">In the search for compds. active against human immunodeficiency virus (HIV), it was found that members of a novel series of tetrahydro-imidazol[4,5,1-jk][1,4]-benzodiazepin-2(1H)-one and -thione (TIBO) derivs. inhibit the replication of HIV-1, the main etiol. agent of AIDS, but not of HIV-2 or of any other DNA or RNA viruses.  In five cell systems, HIV-1 is inhibited by TIBO derivs. in nanomolar amts., which are 104-105 times lower that the cytotoxic concn.  The unprecedented specificity of these compds. may be due to an interaction with a reverse transcriptase-assocd. process.  By contrast, AZT (3'-azido-2',3'-dideoxythymidine), which is used for the treatment of AIDS, and DDC (2',3'-dideoxycytidine) and DDI (2',3'-dideoxyinosine), whose clin. application is being assessed, inhibit both HIV-1 and HIV-2 at concns. that, depending on the cell systems, are 2 to 4 orders of magnitude below their cytotoxic concn.  TIBO-derivs. are new chems. unrelated to any other antiviral agents.  They may be the most specific and potent inhibitors of HIV-1 replication studied so far.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodXWsMmazOdrVg90H21EOLACvtfcHk0ljwVWvFGse-UQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXhslGntL0%253D&md5=c303b47ff312a49dded6132ebbaa4ca1</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1038%2F343470a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F343470a0%26sid%3Dliteratum%253Aachs%26aulast%3DPauwels%26aufirst%3DR.%26aulast%3DAndries%26aufirst%3DK.%26aulast%3DDesmyter%26aufirst%3DJ.%26aulast%3DSchols%26aufirst%3DD.%26aulast%3DKukla%26aufirst%3DM.%2BJ.%26aulast%3DBreslin%26aufirst%3DH.%2BJ.%26aulast%3DRaeymaeckers%26aufirst%3DA.%26aulast%3DVan%2BGelder%26aufirst%3DJ.%26aulast%3DWoestenborghs%26aufirst%3DR.%26aulast%3DHeykants%26aufirst%3DJ.%26aulast%3DSchellekens%26aufirst%3DK.%26aulast%3DJanssen%26aufirst%3DM.%2BA.%2BC.%26aulast%3DDe%2BClercq%26aufirst%3DE.%26aulast%3DJanssen%26aufirst%3DP.%2BA.%2BJ.%26atitle%3DPotent%2520and%2520selective%2520inhibition%2520of%2520HIV-1%2520replication%2520in%2520vitro%2520by%2520a%2520novel%2520series%2520of%2520TIBO%2520derivatives%26jtitle%3DNature%26date%3D1990%26volume%3D343%26spage%3D470%26epage%3D474%26doi%3D10.1038%2F343470a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Debyser, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pauwels, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andries, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desmyter, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kukla, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janssen, P. A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De
Clercq, E.</span></span> <span> </span><span class="NLM_article-title">An antiviral target on reverse transcriptase of human immunodeficiency virus type 1 revealed by tetrahydroimidazo-[4,5,1-jk][1,4-benzodiazepin-2(1H)-one and -thione derivatives</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>88</i></span>,  <span class="NLM_fpage">1451</span>– <span class="NLM_lpage">1455</span>, <span class="refDoi"> DOI: 10.1073/pnas.88.4.1451</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1073%2Fpnas.88.4.1451" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1705038" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADyaK3MXhvF2isLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=88&publication_year=1991&pages=1451-1455&author=Z.+Debyserauthor=R.+Pauwelsauthor=K.+Andriesauthor=J.+Desmyterauthor=M.+J.+Kuklaauthor=P.+A.+J.+Janssenauthor=E.+De%0AClercq&title=An+antiviral+target+on+reverse+transcriptase+of+human+immunodeficiency+virus+type+1+revealed+by+tetrahydroimidazo-%5B4%2C5%2C1-jk%5D%5B1%2C4-benzodiazepin-2%281H%29-one+and+-thione+derivatives&doi=10.1073%2Fpnas.88.4.1451"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">An antiviral target on reverse transcriptase of human immunodeficiency virus type 1 revealed by tetrahydroimidazo[4,5,1-jk][1,4]benzodiazepin-2(1H)-one and -thione derivatives</span></div><div class="casAuthors">Debyser, Z.; Pauwels, R.; Andries, K.; Desmyter, J.; Kukla, M.; Janssen, P. A. J.; De Clercq, E.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">88</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1451-5</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    </div><div class="casAbstract">Screening of pharmacol. acceptable prototype compds. has recently led to the discovery of a series of ultraselective inhibitors of human immunodeficiency virus (HIV)-1 replication, the tetrahydroimidazo[4,5,1-jk][1,4]benzodiazepin-2(1H)-one and -thione (TIBO) derivs.  The TIBO compds. completely suppress the formation of proviral DNA in acutely infected cells, as revealed by polymerase chain reaction (PCR) anal.  TIBO derivs. are inhibitory to the reverse transcriptase (RT) of HIV-1 but not that of HIV-2 or other retroviruses.  The inhibition is most effective with poly(C)·oligo(dG) as the template/primer, and it is selectively directed against the RNA-dependent DNA polymerase activity and not the accompanying DNA-dependent DNA polymerase and RNase H activity of HIV-1 RT.  Kinetic studies point to an uncompetitive inhibition with regard to the template/primer.  TIBO compds. are active against HIV-1 replication through a unique interaction with HIV-1 RT.  The exptl. data indicate the existence of a target on HIV-1 RT that is responsible for the inhibition of replication and a mode of action unrelated to that of previously studied RT inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpN8No7nB72TrVg90H21EOLACvtfcHk0ljctkXAwhe03A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXhvF2isLc%253D&md5=5bea83a78e98a232c6a5669bcc54e73a</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1073%2Fpnas.88.4.1451&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.88.4.1451%26sid%3Dliteratum%253Aachs%26aulast%3DDebyser%26aufirst%3DZ.%26aulast%3DPauwels%26aufirst%3DR.%26aulast%3DAndries%26aufirst%3DK.%26aulast%3DDesmyter%26aufirst%3DJ.%26aulast%3DKukla%26aufirst%3DM.%2BJ.%26aulast%3DJanssen%26aufirst%3DP.%2BA.%2BJ.%26aulast%3DDe%2BClercq%26aufirst%3DE.%26atitle%3DAn%2520antiviral%2520target%2520on%2520reverse%2520transcriptase%2520of%2520human%2520immunodeficiency%2520virus%2520type%25201%2520revealed%2520by%2520tetrahydroimidazo-%255B4%252C5%252C1-jk%255D%255B1%252C4-benzodiazepin-2%25281H%2529-one%2520and%2520-thione%2520derivatives%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1991%26volume%3D88%26spage%3D1451%26epage%3D1455%26doi%3D10.1073%2Fpnas.88.4.1451" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baba, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ubasawa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takashima, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sekiya, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nitta, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Umezu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakashima, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mori, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shigeta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyasaka, T.</span></span> <span> </span><span class="NLM_article-title">Potent and selective inhibition of human immunodeficiency virus type 1 (HIV-1) by 5-ethyl-6-phenylthiouracil derivatives through their interaction with the HIV-1 reverse transcriptase</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>88</i></span>,  <span class="NLM_fpage">2356</span>– <span class="NLM_lpage">2360</span>, <span class="refDoi"> DOI: 10.1073/pnas.88.6.2356</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1073%2Fpnas.88.6.2356" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1706522" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADyaK3MXhvF2itr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=88&publication_year=1991&pages=2356-2360&author=M.+Babaauthor=E.+De+Clercqauthor=H.+Tanakaauthor=M.+Ubasawaauthor=H.+Takashimaauthor=K.+Sekiyaauthor=I.+Nittaauthor=K.+Umezuauthor=H.+Nakashimaauthor=S.+Moriauthor=S.+Shigetaauthor=R.+T.+Walkerauthor=T.+Miyasaka&title=Potent+and+selective+inhibition+of+human+immunodeficiency+virus+type+1+%28HIV-1%29+by+5-ethyl-6-phenylthiouracil+derivatives+through+their+interaction+with+the+HIV-1+reverse+transcriptase&doi=10.1073%2Fpnas.88.6.2356"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Potent and selective inhibition of human immunodeficiency virus type 1 (HIV-1) by 5-ethyl-6-phenylthiouracil derivatives through their interaction with the HIV-1 reverse transcriptase</span></div><div class="casAuthors">Baba, Masanori; De Clercq, Erik; Tanaka, Hiromichi; Ubasawa, Masaru; Takashima, Hideaki; Sekiya, Kouichi; Nitta, Issei; Umezu, Kohei; Nakashima, Hideki; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">88</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2356-60</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    </div><div class="casAbstract">Several 5-ethyl-6-(phenylthio)uracil analogs with potent and selective activity against human immunodeficiency virus (HIV) type 1 are described.  1-Benzyloxymethyl-5-ethyl-6-phenylthiouracil (I), the most potent congener of the series, inhibits HIV-1 replication in a variety of cell systems, including peripheral blood lymphocytes, at a concn. of 1.5-7.0 nM, which is lower by a factor of 103 than the 50% antivirally effective concn. of the parent compd. 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT).  The 5-ethyl-6-(phenylthio)uracil analogs, like HEPT itself, do not inhibit HIV-2 replication but do inhibit replication of 3'-azido-3'-deoxythymidine-resistant mutants of HIV-1.  1-Benzyloxymethyl-5-ethyl-6-phenylthiouracil and its congeners are targeted at the HIV-1 reverse transcriptase (RT).  They do not inhibit HIV-2 RT.  They do not need to be metabolized to exert their inhibitory effect on HIV-1 RT.  Yet this inhibitory effect is competitive with the natural substrate dTTP.  The HEPT derivs. represent a group of RT inhibitors with a unique mode of interaction with HIV-1 RT.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYnSYWYZLeGLVg90H21EOLACvtfcHk0ljctkXAwhe03A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXhvF2itr4%253D&md5=4146b2f499ed22492194b3acbb378c2d</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1073%2Fpnas.88.6.2356&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.88.6.2356%26sid%3Dliteratum%253Aachs%26aulast%3DBaba%26aufirst%3DM.%26aulast%3DDe%2BClercq%26aufirst%3DE.%26aulast%3DTanaka%26aufirst%3DH.%26aulast%3DUbasawa%26aufirst%3DM.%26aulast%3DTakashima%26aufirst%3DH.%26aulast%3DSekiya%26aufirst%3DK.%26aulast%3DNitta%26aufirst%3DI.%26aulast%3DUmezu%26aufirst%3DK.%26aulast%3DNakashima%26aufirst%3DH.%26aulast%3DMori%26aufirst%3DS.%26aulast%3DShigeta%26aufirst%3DS.%26aulast%3DWalker%26aufirst%3DR.%2BT.%26aulast%3DMiyasaka%26aufirst%3DT.%26atitle%3DPotent%2520and%2520selective%2520inhibition%2520of%2520human%2520immunodeficiency%2520virus%2520type%25201%2520%2528HIV-1%2529%2520by%25205-ethyl-6-phenylthiouracil%2520derivatives%2520through%2520their%2520interaction%2520with%2520the%2520HIV-1%2520reverse%2520transcriptase%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1991%26volume%3D88%26spage%3D2356%26epage%3D2360%26doi%3D10.1073%2Fpnas.88.6.2356" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baba, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ubasawa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takashima, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sekiya, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nitta, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Umezu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mori, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shigeta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyasaka, T.</span></span> <span> </span><span class="NLM_article-title">Highly potent and selective inhibition of human immunodeficiency virus type 1 by a novel series of 6-substituted acyclouridine derivatives</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">805</span>– <span class="NLM_lpage">810</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1711148" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADyaK3MXmslSjsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=1991&pages=805-810&author=M.+Babaauthor=E.+De+Clercqauthor=H.+Tanakaauthor=M.+Ubasawaauthor=H.+Takashimaauthor=K.+Sekiyaauthor=I.+Nittaauthor=K.+Umezuauthor=R.+T.+Walkerauthor=S.+Moriauthor=M.+Itoauthor=S.+Shigetaauthor=T.+Miyasaka&title=Highly+potent+and+selective+inhibition+of+human+immunodeficiency+virus+type+1+by+a+novel+series+of+6-substituted+acyclouridine+derivatives"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Highly potent and selective inhibition of human immunodeficiency virus type 1 by a novel series of 6-substituted acyclouridine derivatives</span></div><div class="casAuthors">Baba, Masanori; De Clercq, Erik; Tanaka, Hiromichi; Ubasawa, Masaru; Takashima, Hideaki; Sekiya, Kouichi; Nitta, Issei; Umezu, Kohei; Walker, Richard T.; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">805-10</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    </div><div class="casAbstract">In the search for novel derivs. of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT), the authors have found that several 5-ethyl-6-(3,5-dimethylphenylthio)uracil and 5-ethyl-6-(3,5-dimethylbenzyl)uracil analogs are potent and selective inhibitors of human immunodeficiency virus type 1 (HIV-1) replication in a variety of cell culture systems.  Of this series, 5-ethyl-1-ethoxymethyl-6-(3,5-dimethylbenzyl)uracil (E-EBU-dM) emerged as the most active congener.  Its 50% inhibitory concn. for HIV-1 (HTLV-IIIB) in MT-4 cells and peripheral blood lymphocytes is 2.2 and 0.45 nM, resp.  These concns. are more than 105-fold lower than the 50% cytotoxic concns. of E-EBU-dM for the host cells.  All compds. proved equally inhibitory to a no. of clin. HIV-1 isolates, including a 3'-azido-2',3'-dideoxythymidine-resistant variant.  However, as previously noted for HEPT, they do not inhibit human immunodeficiency virus type 2 replication.  Reverse transcriptase assays have revealed that these HEPT derivs. act specifically on HIV-1 reverse transcriptase, according to a mechanism that is different from that of the dideoxynucleosides.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdV0375oS1SbVg90H21EOLACvtfcHk0ljctkXAwhe03A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXmslSjsb0%253D&md5=4fb2a59c01b75b9cb24298bc5ec75ec7</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBaba%26aufirst%3DM.%26aulast%3DDe%2BClercq%26aufirst%3DE.%26aulast%3DTanaka%26aufirst%3DH.%26aulast%3DUbasawa%26aufirst%3DM.%26aulast%3DTakashima%26aufirst%3DH.%26aulast%3DSekiya%26aufirst%3DK.%26aulast%3DNitta%26aufirst%3DI.%26aulast%3DUmezu%26aufirst%3DK.%26aulast%3DWalker%26aufirst%3DR.%2BT.%26aulast%3DMori%26aufirst%3DS.%26aulast%3DIto%26aufirst%3DM.%26aulast%3DShigeta%26aufirst%3DS.%26aulast%3DMiyasaka%26aufirst%3DT.%26atitle%3DHighly%2520potent%2520and%2520selective%2520inhibition%2520of%2520human%2520immunodeficiency%2520virus%2520type%25201%2520by%2520a%2520novel%2520series%2520of%25206-substituted%2520acyclouridine%2520derivatives%26jtitle%3DMol.%2520Pharmacol.%26date%3D1991%26volume%3D39%26spage%3D805%26epage%3D810" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baba, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shigeta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuasa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takashima, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sekiya, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ubasawa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyasaka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span> <span> </span><span class="NLM_article-title">Preclinical evaluation of MKC-442, a highly potent and specific inhibitor of human immunodeficiency virus type 1 <i>in vitro</i></span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">688</span>– <span class="NLM_lpage">692</span>, <span class="refDoi"> DOI: 10.1128/AAC.38.4.688</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1128%2FAAC.38.4.688" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=7518216" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADyaK2cXis1SltLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=1994&pages=688-692&author=M.+Babaauthor=S.+Shigetaauthor=S.+Yuasaauthor=H.+Takashimaauthor=K.+Sekiyaauthor=M.+Ubasawaauthor=H.+Tanakaauthor=T.+Miyasakaauthor=R.+T.+Walkerauthor=E.+De+Clercq&title=Preclinical+evaluation+of+MKC-442%2C+a+highly+potent+and+specific+inhibitor+of+human+immunodeficiency+virus+type+1+in+vitro&doi=10.1128%2FAAC.38.4.688"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical evaluation of MKC-442, a highly potent and specific inhibitor of human immunodeficiency virus type 1 in vitro</span></div><div class="casAuthors">Baba, Masanori; Shigeta, Shiro; Yuasa, Satoshi; Takashima, Hideaki; Sekiya, Kouichi; Ubasawa, Masaru; Tanaka, Hiromichi; Miyasaka, Tadashi; Walker, Richard T.; De Clercq, Erik</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">688-92</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    </div><div class="casAbstract">MKC-442 (6-benzyl-1-ethoxymethyl-5-isopropyluracil or I-EBU) has recently been identified as a highly potent and specific inhibitor of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase.  Since the compd. has favorable pharmacokinetic and toxicity profiles in vivo, the authors have evaluated MKC-442 for its inhibitory effect on the replication of HIV-1 in various cell cultures, including human peripheral blood lymphocytes and monocyte-macrophages.  The 50 and 90% effective concns. for HIV-1 (HTLV-IIIB strain) replication in MT-4 cells were 15 and 98 nM, resp.  MKC-442 was also inhibitory to HIV-1 replication in peripheral blood lymphocytes and monocyte-macrophages as detd. by the prodn. of p24 antigens in the culture supernatant.  Fluorescence-activated cell sorter anal. revealed that MKC-442 was equally active against zidovudine-resistant mutants and zidovudine-susceptible strains.  Furthermore, combinations of MKC-442 with either 3'-azido-3'-deoxythymidine, 2',3'-dideoxycytidine, or 2',3'-dideoxyinosine synergistically inhibited the replication of HIV-1.  Thus, MKC-442 has been considered as a candidate for clin. efficacy studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoU-uQYSEovsbVg90H21EOLACvtfcHk0ljWuDWTxL0Dbg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXis1SltLo%253D&md5=9afb2a93369d5bdf1d734c4148902677</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1128%2FAAC.38.4.688&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.38.4.688%26sid%3Dliteratum%253Aachs%26aulast%3DBaba%26aufirst%3DM.%26aulast%3DShigeta%26aufirst%3DS.%26aulast%3DYuasa%26aufirst%3DS.%26aulast%3DTakashima%26aufirst%3DH.%26aulast%3DSekiya%26aufirst%3DK.%26aulast%3DUbasawa%26aufirst%3DM.%26aulast%3DTanaka%26aufirst%3DH.%26aulast%3DMiyasaka%26aufirst%3DT.%26aulast%3DWalker%26aufirst%3DR.%2BT.%26aulast%3DDe%2BClercq%26aufirst%3DE.%26atitle%3DPreclinical%2520evaluation%2520of%2520MKC-442%252C%2520a%2520highly%2520potent%2520and%2520specific%2520inhibitor%2520of%2520human%2520immunodeficiency%2520virus%2520type%25201%2520in%2520vitro%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D1994%26volume%3D38%26spage%3D688%26epage%3D692%26doi%3D10.1128%2FAAC.38.4.688" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baeten, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palanee-Phillips, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soto-Torres, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Govender, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mgodi, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matovu Kiweewa, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nair, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mhlanga, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siva, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bekker, L.-G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeenarain, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaffoor, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinson, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makanani, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pather, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naidoo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Husnik, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parikh, U. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mellors, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marzinke, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendrix, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Straten, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramjee, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chirenje, Z. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakabiito, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taha, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheckter, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berthiaume, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Livant, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ndase, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patterson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Germuga, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galaska, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bunge, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szydlo, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montgomery, E. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mensch, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torjesen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grossman, C. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chakhtoura, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenberg, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGowan, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hillier, S.</span></span> <span> </span><span class="NLM_article-title">Use of a vaginal ring containing dapivirine for HIV-1 prevention in women</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>375</i></span>,  <span class="NLM_fpage">2121</span>– <span class="NLM_lpage">2132</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1506110</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1056%2FNEJMoa1506110" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=26900902" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADC%252BC28XitFaqt7%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=375&publication_year=2016&pages=2121-2132&author=J.+M.+Baetenauthor=T.+Palanee-Phillipsauthor=E.+R.+Brownauthor=K.+Schwartzauthor=L.+E.+Soto-Torresauthor=V.+Govenderauthor=N.+M.+Mgodiauthor=F.+Matovu+Kiweewaauthor=G.+Nairauthor=F.+Mhlangaauthor=S.+Sivaauthor=L.-G.+Bekkerauthor=N.+Jeenarainauthor=Z.+Gaffoorauthor=F.+Martinsonauthor=B.+Makananiauthor=A.+Patherauthor=L.+Naidooauthor=M.+Husnikauthor=B.+A.+Richardsonauthor=U.+M.+Parikhauthor=J.+W.+Mellorsauthor=M.+A.+Marzinkeauthor=C.+W.+Hendrixauthor=A.+van+der+Stratenauthor=G.+Ramjeeauthor=Z.+M.+Chirenjeauthor=C.+Nakabiitoauthor=T.+E.+Tahaauthor=J.+Jonesauthor=A.+Mayoauthor=R.+Scheckterauthor=J.+Berthiaumeauthor=E.+Livantauthor=C.+Jacobsonauthor=P.+Ndaseauthor=R.+Whiteauthor=K.+Pattersonauthor=D.+Germugaauthor=B.+Galaskaauthor=K.+Bungeauthor=D.+Singhauthor=D.+W.+Szydloauthor=E.+T.+Montgomeryauthor=B.+S.+Menschauthor=K.+Torjesenauthor=C.+I.+Grossmanauthor=N.+Chakhtouraauthor=A.+Nelauthor=Z.+Rosenbergauthor=I.+McGowanauthor=S.+Hillier&title=Use+of+a+vaginal+ring+containing+dapivirine+for+HIV-1+prevention+in+women&doi=10.1056%2FNEJMoa1506110"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Use of a vaginal ring containing dapivirine for HIV-1 prevention in women</span></div><div class="casAuthors">Baeten, J. M.; Palanee-Phillips, T.; Brown, E. R.; Schwartz, K.; Soto-Torres, L. E.; Govender, V.; Mgodi, N. M.; Kiweewa, F. Matovu; Nair, G.; Mhlanga, F.; Siva, S.; Bekker, L.-G.; Jeenarain, N.; Gaffoor, Z.; Martinson, F.; Makanani, B.; Pather, A.; Naidoo, L.; Husnik, M.; Richardson, B. A.; Parikh, U. M.; Mellors, J. W.; Marzinke, M. A.; Hendrix, C. W.; van der Straten, A.; Ramjee, G.; Chirenje, Z. M.; Nakabiito, C.; Taha, T. E.; Jones, J.; Mayo, A.; Scheckter, R.; Berthiaume, J.; Livant, E.; Jacobson, C.; Ndase, P.; White, R.; Patterson, K.; Germuga, D.; Galaska, B.; Bunge, K.; Singh, D.; Szydlo, D. W.; Montgomery, E. T.; Mensch, B. S.; Torjesen, K.; Grossman, C. I.; Chakhtoura, N.; Nel, A.; Rosenberg, Z.; McGowan, I.; Hillier, S.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">375</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">2121-2132</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND Antiretroviral medications that are used as prophylaxis can prevent acquisition of human immunodeficiency virus type 1 (HIV-1) infection.  However, in clin. trials among African women, the incidence of HIV-1 infection was not reduced, probably because of low adherence.  Longer-acting methods of drug delivery, such as vaginal rings, may simplify use of antiretroviral medications and provide HIV-1 protection.  METHODS We conducted a phase 3, randomized, double-blind, placebo-controlled trial of a monthly vaginal ring contg. dapivirine, a non-nucleoside HIV-1 reverse-transcriptase inhibitor, involving women between the ages of 18 and 45 years in Malawi, South Africa, Uganda, and Zimbabwe.  RESULTS Among the 2629 women who were enrolled, 168 HIV-1 infections occurred: 71 in the dapivirine group and 97 in the placebo group (incidence, 3.3 and 4.5 per 100 personyears, resp.).  The incidence of HIV-1 infection in the dapivirine group was lower by 27% (95% confidence interval [CI], 1 to 46; P = 0.046) than that in the placebo group.  In an anal. that excluded data from two sites that had reduced rates of retention and adherence, the incidence of HIV-1 infection in the dapivirine group was lower by 37% (95% CI, 12 to 56; P = 0.007) than that in the placebo group.  In a post hoc anal., higher rates of HIV-1 protection were obsd. among women over the age of 21 years (56%; 95% CI, 31 to 71; P<0.001) but not among those 21 years of age or younger (-27%; 95% CI, -133 to 31; P = 0.45), a difference that was correlated with reduced adherence.  The rates of adverse medical events and antiretroviral resistance among women who acquired HIV-1 infection were similar in the two groups.  CONCLUSIONS A monthly vaginal ring contg. dapivirine reduced the risk of HIV-1 infection among African women, with increased efficacy in subgroups with evidence of increased adherence.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohJjDza7DrCrVg90H21EOLACvtfcHk0ljWuDWTxL0Dbg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitFaqt7%252FN&md5=be3a0c5c5d1a57d7b3343d84b9a28e9c</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1506110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1506110%26sid%3Dliteratum%253Aachs%26aulast%3DBaeten%26aufirst%3DJ.%2BM.%26aulast%3DPalanee-Phillips%26aufirst%3DT.%26aulast%3DBrown%26aufirst%3DE.%2BR.%26aulast%3DSchwartz%26aufirst%3DK.%26aulast%3DSoto-Torres%26aufirst%3DL.%2BE.%26aulast%3DGovender%26aufirst%3DV.%26aulast%3DMgodi%26aufirst%3DN.%2BM.%26aulast%3DMatovu%2BKiweewa%26aufirst%3DF.%26aulast%3DNair%26aufirst%3DG.%26aulast%3DMhlanga%26aufirst%3DF.%26aulast%3DSiva%26aufirst%3DS.%26aulast%3DBekker%26aufirst%3DL.-G.%26aulast%3DJeenarain%26aufirst%3DN.%26aulast%3DGaffoor%26aufirst%3DZ.%26aulast%3DMartinson%26aufirst%3DF.%26aulast%3DMakanani%26aufirst%3DB.%26aulast%3DPather%26aufirst%3DA.%26aulast%3DNaidoo%26aufirst%3DL.%26aulast%3DHusnik%26aufirst%3DM.%26aulast%3DRichardson%26aufirst%3DB.%2BA.%26aulast%3DParikh%26aufirst%3DU.%2BM.%26aulast%3DMellors%26aufirst%3DJ.%2BW.%26aulast%3DMarzinke%26aufirst%3DM.%2BA.%26aulast%3DHendrix%26aufirst%3DC.%2BW.%26aulast%3Dvan%2Bder%2BStraten%26aufirst%3DA.%26aulast%3DRamjee%26aufirst%3DG.%26aulast%3DChirenje%26aufirst%3DZ.%2BM.%26aulast%3DNakabiito%26aufirst%3DC.%26aulast%3DTaha%26aufirst%3DT.%2BE.%26aulast%3DJones%26aufirst%3DJ.%26aulast%3DMayo%26aufirst%3DA.%26aulast%3DScheckter%26aufirst%3DR.%26aulast%3DBerthiaume%26aufirst%3DJ.%26aulast%3DLivant%26aufirst%3DE.%26aulast%3DJacobson%26aufirst%3DC.%26aulast%3DNdase%26aufirst%3DP.%26aulast%3DWhite%26aufirst%3DR.%26aulast%3DPatterson%26aufirst%3DK.%26aulast%3DGermuga%26aufirst%3DD.%26aulast%3DGalaska%26aufirst%3DB.%26aulast%3DBunge%26aufirst%3DK.%26aulast%3DSingh%26aufirst%3DD.%26aulast%3DSzydlo%26aufirst%3DD.%2BW.%26aulast%3DMontgomery%26aufirst%3DE.%2BT.%26aulast%3DMensch%26aufirst%3DB.%2BS.%26aulast%3DTorjesen%26aufirst%3DK.%26aulast%3DGrossman%26aufirst%3DC.%2BI.%26aulast%3DChakhtoura%26aufirst%3DN.%26aulast%3DNel%26aufirst%3DA.%26aulast%3DRosenberg%26aufirst%3DZ.%26aulast%3DMcGowan%26aufirst%3DI.%26aulast%3DHillier%26aufirst%3DS.%26atitle%3DUse%2520of%2520a%2520vaginal%2520ring%2520containing%2520dapivirine%2520for%2520HIV-1%2520prevention%2520in%2520women%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2016%26volume%3D375%26spage%3D2121%26epage%3D2132%26doi%3D10.1056%2FNEJMoa1506110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Niekerk, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kapiga, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bekker, L.-G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gama, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gill, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamali, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kotze, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Louw, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mabude, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miti, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kusemererwa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tempelman, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carstens, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devlin, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isaacs, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malherbe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mans, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nuttall, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russell, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ntshele, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smit, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solai, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spence, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steytler, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Windle, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borremans, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Resseler, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Roey, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parys, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vangeneugden, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Baelen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenberg, Z.</span></span> <span> </span><span class="NLM_article-title">Safety and efficacy of a dapivirine vaginal ring for HIV prevention in women</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>375</i></span>,  <span class="NLM_fpage">2133</span>– <span class="NLM_lpage">2143</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1602046</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1056%2FNEJMoa1602046" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=27959766" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADC%252BC28XitFaqt7%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=375&publication_year=2016&pages=2133-2143&author=A.+Nelauthor=N.+van+Niekerkauthor=S.+Kapigaauthor=L.-G.+Bekkerauthor=C.+Gamaauthor=K.+Gillauthor=A.+Kamaliauthor=P.+Kotzeauthor=C.+Louwauthor=Z.+Mabudeauthor=N.+Mitiauthor=S.+Kusemererwaauthor=H.+Tempelmanauthor=H.+Carstensauthor=B.+Devlinauthor=M.+Isaacsauthor=M.+Malherbeauthor=W.+Mansauthor=J.+Nuttallauthor=M.+Russellauthor=S.+Ntsheleauthor=M.+Smitauthor=L.+Solaiauthor=P.+Spenceauthor=J.+Steytlerauthor=K.+Windleauthor=M.+Borremansauthor=S.+Resselerauthor=J.+Van+Roeyauthor=W.+Parysauthor=T.+Vangeneugdenauthor=B.+Van+Baelenauthor=Z.+Rosenberg&title=Safety+and+efficacy+of+a+dapivirine+vaginal+ring+for+HIV+prevention+in+women&doi=10.1056%2FNEJMoa1602046"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Safety and efficacy of a dapivirine vaginal ring for HIV prevention in women</span></div><div class="casAuthors">Nel, A.; van Niekerk, N.; Kapiga, S.; Bekker, L.-G.; Gama, C.; Gill, K.; Kamali, A.; Kotze, P.; Louw, C.; Mabude, Z.; Miti, N.; Kusemererwa, S.; Tempelman, H.; Carstens, H.; Devlin, B.; Isaacs, M.; Malherbe, M.; Mans, W.; Nuttall, J.; Russell, M.; Ntshele, S.; Smit, M.; Solai, L.; Spence, P.; Steytler, J.; Windle, K.; Borremans, M.; Resseler, S.; Van Roey, J.; Parys, W.; Vangeneugden, T.; Van Baelen, B.; Rosenberg, Z.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">375</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">2133-2143</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: The incidence of human immunodeficiency virus (HIV) infection remains high among women in sub-Saharan Africa.  We evaluated the safety and efficacy of extended use of a vaginal ring contg. dapivirine for the prevention of HIV infection in 1959 healthy, sexually active women, 18 to 45 years of age, from seven communities in South Africa and Uganda.  METHODS: In this randomized, double-blind, placebo-controlled, phase 3 trial, we randomly assigned participants in a 2:1 ratio to receive vaginal rings contg. either 25 mg of dapivirine or placebo.  Participants inserted the rings themselves every 4 wk for up to 24 mo.  The primary efficacy end point was the rate of HIV type 1 (HIV-1) seroconversion.  RESULTS: A total of 77 participants in the dapivirine group underwent HIV-1 seroconversion during 1888 person-years of follow-up (4.1 seroconversions per 100 person-years), as compared with 56 in the placebo group who underwent HIV-1 seroconversion during 917 person-years of follow-up (6.1 seroconversions per 100 person-years).  The incidence of HIV-1 infection was 31% lower in the dapivirine group than in the placebo group (hazard ratio, 0.69; 95% confidence interval [CI], 0.49 to 0.99; P = 0.04).  There was no significant difference in efficacy of the dapivirine ring among women older than 21 years of age (hazard ratio for infection, 0.63; 95% CI, 0.41 to 0.97) and those 21 years of age or younger (hazard ratio, 0.85; 95% CI, 0.45 to 1.60; P = 0.43 for treatment-by-age interaction).  Among participants with HIV-1 infection, nonnucleoside reverse-transcriptase inhibitor resistance mutations were detected in 14 of 77 participants in the dapivirine group (18.2%) and in 9 of 56 (16.1%) in the placebo group.  Serious adverse events occurred more often in the dapivirine group (in 38 participants [2.9%]) than in the placebo group (in 6 [0.9%]).  However, no clear pattern was identified.  CONCLUSIONS: Among women in sub-Saharan Africa, the dapivirine ring was not assocd. with any safety concerns and was assocd. with a rate of acquisition of HIV-1 infection that was lower than the rate with placebo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_wx1pEUBBCrVg90H21EOLACvtfcHk0ljGvyRz7i2Tyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitFaqt7%252FM&md5=970e69fc1a0fc725671e9e372fba6737</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1602046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1602046%26sid%3Dliteratum%253Aachs%26aulast%3DNel%26aufirst%3DA.%26aulast%3Dvan%2BNiekerk%26aufirst%3DN.%26aulast%3DKapiga%26aufirst%3DS.%26aulast%3DBekker%26aufirst%3DL.-G.%26aulast%3DGama%26aufirst%3DC.%26aulast%3DGill%26aufirst%3DK.%26aulast%3DKamali%26aufirst%3DA.%26aulast%3DKotze%26aufirst%3DP.%26aulast%3DLouw%26aufirst%3DC.%26aulast%3DMabude%26aufirst%3DZ.%26aulast%3DMiti%26aufirst%3DN.%26aulast%3DKusemererwa%26aufirst%3DS.%26aulast%3DTempelman%26aufirst%3DH.%26aulast%3DCarstens%26aufirst%3DH.%26aulast%3DDevlin%26aufirst%3DB.%26aulast%3DIsaacs%26aufirst%3DM.%26aulast%3DMalherbe%26aufirst%3DM.%26aulast%3DMans%26aufirst%3DW.%26aulast%3DNuttall%26aufirst%3DJ.%26aulast%3DRussell%26aufirst%3DM.%26aulast%3DNtshele%26aufirst%3DS.%26aulast%3DSmit%26aufirst%3DM.%26aulast%3DSolai%26aufirst%3DL.%26aulast%3DSpence%26aufirst%3DP.%26aulast%3DSteytler%26aufirst%3DJ.%26aulast%3DWindle%26aufirst%3DK.%26aulast%3DBorremans%26aufirst%3DM.%26aulast%3DResseler%26aufirst%3DS.%26aulast%3DVan%2BRoey%26aufirst%3DJ.%26aulast%3DParys%26aufirst%3DW.%26aulast%3DVangeneugden%26aufirst%3DT.%26aulast%3DVan%2BBaelen%26aufirst%3DB.%26aulast%3DRosenberg%26aufirst%3DZ.%26atitle%3DSafety%2520and%2520efficacy%2520of%2520a%2520dapivirine%2520vaginal%2520ring%2520for%2520HIV%2520prevention%2520in%2520women%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2016%26volume%3D375%26spage%3D2133%26epage%3D2143%26doi%3D10.1056%2FNEJMoa1602046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tantillo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobo-Molina, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nanni, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyer, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pauwels, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andries, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janssen, P. A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnold, E.</span></span> <span> </span><span class="NLM_article-title">Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse tTranscriptase: implications for mechanisms of drug inhibition and resistance</span>. <i>J. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>243</i></span>,  <span class="NLM_fpage">369</span>– <span class="NLM_lpage">387</span>, <span class="refDoi"> DOI: 10.1006/jmbi.1994.1665</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1006%2Fjmbi.1994.1665" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=7525966" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADyaK2cXmvFWrt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=243&publication_year=1994&pages=369-387&author=C.+Tantilloauthor=J.+Dingauthor=A.+Jacobo-Molinaauthor=R.+G.+Nanniauthor=P.+L.+Boyerauthor=S.+H.+Hughesauthor=R.+Pauwelsauthor=K.+Andriesauthor=P.+A.+J.+Janssenauthor=E.+Arnold&title=Locations+of+anti-AIDS+drug+binding+sites+and+resistance+mutations+in+the+three-dimensional+structure+of+HIV-1+reverse+tTranscriptase%3A+implications+for+mechanisms+of+drug+inhibition+and+resistance&doi=10.1006%2Fjmbi.1994.1665"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase: implications for mechanisms of drug inhibition and resistance</span></div><div class="casAuthors">Tantillo, Chris; Ding, Jianping; Jacobo-Molina, Alfredo; Nanni, Raymond G.; Boyer, Paul L.; Hughes, Stephen H.; Pauwels, Rudi; Andries, Koen; Janssen, Paul A. J.; Arnold, Edward</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">243</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">369-87</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Academic</span>)
        </div><div class="casAbstract">A review with many refs.  The locations HIV-1 reverse transcriptase (RT) nucleoside and non-nucleoside inhibitor-binding sites and inhibitor-resistance mutations are analyzed in the context of the three-dimensional structure of the enzyme and implications for mechanisms of drug inhibition and resistance are discussed.  In order to help identify residues that may play a role in inhibitor binding, solvent accessibilities of amino acids that comprise the inhibitor-binding sites in the structure of HIV-1 RT complexed with a dsDNA template-primer are anal.  While some mutations that cause resistance to nucleoside analogs, such as AZT, ddI, and ddC, are located near enough to the dNTP-binding site to directly interfere with binding of nucleoside analogs, many are located away from the dNTP-binding site and more likely confer resistance by other mechanisms.  Many of the latter mutations are located on the surface of the DNA-binding cleft and may lead to altered template-primer positioning or conformation, causing a distortion of the geometry of the polymerase active site and consequent discrimination between normal and altered dNTP substrates.  Other nucleoside analog-resistance mutations located on the periphery of the dNTP-binding site may exert their effects via altered interactions with dNTP-binding site residues.  The structure of the hydrophobic region in HIV-I RT that binds non-nucleoside inhibitors, for example, nevirapine and TIBO, has been analyzed in the absence of bound ligand.  The pocket that is present when non-nucleoside inhibitors are bound is not obsd. in the inhibitor-free structure of HIV-1 RT with dsDNA.  In particular, it is filled by Tyr181 and Tyr188, suggesting that the pocket is formed primarily by rotation of these large arom. side chains.  Existing biochem. data, taken together with the three-dimensional structure of HIV-I RT, makes it possible to propose potential mechanisms of inhibition by non-nucleoside inhibitors.  One such mechanism is local distortion of HIV-1 RT structural elements thought to participate in catalysis: the β9-β10 hairpin (which contains polymerase active site residues) and the β12-β13 hairpin ("primer grip").  An alternative possibility is restricted mobility of the p66 thumb subdomain, which is supported by the observation that structural elements of the non-nucleoside inhibitor-binding pocket may act as a "hinge" for the thumb.  Mutations that have been shown to confer resistance to non-nucleoside inhibitors are obsd. to cluster around the pocket, suggest that most of these resistance mutations lead to direct alteration of inhibitor binding.  A comparison of residues in the non-nucleoside inhibitor-binding pocket of HIV-1 RT and the corresponding residues in HIV-2 RT can explain the low activity of non-nucleoside compds. against HIV-2 RT.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRLzLpBoN22LVg90H21EOLACvtfcHk0ljGvyRz7i2Tyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXmvFWrt7k%253D&md5=212f30b81658c8549abdacf4af19f1c6</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1006%2Fjmbi.1994.1665&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fjmbi.1994.1665%26sid%3Dliteratum%253Aachs%26aulast%3DTantillo%26aufirst%3DC.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DJacobo-Molina%26aufirst%3DA.%26aulast%3DNanni%26aufirst%3DR.%2BG.%26aulast%3DBoyer%26aufirst%3DP.%2BL.%26aulast%3DHughes%26aufirst%3DS.%2BH.%26aulast%3DPauwels%26aufirst%3DR.%26aulast%3DAndries%26aufirst%3DK.%26aulast%3DJanssen%26aufirst%3DP.%2BA.%2BJ.%26aulast%3DArnold%26aufirst%3DE.%26atitle%3DLocations%2520of%2520anti-AIDS%2520drug%2520binding%2520sites%2520and%2520resistance%2520mutations%2520in%2520the%2520three-dimensional%2520structure%2520of%2520HIV-1%2520reverse%2520tTranscriptase%253A%2520implications%2520for%2520mechanisms%2520of%2520drug%2520inhibition%2520and%2520resistance%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D1994%26volume%3D243%26spage%3D369%26epage%3D387%26doi%3D10.1006%2Fjmbi.1994.1665" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ding, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moereels, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koymans, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andries, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janssen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnold, E.</span></span> <span> </span><span class="NLM_article-title">Structure of HIV-1 RT/TIBO R 86183 complex reveals similarity in the binding of diverse nonnucleoside inhibitors</span>. <i>Nat. Struct. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">407</span>– <span class="NLM_lpage">415</span>, <span class="refDoi"> DOI: 10.1038/nsb0595-407</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1038%2Fnsb0595-407" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=1995&pages=407-415&author=J.+Dingauthor=K.+Dasauthor=H.+Moereelsauthor=L.+Koymansauthor=P.+Andriesauthor=S.+Janssenauthor=E.+Hughesauthor=E.+Arnold&title=Structure+of+HIV-1+RT%2FTIBO+R+86183+complex+reveals+similarity+in+the+binding+of+diverse+nonnucleoside+inhibitors&doi=10.1038%2Fnsb0595-407"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1038%2Fnsb0595-407&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsb0595-407%26sid%3Dliteratum%253Aachs%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DDas%26aufirst%3DK.%26aulast%3DMoereels%26aufirst%3DH.%26aulast%3DKoymans%26aufirst%3DL.%26aulast%3DAndries%26aufirst%3DP.%26aulast%3DJanssen%26aufirst%3DS.%26aulast%3DHughes%26aufirst%3DE.%26aulast%3DArnold%26aufirst%3DE.%26atitle%3DStructure%2520of%2520HIV-1%2520RT%252FTIBO%2520R%252086183%2520complex%2520reveals%2520similarity%2520in%2520the%2520binding%2520of%2520diverse%2520nonnucleoside%2520inhibitors%26jtitle%3DNat.%2520Struct.%2520Mol.%2520Biol.%26date%3D1995%26volume%3D2%26spage%3D407%26epage%3D415%26doi%3D10.1038%2Fnsb0595-407" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chimirri, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grasso, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monforte, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monforte, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zappalà, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruno, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicolò, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pannecouque, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witvrouw, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span> <span> </span><span class="NLM_article-title">Synthesis, structure and in vitro anti-human immunodeficiency virus activity of novel 3-Methyl-1H,3H-Thiazolo[3,4-a]Benzimidazoles</span>. <i>Antiviral Chem. Chemother.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">431</span>– <span class="NLM_lpage">438</span>, <span class="refDoi"> DOI: 10.1177/095632029800900507</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1177%2F095632029800900507" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=9875396" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADyaK1cXmsFCmsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=1998&pages=431-438&author=A.+Chimirriauthor=S.+Grassoauthor=A.+Monforteauthor=P.+Monforteauthor=A.+Raoauthor=M.+Zappal%C3%A0author=G.+Brunoauthor=F.+Nicol%C3%B2author=C.+Pannecouqueauthor=M.+Witvrouwauthor=E.+De+Clercq&title=Synthesis%2C+structure+and+in+vitro+anti-human+immunodeficiency+virus+activity+of+novel+3-Methyl-1H%2C3H-Thiazolo%5B3%2C4-a%5DBenzimidazoles&doi=10.1177%2F095632029800900507"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, structure and in vitro anti-human immunodeficiency virus activity of novel 3-methyl-1H,3H-thiazolo[3,4-a]benzimidazoles</span></div><div class="casAuthors">Chimirri, A.; Monforte, A. M.; Monforte, P.; Rao, A.; Zappala, M.; Bruno, G.; Nicolo, F.; Pannecouque, C.; Witvrouw, M.; De Clercq, E.</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Chemistry & Chemotherapy</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">431-438</span>CODEN:
                <span class="NLM_cas:coden">ACCHEH</span>;
        ISSN:<span class="NLM_cas:issn">0956-3202</span>.
    
            (<span class="NLM_cas:orgname">International Medical Press</span>)
        </div><div class="casAbstract">A series of novel 1-aryl-3-methyl-1H,3H-thiazolo[3,4-a]benzimidazoles (TBZ analogs) were synthesized and investigated as anti-human immunodeficiency virus (HIV) agents to study the effects of structural modifications on antiviral activity and cytotoxicity.  They were proved to inhibit significantly HIV-1 replication in vitro without showing inhibitory activity on HIV-2 or simian immunodeficiency virus.  Their potency was influenced by the presence of suitable substituents in the Ph ring at C-1 as well as by their stereochem. characteristics.  In fact, the most active compd. of the series was the trans-1-(2,6-difluorophenyl)-3-methyl-1H,3H-thiazolo[3,4-a]benzimidazole, in which the butterfly-like conformation is stabilized by two intramol. hydrogen bonds between the fluorine atoms and H-1 and H-3.  This was made possible by the trans arrangement of C-1 and C-3 substituents, as shown by x-ray and NMR anal.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVKhkh2GecubVg90H21EOLACvtfcHk0liZfphwO4BMAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXmsFCmsrk%253D&md5=ebf72ed3bd2963fc2b3794c1a4071a05</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1177%2F095632029800900507&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F095632029800900507%26sid%3Dliteratum%253Aachs%26aulast%3DChimirri%26aufirst%3DA.%26aulast%3DGrasso%26aufirst%3DS.%26aulast%3DMonforte%26aufirst%3DA.%26aulast%3DMonforte%26aufirst%3DP.%26aulast%3DRao%26aufirst%3DA.%26aulast%3DZappal%25C3%25A0%26aufirst%3DM.%26aulast%3DBruno%26aufirst%3DG.%26aulast%3DNicol%25C3%25B2%26aufirst%3DF.%26aulast%3DPannecouque%26aufirst%3DC.%26aulast%3DWitvrouw%26aufirst%3DM.%26aulast%3DDe%2BClercq%26aufirst%3DE.%26atitle%3DSynthesis%252C%2520structure%2520and%2520in%2520vitro%2520anti-human%2520immunodeficiency%2520virus%2520activity%2520of%2520novel%25203-Methyl-1H%252C3H-Thiazolo%255B3%252C4-a%255DBenzimidazoles%26jtitle%3DAntiviral%2520Chem.%2520Chemother.%26date%3D1998%26volume%3D9%26spage%3D431%26epage%3D438%26doi%3D10.1177%2F095632029800900507" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span> <span> </span><span class="NLM_article-title">Non-nucleoside reverse transcriptase inhibitors (NNRTIs): past, present and future</span>. <i>Chem. Biodiversity</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">44</span>– <span class="NLM_lpage">64</span>, <span class="refDoi"> DOI: 10.1002/cbdv.200490012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1002%2Fcbdv.200490012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=17191775" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADC%252BD2cXitV2nsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2004&pages=44-64&author=E.+De+Clercq&title=Non-nucleoside+reverse+transcriptase+inhibitors+%28NNRTIs%29%3A+past%2C+present+and+future&doi=10.1002%2Fcbdv.200490012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Non-nucleoside reverse transcriptase inhibitors (NNRTIs): past, present, and future</span></div><div class="casAuthors">De Clercq, Erik</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biodiversity</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">44-64</span>CODEN:
                <span class="NLM_cas:coden">CBHIAM</span>;
        ISSN:<span class="NLM_cas:issn">1612-1872</span>.
    
            (<span class="NLM_cas:orgname">Verlag Helvetica Chimica Acta AG</span>)
        </div><div class="casAbstract">A review with refs.  Non-nucleoside reverse transcriptase (RT) inhibitors (NNRTIs) have become an inherent ingredient of the drug combination schemes that are currently used in the treatment of human immunodeficiency virus type 1 (HIV-1) infections.  Starting from the 1-[(2-hydroxyethoxy)methyl]-6-(phenylsulfanyl)thymine (HEPT) and 4,5,6,7-tetrahydroimidazo[4,5,1-jk][1,4]benzodiazepin-2(1H)-one and -thione (TIBO) derivs., numerous classes of compds. have been described as NNRTIs.  Only three compds. have so far been approved for clin. use: nevirapine, delavirdine, and efavirenz.  NNRTIs are notorious for rapidly leading to virus-drug resistance development, primarily based on the emergence of the K103N and Y181C mutations in the HIV-1 RT.  Newer NNRTIs, such as capravirine, dapivirine (TMC 125), and DPC 083, are resilient to these "NNRTI" mutations, and, therefore, offer considerable promise as future anti-HIV-1 drugs.  NNRTIs are targeted at a specific "pocket" binding site within the HIV-1 RT, that is distinct from, but both spatially and functionally related to, the catalytic site, where the nucleoside RT inhibitors (NRTIs) and nucleotide RT inhibitors (NtRTIs) interact.  NNRTIs have acquired a definitive position, as part of a combination regimen with NRTIs and NtRTIs, in the first-line treatment of HIV-1 infections.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjIKlSEqbUHLVg90H21EOLACvtfcHk0liZfphwO4BMAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXitV2nsrY%253D&md5=4e681cc76745c156d8494e57136fd777</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1002%2Fcbdv.200490012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcbdv.200490012%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BClercq%26aufirst%3DE.%26atitle%3DNon-nucleoside%2520reverse%2520transcriptase%2520inhibitors%2520%2528NNRTIs%2529%253A%2520past%252C%2520present%2520and%2520future%26jtitle%3DChem.%2520Biodiversity%26date%3D2004%26volume%3D1%26spage%3D44%26epage%3D64%26doi%3D10.1002%2Fcbdv.200490012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Janssen, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewi, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnold, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daeyaert, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Jonge, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heeres, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koymans, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vinkers, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guillemont, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasquier, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kukla, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ludovici, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andries, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Bethune, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pauwels, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, A. D.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frenkel, Y. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medaer, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Knaep, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohets, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Clerck, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lampo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoffels, P.</span></span> <span> </span><span class="NLM_article-title">In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2- pyrimidinyl]amino]benzonitrile (R278474, rilpivirine)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">1901</span>– <span class="NLM_lpage">1909</span>, <span class="refDoi"> DOI: 10.1021/jm040840e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm040840e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADC%252BD2cXptlOisb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=1901-1909&author=P.+A.+Janssenauthor=P.+J.+Lewiauthor=E.+Arnoldauthor=F.+Daeyaertauthor=M.+de+Jongeauthor=J.+Heeresauthor=L.+Koymansauthor=M.+Vinkersauthor=J.+Guillemontauthor=E.+Pasquierauthor=M.+Kuklaauthor=D.+Ludoviciauthor=K.+Andriesauthor=M.+P.+de+Bethuneauthor=R.+Pauwelsauthor=K.+Dasauthor=A.+D.+Clarkauthor=Y.+V.+Frenkelauthor=S.+H.+Hughesauthor=B.+Medaerauthor=F.+De+Knaepauthor=H.+Bohetsauthor=F.+De+Clerckauthor=A.+Lampoauthor=P.+Williamsauthor=P.+Stoffels&title=In+search+of+a+novel+anti-HIV+drug%3A+multidisciplinary+coordination+in+the+discovery+of+4-%5B%5B4-%5B%5B4-%5B%281E%29-2-cyanoethenyl%5D-2%2C6-dimethylphenyl%5Damino%5D-2-+pyrimidinyl%5Damino%5Dbenzonitrile+%28R278474%2C+rilpivirine%29&doi=10.1021%2Fjm040840e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">In Search of a Novel Anti-HIV Drug: Multidisciplinary Coordination in the Discovery of 4-[[4-[[4-[(1E)-2-Cyanoethenyl]-2,6-dimethylphenyl]amino]-2- pyrimidinyl]amino]benzonitrile (R278474, Rilpivirine)</span></div><div class="casAuthors">Janssen, Paul A. J.; Lewi, Paul J.; Arnold, Eddy; Daeyaert, Frits; de Jonge, Marc; Heeres, Jan; Koymans, Luc; Vinkers, Maarten; Guillemont, Jerome; Pasquier, Elisabeth; Kukla, Mike; Ludovici, Don; Andries, Koen; de Bethune, Marie-Pierre; Pauwels, Rudi; Das, Kalyan; Clark, Art D., Jr.; Frenkel, Yulia Volovik; Hughes, Stephen H.; Medaer, Bart; De Knaep, Fons; Bohets, Hilde; De Clerck, Fred; Lampo, Ann; Williams, Peter; Stoffels, Paul</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1901-1909</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Ideally, an anti-HIV drug should (1) be highly active against wild-type and mutant HIV without allowing breakthrough; (2) have high oral bioavailability and long elimination half-life, allowing once-daily oral treatment at low doses; (3) have minimal adverse effects; and (4) be easy to synthesize and formulate.  R278474, a new diarylpyrimidine (DAPY) non-nucleoside reverse transcriptase inhibitor (NNRTI), appears to meet these criteria and to be suitable for high compliance oral treatment of HIV-1 infection.  The discovery of R278474 was the result of a coordinated multidisciplinary effort involving medicinal chemists, virologists, crystallographers, mol. modelers, toxicologists, anal. chemists, pharmacists, and many others.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8upgC3x1GuLVg90H21EOLACvtfcHk0lhY6Gen6Nxc5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXptlOisb8%253D&md5=d4b650dcaa248d5cdb1dd500135c8f7e</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1021%2Fjm040840e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm040840e%26sid%3Dliteratum%253Aachs%26aulast%3DJanssen%26aufirst%3DP.%2BA.%26aulast%3DLewi%26aufirst%3DP.%2BJ.%26aulast%3DArnold%26aufirst%3DE.%26aulast%3DDaeyaert%26aufirst%3DF.%26aulast%3Dde%2BJonge%26aufirst%3DM.%26aulast%3DHeeres%26aufirst%3DJ.%26aulast%3DKoymans%26aufirst%3DL.%26aulast%3DVinkers%26aufirst%3DM.%26aulast%3DGuillemont%26aufirst%3DJ.%26aulast%3DPasquier%26aufirst%3DE.%26aulast%3DKukla%26aufirst%3DM.%26aulast%3DLudovici%26aufirst%3DD.%26aulast%3DAndries%26aufirst%3DK.%26aulast%3Dde%2BBethune%26aufirst%3DM.%2BP.%26aulast%3DPauwels%26aufirst%3DR.%26aulast%3DDas%26aufirst%3DK.%26aulast%3DClark%26aufirst%3DA.%2BD.%26aulast%3DFrenkel%26aufirst%3DY.%2BV.%26aulast%3DHughes%26aufirst%3DS.%2BH.%26aulast%3DMedaer%26aufirst%3DB.%26aulast%3DDe%2BKnaep%26aufirst%3DF.%26aulast%3DBohets%26aufirst%3DH.%26aulast%3DDe%2BClerck%26aufirst%3DF.%26aulast%3DLampo%26aufirst%3DA.%26aulast%3DWilliams%26aufirst%3DP.%26aulast%3DStoffels%26aufirst%3DP.%26atitle%3DIn%2520search%2520of%2520a%2520novel%2520anti-HIV%2520drug%253A%2520multidisciplinary%2520coordination%2520in%2520the%2520discovery%2520of%25204-%255B%255B4-%255B%255B4-%255B%25281E%2529-2-cyanoethenyl%255D-2%252C6-dimethylphenyl%255Damino%255D-2-%2520pyrimidinyl%255Damino%255Dbenzonitrile%2520%2528R278474%252C%2520rilpivirine%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D1901%26epage%3D1909%26doi%3D10.1021%2Fjm040840e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pauwels, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baba, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schols, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakashima, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balzarini, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debyser, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murrer, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thornton, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bridger, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fricker, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henson, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abrams, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Picker, D.</span></span> <span> </span><span class="NLM_article-title">Potent and selective inhibition of human immunodeficiency virus (HIV)-1 and HIV-2 replication by a class of bicyclams interacting with a viral uncoating event</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>89</i></span>,  <span class="NLM_fpage">5286</span>– <span class="NLM_lpage">5290</span>, <span class="refDoi"> DOI: 10.1073/pnas.89.12.5286</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1073%2Fpnas.89.12.5286" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1608936" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADyaK38XkvVaqtro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=1992&pages=5286-5290&author=E.+De+Clercqauthor=N.+Yamamotoauthor=R.+Pauwelsauthor=M.+Babaauthor=D.+Scholsauthor=H.+Nakashimaauthor=J.+Balzariniauthor=Z.+Debyserauthor=B.+A.+Murrerauthor=D.+Schwartzauthor=D.+Thorntonauthor=G.+Bridgerauthor=S.+Frickerauthor=G.+Hensonauthor=M.+Abramsauthor=D.+Picker&title=Potent+and+selective+inhibition+of+human+immunodeficiency+virus+%28HIV%29-1+and+HIV-2+replication+by+a+class+of+bicyclams+interacting+with+a+viral+uncoating+event&doi=10.1073%2Fpnas.89.12.5286"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Potent and selective inhibition of human immunodeficiency virus (HIV)-1 and HIV-2 replication by a class of cicyclams interacting with a viral uncoating event</span></div><div class="casAuthors">De Clercq, Erik; Yamamoto, Naohiko; Pauwels, Rudi; Baba, Masanori; Schols, Dominique; Nakashima, Hideki; Balzarini, Jan; Debyser, Zeger; Murrer, Barry A.; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5286-90</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    </div><div class="casAbstract">A series of bicyclams have been shown to be potent and selective inhibitors of human immunodeficiency virus (HIV).  The compds. are inhibitory to the replication of various HIV-1 and HIV-2 strains in various human T-cell systems, including peripheral blood lymphocytes, at 0.14-1.4 μM, without being toxic to the host cells at 2.2 mM.  The bicyclam JM2763 (I) is active against 3'-azido-3'-deoxythymidine (zidovudine; AZT)-resistant HIV-1 strains and acts additively with AZT.  Mechanism of action studies revealed that the bicyclams (i.e., I) interact with an early event of the retrovirus replicative cycle, which could be tentatively identified as a viral uncoating event.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdkZ-WLPGwyLVg90H21EOLACvtfcHk0lhY6Gen6Nxc5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38XkvVaqtro%253D&md5=67db6384097fedeb73572d8f7628be34</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1073%2Fpnas.89.12.5286&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.89.12.5286%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BClercq%26aufirst%3DE.%26aulast%3DYamamoto%26aufirst%3DN.%26aulast%3DPauwels%26aufirst%3DR.%26aulast%3DBaba%26aufirst%3DM.%26aulast%3DSchols%26aufirst%3DD.%26aulast%3DNakashima%26aufirst%3DH.%26aulast%3DBalzarini%26aufirst%3DJ.%26aulast%3DDebyser%26aufirst%3DZ.%26aulast%3DMurrer%26aufirst%3DB.%2BA.%26aulast%3DSchwartz%26aufirst%3DD.%26aulast%3DThornton%26aufirst%3DD.%26aulast%3DBridger%26aufirst%3DG.%26aulast%3DFricker%26aufirst%3DS.%26aulast%3DHenson%26aufirst%3DG.%26aulast%3DAbrams%26aufirst%3DM.%26aulast%3DPicker%26aufirst%3DD.%26atitle%3DPotent%2520and%2520selective%2520inhibition%2520of%2520human%2520immunodeficiency%2520virus%2520%2528HIV%2529-1%2520and%2520HIV-2%2520replication%2520by%2520a%2520class%2520of%2520bicyclams%2520interacting%2520with%2520a%2520viral%2520uncoating%2520event%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1992%26volume%3D89%26spage%3D5286%26epage%3D5290%26doi%3D10.1073%2Fpnas.89.12.5286" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pauwels, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balzarini, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witvrouw, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Vreese, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debyser, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenwirth, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peichl, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Datema, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thornton, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skerlj, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaul, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padmanabhan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bridger, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henson, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abrams, M.</span></span> <span> </span><span class="NLM_article-title">Highly potent and selective inhibition of human immunodeficiency virus by the bicyclam derivative JM3100</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">668</span>– <span class="NLM_lpage">674</span>, <span class="refDoi"> DOI: 10.1128/AAC.38.4.668</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1128%2FAAC.38.4.668" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=7913308" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A280%3ADyaK2czgsVWjtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=1994&pages=668-674&author=E.+De+Clercqauthor=N.+Yamamotoauthor=R.+Pauwelsauthor=J.+Balzariniauthor=M.+Witvrouwauthor=K.+De+Vreeseauthor=Z.+Debyserauthor=B.+Rosenwirthauthor=P.+Peichlauthor=R.+Datemaauthor=D.+Thorntonauthor=R.+Skerljauthor=F.+Gaulauthor=S.+Padmanabhanauthor=G.+Bridgerauthor=G.+Hensonauthor=M.+Abrams&title=Highly+potent+and+selective+inhibition+of+human+immunodeficiency+virus+by+the+bicyclam+derivative+JM3100&doi=10.1128%2FAAC.38.4.668"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Highly potent and selective inhibition of human immunodeficiency virus by the bicyclam derivative JM3100</span></div><div class="casAuthors">De Clercq E; Yamamoto N; Pauwels R; Balzarini J; Witvrouw M; De Vreese K; Debyser Z; Rosenwirth B; Peichl P; Datema R</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial agents and chemotherapy</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">668-74</span>
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    </div><div class="casAbstract">Bicyclams, in which the cyclam (1,4,8,11-tetraazacyclotetradecane) moieties are tethered via an aliphatic bridge (i.e., propylene, as in JM2763) are potent and selective inhibitors of human immunodeficiency virus type 1 (HIV-1) and type 2 (HIV-2) (E.  De Clercq, N.  Yamamoto, R.  Pauwels, M.  Baba, D.  Schols, H.  Nakashima, J.  Balzarini, Z.  Debyser, B.  A.  Murrer, D.  Schwartz, D.  Thornton, G.  Bridger, S.  Fricker, G.  Henson, M.  Abrams, and D.  Picker, Proc.  Natl.  Acad.  Sci.  USA 89:5286-5290, 1992).  We have now found that the bicyclam JM3100, in which the cyclam moieties are tethered by an aromatic bridge [i.e., phenylenebis(methylene)], inhibits the replication of various HIV-1 and HIV-2 strains in various cell lines at a 50% effective concentration (EC50) of 1 to 10 ng/ml, which is about 100-fold lower than the concentration required for JM2763 to inhibit HIV replication and at least 100,000-fold lower than the cytotoxic concentration (> 500 micrograms/ml).  In primary T4 lymphocytes or primary monocytes, JM3100 proved inhibitory to HIV-1(IIIB) and several clinical HIV-1 isolates at an EC50 of less than 1 ng/ml.  On the basis of time-of-addition experiments, JM3100 appeared to interact with a viral uncoating event, and this was further corroborated by an uncoating assay in which RNase sensitivity of [5-3H]uridine-labeled virions was monitored.  In addition, but possibly mechanistically related, JM3100 blocks formation of infectious particles.  JM3100 was also found to interfere directly with virus-induced syncytium formation, albeit at a higher concentration (1 to 2 microgram/ml) than that required for inhibition of viral replication.  Following subcutaneous injection of 10 mg of JM3100 per kg of body weight to rabbits, anti-HIV activity was detected in serum corresponding to serum drug levels exceeding for at least 6 h by >100-fold the EC(50) required to inhibit HIV replication in vitro.  When combined with either 3'-azido-2',3' -dideoxythymidine or 2',3' -dideoxyinosine, JM3100 achieved a additive inhibition of HIV replication, and when repeatedly subcultivated in the presence of JM3100, the virus remained sensitive to the compound for at least 30 passages (120 days) in cell culture.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTwBIyQ7x-DR8K3uFsUIZtkfW6udTcc2eY6YfN5BSOLvLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK2czgsVWjtQ%253D%253D&md5=8dc19841c28dcd2ce9277898f69addf1</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1128%2FAAC.38.4.668&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.38.4.668%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BClercq%26aufirst%3DE.%26aulast%3DYamamoto%26aufirst%3DN.%26aulast%3DPauwels%26aufirst%3DR.%26aulast%3DBalzarini%26aufirst%3DJ.%26aulast%3DWitvrouw%26aufirst%3DM.%26aulast%3DDe%2BVreese%26aufirst%3DK.%26aulast%3DDebyser%26aufirst%3DZ.%26aulast%3DRosenwirth%26aufirst%3DB.%26aulast%3DPeichl%26aufirst%3DP.%26aulast%3DDatema%26aufirst%3DR.%26aulast%3DThornton%26aufirst%3DD.%26aulast%3DSkerlj%26aufirst%3DR.%26aulast%3DGaul%26aufirst%3DF.%26aulast%3DPadmanabhan%26aufirst%3DS.%26aulast%3DBridger%26aufirst%3DG.%26aulast%3DHenson%26aufirst%3DG.%26aulast%3DAbrams%26aufirst%3DM.%26atitle%3DHighly%2520potent%2520and%2520selective%2520inhibition%2520of%2520human%2520immunodeficiency%2520virus%2520by%2520the%2520bicyclam%2520derivative%2520JM3100%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D1994%26volume%3D38%26spage%3D668%26epage%3D674%26doi%3D10.1128%2FAAC.38.4.668" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schols, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esté, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henson, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span> <span> </span><span class="NLM_article-title">Bicyclams, a class of potent anti-HIV agents, are targeted at the HIV coreceptor fusin/CXCR-4</span>. <i>Antiviral Res.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">147</span>– <span class="NLM_lpage">156</span>, <span class="refDoi"> DOI: 10.1016/S0166-3542(97)00025-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1016%2FS0166-3542%2897%2900025-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=9298754" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADyaK2sXltl2nt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=1997&pages=147-156&author=D.+Scholsauthor=J.+A.+Est%C3%A9author=G.+Hensonauthor=E.+De+Clercq&title=Bicyclams%2C+a+class+of+potent+anti-HIV+agents%2C+are+targeted+at+the+HIV+coreceptor+fusin%2FCXCR-4&doi=10.1016%2FS0166-3542%2897%2900025-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Bicyclams, a class of potent anti-HIV agents, are targeted at the HIV coreceptor Fusin/CXCR-4</span></div><div class="casAuthors">Schols, Dominique; Este, JoseA.; Henson, Geoffrey; De Clercq, Erik</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">147-156</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Bicyclams are a novel class of antiviral compds. which are highly potent and selective inhibitors of the replication of HIV-1 and HIV-2.  The prototype compd., AMD3100, has an IC50 of 1-10 ng/mL, which is a least 100000 fold lower than the cytotoxic concn.  AMD3100 does not inhibit virus binding to the CD4 receptor and based on time-of-addn. expts., has been assumed to interact with the HIV fusion-uncoating process.  Resistance of HIV-1 strains to AMD3100 is assocd. with the accumulation of several mutations in the viral envelope glycoprotein gp120.  Here, we demonstrate that AMD3100 interacts with fusin (CXCR-4), the coreceptor used by T-tropic viruses to infect the target cells.  The replication of NL4-3 wild type virus and NL4-3 dextran sulfate-resistant virus was inhibited by the CXC-chemokine, stromal cell-derived factor 1 (SDF-1), the natural ligand for CXCR-4.  In contrast, the replication of the HIV-1 NL4-3 AMD3100-resistant virus was no longer inhibited by SDF-1.  The bicyclams are the first low-mol.-wt. anti-HIV agents shown to interact with the coreceptor for T-tropic viruses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGNGBTNI6aUrVg90H21EOLACvtfcHk0lhynfd_3w5S9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXltl2nt7w%253D&md5=f718cc6007c7874c015c9724903aa1e5</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1016%2FS0166-3542%2897%2900025-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0166-3542%252897%252900025-9%26sid%3Dliteratum%253Aachs%26aulast%3DSchols%26aufirst%3DD.%26aulast%3DEst%25C3%25A9%26aufirst%3DJ.%2BA.%26aulast%3DHenson%26aufirst%3DG.%26aulast%3DDe%2BClercq%26aufirst%3DE.%26atitle%3DBicyclams%252C%2520a%2520class%2520of%2520potent%2520anti-HIV%2520agents%252C%2520are%2520targeted%2520at%2520the%2520HIV%2520coreceptor%2520fusin%252FCXCR-4%26jtitle%3DAntiviral%2520Res.%26date%3D1997%26volume%3D35%26spage%3D147%26epage%3D156%26doi%3D10.1016%2FS0166-3542%2897%2900025-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schols, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Struyf, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Damme, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esté, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henson, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span> <span> </span><span class="NLM_article-title">Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor CXCR4</span>. <i>J. Exp. Med.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>186</i></span>,  <span class="NLM_fpage">1383</span>– <span class="NLM_lpage">1388</span>, <span class="refDoi"> DOI: 10.1084/jem.186.8.1383</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1084%2Fjem.186.8.1383" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=9334378" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADyaK2sXmvVelu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=186&publication_year=1997&pages=1383-1388&author=D.+Scholsauthor=S.+Struyfauthor=J.+Van+Dammeauthor=J.+Est%C3%A9author=G.+Hensonauthor=E.+De+Clercq&title=Inhibition+of+T-tropic+HIV+strains+by+selective+antagonization+of+the+chemokine+receptor+CXCR4&doi=10.1084%2Fjem.186.8.1383"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor CXCR4</span></div><div class="casAuthors">Schols, Dominique; Struyf, Sofie; Van Damme, Jo; Este, Jose A.; Henson, Geoffrey; De Clercq, Erik</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Experimental Medicine</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">186</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1383-1388</span>CODEN:
                <span class="NLM_cas:coden">JEMEAV</span>;
        ISSN:<span class="NLM_cas:issn">0022-1007</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">Bicyclams are a novel class of antiviral compds. that are highly potent and selective inhibitors of the replication of HIV-1 and HIV-2.  Surprisingly, however, when the prototype compd. AMD3100 was tested against M-tropic virus strains such as BaL, ADA, JR-CSF, and SF-162 in human peripheral blood mononuclear cells, the compd. was completely inactive.  Because of the specific and potent inhibitory effect of AMD3100 on T-tropic viruses, but not M-tropic viruses, it was verified that AMD3100 interacts with the CXC-chemokine receptor CXCR4, the main coreceptor used by T-tropic viruses.  AMD3100 dose dependently inhibited the binding of a specific CXCR4 monoclonal antibody to SUP-T1 cells as measured by flow cytometry.  It did not inhibit the binding of the biotinylated CC-chemokine macrophage inflammatory protein (MIP) α1 or MIP-1β, ligands for the chemokine receptor CCR5 (the main coreceptor for M-tropic viruses).  In addn., AMD3100 completely blocked (a) the Ca2+ flux at 100 ng/mL in lymphocytic SUP-T1 and monocytic THP-1 cells, and (b) the chemotactic responses of THP-1 cells induced by stromal cell-derived factor 1α, the natural ligand for CXCR4.  Finally, AMD3100 had no effect on the Ca2+ flux induced by the CC-chemokines MIP-1α, regulated on activation normal T cell expressed and secreted (RANTES; also a ligand for CCR5), or monocyte chemoattractant protein 3 (a ligand for CCR1 and CCR2b), nor was it able to induce Ca2+ fluxes by itself.  The bicyclams are, to our knowledge, the first low mol. wt. anti-HIV agents shown to act as potent and selective CXCR4 antagonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQ5dssLvsuLrVg90H21EOLACvtfcHk0ljqFrKLNgqrqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXmvVelu7s%253D&md5=1d0dce8df250d0723de73cf83c98d92a</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1084%2Fjem.186.8.1383&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1084%252Fjem.186.8.1383%26sid%3Dliteratum%253Aachs%26aulast%3DSchols%26aufirst%3DD.%26aulast%3DStruyf%26aufirst%3DS.%26aulast%3DVan%2BDamme%26aufirst%3DJ.%26aulast%3DEst%25C3%25A9%26aufirst%3DJ.%26aulast%3DHenson%26aufirst%3DG.%26aulast%3DDe%2BClercq%26aufirst%3DE.%26atitle%3DInhibition%2520of%2520T-tropic%2520HIV%2520strains%2520by%2520selective%2520antagonization%2520of%2520the%2520chemokine%2520receptor%2520CXCR4%26jtitle%3DJ.%2520Exp.%2520Med.%26date%3D1997%26volume%3D186%26spage%3D1383%26epage%3D1388%26doi%3D10.1084%2Fjem.186.8.1383" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hendrix, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flexner, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacFarland, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giandomenico, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuchs, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Redpath, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bridger, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henson, G. W.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">1667</span>– <span class="NLM_lpage">1673</span>, <span class="refDoi"> DOI: 10.1128/AAC.44.6.1667-1673.2000</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1128%2FAAC.44.6.1667-1673.2000" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10817726" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADC%252BD3cXjs1Ols70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2000&pages=1667-1673&author=C.+W.+Hendrixauthor=C.+Flexnerauthor=R.+T.+MacFarlandauthor=C.+Giandomenicoauthor=E.+J.+Fuchsauthor=E.+Redpathauthor=G.+Bridgerauthor=G.+W.+Henson&title=Pharmacokinetics+and+safety+of+AMD-3100%2C+a+novel+antagonist+of+the+CXCR-4+chemokine+receptor%2C+in+human+volunteers&doi=10.1128%2FAAC.44.6.1667-1673.2000"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers</span></div><div class="casAuthors">Hendrix, Craig W.; Flexner, Charles; MacFarland, Ronald T.; Giandomenico, Christen; Fuchs, Edward J.; Redpath, Ella; Bridger, Gary; Henson, Geoffrey W.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1667-1673</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">AMD-3100, a bicyclam, is a novel agent that uniquely inhibits the entry of human immunodeficiency virus type 1 (HIV-1) into CD4+ T cells via selective blockade of the chemokine CXCR-4 receptor.  Twelve healthy volunteers were given AMD-3100 as a single 15-min i.v. infusion at 10, 20, 40, or 80 μg/kg.  Five subjects also received a single s.c. injection of AMD-3100 (40 or 80 μg/kg).  Three subjects received two escalating oral doses each (80 and 160 μg/kg).  All subjects tolerated their dose(s) well without any grade 2 toxicity or dose adjustment.  Six subjects experienced mild, transient symptoms, primarily gastrointestinal in nature and not dose related.  All subjects experienced a dose-related elevation of the white blood cell count, from 1.5 to 3.1 times the baseline, which returned to the baseline 24 h after dosing.  AMD-3100 demonstrated dose proportionality for the max. drug concn. in serum (Cmax) and the area under the concn.-time curve from 0 h to ∞ (AUC0-∞) over the entire dose range.  At the highest i.v. dose (80 μg/kg), the median Cmax was 515 (range, 470 to 521) ng/mL and the AUC0-∞ was 1,044 (range, 980 to 1,403) ng-h/mL.  The median systemic absorption after s.c. dosing was 87% (range, 67 to 106%).  No drug was detectable in the blood following oral dosing.  Using a two-compartment model, the median pharmacokinetic parameter ests. (ranges) were as follows: vol. of distribution, 0.34 (0.27 to 0.36) liter/kg; clearance, 1.30 (0.97 to 1.34) liters/h; elimination half-life, 3.6 (3.5 to 4.9) h.  After a single, well-tolerated i.v. dose of AMD-3100, concns. were sustained for 12 h above the in vitro antiretroviral 90% inhibitory concns. and for 8 h above antiviral concns. identified in the SCID-hu Thy/Liv mouse model of HIV infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqE-1RkZBONd7Vg90H21EOLACvtfcHk0ljqFrKLNgqrqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXjs1Ols70%253D&md5=972608b60b1d2cb7a0150ebd0280b629</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1128%2FAAC.44.6.1667-1673.2000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.44.6.1667-1673.2000%26sid%3Dliteratum%253Aachs%26aulast%3DHendrix%26aufirst%3DC.%2BW.%26aulast%3DFlexner%26aufirst%3DC.%26aulast%3DMacFarland%26aufirst%3DR.%2BT.%26aulast%3DGiandomenico%26aufirst%3DC.%26aulast%3DFuchs%26aufirst%3DE.%2BJ.%26aulast%3DRedpath%26aufirst%3DE.%26aulast%3DBridger%26aufirst%3DG.%26aulast%3DHenson%26aufirst%3DG.%2BW.%26atitle%3DPharmacokinetics%2520and%2520safety%2520of%2520AMD-3100%252C%2520a%2520novel%2520antagonist%2520of%2520the%2520CXCR-4%2520chemokine%2520receptor%252C%2520in%2520human%2520volunteers%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2000%26volume%3D44%26spage%3D1667%26epage%3D1673%26doi%3D10.1128%2FAAC.44.6.1667-1673.2000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liles, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broxmeyer, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodger, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hübel, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hangoc, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bridger, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henson, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calandra, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dale, D. C.</span></span> <span> </span><span class="NLM_article-title">Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>102</i></span>,  <span class="NLM_fpage">2728</span>– <span class="NLM_lpage">2730</span>, <span class="refDoi"> DOI: 10.1182/blood-2003-02-0663</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1182%2Fblood-2003-02-0663" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=12855591" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADC%252BD3sXotF2ntb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2003&pages=2728-2730&author=W.+C.+Lilesauthor=H.+E.+Broxmeyerauthor=E.+Rodgerauthor=B.+Woodauthor=K.+H%C3%BCbelauthor=S.+Cooperauthor=G.+Hangocauthor=G.+J.+Bridgerauthor=G.+W.+Hensonauthor=G.+Calandraauthor=D.+C.+Dale&title=Mobilization+of+hematopoietic+progenitor+cells+in+healthy+volunteers+by+AMD3100%2C+a+CXCR4+antagonist&doi=10.1182%2Fblood-2003-02-0663"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist</span></div><div class="casAuthors">Liles, W. Conrad; Broxmeyer, Hal E.; Rodger, Elin; Wood, Brent; Huebel, Kai; Cooper, Scott; Hangoc, Giao; Bridger, Gary J.; Henson, Geoffrey W.; Calandra, Gary; Dale, David C.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2728-2730</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Stromal cell-derived factor 1 (SDF1/CXCL12) and its cognate receptor, CXCR4, play key regulatory roles in CD34+ cell trafficking.  We investigated whether AMD3100, a selective CXCR4 antagonist, could mobilize hematopoietic progenitor cells from marrow to peripheral blood in healthy human volunteers.  Initially, 10 persons each received a single dose of AMD3100 (80 μg/kg s.c.), which induced rapid, generalized leukocytosis assocd. with an increase in peripheral blood CD34+ cells, representing pluripotent hematopoietic progenitors by in vitro colony-forming unit assays, from 3.8 ± 0.5/μL to 20.7 ± 3.5/μL at 6 h.  Subsequent dose-response studies showed a max. increase in circulating CD34+ cells from 2.6 ± 0.3/μL to 40.4 ± 3.4/μL at 9 h after 240 μg/kg AMD3100.  Serial administration of AMD3100 (80 μg/kg/d for 3 days) resulted in consistent, reversible increases in peripheral blood CD34+ cells.  AMD3100 was well tolerated and caused only mild, transient toxicity.  These findings suggest potential clin. application of AMD3100 for CD34+ cell mobilization and collection for hematopoietic stem cell transplantation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTITlBQQs3EbVg90H21EOLACvtfcHk0ljqFrKLNgqrqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXotF2ntb8%253D&md5=c0a000f9ac7f12cf85f4bd086f205240</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1182%2Fblood-2003-02-0663&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2003-02-0663%26sid%3Dliteratum%253Aachs%26aulast%3DLiles%26aufirst%3DW.%2BC.%26aulast%3DBroxmeyer%26aufirst%3DH.%2BE.%26aulast%3DRodger%26aufirst%3DE.%26aulast%3DWood%26aufirst%3DB.%26aulast%3DH%25C3%25BCbel%26aufirst%3DK.%26aulast%3DCooper%26aufirst%3DS.%26aulast%3DHangoc%26aufirst%3DG.%26aulast%3DBridger%26aufirst%3DG.%2BJ.%26aulast%3DHenson%26aufirst%3DG.%2BW.%26aulast%3DCalandra%26aufirst%3DG.%26aulast%3DDale%26aufirst%3DD.%2BC.%26atitle%3DMobilization%2520of%2520hematopoietic%2520progenitor%2520cells%2520in%2520healthy%2520volunteers%2520by%2520AMD3100%252C%2520a%2520CXCR4%2520antagonist%26jtitle%3DBlood%26date%3D2003%26volume%3D102%26spage%3D2728%26epage%3D2730%26doi%3D10.1182%2Fblood-2003-02-0663" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Broxmeyer, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orschell, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clapp, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hangoc, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plett, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liles, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham-Evans, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calandra, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bridger, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dale, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srour, E. F.</span></span> <span> </span><span class="NLM_article-title">Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist</span>. <i>J. Exp. Med.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>201</i></span>,  <span class="NLM_fpage">1307</span>– <span class="NLM_lpage">1318</span>, <span class="refDoi"> DOI: 10.1084/jem.20041385</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1084%2Fjem.20041385" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=15837815" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjs1Citbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=201&publication_year=2005&pages=1307-1318&author=H.+E.+Broxmeyerauthor=C.+M.+Orschellauthor=D.+W.+Clappauthor=G.+Hangocauthor=S.+Cooperauthor=P.+A.+Plettauthor=W.+C.+Lilesauthor=X.+Liauthor=B.+Graham-Evansauthor=T.+B.+Campbellauthor=G.+Calandraauthor=G.+Bridgerauthor=D.+C.+Daleauthor=E.+F.+Srour&title=Rapid+mobilization+of+murine+and+human+hematopoietic+stem+and+progenitor+cells+with+AMD3100%2C+a+CXCR4+antagonist&doi=10.1084%2Fjem.20041385"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist</span></div><div class="casAuthors">Broxmeyer, Hal E.; Orschell, Christie M.; Clapp, D. Wade; Hangoc, Giao; Cooper, Scott; Plett, P. Artur; Liles, W. Conrad; Li, Xiaxin; Graham-Evans, Barbara; Campbell, Timothy B.; Calandra, Gary; Bridger, Gary; Dale, David C.; Srour, Edward F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Experimental Medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">201</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1307-1318</span>CODEN:
                <span class="NLM_cas:coden">JEMEAV</span>;
        ISSN:<span class="NLM_cas:issn">0022-1007</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">Improving approaches for hematopoietic stem cell (HSC) and hematopoietic progenitor cell (HPC) mobilization is clin. important because increased nos. of these cells are needed for enhanced transplantation.  Chemokine stromal cell derived factor-1 (also known as CXCL12) is believed to be involved in retention of HSCs and HPCs in bone marrow.  AMD3100, a selective antagonist of CXCL12 that binds to its receptor, CXCR4, was evaluated in murine and human systems for mobilizing capacity, alone and in combination with granulocyte colony-stimulating factor (G-CSF).  AMD3100 induced rapid mobilization of mouse and human HPCs and synergistically augmented G-CSF-induced mobilization of HPCs.  AMD3100 also mobilized murine long-term repopulating (LTR) cells that engrafted primary and secondary lethally-irradiated mice, and human CD34+ cells that can repopulate nonobese diabetic-severe combined immunodeficiency (SCID) mice.  AMD3100 synergized with G-CSF to mobilize murine LTR cells and human SCID repopulating cells (SRCs).  Human CD34+ cells isolated after treatment with G-CSF plus AMD3100 expressed a phenotype that was characteristic of highly engrafting mouse HSCs.  Synergy of AMD3100 and G-CSF in mobilization was due to enhanced nos. and perhaps other characteristics of the mobilized cells.  These results support the hypothesis that the CXCL12-CXCR4 axis is involved in marrow retention of HSCs and HPCs, and demonstrate the clin. potential of AMD3100 for HSC mobilization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDUgOByTJX07Vg90H21EOLACvtfcHk0lhV8M7nn03aPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjs1Citbo%253D&md5=e5942dc81a7687a8b7c10f9542cbf29d</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1084%2Fjem.20041385&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1084%252Fjem.20041385%26sid%3Dliteratum%253Aachs%26aulast%3DBroxmeyer%26aufirst%3DH.%2BE.%26aulast%3DOrschell%26aufirst%3DC.%2BM.%26aulast%3DClapp%26aufirst%3DD.%2BW.%26aulast%3DHangoc%26aufirst%3DG.%26aulast%3DCooper%26aufirst%3DS.%26aulast%3DPlett%26aufirst%3DP.%2BA.%26aulast%3DLiles%26aufirst%3DW.%2BC.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DGraham-Evans%26aufirst%3DB.%26aulast%3DCampbell%26aufirst%3DT.%2BB.%26aulast%3DCalandra%26aufirst%3DG.%26aulast%3DBridger%26aufirst%3DG.%26aulast%3DDale%26aufirst%3DD.%2BC.%26aulast%3DSrour%26aufirst%3DE.%2BF.%26atitle%3DRapid%2520mobilization%2520of%2520murine%2520and%2520human%2520hematopoietic%2520stem%2520and%2520progenitor%2520cells%2520with%2520AMD3100%252C%2520a%2520CXCR4%2520antagonist%26jtitle%3DJ.%2520Exp.%2520Med.%26date%3D2005%26volume%3D201%26spage%3D1307%26epage%3D1318%26doi%3D10.1084%2Fjem.20041385" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span> <span> </span><span class="NLM_article-title">The bicyclam AMD3100 story</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">581</span>– <span class="NLM_lpage">587</span>, <span class="refDoi"> DOI: 10.1038/nrd1134</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1038%2Fnrd1134" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=12815382" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADC%252BD3sXks1Oqsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2003&pages=581-587&author=E.+De+Clercq&title=The+bicyclam+AMD3100+story&doi=10.1038%2Fnrd1134"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Timeline: The bicyclam AMD3100 story</span></div><div class="casAuthors">De Clercq, Erik</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">581-587</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The discovery and development of the bicyclam AMD3100 - a chemokine receptor antagonist - has highlighted the therapeutic potential of such compds. in HIV infection, inflammatory diseases, cancer and stem-cell mobilization.  Here, the author describes the development process of AMD3100, which began about 15 yr ago with the isolation of an impurity, and the basis for the clin. application of AMD3100 and its congeners.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqB-TkHJ79RrbVg90H21EOLACvtfcHk0lhV8M7nn03aPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXks1Oqsr8%253D&md5=cf8344ba0e19da8ffaadfe8c9b57200c</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1038%2Fnrd1134&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd1134%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BClercq%26aufirst%3DE.%26atitle%3DThe%2520bicyclam%2520AMD3100%2520story%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2003%26volume%3D2%26spage%3D581%26epage%3D587%26doi%3D10.1038%2Fnrd1134" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span> <span> </span><span class="NLM_article-title">The AMD3100 story: The path to the discovery of a stem cell mobilizer (Mozobil)</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">1655</span>– <span class="NLM_lpage">1664</span>, <span class="refDoi"> DOI: 10.1016/j.bcp.2008.12.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1016%2Fj.bcp.2008.12.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=19161986" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADC%252BD1MXkvVSqsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2009&pages=1655-1664&author=E.+De+Clercq&title=The+AMD3100+story%3A+The+path+to+the+discovery+of+a+stem+cell+mobilizer+%28Mozobil%29&doi=10.1016%2Fj.bcp.2008.12.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">The AMD3100 story: The path to the discovery of a stem cell mobilizer (Mozobil)</span></div><div class="casAuthors">De Clercq, Erik</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1655-1664</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  AMD3100 was found to inhibit HIV-1 and HIV-2 within the 1-10 nM concn. range while not being toxic to the host cells at concns. up to 500 μM, thus achieving a selectivity index of approx. 100,000.  The target of action was initially thought to be the viral envelope glycoprotein gp120.  It appeared only to be the indirect target.  The direct target of action turned out to be the co-receptor CXCR4 used by T-lymphotropic HIV strains (now referred to as X4 strains) to enter the cells.  Initial (phase I) clin. trials undertaken with AMD3100, as a prelude to its development as a candidate anti-HIV drug for the treatment of AIDS, showed an unexpected side effect: an increase in the white blood cell counts.  Apparently, AMD3100 specifically increased CD34+ hematopoietic stem cell counts in the peripheral blood.  Stromal derived factor 1 (SDF-1), through its interaction with CXCR4, retains the stem cells in the bone marrow (a process referred to as homing), and AMD3100 specifically antagonizes this interaction.  AMD3100 in combination with granulocyte colony-stimulating factor (G-CSF) resulted in the collection of more progenitor cells than G-CSF alone.  At present, the major indication for clin. use of AMD3100 (Mozobil) is the mobilization of hematopoietic stem cells from the bone marrow into the circulating blood for transplantation in patients with hematol. malignancies such as non-Hodgkin's lymphoma or multiple myeloma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-vof1PYEX37Vg90H21EOLACvtfcHk0lhV8M7nn03aPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXkvVSqsbc%253D&md5=19d5f76b85ef1c09e41a4d17ffbb2463</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2008.12.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2008.12.014%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BClercq%26aufirst%3DE.%26atitle%3DThe%2520AMD3100%2520story%253A%2520The%2520path%2520to%2520the%2520discovery%2520of%2520a%2520stem%2520cell%2520mobilizer%2520%2528Mozobil%2529%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2009%26volume%3D77%26spage%3D1655%26epage%3D1664%26doi%3D10.1016%2Fj.bcp.2008.12.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span> <span> </span><span class="NLM_article-title">Recent advances on the use of the CXCR4 antagonist plerixafor (AMD3100, Mozobil) and potential of other CXCR4 antagonists as stem cell mobilizers</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>128</i></span>,  <span class="NLM_fpage">509</span>– <span class="NLM_lpage">518</span>, <span class="refDoi"> DOI: 10.1016/j.pharmthera.2010.08.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1016%2Fj.pharmthera.2010.08.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=20826182" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlKhs7zO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2010&pages=509-518&author=E.+De+Clercq&title=Recent+advances+on+the+use+of+the+CXCR4+antagonist+plerixafor+%28AMD3100%2C+Mozobil%29+and+potential+of+other+CXCR4+antagonists+as+stem+cell+mobilizers&doi=10.1016%2Fj.pharmthera.2010.08.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Recent advances on the use of the CXCR4 antagonist plerixafor (AMD3100, Mozobil) and potential of other CXCR4 antagonists as stem cell mobilizers</span></div><div class="casAuthors">De Clercq, Erik</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">128</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">509-518</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  AMD3100 was originally discovered as an anti-HIV agent effective in inhibiting the replication of HIV in vitro at nanomolar concns.  We found it to be a potent and selective antagonist of CXCR4, the receptor for the chemokine SDF-1 (now called CXCL12).  AMD3100 was then developed, and marketed, as a stem cell mobilizer, and renamed plerixafor (Mozobil).  The path to the discovery of Mozobil as a stem cell mobilizer was described in Biochem.  Pharmacol. 77: 1655-1664 (2009).  Here I review the recent advances that have consolidated the role of plerixafor in mobilizing hematopoietic stem cells (HSCs) and hematopoietic progenitor cells (HPCs) from the bone marrow into the blood circulation.  Plerixafor acts synergistically with granulocyte colony-stimulating factor (G-CSF), and its usefulness has been proven particularly for the mobilization of HSCs and HPCs for autologous stem cell transplantation in patients with non-Hodgkin's lymphoma (NHL) or multiple myeloma (MM).  Plerixafor also has great potential for the treatment of hematol. malignancies other than NHL and MM, and non-hematol. malignancies, and, eventually, several other diseases depending on the CXCL12-CXCR4 interaction.  Various AMD3100 analogs have been described (i.e. AMD11070, AMD3465, KRH-3955, T-140, and 4F-benzoyl-TN14003), primarily as potential anti-HIV agents.  They are all strong CXCR4 antagonists.  Their role in stem cell mobilization remains to be assessed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgNBMywfEvpbVg90H21EOLACvtfcHk0lgNISrnz4AcAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlKhs7zO&md5=cb344c4a5966627126ec462e271e3d9e</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2010.08.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2010.08.009%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BClercq%26aufirst%3DE.%26atitle%3DRecent%2520advances%2520on%2520the%2520use%2520of%2520the%2520CXCR4%2520antagonist%2520plerixafor%2520%2528AMD3100%252C%2520Mozobil%2529%2520and%2520potential%2520of%2520other%2520CXCR4%2520antagonists%2520as%2520stem%2520cell%2520mobilizers%26jtitle%3DPharmacol.%2520Ther.%26date%3D2010%26volume%3D128%26spage%3D509%26epage%3D518%26doi%3D10.1016%2Fj.pharmthera.2010.08.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span> <span> </span><span class="NLM_article-title">AMD3100/CXCR4 inhibitor</span>. <i>Front. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">276</span>, <span class="refDoi"> DOI: 10.3389/fimmu.2015.00276</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.3389%2Ffimmu.2015.00276" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=26106388" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A280%3ADC%252BC2Mbmslaksg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=276&author=E.+De+Clercq&title=AMD3100%2FCXCR4+inhibitor&doi=10.3389%2Ffimmu.2015.00276"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">AMD3100/CXCR4 Inhibitor</span></div><div class="casAuthors">De Clercq Erik</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in immunology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">276</span>
        ISSN:<span class="NLM_cas:issn">1664-3224</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcThQWXPjMQFgkwlCcfExbvbfW6udTcc2eYAyNTGR2dpCLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2Mbmslaksg%253D%253D&md5=29bd7fd37dca8c6c43a4c5abdf4b9fe2</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.3389%2Ffimmu.2015.00276&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffimmu.2015.00276%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BClercq%26aufirst%3DE.%26atitle%3DAMD3100%252FCXCR4%2520inhibitor%26jtitle%3DFront.%2520Immunol.%26date%3D2015%26volume%3D6%26spage%3D276%26doi%3D10.3389%2Ffimmu.2015.00276" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span>, <span> </span><span class="NLM_article-title">Mozobil (Plerixafor, AMD3100), 10 years after its approval by the US Food and Drug Administration (FDA)</span>.  <i>Antiviral Chem. Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume">27</span>, <span class="refDoi"> DOI: 10.1177/2040206619829382</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1177%2F2040206619829382" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=30776910" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2019&author=E.+De+Clercq&title=Mozobil+%28Plerixafor%2C+AMD3100%29%2C+10+years+after+its+approval+by+the+US+Food+and+Drug+Administration+%28FDA%29&doi=10.1177%2F2040206619829382"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1177%2F2040206619829382&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F2040206619829382%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BClercq%26aufirst%3DE.%26atitle%3DMozobil%2520%2528Plerixafor%252C%2520AMD3100%2529%252C%252010%2520years%2520after%2520its%2520approval%2520by%2520the%2520US%2520Food%2520and%2520Drug%2520Administration%2520%2528FDA%2529%26jtitle%3DAntiviral%2520Chem.%2520Chemother.%26date%3D2019%26volume%3D27%26doi%3D10.1177%2F2040206619829382" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Balzarini, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holý, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jindrich, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naesens, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snoeck, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schols, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span> <span> </span><span class="NLM_article-title">Differential antiherpesvirus and antiretrovirus effects of the (S) and (R) enantiomers of acyclic nucleoside phosphonates: potent and selective in vitro and in vivo antiretrovirus activities of (R)-9-(2-phosphonomethoxypropyl)-2,6-diaminopurine</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">332</span>– <span class="NLM_lpage">338</span>, <span class="refDoi"> DOI: 10.1128/AAC.37.2.332</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1128%2FAAC.37.2.332" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=8452366" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADyaK3sXhvVakurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=1993&pages=332-338&author=J.+Balzariniauthor=A.+Hol%C3%BDauthor=J.+Jindrichauthor=L.+Naesensauthor=R.+Snoeckauthor=D.+Scholsauthor=E.+De+Clercq&title=Differential+antiherpesvirus+and+antiretrovirus+effects+of+the+%28S%29+and+%28R%29+enantiomers+of+acyclic+nucleoside+phosphonates%3A+potent+and+selective+in+vitro+and+in+vivo+antiretrovirus+activities+of+%28R%29-9-%282-phosphonomethoxypropyl%29-2%2C6-diaminopurine&doi=10.1128%2FAAC.37.2.332"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Differential anti-herpes virus and anti-retrovirus effects of the (S) and (R) enantiomers of acyclic nucleoside phosphonates: potent and selective in vitro and in vivo antiretrovirus activities of (R)-9-(2-phosphonomethoxypropyl)-2,6-diaminopurine</span></div><div class="casAuthors">Balzarini, J.; Holy, A.; Jindrich, J.; Naesens, L.; Snoeck, R.; Schols, D.; De Clercq, E.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">332-8</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    </div><div class="casAbstract">The (S)- and (R)-enantiomers of acyclic purine nucleoside phosphonate analogs [i.e., 3-hydroxy-2-phosphonomethoxypropyl (HPMP) derivs., 3-fluoro-2-phosphonomethoxypropyl (FPMP) derivs., and 2-phosphonomethoxypropyl (PMP) derivs. of adenine (A), 2-aminopurine, 2,6-diaminopurine (DAP), and guanine (G)] were synthesized and evaluated for antiviral activity.  The HPMP derivs. were effective against DNA viruses but not RNA viruses or retroviruses.  In particular, (S)-HPMPA, (S)-HPMPDAP, and (R)- and (S)-HPMPG were exclusively inhibitory to herpes simplex virus type 1 (50% effective concns., 0.63, 0.22, 0.10, and 0.66 μM, resp.).  The FPMP and PMP derivs. showed marked inhibitory activities against retroviruses but not DNA viruses.  The (S)-enantiomer of FPMPA and the (R)-enantiomer of PMPA were ∼30- to 100-fold more effective against human immunodeficiency virus and Moloney murine sarcoma virus (MSV) than their enantiomeric counterparts.  In contrast, both (S)- and (R)-enantiomers of the DAP and G derivs. were equally effective against retroviruses, except for (R)-PMPDAP, which was 15- to 40-fold more inhibitory than (S)-PMPDAP.  (R)-PMPDAP emerged as the most potent and selective inhibitor of MSV-induced transformation of murine C3H/3T3 cells and human immunodeficiency virus-induced cytotoxicity in MT-4 and CEM cells (50% effective concn., ∼0.1 to 0.6 μM).  When administered i.p. in a single dose as low as 2 mg/kg, (R)-PMPDAP efficiently decreased MSV-induced tumor formation in newborn NMRI mice and significantly increased the survival time of MSV-infected mice.  In addn., upon oral administration of MSV-infected mice, (R)-PMPDAP showed marked antiretroviral efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGre_TvFcgxmE7Vg90H21EOLACvtfcHk0lgNISrnz4AcAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXhvVakurw%253D&md5=24c89ba7236fd3a24db4d9c9dc7c5f56</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1128%2FAAC.37.2.332&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.37.2.332%26sid%3Dliteratum%253Aachs%26aulast%3DBalzarini%26aufirst%3DJ.%26aulast%3DHol%25C3%25BD%26aufirst%3DA.%26aulast%3DJindrich%26aufirst%3DJ.%26aulast%3DNaesens%26aufirst%3DL.%26aulast%3DSnoeck%26aufirst%3DR.%26aulast%3DSchols%26aufirst%3DD.%26aulast%3DDe%2BClercq%26aufirst%3DE.%26atitle%3DDifferential%2520antiherpesvirus%2520and%2520antiretrovirus%2520effects%2520of%2520the%2520%2528S%2529%2520and%2520%2528R%2529%2520enantiomers%2520of%2520acyclic%2520nucleoside%2520phosphonates%253A%2520potent%2520and%2520selective%2520in%2520vitro%2520and%2520in%2520vivo%2520antiretrovirus%2520activities%2520of%2520%2528R%2529-9-%25282-phosphonomethoxypropyl%2529-2%252C6-diaminopurine%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D1993%26volume%3D37%26spage%3D332%26epage%3D338%26doi%3D10.1128%2FAAC.37.2.332" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Robbins, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srinivas, R. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bischofberger, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fridland, A.</span></span> <span> </span><span class="NLM_article-title">Anti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-<i>R</i>-(2-Phosphonomethoxypropyl)adenine (PMPA), Bis(isopropyloxymethylcarbonyl)PMPA</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">612</span>– <span class="NLM_lpage">617</span>, <span class="refDoi"> DOI: 10.1128/AAC.42.3.612</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1128%2FAAC.42.3.612" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=9517941" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADyaK1cXhvV2ktLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=1998&pages=612-617&author=B.+L.+Robbinsauthor=R.+V.+Srinivasauthor=C.+Kimauthor=N.+Bischofbergerauthor=A.+Fridland&title=Anti-human+immunodeficiency+virus+activity+and+cellular+metabolism+of+a+potential+prodrug+of+the+acyclic+nucleoside+phosphonate+9-R-%282-Phosphonomethoxypropyl%29adenine+%28PMPA%29%2C+Bis%28isopropyloxymethylcarbonyl%29PMPA&doi=10.1128%2FAAC.42.3.612"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2-phosphonomethoxypropyl)adenine (PMPA), bis(isopropyloxymethylcarbonyl)PMPA</span></div><div class="casAuthors">Robbins, Brian L.; Srinivas, Ranga V.; Kim, Choung; Bischofberger, Norbert; Fridland, Arnold</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">612-617</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Bis(isopropyloxymethylcarbonyl) 9-R-(2-phosphonomethoxypropyl)adenine [bis(POC)PMPA] has been identified as a novel prodrug of PMPA.  The anti-human immunodeficiency virus activity of bis(POC)PMPA was >100-fold greater than that of PMPA in both an established T-cell line and primary peripheral blood lymphocytes.  This improved efficacy was shown to be due to a rapid intracellular uptake of the prodrug resulting in an increased intracellular accumulation of PMPA diphosphate (PMPApp), the pharmacol. active metabolite.  PMPApp levels in bis(POC)PMPA-treated cells exceeded by >1000-fold the levels seen in cells treated with unmodified PMPA in both resting and activated peripheral blood lymphocytes.  Significant differences in the intracellular catabolism of PMPA metabolites were noted between the resting and activated lymphocytes.  The half-life for the disappearance of PMPApp, derived from either bis(POC)PMPA or PMPA, was 12 to 15 h in the activated lymphocytes and 33 to 50 h in the resting lymphocytes.  This long persistence of PMPApp, particularly in resting lymphocytes, may be unique to the nucleoside phosphonate analogs and indicates that effective levels of the active metabolite can be achieved and maintained with relatively infrequent administration of the parent drug.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfLivj9uSR77Vg90H21EOLACvtfcHk0li6jhUkfx43Hw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXhvV2ktLg%253D&md5=15e644a262a5be0b5319dd853d31d2a6</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1128%2FAAC.42.3.612&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.42.3.612%26sid%3Dliteratum%253Aachs%26aulast%3DRobbins%26aufirst%3DB.%2BL.%26aulast%3DSrinivas%26aufirst%3DR.%2BV.%26aulast%3DKim%26aufirst%3DC.%26aulast%3DBischofberger%26aufirst%3DN.%26aulast%3DFridland%26aufirst%3DA.%26atitle%3DAnti-human%2520immunodeficiency%2520virus%2520activity%2520and%2520cellular%2520metabolism%2520of%2520a%2520potential%2520prodrug%2520of%2520the%2520acyclic%2520nucleoside%2520phosphonate%25209-R-%25282-Phosphonomethoxypropyl%2529adenine%2520%2528PMPA%2529%252C%2520Bis%2528isopropyloxymethylcarbonyl%2529PMPA%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D1998%26volume%3D42%26spage%3D612%26epage%3D617%26doi%3D10.1128%2FAAC.42.3.612" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Naesens, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bischofberger, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Augustijns, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Annaert, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van den
Mooter, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arimilli, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, C. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span> <span> </span><span class="NLM_article-title">Antiretroviral efficacy and pharmacokinetics of oral bis(isopropyloxycarbonyloxymethyl)-9-(2-phosphonylmethoxypropyl)adenine in mice</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">1568</span>– <span class="NLM_lpage">1573</span>, <span class="refDoi"> DOI: 10.1128/AAC.42.7.1568</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1128%2FAAC.42.7.1568" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=9660984" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADyaK1cXktlKhtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=1998&pages=1568-1573&author=L.+Naesensauthor=N.+Bischofbergerauthor=P.+Augustijnsauthor=P.+Annaertauthor=G.+Van+den%0AMooterauthor=M.+N.+Arimilliauthor=C.+U.+Kimauthor=E.+De+Clercq&title=Antiretroviral+efficacy+and+pharmacokinetics+of+oral+bis%28isopropyloxycarbonyloxymethyl%29-9-%282-phosphonylmethoxypropyl%29adenine+in+mice&doi=10.1128%2FAAC.42.7.1568"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Antiretroviral efficacy and pharmacokinetics of oral bis(isopropyloxycarbonyloxymethyl)-9-(2-phosphonylmethoxypropyl)adenine in mice</span></div><div class="casAuthors">Naesens, Lieve; Bischofberger, Norbert; Augustijns, Patrick; Annaert, Pieter; Van Den Mooter, Guy; Arimilli, Murty N.; Kim, Choung U.; De Clercq, Erik</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1568-1673</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">To overcome the low oral bioavailability of the highly potent and selective antiretroviral agent (R)-9-(2-phosphonylmethoxypropyl)adenine (PMPA), its lipophilic ester deriv. bis(isopropyloxycarbonyloxymethyl)-ester [bis(POC)-PMPA] was prepd.  The usefulness of bis(POC)-PMPA as an oral prodrug for PMPA was investigated in the intestinal mucosa Caco-2 cell monolayer model.  The total transport of bis(POC)-PMPA was 2.7%, whereas it was <0.1% for PMPA.  Bis(POC)-PMPA was considerably metabolized inside the epithelial cells, since the majority of the compd. was recovered after transport in the form of the monoester metabolite mono(POC)-PMPA.  Bis(POC)-PMPA was relatively resistant to degrdn. at the luminal side of the Caco-2 cells.  Pharmacokinetic studies in mice showed that the oral bioavailability of bis(POC)-PMPA calcd. from the curves of the concn. of free PMPA in blood plasma was 20%.  Neither bis(POC)-PMPA nor mono(POC)-PMPA could be recovered from blood plasma, suggesting the efficient release of the active drug PMPA after oral administration of bis(POC)-PMPA.  Severe combined immunodeficient (SCID) mice infected with Moloney murine sarcoma virus (MSV) and treated orally with bis(POC)-PMPA for 5 or 10 days at dosages of 50, 100, or 200 mg PMPA equiv./kg/day showed a significant delay in MSV-induced tumor appearance and tumor-assocd. death.  The antiviral efficacy of oral bis(POC)-PMPA was related to the dosage and treatment period and was not significantly different from that of s.c. PMPA given at equiv. doses.  The favorable pharmacokinetic profile, marked antiviral efficacy, and low toxicity make bis(POC)-PMPA an attractive oral prodrug of PMPA that should be pursued in clin. studies in patients infected with human immunodeficiency virus or hepatitis B virus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdsnK-h4XpJrVg90H21EOLACvtfcHk0li6jhUkfx43Hw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXktlKhtbg%253D&md5=1c653e6c96203eed031773867594c223</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1128%2FAAC.42.7.1568&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.42.7.1568%26sid%3Dliteratum%253Aachs%26aulast%3DNaesens%26aufirst%3DL.%26aulast%3DBischofberger%26aufirst%3DN.%26aulast%3DAugustijns%26aufirst%3DP.%26aulast%3DAnnaert%26aufirst%3DP.%26aulast%3DVan%2Bden%2BMooter%26aufirst%3DG.%26aulast%3DArimilli%26aufirst%3DM.%2BN.%26aulast%3DKim%26aufirst%3DC.%2BU.%26aulast%3DDe%2BClercq%26aufirst%3DE.%26atitle%3DAntiretroviral%2520efficacy%2520and%2520pharmacokinetics%2520of%2520oral%2520bis%2528isopropyloxycarbonyloxymethyl%2529-9-%25282-phosphonylmethoxypropyl%2529adenine%2520in%2520mice%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D1998%26volume%3D42%26spage%3D1568%26epage%3D1573%26doi%3D10.1128%2FAAC.42.7.1568" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, C.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Follis, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grant, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bischofberger, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benveniste, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Black, R.</span></span> <span> </span><span class="NLM_article-title">Prevention of SIV infection in macaques by (<i>R</i>)-9-(2-Phosphonylmethoxypropyl)adenine</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>270</i></span>,  <span class="NLM_fpage">1197</span>– <span class="NLM_lpage">1199</span>, <span class="refDoi"> DOI: 10.1126/science.270.5239.1197</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1126%2Fscience.270.5239.1197" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=7502044" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADyaK2MXpsVyktLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=270&publication_year=1995&pages=1197-1199&author=C.-C.+Tsaiauthor=K.+E.+Follisauthor=A.+Saboauthor=T.+W.+Beckauthor=R.+F.+Grantauthor=N.+Bischofbergerauthor=R.+E.+Benvenisteauthor=R.+Black&title=Prevention+of+SIV+infection+in+macaques+by+%28R%29-9-%282-Phosphonylmethoxypropyl%29adenine&doi=10.1126%2Fscience.270.5239.1197"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine</span></div><div class="casAuthors">Tsai, Che-Chung; Follis, Kathryn E.; Sabo, Alexander; Beck, Thomas W.; Grant, Richard F.; Bischofberger, Norbert; Benveniste, Raoul E.; Black, Roberta</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">270</span>
        (<span class="NLM_cas:issue">5239</span>),
    <span class="NLM_cas:pages">1197-9</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The efficacy of pre- and postexposure treatment with the antiviral compd. (R)-9-(2-phosphonylmethoxypropyl)adenine (PMPA) was tested against simian immunodeficiency virus (SIV) in macaques as a model for human immunodeficiency virus (HIV).  PMPA was administered s.c. once daily beginning either 48 h before, 4 h after, or 24 h after virus inoculation.  Treatment continued for 4 wk and the virol., immunol., and clin. status of the macaques was monitored for up to 56 wk.  PMPA prevented SIV infection in all macaques without toxicity, whereas all control macaques became infected.  These results suggest a potential role for PMPA prophylaxis against early HIV infection in cases of known exposure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrv0wYvoJWcxLVg90H21EOLACvtfcHk0lgUiszr5HO-XQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXpsVyktLY%253D&md5=ee0ece078305323a3b11a2c792cd88ba</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1126%2Fscience.270.5239.1197&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.270.5239.1197%26sid%3Dliteratum%253Aachs%26aulast%3DTsai%26aufirst%3DC.-C.%26aulast%3DFollis%26aufirst%3DK.%2BE.%26aulast%3DSabo%26aufirst%3DA.%26aulast%3DBeck%26aufirst%3DT.%2BW.%26aulast%3DGrant%26aufirst%3DR.%2BF.%26aulast%3DBischofberger%26aufirst%3DN.%26aulast%3DBenveniste%26aufirst%3DR.%2BE.%26aulast%3DBlack%26aufirst%3DR.%26atitle%3DPrevention%2520of%2520SIV%2520infection%2520in%2520macaques%2520by%2520%2528R%2529-9-%25282-Phosphonylmethoxypropyl%2529adenine%26jtitle%3DScience%26date%3D1995%26volume%3D270%26spage%3D1197%26epage%3D1199%26doi%3D10.1126%2Fscience.270.5239.1197" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Van Damme, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corneli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmed, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agot, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lombaard, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kapiga, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malahleha, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owino, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manongi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Onyango, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Temu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monedi, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mak’Oketch, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makanda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reblin, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makatu, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saylor, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiernan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirkendale, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grant, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kashuba, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nanda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandala, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fransen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deese, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crucitti, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mastro, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, D.</span></span> <span> </span><span class="NLM_article-title">Preexposure prophylaxis for HIV infection among African women</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>367</i></span>,  <span class="NLM_fpage">411</span>– <span class="NLM_lpage">422</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1202614</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1056%2FNEJMoa1202614" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=22784040" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlSltrbL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=367&publication_year=2012&pages=411-422&author=L.+Van+Dammeauthor=A.+Corneliauthor=K.+Ahmedauthor=K.+Agotauthor=J.+Lombaardauthor=S.+Kapigaauthor=M.+Malahlehaauthor=F.+Owinoauthor=R.+Manongiauthor=J.+Onyangoauthor=L.+Temuauthor=M.+C.+Monediauthor=P.+Mak%E2%80%99Oketchauthor=M.+Makandaauthor=I.+Reblinauthor=S.+E.+Makatuauthor=L.+Saylorauthor=H.+Kiernanauthor=S.+Kirkendaleauthor=C.+Wongauthor=R.+F.+Grantauthor=A.+Kashubaauthor=K.+Nandaauthor=J.+Mandalaauthor=K.+Fransenauthor=J.+Deeseauthor=T.+Crucittiauthor=T.+D.+Mastroauthor=D.+Taylor&title=Preexposure+prophylaxis+for+HIV+infection+among+African+women&doi=10.1056%2FNEJMoa1202614"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Preexposure prophylaxis for HIV infection among African women</span></div><div class="casAuthors">Van Damme, Lut; Corneli, Amy; Ahmed, Khatija; Agot, Kawango; Lombaard, Johan; Kapiga, Saidi; Malahleha, Mookho; Owino, Fredrick; Manongi, Rachel; Onyango, Jacob; Temu, Lucky; Monedi, Modie Constance; Mak'Oketch, Paul; Makanda, Mankalimeng; Reblin, Ilse; Makatu, Shumani Elsie; Saylor, Lisa; Kiernan, Haddie; Kirkendale, Stella; Wong, Christina; Grant, Robert; Kashuba, Angela; Nanda, Kavita; Mandala, Justin; Fransen, Katrien; Deese, Jennifer; Crucitti, Tania; Mastro, Timothy D.; Taylor, Douglas</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">367</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">411-422</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: Preexposure prophylaxis with antiretroviral drugs has been effective in the prevention of human immunodeficiency virus (HIV) infection in some trials but not in others.  Methods: In this randomized, double-blind, placebo-controlled trial, we assigned 2120 HIV-neg. women in Kenya, South Africa, and Tanzania to receive either a combination of tenofovir disoproxil fumarate and emtricitabine (TDF-FTC) or placebo once daily.  The primary objective was to assess the effectiveness of TDF-FTC in preventing HIV acquisition and to evaluate safety.  Results: HIV infections occurred in 33 women in the TDF-FTC group (incidence rate, 4.7 per 100 person-years) and in 35 in the placebo group (incidence rate, 5.0 per 100 person-years), for an estd. hazard ratio in the TDF-FTC group of 0.94 (95% confidence interval, 0.59 to 1.52; P = 0.81).  The proportions of women with nausea, vomiting, or elevated alanine aminotransferase levels were significantly higher in the TDF-FTC group (P = 0.04, P<0.001, and P = 0.03, resp.).  Rates of drug discontinuation because of hepatic or renal abnormalities were higher in the TDF-FTC group (4.7%) than in the placebo group (3.0%, P = 0.051).  Less than 40% of the HIV-uninfected women in the TDF-FTC group had evidence of recent pill use at visits that were matched to the HIV-infection window for women with seroconversion.  The study was stopped early, on Apr. 18, 2011, because of lack of efficacy.  Conclusions: Prophylaxis with TDF-FTC did not significantly reduce the rate of HIV infection and was assocd. with increased rates of side effects, as compared with placebo.  Despite substantial counseling efforts, drug adherence appeared to be low.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-zDy6lkjhp7Vg90H21EOLACvtfcHk0lgUiszr5HO-XQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtlSltrbL&md5=b570dd1c89c2fe20667ddd92f2f1cba0</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1202614&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1202614%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2BDamme%26aufirst%3DL.%26aulast%3DCorneli%26aufirst%3DA.%26aulast%3DAhmed%26aufirst%3DK.%26aulast%3DAgot%26aufirst%3DK.%26aulast%3DLombaard%26aufirst%3DJ.%26aulast%3DKapiga%26aufirst%3DS.%26aulast%3DMalahleha%26aufirst%3DM.%26aulast%3DOwino%26aufirst%3DF.%26aulast%3DManongi%26aufirst%3DR.%26aulast%3DOnyango%26aufirst%3DJ.%26aulast%3DTemu%26aufirst%3DL.%26aulast%3DMonedi%26aufirst%3DM.%2BC.%26aulast%3DMak%25E2%2580%2599Oketch%26aufirst%3DP.%26aulast%3DMakanda%26aufirst%3DM.%26aulast%3DReblin%26aufirst%3DI.%26aulast%3DMakatu%26aufirst%3DS.%2BE.%26aulast%3DSaylor%26aufirst%3DL.%26aulast%3DKiernan%26aufirst%3DH.%26aulast%3DKirkendale%26aufirst%3DS.%26aulast%3DWong%26aufirst%3DC.%26aulast%3DGrant%26aufirst%3DR.%2BF.%26aulast%3DKashuba%26aufirst%3DA.%26aulast%3DNanda%26aufirst%3DK.%26aulast%3DMandala%26aufirst%3DJ.%26aulast%3DFransen%26aufirst%3DK.%26aulast%3DDeese%26aufirst%3DJ.%26aulast%3DCrucitti%26aufirst%3DT.%26aulast%3DMastro%26aufirst%3DT.%2BD.%26aulast%3DTaylor%26aufirst%3DD.%26atitle%3DPreexposure%2520prophylaxis%2520for%2520HIV%2520infection%2520among%2520African%2520women%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2012%26volume%3D367%26spage%3D411%26epage%3D422%26doi%3D10.1056%2FNEJMoa1202614" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marrazzo, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramjee, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomez, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mgodi, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nair, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palanee, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakabiito, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Straten, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noguchi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendrix, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganesh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mkhize, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taljaard, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parikh, U. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piper, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mâsse, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grossman, C. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rooney, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watts, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marzinke, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hillier, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGowan, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chirenje, Z. M.</span></span> <span> </span><span class="NLM_article-title">Tenofovir-based preexposure prophylaxis for HIV infection among African women</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>372</i></span>,  <span class="NLM_fpage">509</span>– <span class="NLM_lpage">518</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1402269</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1056%2FNEJMoa1402269" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=25651245" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADC%252BC2MXisFGkur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=372&publication_year=2015&pages=509-518&author=J.+M.+Marrazzoauthor=G.+Ramjeeauthor=B.+A.+Richardsonauthor=K.+Gomezauthor=N.+M.+Mgodiauthor=G.+Nairauthor=T.+Palaneeauthor=C.+Nakabiitoauthor=A.+van+der+Stratenauthor=L.+Noguchiauthor=C.+W.+Hendrixauthor=J.+Y.+Daiauthor=S.+Ganeshauthor=B.+Mkhizeauthor=M.+Taljaardauthor=U.+M.+Parikhauthor=J.+Piperauthor=B.+M%C3%A2sseauthor=C.+I.+Grossmanauthor=J.+Rooneyauthor=J.+L.+Schwartzauthor=H.+Wattsauthor=M.+A.+Marzinkeauthor=S.+L.+Hillierauthor=I.+M.+McGowanauthor=Z.+M.+Chirenje&title=Tenofovir-based+preexposure+prophylaxis+for+HIV+infection+among+African+women&doi=10.1056%2FNEJMoa1402269"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Tenofovir-based preexposure prophylaxis for HIV infection among African women</span></div><div class="casAuthors">Marrazzo, Jeanne M.; Ramjee, Gita; Richardson, Barbra A.; Gomez, Kailazarid; Mgodi, Nyaradzo; Nair, Gonasagrie; Palanee, Thesla; Nakabiito, Clemensia; van der Straten, Ariane; Noguchi, Lisa; Hendrix, Craig W.; Dai, James Y.; Ganesh, Shayhana; Mkhize, Baningi; Taljaard, Marthinette; Parikh, Urvi M.; Piper, Jeanna; Masse, Benoit; Grossman, Cynthia; Rooney, James; Schwartz, Jill L.; Watts, Heather; Marzinke, Mark A.; Hillier, Sharon L.; McGowan, Ian M.; Chirenje, Z. Mike</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">372</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">509-518/1-509-518/10, 10 pp.</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Reproductive-age women need effective interventions to prevent the acquisition of human immunodeficiency virus type 1 (HIV-1) infection.  We conducted a randomized, placebo-controlled trial to assess daily treatment with oral tenofovir disoproxil fumarate (TDF), oral tenofovir-emtricitabine (TDF-FTC), or 1% tenofovir (TFV) vaginal gel as preexposure prophylaxis against HIV-1 infection in women in South Africa, Uganda, and Zimbabwe.  HIV-1 testing was performed monthly, and plasma TFV levels were assessed quarterly.  Of 12,320 women who were screened, 5029 were enrolled in the study.  The rate of retention in the study was 91% during 5509 person-years of follow-up.  A total of 312 HIV-1 infections occurred; the incidence of HIV-1 infection was 5.7 per 100 person-years.  In the modified intention-to-treat anal., the effectiveness was -49.0% with TDF (hazard ratio for infection, 1.49; 95% confidence interval [CI], 0.97 to 2.29), -4.4% with TDF-FTC (hazard ratio, 1.04; 95% CI, 0.73 to 1.49), and 14.5% with TFV gel (hazard ratio, 0.85; 95% CI, 0.61 to 1.21).  In a random sample, TFV was detected in 30%, 29%, and 25% of available plasma samples from participants randomly assigned to receive TDF, TDF-FTC, and TFV gel, resp.  Independent predictors of TFV detection included being married, being older than 25 years of age, and being multiparous.  Detection of TFV in plasma was neg. assocd. with characteristics predictive of HIV-1 acquisition.  Elevations of serum creatinine levels were seen more frequently among participants randomly assigned to receive oral TDF-FTC than among those assigned to receive oral placebo (1.3% vs. 0.2%, P = 0.004).  We obsd. no significant differences in the frequencies of other adverse events.  None of the drug regimens we evaluated reduced the rates of HIV-1 acquisition in an intention-to-treat anal.  Adherence to study drugs was low.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjwMI6Bbu9d7Vg90H21EOLACvtfcHk0lgUiszr5HO-XQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXisFGkur4%253D&md5=dfa4a90697a305320dc82815b0d60a1f</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1402269&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1402269%26sid%3Dliteratum%253Aachs%26aulast%3DMarrazzo%26aufirst%3DJ.%2BM.%26aulast%3DRamjee%26aufirst%3DG.%26aulast%3DRichardson%26aufirst%3DB.%2BA.%26aulast%3DGomez%26aufirst%3DK.%26aulast%3DMgodi%26aufirst%3DN.%2BM.%26aulast%3DNair%26aufirst%3DG.%26aulast%3DPalanee%26aufirst%3DT.%26aulast%3DNakabiito%26aufirst%3DC.%26aulast%3Dvan%2Bder%2BStraten%26aufirst%3DA.%26aulast%3DNoguchi%26aufirst%3DL.%26aulast%3DHendrix%26aufirst%3DC.%2BW.%26aulast%3DDai%26aufirst%3DJ.%2BY.%26aulast%3DGanesh%26aufirst%3DS.%26aulast%3DMkhize%26aufirst%3DB.%26aulast%3DTaljaard%26aufirst%3DM.%26aulast%3DParikh%26aufirst%3DU.%2BM.%26aulast%3DPiper%26aufirst%3DJ.%26aulast%3DM%25C3%25A2sse%26aufirst%3DB.%26aulast%3DGrossman%26aufirst%3DC.%2BI.%26aulast%3DRooney%26aufirst%3DJ.%26aulast%3DSchwartz%26aufirst%3DJ.%2BL.%26aulast%3DWatts%26aufirst%3DH.%26aulast%3DMarzinke%26aufirst%3DM.%2BA.%26aulast%3DHillier%26aufirst%3DS.%2BL.%26aulast%3DMcGowan%26aufirst%3DI.%2BM.%26aulast%3DChirenje%26aufirst%3DZ.%2BM.%26atitle%3DTenofovir-based%2520preexposure%2520prophylaxis%2520for%2520HIV%2520infection%2520among%2520African%2520women%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2015%26volume%3D372%26spage%3D509%26epage%3D518%26doi%3D10.1056%2FNEJMoa1402269" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, G.-X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eisenberg, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cihlar, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swaminathan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulato, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cundy, K. C.</span></span> <span> </span><span class="NLM_article-title">Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">1898</span>– <span class="NLM_lpage">1906</span>, <span class="refDoi"> DOI: 10.1128/AAC.49.5.1898-1906.2005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1128%2FAAC.49.5.1898-1906.2005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=15855512" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADC%252BD2MXktFSntL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2005&pages=1898-1906&author=W.+A.+Leeauthor=G.-X.+Heauthor=E.+Eisenbergauthor=T.+Cihlarauthor=S.+Swaminathanauthor=A.+Mulatoauthor=K.+C.+Cundy&title=Selective+intracellular+activation+of+a+novel+prodrug+of+the+human+immunodeficiency+virus+reverse+transcriptase+inhibitor+tenofovir+leads+to+preferential+distribution+and+accumulation+in+lymphatic+tissue&doi=10.1128%2FAAC.49.5.1898-1906.2005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue</span></div><div class="casAuthors">Lee, William A.; He, Gong-Xin; Eisenberg, Eugene; Cihlar, Tomas; Swaminathan, Swami; Mulato, Andrew; Cundy, Kenneth C.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1898-1906</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">An isopropylalaninyl monoamidate Ph monoester prodrug of tenofovir (GS 7340) was prepd., and its in vitro antiviral activity, metab., and pharmacokinetics in dogs were detd.  The 50% effective concn. (EC50) of GS 7340 against human immunodeficiency virus type 1 in MT-2 cells was 0.005 μM compared to an EC50 of 5 μM for the parent drug, tenofovir.  The (L)-alaninyl analog (GS 7340) was >1000-fold more active than the (D)-alaninyl analog.  GS 7340 has a half-life of 90 min in human plasma at 37° and a half-life of 28.3 min in an MT-2 cell ext. at 37°.  The antiviral activity (>10× the EC50) and the metabolic stability in MT-2 cell exts. (>35×) and plasma (>2.5×) were also sensitive to the stereochem. at the phosphorus.  After a single oral dose of GS 7340 (10 mg-eq/kg tenofovir) to male beagle dogs, the plasma bioavailability of tenofovir compared to an i.v. dose of tenofovir was 17%.  The total intracellular concn. of all tenofovir species in isolated peripheral blood mononuclear cells at 24 h was 63 μg-eq/mL compared to 0.2 μg-eq/mL in plasma.  A radiolabeled distribution study with dogs resulted in an increased distribution of tenofovir to tissues of lymphatic origin compared to the com. available prodrug tenofovir DF (Viread).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbOoU4rGP0xrVg90H21EOLACvtfcHk0liK9sBPFGl95g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXktFSntL0%253D&md5=b5e724620a1cafa4b473a84aea841282</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1128%2FAAC.49.5.1898-1906.2005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.49.5.1898-1906.2005%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DW.%2BA.%26aulast%3DHe%26aufirst%3DG.-X.%26aulast%3DEisenberg%26aufirst%3DE.%26aulast%3DCihlar%26aufirst%3DT.%26aulast%3DSwaminathan%26aufirst%3DS.%26aulast%3DMulato%26aufirst%3DA.%26aulast%3DCundy%26aufirst%3DK.%2BC.%26atitle%3DSelective%2520intracellular%2520activation%2520of%2520a%2520novel%2520prodrug%2520of%2520the%2520human%2520immunodeficiency%2520virus%2520reverse%2520transcriptase%2520inhibitor%2520tenofovir%2520leads%2520to%2520preferential%2520distribution%2520and%2520accumulation%2520in%2520lymphatic%2520tissue%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2005%26volume%3D49%26spage%3D1898%26epage%3D1906%26doi%3D10.1128%2FAAC.49.5.1898-1906.2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Birkus, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bam, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willkom, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frey, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stray, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yant, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cihlar, T.</span></span> <span> </span><span class="NLM_article-title">Intracellular activation of tenofovir alafenamide and the effect of viral and host protease inhibitors</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">316</span>– <span class="NLM_lpage">322</span>, <span class="refDoi"> DOI: 10.1128/AAC.01834-15</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1128%2FAAC.01834-15" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=26503655" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVCrs7nP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2016&pages=316-322&author=G.+Birkusauthor=R.+A.+Bamauthor=M.+Willkomauthor=C.+R.+Freyauthor=L.+Tsaiauthor=K.+M.+Strayauthor=S.+R.+Yantauthor=T.+Cihlar&title=Intracellular+activation+of+tenofovir+alafenamide+and+the+effect+of+viral+and+host+protease+inhibitors&doi=10.1128%2FAAC.01834-15"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Intracellular activation of tenofovir alafenamide and the effect of viral and host protease inhibitors</span></div><div class="casAuthors">Birkus, Gabriel; Bam, Rujuta A.; Willkom, Madeleine; Frey, Christian R.; Tsai, Luong; Stray, Kirsten M.; Yant, Stephen R.; Cihlar, Tomas</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">316-322</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Tenofovir alafenamide fumarate (TAF) is an oral phosphonoamidate prodrug of the HIV reverse transcriptase nucleotide inhibitor tenofovir (TFV).  Previous studies suggested a principal role for the lysosomal serine protease cathepsin A (CatA) in the intracellular activation of TAF.  Here we further investigated the role of CatA and other human hydrolases in the metab. of TAF.  Overexpression of CatA or liver carboxylesterase 1 (Ces1) in HEK293T cells increased intracellular TAF hydrolysis 2- and 5-fold, resp.  Knockdown of CatA expression with RNA interference (RNAi) in HeLa cells reduced intracellular TAF metab. 5-fold.  Addnl., the anti-HIV activity and the rate of CatA hydrolysis showed good correlation within a large set of TFV phosphonoamidate prodrugs.  The covalent hepatitis C virus (HCV) protease inhibitors (PIs) telaprevir and boceprevir potently inhibited CatA-mediated TAF activation (50% inhibitory concn. [IC50] = 0.27 and 0.16 μM, resp.) in vitro and also reduced its anti-HIV activity in primary human CD4+ T lymphocytes (21- and 3-fold, resp.) at pharmacol. relevant concns.  In contrast, there was no inhibition of CatA or any significant effect on anti-HIV activity of TAF obsd. with cobicistat, noncovalent HIV and HCV PIs, or various prescribed inhibitors of host serine proteases.  Collectively, these studies confirm that CatA plays a pivotal role in the intracellular metab. of TAF, whereas the liver esterase Ces1 likely contributes to the hepatic activation of TAF.  Moreover, this work demonstrates that a wide range of viral and host PIs, with the exception of telaprevir and boceprevir, do not interfere with the antiretroviral activity of TAF.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrn2HFR0GCGELVg90H21EOLACvtfcHk0liK9sBPFGl95g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVCrs7nP&md5=2deb35c0d451b36c296d76dc59c5b6d4</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1128%2FAAC.01834-15&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.01834-15%26sid%3Dliteratum%253Aachs%26aulast%3DBirkus%26aufirst%3DG.%26aulast%3DBam%26aufirst%3DR.%2BA.%26aulast%3DWillkom%26aufirst%3DM.%26aulast%3DFrey%26aufirst%3DC.%2BR.%26aulast%3DTsai%26aufirst%3DL.%26aulast%3DStray%26aufirst%3DK.%2BM.%26aulast%3DYant%26aufirst%3DS.%2BR.%26aulast%3DCihlar%26aufirst%3DT.%26atitle%3DIntracellular%2520activation%2520of%2520tenofovir%2520alafenamide%2520and%2520the%2520effect%2520of%2520viral%2520and%2520host%2520protease%2520inhibitors%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2016%26volume%3D60%26spage%3D316%26epage%3D322%26doi%3D10.1128%2FAAC.01834-15" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rose, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crosswell, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bronson, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, J. C.</span></span> <span> </span><span class="NLM_article-title">In vivo antitumor activity of 9-[(2-phosphonylmethoxy)ethyl]-guanine and related phosphonate nucleotide analogues</span>. <i>J. Natl. Cancer Inst.</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>82</i></span>,  <span class="NLM_fpage">510</span>– <span class="NLM_lpage">512</span>, <span class="refDoi"> DOI: 10.1093/jnci/82.6.510</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1093%2Fjnci%2F82.6.510" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=2313724" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADyaK3cXktFOntbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=1990&pages=510-512&author=W.+C.+Roseauthor=A.+R.+Crosswellauthor=J.+J.+Bronsonauthor=J.+C.+Martin&title=In+vivo+antitumor+activity+of+9-%5B%282-phosphonylmethoxy%29ethyl%5D-guanine+and+related+phosphonate+nucleotide+analogues&doi=10.1093%2Fjnci%2F82.6.510"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">In vivo antitumor activity of 9-[(2-phosphonylmethoxy)ethyl]guanine and related phosphonate nucleotide analogs</span></div><div class="casAuthors">Rose, William C.; Crosswell, Alfred R.; Bronson, Joanne J.; Martin, John C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the National Cancer Institute</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">82</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">510-12</span>CODEN:
                <span class="NLM_cas:coden">JNCIEQ</span>;
        ISSN:<span class="NLM_cas:issn">0027-8874</span>.
    </div><div class="casAbstract">Phosphonylmethoxyalkylpurine analogs (I; R = OH or NH2, R1 = H or NH2, and R2 = H or CH2OH) were evaluated for their antitumor activity in murine tumor models.  Three compds., I (R = NH2, R1 = H, and R2 = CH2OH), I (R = NH2, R1 = R2 = H), and PMEG (I; R = OH, R1 = NH2, R2 = H) were modestly active with treated vs. control (T/C) values of 125-175% against i.p. P388 leukemia, but were inactive against i.v.-implanted P388.  The most active and most potent of the 3 was PMEG, which was also evaluated against s.c.-implanted B16 melanoma.  In confirmatory expts., optimal therapy with PMEG yielded reproducible increases in life span (T/C values of 164-170%) and delays in primary tumor growth (7.3- to 13.0-day T-C values).  PMEG is representative of a new class of antitumor antimetabolites heretofore recognized only for their antiviral properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjfTRyf74VPbVg90H21EOLACvtfcHk0lg2Vk7AJzCrAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXktFOntbk%253D&md5=2c9a68cf4dde136414960c030ee77f0a</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2F82.6.510&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252F82.6.510%26sid%3Dliteratum%253Aachs%26aulast%3DRose%26aufirst%3DW.%2BC.%26aulast%3DCrosswell%26aufirst%3DA.%2BR.%26aulast%3DBronson%26aufirst%3DJ.%2BJ.%26aulast%3DMartin%26aufirst%3DJ.%2BC.%26atitle%3DIn%2520vivo%2520antitumor%2520activity%2520of%25209-%255B%25282-phosphonylmethoxy%2529ethyl%255D-guanine%2520and%2520related%2520phosphonate%2520nucleotide%2520analogues%26jtitle%3DJ.%2520Natl.%2520Cancer%2520Inst.%26date%3D1990%26volume%3D82%26spage%3D510%26epage%3D512%26doi%3D10.1093%2Fjnci%2F82.6.510" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Naesens, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatse, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Segers, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verbeken, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balzarini, J.</span></span> <span> </span><span class="NLM_article-title">9-(2-Phosphonylmethoxyethyl)-N6-cyclopropyl-2,6-diaminopurine: a novel prodrug of 9-(2-phosphonylmethoxyethyl)guanine with improved antitumor efficacy and selectivity in choriocarcinoma-bearing rats</span>. <i>Oncol.Res.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">195</span>– <span class="NLM_lpage">203</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10566618" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADC%252BD3cXltFOgurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=1999&pages=195-203&author=L.+Naesensauthor=S.+Hatseauthor=C.+Segersauthor=E.+Verbekenauthor=E.+De+Clercqauthor=M.+Waerauthor=J.+Balzarini&title=9-%282-Phosphonylmethoxyethyl%29-N6-cyclopropyl-2%2C6-diaminopurine%3A+a+novel+prodrug+of+9-%282-phosphonylmethoxyethyl%29guanine+with+improved+antitumor+efficacy+and+selectivity+in+choriocarcinoma-bearing+rats"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">9-(2-Phosphonylmethoxyethyl)-N6-cyclopropyl-2,6-diaminopurine: A novel prodrug of 9-(2-phosphonylmethoxyethyl)guanine with improved antitumor efficacy and selectivity in choriocarcinoma-bearing rats</span></div><div class="casAuthors">Naesens, Lieve; Hatse, Sigrid; Segers, Constant; Verbeken, Erik; De Clercq, Erik; Waer, Mark; Balzarini, Jan</div><div class="citationInfo"><span class="NLM_cas:title">Oncology Research</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">195-203</span>CODEN:
                <span class="NLM_cas:coden">ONREE8</span>;
        ISSN:<span class="NLM_cas:issn">0965-0407</span>.
    
            (<span class="NLM_cas:orgname">Cognizant Communication Corp.</span>)
        </div><div class="casAbstract">The novel acyclic nucleoside phosphonate analog 9-(2-phosphonylmethoxyethyl)-N6-cyclopropyl-2,6-diaminopurine (cPr-PMEDAP) was shown in vitro to act as an intracellular prodrug of 9-(2-phosphonylmethoxyethyl)guanine (PMEG).  We compared the in vivo antitumor efficacy and selectivity of cPr-PMEDAP, its progenitor PMEDAP, and PMEG in a rat choriocarcinoma tumor model.  The rats, inoculated with rat choriocarcinoma (RCHO) cells under the renal capsule, were treated IP during 10 days.  Macroscopical and histol. examn. of the RCHO-inoculated kidneys was performed at two time points (i.e., immediately after the end of treatment or after an addnl. drug-free period of 2 wk).  Complete inhibition of choriocarcinoma tumor development was achieved upon treatment with cPr-PMEDAP, PMEG, and PMEDAP at a daily dose of 10, 1, and 50 mg/kg, resp.  At these doses, all three compds. produced moderate to strong toxicity (evidenced by atrophy of lymphoid organs and reduced body wt. gain).  When compared at the max. tolerated (sublethal) doses (i.e., 0.5, 10, and 50 mg/kg for PMEG, cPr-PMEDAP, and PMEDAP, resp.), cPr-PMEDAP proved superior to PMEG and PMEDAP in achieving a complete inhibition of tumor development.  Also, whereas PMEG was unable to produce a prolonged antitumor effect, the animals treated with cPr-PMEDAP still showed prominent inhibition of tumor development when tumor size was evaluated at 2 wk after end of treatment.  Based on its efficacy and therapeutic safety, cPr-PMEDAP can be regarded as a promising antitumor agent, which merits further in vivo evaluation in addnl. tumor models for human neoplasms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDxQQIWDJUgbVg90H21EOLACvtfcHk0lg2Vk7AJzCrAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXltFOgurg%253D&md5=f4b19409d519142f842313078fbaf53a</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNaesens%26aufirst%3DL.%26aulast%3DHatse%26aufirst%3DS.%26aulast%3DSegers%26aufirst%3DC.%26aulast%3DVerbeken%26aufirst%3DE.%26aulast%3DDe%2BClercq%26aufirst%3DE.%26aulast%3DWaer%26aufirst%3DM.%26aulast%3DBalzarini%26aufirst%3DJ.%26atitle%3D9-%25282-Phosphonylmethoxyethyl%2529-N6-cyclopropyl-2%252C6-diaminopurine%253A%2520a%2520novel%2520prodrug%2520of%25209-%25282-phosphonylmethoxyethyl%2529guanine%2520with%2520improved%2520antitumor%2520efficacy%2520and%2520selectivity%2520in%2520choriocarcinoma-bearing%2520rats%26jtitle%3DOncol.Res.%26date%3D1999%26volume%3D11%26spage%3D195%26epage%3D203" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schinkmanová, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Votruba, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holý, A.</span></span> <span> </span><span class="NLM_article-title">N6-Methyl-AMP aminohydrolase activates N6-substituted purine acyclic nucleoside phosphonates</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">1370</span>– <span class="NLM_lpage">1376</span>, <span class="refDoi"> DOI: 10.1016/j.bcp.2006.01.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1016%2Fj.bcp.2006.01.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=16513094" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADC%252BD28XivVOjtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2006&pages=1370-1376&author=M.+Schinkmanov%C3%A1author=I.+Votrubaauthor=A.+Hol%C3%BD&title=N6-Methyl-AMP+aminohydrolase+activates+N6-substituted+purine+acyclic+nucleoside+phosphonates&doi=10.1016%2Fj.bcp.2006.01.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">N6-Methyl-AMP aminohydrolase activates N6-substituted purine acyclic nucleoside phosphonates</span></div><div class="casAuthors">Schinkmanova, Marketa; Votruba, Ivan; Holy, Antonin</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1370-1376</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">In this study the authors present the identification and characterization of the enzyme involved in the N6-cyclopropyl-2,6-diamino-9-[2-(phosphonomethoxy)ethyl]purine (N6-cyclopropyl-PMEDAP) conversion to biol. active 9-[2-(phosphonomethoxy)ethyl]guanine (PMEG) as well as abacavir 5'-phosphate to carbovir 5'-phosphate.  This enzyme was purified from rat liver to homogeneity; it appears to be composed from six 42 kDa subunits and its native form has the mol. wt. 260 kDa.  This so far unknown enzyme catalyzes conversion of both N6-methyl-AMP and N6-methyl-dAMP to IMP and/or dIMP, resp.  The enzyme acts as 6-(N-substituted amino)purine 5'-nucleotide aminohydrolase with the reaction mechanism very similar to AMP deaminase.  The enzyme does not deaminate AMP and dAMP, or the corresponding nucleosides.  It is inhibited by deoxycoformycin 5'-phosphate but not by deoxycoformycin or erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmlkF2bLqPHLVg90H21EOLACvtfcHk0lg2Vk7AJzCrAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XivVOjtrs%253D&md5=3cb8a4bc889e5353b069432a04f05614</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2006.01.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2006.01.013%26sid%3Dliteratum%253Aachs%26aulast%3DSchinkmanov%25C3%25A1%26aufirst%3DM.%26aulast%3DVotruba%26aufirst%3DI.%26aulast%3DHol%25C3%25BD%26aufirst%3DA.%26atitle%3DN6-Methyl-AMP%2520aminohydrolase%2520activates%2520N6-substituted%2520purine%2520acyclic%2520nucleoside%2520phosphonates%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2006%26volume%3D71%26spage%3D1370%26epage%3D1376%26doi%3D10.1016%2Fj.bcp.2006.01.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reiser, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ray, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shibata, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birkus, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cihlar, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henne, I. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolfgang, G. H. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desai, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rhodes, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fridland, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plunkett, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vail, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thamm, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeraj, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tumas, D. B.</span></span> <span> </span><span class="NLM_article-title">GS-9219—A Novel acyclic nucleotide analogue with potent antineoplastic activity in dogs with spontaneous non-Hodgkin’s lymphoma</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">2824</span>– <span class="NLM_lpage">2832</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-07-2061</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1158%2F1078-0432.CCR-07-2061" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=18451250" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADC%252BD1cXlsFSjsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=2824-2832&author=H.+Reiserauthor=J.+Wangauthor=L.+Chongauthor=W.+J.+Watkinsauthor=A.+S.+Rayauthor=R.+Shibataauthor=G.+Birkusauthor=T.+Cihlarauthor=S.+Wuauthor=B.+Liauthor=X.+Liuauthor=I.+N.+Henneauthor=G.+H.+I.+Wolfgangauthor=M.+Desaiauthor=G.+R.+Rhodesauthor=A.+Fridlandauthor=W.+A.+Leeauthor=W.+Plunkettauthor=D.+Vailauthor=D.+H.+Thammauthor=R.+Jerajauthor=D.+B.+Tumas&title=GS-9219%E2%80%94A+Novel+acyclic+nucleotide+analogue+with+potent+antineoplastic+activity+in+dogs+with+spontaneous+non-Hodgkin%E2%80%99s+lymphoma&doi=10.1158%2F1078-0432.CCR-07-2061"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">GS-9219-A Novel Acyclic Nucleotide Analogue with Potent Antineoplastic Activity in Dogs with Spontaneous Non-Hodgkin's Lymphoma</span></div><div class="casAuthors">Reiser, Hans; Wang, Jianying; Chong, Lee; Watkins, William J.; Ray, Adrian S.; Shibata, Riri; Birkus, Gabriel; Cihlar, Tomas; Wu, Sylvia; Li, Bei; Liu, Xiaohong; Henne, Ilana N.; Wolfgang, Grushenka H. I.; Desai, Manoj; Rhodes, Gerald R.; Fridland, Arnold; Lee, William A.; Plunkett, William; Vail, David; Thamm, Douglas H.; Jeraj, Robert; Tumas, Daniel B.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2824-2832</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: GS-9219, a novel prodrug of the nucleotide analog 9-(2-phosphonylmethoxyethyl)guanine (PMEG), was designed as a cytotoxic agent that preferentially targets lymphoid cells.  Our objective was to characterize the antiproliferative activity, pharmacokinetics, pharmacodynamics, and safety of GS-9219.  Exptl. Design: GS-9219 was selected through screening in proliferation assays and through pharmacokinetic screening.  The activation pathway of GS-9219 was characterized in lymphocytes, and its cytotoxic activity was evaluated against a panel of hematopoietic and nonhematopoietic cell types.  To test whether the prodrug moieties present in GS-9219 confer an advantage over PMEG in vivo, the pharmacokinetics, pharmacodynamics (lymph node germinal center depletion), and toxicity of equimolar doses of GS-9219 and PMEG were evaluated after i.v. administration to normal beagle dogs.  Finally, proof of concept of the antitumor efficacy of GS-9219 was evaluated in five pet dogs with spontaneous, advanced-stage non-Hodgkin's lymphoma (NHL) following a single i.v. administration of GS-9219 as monotherapy.  RESULTS: In lymphocytes, GS-9219 is converted to its active metabolite, PMEG diphosphate, via enzymic hydrolysis, deamination, and phosphorylation.  GS-9219 has substantial antiproliferative activity against activated lymphocytes and hematopoietic tumor cell lines.  In contrast, resting lymphocytes and solid tumor lines were less sensitive to GS-9219.  GS-9219, but not PMEG, depleted the germinal centers in lymphoid tissues of normal beagle dogs at doses that were tolerated.  In addn., GS-9219 displayed significant in vivo efficacy in five dogs with spontaneous NHL after a single administration, with either no or low-grade adverse events.  CONCLUSION: GS-9219 may have utility for the treatment of NHL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKeCNsKzbneLVg90H21EOLACvtfcHk0lgbGkaMF8rgPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXlsFSjsrs%253D&md5=45263fba4227c41be39117929f6e6cbd</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-07-2061&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-07-2061%26sid%3Dliteratum%253Aachs%26aulast%3DReiser%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DChong%26aufirst%3DL.%26aulast%3DWatkins%26aufirst%3DW.%2BJ.%26aulast%3DRay%26aufirst%3DA.%2BS.%26aulast%3DShibata%26aufirst%3DR.%26aulast%3DBirkus%26aufirst%3DG.%26aulast%3DCihlar%26aufirst%3DT.%26aulast%3DWu%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DHenne%26aufirst%3DI.%2BN.%26aulast%3DWolfgang%26aufirst%3DG.%2BH.%2BI.%26aulast%3DDesai%26aufirst%3DM.%26aulast%3DRhodes%26aufirst%3DG.%2BR.%26aulast%3DFridland%26aufirst%3DA.%26aulast%3DLee%26aufirst%3DW.%2BA.%26aulast%3DPlunkett%26aufirst%3DW.%26aulast%3DVail%26aufirst%3DD.%26aulast%3DThamm%26aufirst%3DD.%2BH.%26aulast%3DJeraj%26aufirst%3DR.%26aulast%3DTumas%26aufirst%3DD.%2BB.%26atitle%3DGS-9219%25E2%2580%2594A%2520Novel%2520acyclic%2520nucleotide%2520analogue%2520with%2520potent%2520antineoplastic%2520activity%2520in%2520dogs%2520with%2520spontaneous%2520non-Hodgkin%25E2%2580%2599s%2520lymphoma%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2008%26volume%3D14%26spage%3D2824%26epage%3D2832%26doi%3D10.1158%2F1078-0432.CCR-07-2061" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span> <span> </span><span class="NLM_article-title">Tanovea® for the treatment of lymphoma in dogs</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>154</i></span>,  <span class="NLM_fpage">265</span>– <span class="NLM_lpage">269</span>, <span class="refDoi"> DOI: 10.1016/j.bcp.2018.05.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1016%2Fj.bcp.2018.05.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=29778492" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADC%252BC1cXpslalur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=154&publication_year=2018&pages=265-269&author=E.+De+Clercq&title=Tanovea%C2%AE+for+the+treatment+of+lymphoma+in+dogs&doi=10.1016%2Fj.bcp.2018.05.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Tanovea for the treatment of lymphoma in dogs</span></div><div class="casAuthors">De Clercq, Erik</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">154</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">265-269</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Tanovea (first named GS-9219, then VDC-1101, generic name: rabacfosadine) is a pro-prodrug or "double" prodrug of PMEG [9-(2-phosphonylmethoxyethyl)guanine], which has been conditionally approved by the US FDA (Food and Drug Administration) for the treatment of lymphoma in dogs.  Tanovea has been demonstrated to be effective against non-Hodgkin's lymphoma (NHL) in dogs, as well as canine cutaneous T-cell lymphoma, spontaneous canine multiple myeloma, naive canine multicentric lymphoma and relapsed canine B-cell lymphoma.  As a double prodrug of PMEG, GS-9219 is first converted intracellularly by hydrolysis to cPr-PMEDAP, then deaminated to PMEG, which is then phosphorylated twice to its active metabolite PMEGpp, acting at the level of the cellular DNA polymerases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGBLgcnzyiebVg90H21EOLACvtfcHk0lgbGkaMF8rgPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXpslalur4%253D&md5=b24fa8a7518d2f37d6cdf6f3f9f239d1</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2018.05.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2018.05.010%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BClercq%26aufirst%3DE.%26atitle%3DTanovea%25C2%25AE%2520for%2520the%2520treatment%2520of%2520lymphoma%2520in%2520dogs%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2018%26volume%3D154%26spage%3D265%26epage%3D269%26doi%3D10.1016%2Fj.bcp.2018.05.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McGuigan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barucki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blewett, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carangio, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erichsen, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrei, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snoeck, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balzarini, J.</span></span> <span> </span><span class="NLM_article-title">Highly potent and selective inhibition of varicella-zoster virus by bicyclic furopyrimidine nucleosides bearing an aryl side chain</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">4993</span>– <span class="NLM_lpage">4997</span>, <span class="refDoi"> DOI: 10.1021/jm000210m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm000210m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADC%252BD3cXotFymur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2000&pages=4993-4997&author=C.+McGuiganauthor=H.+Baruckiauthor=S.+Blewettauthor=A.+Carangioauthor=J.+T.+Erichsenauthor=G.+Andreiauthor=R.+Snoeckauthor=E.+De+Clercqauthor=J.+Balzarini&title=Highly+potent+and+selective+inhibition+of+varicella-zoster+virus+by+bicyclic+furopyrimidine+nucleosides+bearing+an+aryl+side+chain&doi=10.1021%2Fjm000210m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Highly Potent and Selective Inhibition of Varicella-Zoster Virus by Bicyclic Furopyrimidine Nucleosides Bearing an Aryl Side Chain</span></div><div class="casAuthors">McGuigan, Christopher; Barucki, Hubert; Blewett, Sally; Carangio, Antonella; Erichsen, Jonathan T.; Andrei, Graciela; Snoeck, Robert; De Clercq, Erik; Balzarini, Jan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">4993-4997</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In addn. to the authors' recent report on the potent anti-varicella-zoster virus (VZV) activity of some unusual bicyclic furopyrimidine nucleosides bearing long alkyl side chains, they herein report the further significant enhancement of the antiviral potency by inclusion of a Ph group in the side chain of these compds.  The target structures were prepd. by the Pd-catalyzed coupling of a series of para-substituted arylacetylenes with 5-iodo-2'-deoxyuridine, to give intermediate 5-alkynyl nucleosides which were cyclized in the presence of Cu to give the desired bicyclic systems.  The compds. display extraordinary potency and selectivity for VZV; the most active are ca. 10,000 times more potent than the ref. compd. acyclovir and ca. 100 times more potent than the alkyl analogs earlier reported by us.  The current compds. show little cytotoxicity, leading to selectivity index values ≥ 1,000,000.  From a range of DNA and RNA viruses tested, only VZV was inhibited by these compds. indicating their extreme selectivity for this target virus.  The novelty of the mols., coupled with their extreme potency and selectivity, their desirable physicochem. properties, and their relative ease of synthesis, makes them of considerable interest for potential drug development for VZV infections.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqu8kNfT53LdrVg90H21EOLACvtfcHk0lgbGkaMF8rgPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXotFymur0%253D&md5=15602d44b75b6560024dfdf616fbf23c</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1021%2Fjm000210m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm000210m%26sid%3Dliteratum%253Aachs%26aulast%3DMcGuigan%26aufirst%3DC.%26aulast%3DBarucki%26aufirst%3DH.%26aulast%3DBlewett%26aufirst%3DS.%26aulast%3DCarangio%26aufirst%3DA.%26aulast%3DErichsen%26aufirst%3DJ.%2BT.%26aulast%3DAndrei%26aufirst%3DG.%26aulast%3DSnoeck%26aufirst%3DR.%26aulast%3DDe%2BClercq%26aufirst%3DE.%26aulast%3DBalzarini%26aufirst%3DJ.%26atitle%3DHighly%2520potent%2520and%2520selective%2520inhibition%2520of%2520varicella-zoster%2520virus%2520by%2520bicyclic%2520furopyrimidine%2520nucleosides%2520bearing%2520an%2520aryl%2520side%2520chain%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2000%26volume%3D43%26spage%3D4993%26epage%3D4997%26doi%3D10.1021%2Fjm000210m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Andrei, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sienaert, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGuigan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balzarini, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snoeck, R.</span></span> <span> </span><span class="NLM_article-title">Susceptibilities of several clinical varicella-zoster virus (VZV) isolates and drug-resistant VZV strains to bicyclic furano pyrimidine nucleosides</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">1081</span>– <span class="NLM_lpage">1086</span>, <span class="refDoi"> DOI: 10.1128/AAC.49.3.1081-1086.2005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1128%2FAAC.49.3.1081-1086.2005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=15728906" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADC%252BD2MXit12murs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2005&pages=1081-1086&author=G.+Andreiauthor=R.+Sienaertauthor=C.+McGuiganauthor=E.+De+Clercqauthor=J.+Balzariniauthor=R.+Snoeck&title=Susceptibilities+of+several+clinical+varicella-zoster+virus+%28VZV%29+isolates+and+drug-resistant+VZV+strains+to+bicyclic+furano+pyrimidine+nucleosides&doi=10.1128%2FAAC.49.3.1081-1086.2005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Susceptibilities of several clinical varicella-zoster virus (VZV) isolates and drug-resistant VZV strains to bicyclic furano pyrimidine nucleosides</span></div><div class="casAuthors">Andrei, Graciela; Sienaert, Rebecca; McGuigan, Chris; De Clercq, Erik; Balzarini, Jan; Snoeck, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1081-1086</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Varicella-zoster virus (VZV) is responsible for primary infections as well as reactivations after latency in the dorsal root ganglia.  The treatment of such infections is mandatory for immunocompromised patients and highly recommended for elderly patients with herpes zoster infections (also called zona or shingles).  The treatment of choice is presently based on four mols., acyclovir (ACV), valaciclovir, famciclovir, and (in Europe) brivudine (BVDU).  We present here our data on the antiviral activity of a new class of potent and selective anti-VZV compds., bicyclic pyrimidine nucleoside analogs (BCNAs), against a broad variety of clin. isolates and different drug-resistant virus strains.  The results show that the BCNAs are far more potent inhibitors than ACV and BVDU against clin. VZV isolates as well as the VZV ref. strains Oka and YS.  The BCNAs were not active against ACV- and BVDU-resistant VZV strains bearing mutations in the viral thymidine kinase gene but kept their inhibitory potential against virus strains with mutations in the VZV DNA polymerase gene.  Mutant virus strains selected in the presence of the BCNAs were solely cross-resistant to drugs, such as ACV and BVDU, that depend for their antiviral action on metabolic activation by the viral thymidine kinase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpV5EJqr0qmUbVg90H21EOLACvtfcHk0lh5G93OBzLVPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXit12murs%253D&md5=ef2628333f3beb4e7eb9f728795e20e5</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1128%2FAAC.49.3.1081-1086.2005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.49.3.1081-1086.2005%26sid%3Dliteratum%253Aachs%26aulast%3DAndrei%26aufirst%3DG.%26aulast%3DSienaert%26aufirst%3DR.%26aulast%3DMcGuigan%26aufirst%3DC.%26aulast%3DDe%2BClercq%26aufirst%3DE.%26aulast%3DBalzarini%26aufirst%3DJ.%26aulast%3DSnoeck%26aufirst%3DR.%26atitle%3DSusceptibilities%2520of%2520several%2520clinical%2520varicella-zoster%2520virus%2520%2528VZV%2529%2520isolates%2520and%2520drug-resistant%2520VZV%2520strains%2520to%2520bicyclic%2520furano%2520pyrimidine%2520nucleosides%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2005%26volume%3D49%26spage%3D1081%26epage%3D1086%26doi%3D10.1128%2FAAC.49.3.1081-1086.2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span> <span> </span><span class="NLM_article-title">Highly potent and selective inhibition of varicella-zoster virus replication by bicyclic furo [2,3-d]pyridine nucleoside analogues</span>. <i>Med. Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">253</span>– <span class="NLM_lpage">274</span>, <span class="refDoi"> DOI: 10.1002/med.10035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1002%2Fmed.10035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=12647310" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADC%252BD3sXjsVWitLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2003&pages=253-274&author=E.+De+Clercq&title=Highly+potent+and+selective+inhibition+of+varicella-zoster+virus+replication+by+bicyclic+furo+%5B2%2C3-d%5Dpyridine+nucleoside+analogues&doi=10.1002%2Fmed.10035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Highly potent and selective inhibition of varicella-zoster virus replication by bicyclic furo [2,3-d]pyrimidine nucleoside analogues</span></div><div class="casAuthors">De Clercq, Erik</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">253-274</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  The bicyclic furo[2,3-d]pyrimidine nucleoside analogs represent an entirely new class of fused furopyrimidine derivs. with unprecedented selectivity for varicella-zoster virus (VZV).  From extensive structure-activity relationship (SAR) studies, the 6-(p-alkylphenyl)substituted furopyrimidine derivs. Cf 1742 and Cf 1743 emerged as the most potent inhibitors of VZV replication: they were found to inhibit both lab. VZV strains and clin. VZV isolates at subnanomolar concns., while not being toxic to the host cells at 100,000-fold higher concns.  Although the precise mechanism of action of these compds. remains to be elucidated, it is clear that for their antiviral activity they depend on phosphorylation by the VZV-encoded thymidine kinase.  The furo[2,3-d]pyrimidine nucleoside analogs are not susceptible to degrdn. by human or bacterial thymidine phosphorylase, which may otherwise release the free aglycon.  Also, the latter is not inhibitory to dihydropyrimidine dehydrogenase, an enzyme involved in the degrdn. of thymine, uracil, and the anticancer agent 5-fluorouracil.  Further development of the furo[2,3-d]pyrimidine nucleoside analogs as new therapeutic modalities for the treatment of VZV infections (i.e., varicella and herpes zoster) seems highly justified.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYtL_aPdxa1LVg90H21EOLACvtfcHk0lh5G93OBzLVPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXjsVWitLo%253D&md5=d32c87d1553be695e113954baa115808</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1002%2Fmed.10035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.10035%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BClercq%26aufirst%3DE.%26atitle%3DHighly%2520potent%2520and%2520selective%2520inhibition%2520of%2520varicella-zoster%2520virus%2520replication%2520by%2520bicyclic%2520furo%2520%255B2%252C3-d%255Dpyridine%2520nucleoside%2520analogues%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2003%26volume%3D23%26spage%3D253%26epage%3D274%26doi%3D10.1002%2Fmed.10035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McGuigan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pathirana, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Migliore, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adak, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luoni, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Díez-Torrubia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camarasa, M.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Velázquez, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henson, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verbeken, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sienaert, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naesens, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snoeck, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrei, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balzarini, J.</span></span> <span> </span><span class="NLM_article-title">Preclinical development of bicyclic nucleoside analogues as potent and selective inhibitors of varicella zoster virus</span>. <i>J. Antimicrob. Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">1316</span>– <span class="NLM_lpage">1330</span>, <span class="refDoi"> DOI: 10.1093/jac/dkm376</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1093%2Fjac%2Fdkm376" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=17956908" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlKmt7fM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2007&pages=1316-1330&author=C.+McGuiganauthor=R.+N.+Pathiranaauthor=M.+Miglioreauthor=R.+Adakauthor=G.+Luoniauthor=A.+T.+Jonesauthor=A.+D%C3%ADez-Torrubiaauthor=M.-J.+Camarasaauthor=S.+Vel%C3%A1zquezauthor=G.+Hensonauthor=E.+Verbekenauthor=R.+Sienaertauthor=L.+Naesensauthor=R.+Snoeckauthor=G.+Andreiauthor=J.+Balzarini&title=Preclinical+development+of+bicyclic+nucleoside+analogues+as+potent+and+selective+inhibitors+of+varicella+zoster+virus&doi=10.1093%2Fjac%2Fdkm376"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical development of bicyclic nucleoside analogues as potent and selective inhibitors of varicella zoster virus</span></div><div class="casAuthors">McGuigan, Christopher; Pathirana, Ranjith N.; Migliore, Marco; Adak, Rina; Luoni, Giovanna; Jones, Arwyn T.; Diez-Torrubia, Alberto; Camarasa, Maria-Jose; Velazquez, Sonsoles; Henson, Geoffrey; Verbeken, Erik; Sienaert, Rebecca; Naesens, Lieve; Snoeck, Robert; Andrei, Graciela; Balzarini, Jan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Antimicrobial Chemotherapy</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1316-1330</span>CODEN:
                <span class="NLM_cas:coden">JACHDX</span>;
        ISSN:<span class="NLM_cas:issn">0305-7453</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Objectives: To progress the anti-varicella-zoster-virus (VZV) aryl bicyclic nucleoside analogs (BCNAs) to the point of Phase 1 clin. trial for herpes zoster.  Methods: A new chromatog.-free synthetic access to the lead anti-VZV aryl BCNAs is reported.  The anti-VZV activity of lead Cf1743 was evaluated in monolayer cell cultures and organotypic epithelial raft cultures of primary human keratinocytes.  Oral dosing in rodents and preliminary pharmacokinetics assessment was made, followed by an exploration of alternative formulations and the prepn. of pro-drugs.  We also studied uptake into cells of both parent drug and pro-drug using fluorescent microscopy and biol. assays.  Results: Cf1743 proved to be significantly more potent than all ref. anti-VZV compds. as measured either by inhibition of infectious virus particles and/or by viral DNA load.  However, the very low water soly. of this compd. gave poor oral bioavailability (∼14%). A Captisol admixt. and the 5'-monophosphate pro-drug of Cf1743 greatly boosted water soly. but did not significantly improve oral bioavailability.  The most promising pro-drug to emerge was the HCl salt of the 5'-valyl ester, designated as FV-100.  Its uptake into cells studied using fluorescent microscopy and biol. assays indicated that the compd. is taken up by the cells after a short period of incubation and limited exposure to drug in vivo may have beneficial effects.  Conclusions: On the basis of its favorable antiviral and pharmacokinetic properties, FV-100 is now being pursued as the clin. BCNA candidate for the treatment of VZV shingles.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMlVPkcYmb57Vg90H21EOLACvtfcHk0lh5G93OBzLVPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlKmt7fM&md5=b8f2aa41ba0035fc69ea892a687bed50</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1093%2Fjac%2Fdkm376&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjac%252Fdkm376%26sid%3Dliteratum%253Aachs%26aulast%3DMcGuigan%26aufirst%3DC.%26aulast%3DPathirana%26aufirst%3DR.%2BN.%26aulast%3DMigliore%26aufirst%3DM.%26aulast%3DAdak%26aufirst%3DR.%26aulast%3DLuoni%26aufirst%3DG.%26aulast%3DJones%26aufirst%3DA.%2BT.%26aulast%3DD%25C3%25ADez-Torrubia%26aufirst%3DA.%26aulast%3DCamarasa%26aufirst%3DM.-J.%26aulast%3DVel%25C3%25A1zquez%26aufirst%3DS.%26aulast%3DHenson%26aufirst%3DG.%26aulast%3DVerbeken%26aufirst%3DE.%26aulast%3DSienaert%26aufirst%3DR.%26aulast%3DNaesens%26aufirst%3DL.%26aulast%3DSnoeck%26aufirst%3DR.%26aulast%3DAndrei%26aufirst%3DG.%26aulast%3DBalzarini%26aufirst%3DJ.%26atitle%3DPreclinical%2520development%2520of%2520bicyclic%2520nucleoside%2520analogues%2520as%2520potent%2520and%2520selective%2520inhibitors%2520of%2520varicella%2520zoster%2520virus%26jtitle%3DJ.%2520Antimicrob.%2520Chemother.%26date%3D2007%26volume%3D60%26spage%3D1316%26epage%3D1330%26doi%3D10.1093%2Fjac%2Fdkm376" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pentikis, H.
S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atiee, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boehlecke, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutchins, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patti, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henson, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, A.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetics and safety of FV-100, a novel oral anti-herpes zoster nucleoside analogue, administered in single and multiple doses to healthy young adult and elderly adult volunteers</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">2847</span>– <span class="NLM_lpage">2854</span>, <span class="refDoi"> DOI: 10.1128/AAC.01446-10</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1128%2FAAC.01446-10" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=21444712" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADC%252BC3MXnt1Kiu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2011&pages=2847-2854&author=H.%0AS.+Pentikisauthor=M.+Matsonauthor=G.+Atieeauthor=B.+Boehleckeauthor=J.+T.+Hutchinsauthor=J.+M.+Pattiauthor=G.+W.+Hensonauthor=A.+Morris&title=Pharmacokinetics+and+safety+of+FV-100%2C+a+novel+oral+anti-herpes+zoster+nucleoside+analogue%2C+administered+in+single+and+multiple+doses+to+healthy+young+adult+and+elderly+adult+volunteers&doi=10.1128%2FAAC.01446-10"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetics and safety of FV-100, a novel oral anti-herpes zoster nucleoside analogue, administered in single and multiple doses to healthy young adult and elderly adult volunteers</span></div><div class="casAuthors">Pentikis, Helen S.; Matson, Mark; Atiee, George; Boehlecke, Brian; Hutchins, Jeff T.; Patti, Joseph M.; Henson, Geoffrey W.; Morris, Amy</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2847-2854</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">FV-100 is the prodrug of the highly potent anti-varicella zoster virus bicyclic nucleoside analog CF-1743.  To characterize the pharmacokinetics and safety of oral FV-100, 3 randomized, double-blind, placebo-controlled clin. trials were conducted: (i) a single-ascending-dose study in 32 healthy subjects aged 18 to 55 years (100-, 200-, 400-, and 800-mg doses) with an evaluation of the food effect in the 400-mg group; (ii) a multiple-ascending-dose study in 48 subjects aged 18 to 55 years (100 mg once daily [QD], 200 mg QD, 400 mg QD, 400 mg twice a day, and 800 mg QD for 7 days); and (iii) a 2-part study in subjects aged 65 years and older with a single 400-mg dose in 15 subjects and a 400-mg QD dosing regimen for 7 days in 12 subjects.  FV-100 was rapidly and extensively converted to CF-1743, the concn. of which remained above that required to reduce viral activity by 50% for the 24-h dosing period.  Renal excretion of CF-1743 was very low.  A high-fat meal reduced exposure to CF-1743; a low-fat meal did not.  Pharmacokinetic parameters for the elderly subjects were comparable to those for the younger subjects.  FV-100 was well tolerated by all subjects.  The pharmacokinetic and safety profiles of FV-100 support its continued investigation for the treatment of herpes zoster and prevention of postherpetic neuralgia with once-daily dosing and without dose modifications for elderly or renally impaired patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYUfzppD_waLVg90H21EOLACvtfcHk0lgCe9qFQDMVKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXnt1Kiu7w%253D&md5=c74cb28adcd457cca073905cc53ac705</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1128%2FAAC.01446-10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.01446-10%26sid%3Dliteratum%253Aachs%26aulast%3DPentikis%26aufirst%3DH.%2BS.%26aulast%3DMatson%26aufirst%3DM.%26aulast%3DAtiee%26aufirst%3DG.%26aulast%3DBoehlecke%26aufirst%3DB.%26aulast%3DHutchins%26aufirst%3DJ.%2BT.%26aulast%3DPatti%26aufirst%3DJ.%2BM.%26aulast%3DHenson%26aufirst%3DG.%2BW.%26aulast%3DMorris%26aufirst%3DA.%26atitle%3DPharmacokinetics%2520and%2520safety%2520of%2520FV-100%252C%2520a%2520novel%2520oral%2520anti-herpes%2520zoster%2520nucleoside%2520analogue%252C%2520administered%2520in%2520single%2520and%2520multiple%2520doses%2520to%2520healthy%2520young%2520adult%2520and%2520elderly%2520adult%2520volunteers%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2011%26volume%3D55%26spage%3D2847%26epage%3D2854%26doi%3D10.1128%2FAAC.01446-10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wolfgang, G. H. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shibata, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ray, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doerrfler, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reiser, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birkus, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christensen, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrei, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snoeck, R.</span></span> <span> </span><span class="NLM_article-title">GS-9191 Is a novel topical prodrug of the nucleotide analog 9-(2-phosphonylmethoxyethyl)guanine with antiproliferative activity and possible utility in the treatment of human papillomavirus lesions</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">2777</span>– <span class="NLM_lpage">2784</span>, <span class="refDoi"> DOI: 10.1128/AAC.00103-09</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1128%2FAAC.00103-09" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=19398642" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADC%252BD1MXotlWqtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2009&pages=2777-2784&author=G.+H.+I.+Wolfgangauthor=R.+Shibataauthor=J.+Wangauthor=A.+S.+Rayauthor=S.+Wuauthor=E.+Doerrflerauthor=H.+Reiserauthor=W.+A.+Leeauthor=G.+Birkusauthor=N.+D.+Christensenauthor=G.+Andreiauthor=R.+Snoeck&title=GS-9191+Is+a+novel+topical+prodrug+of+the+nucleotide+analog+9-%282-phosphonylmethoxyethyl%29guanine+with+antiproliferative+activity+and+possible+utility+in+the+treatment+of+human+papillomavirus+lesions&doi=10.1128%2FAAC.00103-09"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">GS-9191 is a novel topical prodrug of the nucleotide analog 9-(2-phosphonylmethoxyethyl)guanine with antiproliferative activity and possible utility in the treatment of human papillomavirus lesions</span></div><div class="casAuthors">Wolfgang, Grushenka H. I.; Shibata, Riri; Wang, Jianying; Ray, Adrian S.; Wu, Sylvia; Doerrfler, Edward; Reiser, Hans; Lee, William A.; Birkus, Gabriel; Christensen, Neil D.; Andrei, Graciela; Snoeck, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2777-2784</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">GS-9191 is a novel double prodrug of the nucleotide analog 9-(2-phosphonylmethoxyethyl)guanine (PMEG) designed as a topical agent to permeate skin and be metabolized to the active nucleoside triphosphate analog in the epithelial layer.  The prodrug was shown to be metabolized intracellularly to 9-(2-phosphonylmethoxyethyl)-N6-cyclopropyl-2,6,diaminopurine (cPrPMEDAP) and subsequently deaminated to PMEG.  The active form, PMEG diphosphate, was shown to be a potent inhibitor of DNA polymerase α and β while showing weaker activity against mitochondrial DNA polymerase γ (50% enzyme inhibition obsd. at 2.5, 1.6, and 59.4 μM, resp.).  GS-9191 was markedly more potent than PMEG or cPrPMEDAP in a series of human papillomavirus (HPV)-pos. cell lines, with effective concns. to inhibit 50% cell growth (EC50) as low as 0.03, 207, and 284 nM, resp.  In contrast, GS-9191 was generally less potent in non-HPV-infected cells and primary cells (EC50s between 1 and 15 nM).  DNA synthesis was inhibited by GS-9191 within 24 h of treatment; cells were obsd. to be arrested in S phase by 48 h and to subsequently undergo apoptosis (between 3 and 7 days).  In an animal model (cottontail rabbit papillomavirus), topical GS-9191 was shown to decrease the size of papillomas in a dose-related manner.  At the highest dose (0.1%), cures were evident at the end of 5 wk, and lesions did not recur in a 30-day follow-up period.  These data suggest that GS-9191 may have utility in the treatment of HPV-induced lesions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRJcTRFVb_gbVg90H21EOLACvtfcHk0lgCe9qFQDMVKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXotlWqtbs%253D&md5=c59462bbf96e4fe32927a905d3f04c03</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1128%2FAAC.00103-09&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00103-09%26sid%3Dliteratum%253Aachs%26aulast%3DWolfgang%26aufirst%3DG.%2BH.%2BI.%26aulast%3DShibata%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DRay%26aufirst%3DA.%2BS.%26aulast%3DWu%26aufirst%3DS.%26aulast%3DDoerrfler%26aufirst%3DE.%26aulast%3DReiser%26aufirst%3DH.%26aulast%3DLee%26aufirst%3DW.%2BA.%26aulast%3DBirkus%26aufirst%3DG.%26aulast%3DChristensen%26aufirst%3DN.%2BD.%26aulast%3DAndrei%26aufirst%3DG.%26aulast%3DSnoeck%26aufirst%3DR.%26atitle%3DGS-9191%2520Is%2520a%2520novel%2520topical%2520prodrug%2520of%2520the%2520nucleotide%2520analog%25209-%25282-phosphonylmethoxyethyl%2529guanine%2520with%2520antiproliferative%2520activity%2520and%2520possible%2520utility%2520in%2520the%2520treatment%2520of%2520human%2520papillomavirus%2520lesions%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2009%26volume%3D53%26spage%3D2777%26epage%3D2784%26doi%3D10.1128%2FAAC.00103-09" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Holý, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Votruba, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masojídková, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrei, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snoeck, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naesens, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balzarini, J.</span></span> <span> </span><span class="NLM_article-title">6-[2-(Phosphonomethoxy)alkoxy]pyrimidines with Antiviral Activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">1918</span>– <span class="NLM_lpage">1929</span>, <span class="refDoi"> DOI: 10.1021/jm011095y</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm011095y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADC%252BD38Xit12mur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2002&pages=1918-1929&author=A.+Hol%C3%BDauthor=I.+Votrubaauthor=M.+Masoj%C3%ADdkov%C3%A1author=G.+Andreiauthor=R.+Snoeckauthor=L.+Naesensauthor=E.+De+Clercqauthor=J.+Balzarini&title=6-%5B2-%28Phosphonomethoxy%29alkoxy%5Dpyrimidines+with+Antiviral+Activity&doi=10.1021%2Fjm011095y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">6-[2-(Phosphonomethoxy)alkoxy]pyrimidines with Antiviral Activity</span></div><div class="casAuthors">Holy, Antonin; Votruba, Ivan; Masojidkova, Milena; Andrei, Graciela; Snoeck, Robert; Naesens, Lieve; De Clercq, Erik; Balzarini, Jan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1918-1929</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">6-Hydroxypyrimidines substituted at positions 2 and 4 by H, Me, amino, cyclopropylamino, dimethylamino, methylthio, or hydroxyl group afford by the reaction with diisopropyl 2-(chloroethoxy)methylphosphonate in the presence of NaH, Cs2CO3, or DBU a mixt. of N1- and O6-[2-(diisopropylphosphorylmethoxy)ethyl] isomers which were converted to the free phosphonic acids by treatment with bromotrimethylsilane followed by hydrolysis.  Analogously, 2,4-diamino-6-hydroxypyrimidine gave on reaction with [(R)- and (S)-2-(diisopropylphosphorylmethoxy)propyl] tosylate, followed by deprotection, the enantiomeric 6-[2-(phosphonomethoxy)propoxy]pyrimidines.  2,4-Diamino-6-sulfanylpyrimidine gave, on treatment with diisopropyl 2-(chloroethoxy)methylphosphonate in the presence of NaH and subsequent deprotection, 2,4-diamino-6-{[2-(phosphonomethoxy)ethyl]thio}pyrimidine.  2-Amino-4-hydroxy-6-[2-(phosphonomethoxy)ethyl]pyrimidine was obtained from the appropriate 2-amino-4-chloropyrimidine deriv. by alk. hydrolysis and ester cleavage.  Direct alkylation of 2-amino-4,6-dihydroxypyrimidine afforded a mixt. of 2-amino-4,6-bis[2-(phosphonomethoxy)ethyl]- and 2-amino-1,4-bis[2-(phosphonomethoxy)ethyl]pyrimidine.  None of the N1-[2-(phosphonomethoxy)ethyl] isomers exhibited any antiviral activity against DNA viruses or RNA viruses tested in vitro.  On the contrary, the O6-isomers, the compds. derived from 2,4-diamino-, 2-amino-4-hydroxy-, or 2-amino-4-[2-(phosphonomethoxy)ethoxy]-6-hydroxypyrimidine, inhibited the replication of herpes viruses [herpes simplex type 1 (HSV-1) and type 2 (HSV-2), varicella-zoster virus (VZV), and cytomegalovirus (CMV)] and retroviruses [Moloney sarcoma virus (MSV) and human immunodeficiency virus type 1 (HIV-1) and type 2 (HIV-2)], their activity being most pronounced against the latter.  The antiviral activity was lower if the O at the position 6 was replaced by a S atom, as in 2,4-diamino-6-[2-(phosphonomethoxy)ethylthio]pyrimidine.  In analogy to N9-[2-(phosphonomethoxy)propyl]-2,6-diaminopurine (PMPDAP), solely the (R)-2,4-diamino-6-[2-(phosphonomethoxy)propoxy]pyrimidine exerted antiviral activity, whereas its (S)-enantiomer was essentially inactive.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZUOLNwoSlNLVg90H21EOLACvtfcHk0liA_pdOp4GkWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xit12mur8%253D&md5=f086f0e2cae1cdb319cd23a8d9162052</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1021%2Fjm011095y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm011095y%26sid%3Dliteratum%253Aachs%26aulast%3DHol%25C3%25BD%26aufirst%3DA.%26aulast%3DVotruba%26aufirst%3DI.%26aulast%3DMasoj%25C3%25ADdkov%25C3%25A1%26aufirst%3DM.%26aulast%3DAndrei%26aufirst%3DG.%26aulast%3DSnoeck%26aufirst%3DR.%26aulast%3DNaesens%26aufirst%3DL.%26aulast%3DDe%2BClercq%26aufirst%3DE.%26aulast%3DBalzarini%26aufirst%3DJ.%26atitle%3D6-%255B2-%2528Phosphonomethoxy%2529alkoxy%255Dpyrimidines%2520with%2520Antiviral%2520Activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2002%26volume%3D45%26spage%3D1918%26epage%3D1929%26doi%3D10.1021%2Fjm011095y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref93"><div class="reference"><strong class="refLabel"><a href="#ref93" class="rightTabRefNumLink">93</a></strong><div class="NLM_citation" id="rightTab-cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hocková, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holý, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masojídková, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrei, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snoeck, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balzarini, J.</span></span> <span> </span><span class="NLM_article-title">5-substituted-2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]pyrimidines - acyclic nucleoside phosphonate analogues with antiviral activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">5064</span>– <span class="NLM_lpage">5073</span>, <span class="refDoi"> DOI: 10.1021/jm030932o</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm030932o" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADC%252BD3sXotVKltL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=5064-5073&author=D.+Hockov%C3%A1author=A.+Hol%C3%BDauthor=M.+Masoj%C3%ADdkov%C3%A1author=G.+Andreiauthor=R.+Snoeckauthor=E.+De+Clercqauthor=J.+Balzarini&title=5-substituted-2%2C4-diamino-6-%5B2-%28phosphonomethoxy%29ethoxy%5Dpyrimidines+-+acyclic+nucleoside+phosphonate+analogues+with+antiviral+activity&doi=10.1021%2Fjm030932o"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">5-Substituted-2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]pyrimidines-Acyclic Nucleoside Phosphonate Analogues with Antiviral Activity</span></div><div class="casAuthors">Hockova, Dana; Holy, Antonin; Masojidkova, Milena; Andrei, Graciela; Snoeck, Robert; De Clercq, Erik; Balzarini, Jan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">5064-5073</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">2,4-Diamino-6-hydroxypyrimidines substituted in position 5 by an allyl, benzyl, cyanomethyl, ethoxycarbonylmethyl, Ph, cyclopropyl, or Me group were prepd. either by C5-alkylation or by formation of the pyrimidine ring by cyclization.  Their alkylation with 2-[(diisopropoxyphosphoryl)methoxy]ethyl tosylate afforded N1- and O6-regioisomers that were sepd. and converted to the free phosphonic acids by treatment with bromotrimethylsilane followed by hydrolysis.  Reaction of 2,4-diamino-6-{[(diisopropoxyphosphoryl)methoxy]ethoxy}pyrimidine with elemental bromine, N-chloro-, or N-iodosuccinimide gave the corresponding phosphorus-protected 5-bromo-, 5-chloro-, and 5-iodo derivs., resp.  Their deprotection afforded 2,4-diamino-5-bromo- and -5-chloro-6-[2-(phosphonomethoxy)ethoxy]pyrimidines. 2,4-Diamino-5-methyl-6-[2-(phosphonomethoxy)ethoxy]pyrimidine was synthesized also by cross-coupling of the 5-bromo compd. with AlMe3, followed by deprotection.  The compds. showed poor, if any, inhibitory activity against DNA viruses such as herpes simplex virus type 1 and type 2, cytomegalovirus, varicella-zoster virus, and vaccinia virus.  In contrast, several 5-substituted 2,4-diaminopyrimidine derivs. markedly inhibited retrovirus replication in cell culture.  The 5-Me deriv. was exquisitely inhibitory to human immunodeficiency virus and Moloney murine sarcoma virus-induced cytopathicity in cell culture (EC50 ∼ 0.00018 μmol/mL) but also cytostatic to CEM cell cultures.  In contrast, the 5-halogen-substituted derivs. showed pronounced antiretroviral activity (EC50 = 0.0023-0.0110 μmol/mL), comparable to that of the ref. drugs adefovir and tenofovir, but were devoid of measurable toxicity at 0.3 μmol/mL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9CUljBF1DaLVg90H21EOLACvtfcHk0liA_pdOp4GkWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXotVKltL8%253D&md5=5c335da2539c8745e22f10492bab4d48</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1021%2Fjm030932o&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm030932o%26sid%3Dliteratum%253Aachs%26aulast%3DHockov%25C3%25A1%26aufirst%3DD.%26aulast%3DHol%25C3%25BD%26aufirst%3DA.%26aulast%3DMasoj%25C3%25ADdkov%25C3%25A1%26aufirst%3DM.%26aulast%3DAndrei%26aufirst%3DG.%26aulast%3DSnoeck%26aufirst%3DR.%26aulast%3DDe%2BClercq%26aufirst%3DE.%26aulast%3DBalzarini%26aufirst%3DJ.%26atitle%3D5-substituted-2%252C4-diamino-6-%255B2-%2528phosphonomethoxy%2529ethoxy%255Dpyrimidines%2520-%2520acyclic%2520nucleoside%2520phosphonate%2520analogues%2520with%2520antiviral%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D5064%26epage%3D5073%26doi%3D10.1021%2Fjm030932o" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref94"><div class="reference"><strong class="refLabel"><a href="#ref94" class="rightTabRefNumLink">94</a></strong><div class="NLM_citation" id="rightTab-cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrei, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balzarini, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leyssen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naesens, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neyts, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pannecouque, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snoeck, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ying, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hockova, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holý, A.</span></span> <span> </span><span class="NLM_article-title">Antiviral potential of a new generation of acyclic nucleoside phosphonates, the 6-[2-(phosphonomethoxy)alkoxy]-2,4-diaminopyrimidines</span>. <i>Nucleosides, Nucleotides Nucleic Acids</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">331</span>– <span class="NLM_lpage">341</span>, <span class="refDoi"> DOI: 10.1081/NCN-200059772</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1081%2FNCN-200059772" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=16247948" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtFGisb7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2005&pages=331-341&author=E.+De+Clercqauthor=G.+Andreiauthor=J.+Balzariniauthor=P.+Leyssenauthor=L.+Naesensauthor=J.+Neytsauthor=C.+Pannecouqueauthor=R.+Snoeckauthor=C.+Yingauthor=D.+Hockovaauthor=A.+Hol%C3%BD&title=Antiviral+potential+of+a+new+generation+of+acyclic+nucleoside+phosphonates%2C+the+6-%5B2-%28phosphonomethoxy%29alkoxy%5D-2%2C4-diaminopyrimidines&doi=10.1081%2FNCN-200059772"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Antiviral potential of a new generation of acyclic nucleoside phosphonates, the 6-[2-(phosphonomethoxy)alkoxy]-2,4-diaminopyrimidines</span></div><div class="casAuthors">De Clercq, Erik; Andrei, G.; Balzarini, J.; Leyssen, P.; Naesens, L.; Neyts, J.; Pannecouque, C.; Snoeck, R.; Ying, C.; Hockova, D.; Holy, A.</div><div class="citationInfo"><span class="NLM_cas:title">Nucleosides, Nucleotides & Nucleic Acids</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">5-7</span>),
    <span class="NLM_cas:pages">331-341</span>CODEN:
                <span class="NLM_cas:coden">NNNAFY</span>;
        ISSN:<span class="NLM_cas:issn">1525-7770</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis, Inc.</span>)
        </div><div class="casAbstract">A review.  Three acyclic nucleoside phosphonates (ANPs) have been formally approved for clin. use in the treatment of (1) cytomegalovirus retinitis in AIDS patients (cidofovir, by the i.v. route), (2) chronic hepatitis B virus (HBV) infections (adefovir dipivoxil, by the oral route), and (3) human immunodeficiency virus (HIV) infections (tenofovir disoproxil fumarate, by the oral route).  The activity spectrum of cidofovir (S)-1-[3-hydroxy-2-(phosphonomethoxy)propyl]cytosine (S)-HPMPC, like that of (S)-HPMPA (S)-9-[3-hydroxy-2-(phosphonomethoxy)propyl]adenine and (S)-HPMPDAP (S)-9-[3-hydroxy-2-(phosphonomethoxy)propyl]-2,6-diaminopurine, encompasses a broad spectrum of DNA viruses, including polyoma-, papilloma-, adeno-, herpes-, and poxviruses.  Adefovir 9-[2-(phosphonomethoxy)ethyl]adenine (PMEA) and tenofovir (R)-9-[2-(phosphonomethoxy) propyl]adenine (R)-PMPA are particularly active against retroviruses (i.e., HIV) and hepadnaviruses (i.e., HBV); addnl., PMEA also shows activity against herpes- and poxviruses.  We have recently identified a new class of ANPs, namely 6-[2-(phosphonomethoxy)alkoxy]-2,4-diaminopyrimidines, named, in analogy with their alkylpurine counterparts, HPMPO-DAPy, PMEO-DAPy, and (R)-PMPO-DAPy.  These compds. exhibit an antiviral activity spectrum and potency that is similar to that of (S)-HPMPDAP, PMEA, and (R)-PMPA, resp.  Thus, PMEO-DAPy and (R)-PMPO-DAPy, akin to PMEA and (R)-PMPA, proved particularly active against HIV-1, HIV-2, and the murine retrovirus Moloney sarcoma virus (MSV).  PMEO-DAPy and (R)-PMPO-DAPy also showed potent activity against both wild-type and lamivudine-resistant strains of HBV.  HPMPO-DAPy was found to inhibit different poxviruses (i.e., vaccinia, cowpox, and orf) at a similar potency as cidofovir.  HPMPO-DAPy also proved active against adenoviruses.  In vivo, HPMPO-DAPy proved equipotent to cidofovir in suppressing vaccinia virus infection (tail lesion formation) in immunocompetent mice and promoting healing of disseminated vaccinia lesions in athymic-nude mice.  The 6-[2-(phosphonomethoxy)alkoxy]-2,4-diaminopyrimidines offer substantial potential for the treatment of a broad range of retro-, hepadna-, herpes-, adeno-, and poxvirus infections.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpv3hh5tyax17Vg90H21EOLACvtfcHk0liA_pdOp4GkWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtFGisb7I&md5=78c6dbe5b27ddf313792ae64596e0e8a</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1081%2FNCN-200059772&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1081%252FNCN-200059772%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BClercq%26aufirst%3DE.%26aulast%3DAndrei%26aufirst%3DG.%26aulast%3DBalzarini%26aufirst%3DJ.%26aulast%3DLeyssen%26aufirst%3DP.%26aulast%3DNaesens%26aufirst%3DL.%26aulast%3DNeyts%26aufirst%3DJ.%26aulast%3DPannecouque%26aufirst%3DC.%26aulast%3DSnoeck%26aufirst%3DR.%26aulast%3DYing%26aufirst%3DC.%26aulast%3DHockova%26aufirst%3DD.%26aulast%3DHol%25C3%25BD%26aufirst%3DA.%26atitle%3DAntiviral%2520potential%2520of%2520a%2520new%2520generation%2520of%2520acyclic%2520nucleoside%2520phosphonates%252C%2520the%25206-%255B2-%2528phosphonomethoxy%2529alkoxy%255D-2%252C4-diaminopyrimidines%26jtitle%3DNucleosides%252C%2520Nucleotides%2520Nucleic%2520Acids%26date%3D2005%26volume%3D24%26spage%3D331%26epage%3D341%26doi%3D10.1081%2FNCN-200059772" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref95"><div class="reference"><strong class="refLabel"><a href="#ref95" class="rightTabRefNumLink">95</a></strong><div class="NLM_citation" id="rightTab-cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Krečmerová, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holý, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piskala, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masojidková, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrei, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naesens, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neyts, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balzarini, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snoeck, R.</span></span> <span> </span><span class="NLM_article-title">Antiviral activity of triazine analogues of 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]cytosine (cidofovir) and related compounds</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">1069</span>– <span class="NLM_lpage">1077</span>, <span class="refDoi"> DOI: 10.1021/jm061281+</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm061281%2B" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhs1Squ7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=1069-1077&author=M.+Kre%C4%8Dmerov%C3%A1author=A.+Hol%C3%BDauthor=A.+Piskalaauthor=M.+Masojidkov%C3%A1author=G.+Andreiauthor=L.+Naesensauthor=J.+Neytsauthor=J.+Balzariniauthor=E.+De+Clercqauthor=R.+Snoeck&title=Antiviral+activity+of+triazine+analogues+of+1-%28S%29-%5B3-hydroxy-2-%28phosphonomethoxy%29propyl%5Dcytosine+%28cidofovir%29+and+related+compounds&doi=10.1021%2Fjm061281%2B"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Antiviral Activity of Triazine Analogues of 1-(S)-[3-Hydroxy-2-(phosphonomethoxy)propyl]cytosine (Cidofovir) and Related Compounds</span></div><div class="casAuthors">Krecmerova, Marcela; Holy, Antonin; Piskala, Alois; Masojidkova, Milena; Andrei, Graciela; Naesens, Lieve; Neyts, Johan; Balzarini, Jan; De Clercq, Erik; Snoeck, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1069-1077</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Regioselective alkylation of 5-azacytosine sodium salt with diisopropyl [(2-chloroethoxy)methyl]phosphonate followed by removal of ester groups afforded 1-[2-(phosphonomethoxy)ethyl]-5-azacytosine I.  Nucleophilic ring opening of [(trityloxy)methyl]-(2S)-oxirane with 5-azacytosine followed by etherification with diisopropyl (bromomethyl)phosphonate and removal of ester groups gave 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine II.  The analogous synthesis gave 6-azacytosine congener III using N4-benzoyl intermediates.  II was shown to exert strong activity against a broad spectrum of DNA viruses including adenoviruses, poxviruses, and herpesviruses (i.e., herpes simplex viruses, varicella zoster virus, and human cytomegalovirus).  Decompn. of II in alk. solns. resulted in IV and V.  While the N-formylguanidine deriv. IV proved active, the carbamyolguanidine deriv. V was devoid of antiviral activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptgkyvMPA3irVg90H21EOLACvtfcHk0lhPDQlBlHWGww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhs1Squ7c%253D&md5=022a4a5039ac36dc3117f72f9e2c0102</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1021%2Fjm061281%2B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm061281%252B%26sid%3Dliteratum%253Aachs%26aulast%3DKre%25C4%258Dmerov%25C3%25A1%26aufirst%3DM.%26aulast%3DHol%25C3%25BD%26aufirst%3DA.%26aulast%3DPiskala%26aufirst%3DA.%26aulast%3DMasojidkov%25C3%25A1%26aufirst%3DM.%26aulast%3DAndrei%26aufirst%3DG.%26aulast%3DNaesens%26aufirst%3DL.%26aulast%3DNeyts%26aufirst%3DJ.%26aulast%3DBalzarini%26aufirst%3DJ.%26aulast%3DDe%2BClercq%26aufirst%3DE.%26aulast%3DSnoeck%26aufirst%3DR.%26atitle%3DAntiviral%2520activity%2520of%2520triazine%2520analogues%2520of%25201-%2528S%2529-%255B3-hydroxy-2-%2528phosphonomethoxy%2529propyl%255Dcytosine%2520%2528cidofovir%2529%2520and%2520related%2520compounds%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D1069%26epage%3D1077%26doi%3D10.1021%2Fjm061281%2B" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref96"><div class="reference"><strong class="refLabel"><a href="#ref96" class="rightTabRefNumLink">96</a></strong><div class="NLM_citation" id="rightTab-cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Krečmerová, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holý, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pohl, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masojidková, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrei, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naesens, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neyts, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balzarini, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snoeck, R.</span></span> <span> </span><span class="NLM_article-title">Ester prodrugs of cyclic 1-(S)- [3-hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine: synthesis and antiviral activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">5765</span>– <span class="NLM_lpage">5772</span>, <span class="refDoi"> DOI: 10.1021/jm0707166</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0707166" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFyhu7rO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=5765-5772&author=M.+Kre%C4%8Dmerov%C3%A1author=A.+Hol%C3%BDauthor=R.+Pohlauthor=M.+Masojidkov%C3%A1author=G.+Andreiauthor=L.+Naesensauthor=J.+Neytsauthor=J.+Balzariniauthor=E.+De+Clercqauthor=R.+Snoeck&title=Ester+prodrugs+of+cyclic+1-%28S%29-+%5B3-hydroxy-2-%28phosphonomethoxy%29propyl%5D-5-azacytosine%3A+synthesis+and+antiviral+activity&doi=10.1021%2Fjm0707166"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">Ester Prodrugs of Cyclic 1-(S)-[3-Hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine: Synthesis and Antiviral Activity</span></div><div class="casAuthors">Krecmerova, Marcela; Holy, Antonin; Pohl, Radek; Masojidkova, Milena; Andrei, Graciela; Naesens, Lieve; Neyts, Johan; Balzarini, Jan; De Clercq, Erik; Snoeck, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">5765-5772</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Reaction of [hydroxy-(phosphonomethoxy)propyl]-azacytosine I with dicyclohexylcarbodiimide and N,N,-dicyclohexyl-4-morpholinocarboxamidine in DMF at elevated temp. afforded the corresponding cyclic phosphonate II (R = H).  Compd. II (R = H) exerts strong in vitro activity against DNA viruses, comparable with activity of parent compd. I.  Transformation of II (R = H) to its tetrabutylammonium salt followed by reaction with alkyl or acyloxyalkyl halogenides enabled us to prep. a series of structurally diverse ester prodrugs: alkyl (octadecyl), alkenyl (erucyl), alkoxyalkyl (hexadecyloxyethyl), and acyloxyalkyl (pivaloyloxymethyl).  The introduction of an alkyl, alkoxyalkyl, or acyloxyalkyl ester group to the mol. resulted in an increase of antiviral activity; the most active compd. was found to be the hexadecyloxyethyl ester II (R = CH2CH2O(CH2)15Me).  The relative configuration of the diastereoisomer trans-II (R = CH2OCO-t-Bu) was detd. using H,H-NOESY NMR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGroxN7W2KAkVLVg90H21EOLACvtfcHk0lhPDQlBlHWGww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFyhu7rO&md5=dbd739eec70f6d2e0b16589c006c88d7</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1021%2Fjm0707166&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0707166%26sid%3Dliteratum%253Aachs%26aulast%3DKre%25C4%258Dmerov%25C3%25A1%26aufirst%3DM.%26aulast%3DHol%25C3%25BD%26aufirst%3DA.%26aulast%3DPohl%26aufirst%3DR.%26aulast%3DMasojidkov%25C3%25A1%26aufirst%3DM.%26aulast%3DAndrei%26aufirst%3DG.%26aulast%3DNaesens%26aufirst%3DL.%26aulast%3DNeyts%26aufirst%3DJ.%26aulast%3DBalzarini%26aufirst%3DJ.%26aulast%3DDe%2BClercq%26aufirst%3DE.%26aulast%3DSnoeck%26aufirst%3DR.%26atitle%3DEster%2520prodrugs%2520of%2520cyclic%25201-%2528S%2529-%2520%255B3-hydroxy-2-%2528phosphonomethoxy%2529propyl%255D-5-azacytosine%253A%2520synthesis%2520and%2520antiviral%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D5765%26epage%3D5772%26doi%3D10.1021%2Fjm0707166" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref97"><div class="reference"><strong class="refLabel"><a href="#ref97" class="rightTabRefNumLink">97</a></strong><div class="NLM_citation" id="rightTab-cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Naesens, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrei, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Votruba, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krečmerová, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holý, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neyts, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snoeck, R.</span></span> <span> </span><span class="NLM_article-title">Intracellular metabolism of the new antiviral compound 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">997</span>– <span class="NLM_lpage">1005</span>, <span class="refDoi"> DOI: 10.1016/j.bcp.2008.08.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=10.1016%2Fj.bcp.2008.08.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=18773877" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1Sms7nP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2008&pages=997-1005&author=L.+Naesensauthor=G.+Andreiauthor=I.+Votrubaauthor=M.+Kre%C4%8Dmerov%C3%A1author=A.+Hol%C3%BDauthor=J.+Neytsauthor=E.+De+Clercqauthor=R.+Snoeck&title=Intracellular+metabolism+of+the+new+antiviral+compound+1-%28S%29-%5B3-hydroxy-2-%28phosphonomethoxy%29propyl%5D-5-azacytosine&doi=10.1016%2Fj.bcp.2008.08.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Intracellular metabolism of the new antiviral compound 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine</span></div><div class="casAuthors">Naesens, Lieve; Andrei, Graciela; Votruba, Ivan; Krecmerova, Marcela; Holy, Antonin; Neyts, Johan; De Clercq, Erik; Snoeck, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">997-1005</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine [HPMP-5-azaC], the 5-azacytosine analog of cidofovir (HPMPC), represents a new acyclic nucleoside phosphonate with pronounced activity against DNA viruses, and a selectivity index superior to that of cidofovir.  Here we investigated the intracellular metabolic pathway of [6-3H]-HPMP-5-azaC.  By comparing the metab. in mouse lymphosarcoma S49-wild type (S49-WT) and mutant cells deficient for dCMP deaminase, we identified the mono- and diphosphate metabolites generated from HPMP-5-azaC and its deaminated product HPMP-5-azaU.  In human lung carcinoma A549 cells, the relative formation of the deaminated metabolites was only 6%, implying that deamination plays a minor role in the overall metab. of HPMP-5-azaC.  The diphosphorylated metabolite of HPMP-5-azaC accounted for 60% of the total radioactivity, and reached intracellular levels which were 60-fold higher in abs. value than the corresponding diphosphate levels obtained with cidofovir.  Consequently to its increased activation, HPMP-5-azaC showed about 45-fold higher incorporation into cellular DNA than cidofovir.  Herpes-, pox- or adenovirus infection had no marked influence on the metab. of HPMP-5-azaC.  The HPMP-5-azaC-diphosphate metabolite was shown to have long intracellular stability (half-life: 63 h), suggesting that infrequent administration of HPMP-5-azaC should be possible.  HPMP-5-azaC represents a new acyclic nucleoside phosphonate compd. with promising anti-DNA virus activity and a favorable metabolic profile that is characterized by low sensitivity to catabolic deamination and a high rate of phosphorylation and DNA incorporation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcq-gnygklZLVg90H21EOLACvtfcHk0ligxjazhTFKoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1Sms7nP&md5=6ac8640f65fdeeb7b0d1bc6e65b0656e</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2008.08.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2008.08.009%26sid%3Dliteratum%253Aachs%26aulast%3DNaesens%26aufirst%3DL.%26aulast%3DAndrei%26aufirst%3DG.%26aulast%3DVotruba%26aufirst%3DI.%26aulast%3DKre%25C4%258Dmerov%25C3%25A1%26aufirst%3DM.%26aulast%3DHol%25C3%25BD%26aufirst%3DA.%26aulast%3DNeyts%26aufirst%3DJ.%26aulast%3DDe%2BClercq%26aufirst%3DE.%26aulast%3DSnoeck%26aufirst%3DR.%26atitle%3DIntracellular%2520metabolism%2520of%2520the%2520new%2520antiviral%2520compound%25201-%2528S%2529-%255B3-hydroxy-2-%2528phosphonomethoxy%2529propyl%255D-5-azacytosine%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2008%26volume%3D76%26spage%3D997%26epage%3D1005%26doi%3D10.1016%2Fj.bcp.2008.08.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.9b00175&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.9b00175%3Bwebsite%3Awebsite%3Aacspubs%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2019.62.issue-16%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.9b00175" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                9MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67990dd45b1e2254","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
